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5Abstract
This thesis is concerned with the development of a personalised treatment approach to aid
clinical decisions in psychological interventions provided for common mental health disorders
(CMHDs), such as depression and anxiety disorders. It begins with a discussion of
personalised medicine in healthcare and its potential for optimising care for CMHDs. The
thesis then considers how personalised medicine can be used to inform clinical decision
making, specifically clinical decisions in relation to the delivery of treatment in mental health
services. This includes a description of the types of clinical decisions required, as well as
examples from across healthcare that have used decision support tools (DSTs) to aid clinical
judgement. This is followed by a review of patient characteristics that have been associated
with outcomes in CMHD treatment. The review is supplemented by an analysis of a large
dataset (n=10693) of patients receiving psychological treatment for CMHDs. It explores the
associations between routinely available patient characteristics and outcomes. The thesis
then reports on the use of latent profile analysis using the patient characteristics to identify
statistically distinct sub-groups (profiles) of patients, and considers the variation in treatment
outcomes between profiles and by the intensity of treatment. The change in depression and
anxiety symptoms, as measured at every treatment session, is statistically modelled to identify
different trajectories of change within and between the latent profiles. These trajectories
represent differential response to psychological treatment. Information from the identified
profiles is combined with the within treatment change methods to develop a personalised
treatment approach to decisions about appropriate treatment and also clinical decisions during
the course of treatment. The thesis then presents a prototype algorithm that can identify
profiles and the likely trajectories of change pre-treatment, before discussing the clinical
implications of providing this algorithm in routine care, as well as future directions of research.
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Chapter 1. Personalised medicine:
Potential application in mental health
disorders.
Personalised medicine
The potential for a more person-centred approach to the provision of healthcare, referred to
as ‘personalised medicine’ or ‘stratified medicine’, to provide benefits for patients and
treatment services has been increasingly recognised in recent years (Dzau & Ginsburg,
2016; Khoury & Galea, 2016). The goal of this approach is to make treatment decisions
informed by the patient’s individual characteristics, tailored to their individual needs by
selecting the most appropriate treatment to achieve the desired outcome. In the UK, NHS
England has made personalised medicine a key priority and is in the process of producing a
five year strategy (Keogh, 2015), with the government establishing a ‘personalised medicine
all-party parliamentary (APP)’ group.
The personalised medicine initiative has been developed to complement the current
evidence-based medicine approach to healthcare. The major benefits of the evidence-based
treatment approach are that patients with similar conditions can be provided with treatments
that have clear evidence for their effectiveness. For clinicians, best practice guidelines can
be used to guide treatment decisions. However, evidence-based practice has been criticised
for a ‘one-size fits all’ approach to patient care (Pencina & Peterson, 2016), as although the
recommended treatment may be helpful for many patients with a specific condition, for
others it is not. Therefore, a bridge between personalised care and evidence based practice
has been sought by clinicians and researchers.
Personalised medicine has led to vast improvements in the treatment of many common
cancers, specifically by identifying genetic markers of probable treatment response, for
example the identification of BRCA-1 gene mutations and response to chemotherapies for
breast and ovarian cancers (Kennedy et al., 2004). Specific interventions are therefore
targeted for certain patients who are grouped together based on similar characteristics (e.g.
genetic markers). This approach has led to improvements in both response and remission
times in cancer treatment (Schwaederle et al., 2016).
Researchers investigating treatments for cancers appear to be leading the medical fields in
the use of personalised medicine, however those in other fields of medicine have also made
significant improvements to treatments. For example, the use of genetic testing in cystic
fibrosis has helped guide treatment decisions for many years and has become the ‘de facto’
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approach (Ashley, 2015). Pharmacogenetic profiling such as this is able to guide decisions
regarding appropriate dosing or specific pharmacological agents that are likely to be most
successful based on the patient’s genotype (Pirmohamed, 2014). Stratifying patients in this
manner and providing this information to clinicians has the potential to be used to inform
treatment decisions, reducing risk of negative outcomes and minimising harm to patients.
Much of the extant literature on personalised medicine has included the use of genetic
information and other biomarkers which are largely unavailable or as yet unidentified in
mental health fields. However, there are other potential patient characteristics that may be
used to personalise healthcare. Information which can be gathered at assessment such as
knowledge of comorbidities (physical or mental), current symptoms, family history of the
condition or related conditions, and demographic information have been used to identify
individuals who may benefit from a preventive intervention, for example due to an increased
risk of suicide (Barak-Corren et al., 2017) or the short-to-medium term risk of cardiovascular
events (Hippisley-Cox et al., 2007; Kumbhani et al., 2013; Lee, Flammer, Lerman, &
Lerman, 2012).
Large data and digital technology
The rise in personalised medicine has coincided with the increased availability of large
patient datasets which offer an opportunity to explore patient characteristics associated with
health conditions and treatment across large cohorts. Such datasets provide more power for
statistical modelling and have previously been utilised to develop personalised approaches
in healthcare (Abbasi, 2017). The human genome project can be viewed as one of the major
landmarks in personalised medicine, and it is argued that the availability of such a huge
amount of patient data was critical to the growth of this patient-centred approach (Wilson &
Nicholls, 2015). Many of the advances in the personalised treatment of cancers and
cardiovascular diseases have been achieved by using large data sets (Hippisley-Cox et al.,
2007; Verma & Mukesh, 2012). In other healthcare fields, especially mental health, there
has been limited use of large data to inform personalised medicine, although research has
been conducted using large datasets to identify characteristics associated with diagnoses.
For example, the 23andMe study used data from over 500,000 patients and identified 15
genes associated with depression (Hyde et al., 2016).
The use of digital technology has the potential to further aid the delivery of personalised
medicine, and can provide benefits to both patients and services (Richards, Coulter, &
Wicks, 2015). Electronic patient management systems (EPMS), are now widely used across
healthcare settings and in the first instance provide a method of collecting and storing the
same specific characteristics and clinical records across large numbers of patients
(Menachemi & Collum, 2011). In addition, the use of digital technology such as mobile
phone and tablet apps provides opportunities for patients to conveniently store personal
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information that can be useful clinically, and are potentially more ecologically valid than
information collected within healthcare settings (Proudfoot, 2013).
To enable the findings from statistical modelling of patient datasets to be made available to
clinicians in a way that can aid clinical practice, decision support tools (DSTs) and
algorithms that can be used within treatment services are increasingly developed for
healthcare (Sheehan & Sherman, 2012). These decision aids can take the form of
sequenced decision charts such as the NICE stroke and transient ischaemic attack (TIA)
algorithms (NICE, 2008) or risk prediction rules, for example the QRISK (Hippisley-Cox et
al., 2007), which predicts the risk of cardiovascular events for an individual patient over a ten
year period, and have therefore become critical to aiding clinical decisions on whether or not
patients should start a statin to reduce their cardiovascular risk. These tools are already
being routinely used by GPs and emergency health physicians to aid clinical decisions on
preventative treatments.
Personalised medicine in mental health conditions
There are currently few examples of the use of personalised medicine approaches in mental
health research and clinical settings (Ozomaro et al., 2013). Whereas genetic markers have
been found to reliably aid treatment selection in a number of cancers, there has been limited
evidence associating genotyping with improved outcomes in the treatment of common
mental health disorders (CMHDs) (Munafò, Zammit, & Flint, 2014; Simon & Perlis, 2010). A
number of genetic markers have been investigated in relation to CMHDs, primarily serotonin
receptors (Papakostas & Fava, 2008), but the lack of convincing evidence for specific genes
involved in the cause of these disorders, let alone such markers being implicated in
differential response to treatments, has limited the use and utility of this research for the
personalisation of CMHD treatment in routine settings (Cuijpers, 2014; Licinio & Wong,
2011).
As genotyping has had limited success in informing the personalisation of treatments for
CMHDs, perhaps information which is more readily available in routine care settings and
which is more easily recorded than is genetic data, including information on patient
characteristics such as demographics and clinical factors, could be more useful in aiding
decision making for these conditions. Furthermore, as the cost and practical complications
with acquiring biomarkers in routine treatment services at present precludes their use
(Evans, et al., 2006), using self-reported patient data to personalise treatment may have
greater practical and clinical utility. This next section introduces CMHDs and discusses the
issues and limitations of clinical diagnosis in informing treatment decisions. The outcomes
for recommended treatment options for these conditions are discussed along with the
current service configuration of mental health services providing psychological interventions
in the UK.
18
Common Mental Health Disorders
This section briefly introduces the common mental health disorders (CMHDs), the focus of
this thesis. For more information on formal diagnostic criteria please refer to the International
Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10;
WHO, 1992) or the Diagnostic and Statistical Manual of Mental Disorders, 5th revision
(American Psychiatric Association, 2013).
Depression
Depression is characterised by a loss of pleasure and interest in most activities, lowered
mood and a reduction in energy. Other symptoms of depression include poor concentration,
increased tiredness, trouble sleeping, changes in appetite, agitation, irritability, tearfulness,
social withdrawal and decreased libido. A reduction in self-esteem and self-confidence,
feelings of worthlessness, guilt and suicidal ideation may be present. Due to the varying
nature of the symptoms, depression is often considered as occurring on a continuum
(Lewinsohn, et al., 2000).
Panic Disorder
Panic attacks can occur in the context of many mental health disorders, especially the
anxiety disorders. Panic disorder is characterised by the experience of panic attacks or less
severe ‘limited symptom attacks’ and a persistent worry of experiencing further panic
attacks. A panic attack is a short period of intensive fear or anxiety, with symptoms including
shaking, sweating, heart palpitations, nausea, chest pain and dizziness. There may be a
secondary fear of losing control, going mad, fainting, losing control of the bladder or other
bodily functions, or of dying during the panic attack. Panic disorder may or may not be
associated with agoraphobia; an intense fear of being in a situation where escape is
perceived as difficult or impossible, leading to avoidance or frequently only being able to go
through the feared situations when accompanied by a particular trusted individual.
Generalised Anxiety Disorder
The main characteristic of generalised anxiety disorder (GAD) is excessive worry and
anxiety that is not restricted to, or predominating in a particular circumstance. The worries
are perceived as uncontrollable, and associated symptoms include difficulties with
concentration, persistent nervousness, irritability, dizziness, palpitations, restlessness,
physical tension in the body and sleep problems.
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Social anxiety disorder
Social anxiety disorder is characterised by fear of scrutiny or ill-judgement from others, often
resulting in the total avoidance of social situations or the use of implicit or explicit ‘safety
behaviours’ to get through/survive the social situation(s). The fear is often of humiliation or
embarrassment and the individual will tend to experience significant anxiety before, during
and after social situations. Social anxiety disorder will often affect educational or
occupational functioning and is frequently associated with lower self-esteem.
Obsessive-compulsive disorder
The main features of Obsessive-Compulsive Disorder (OCD) are recurrent obsessional
thoughts and compulsive behaviours. The obsessions cause distress and functional
impairment to daily life as the patient tries to resist them. Obsessions are intrusive thoughts,
impulses or images that are unwanted and perceived as uncontrollable. Examples include
thoughts of contamination from dirt, germs or bodily fluids, and thoughts of being responsible
for harming others, or for the occurrence of unwanted or terrible events. Compulsions are
ritualistic behaviours or acts that the individual feels ‘compelled’ to perform again and again.
These may be internalised mental acts that are more difficult to observe such as counting or
repeating prayers in one’s mind, or clearer overt actions, such as frequently washing hands,
checking taps, or hoarding items.
Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder (PTSD) can develop in response to an event where the
patient considers themselves or someone close to them to be at threat of serious harm or
death, such as such as an assault, a motor vehicle accident, natural disasters or military
combat. Sufferers of PTSD may experience symptoms in three domains – re-experiencing
(such as having flashbacks or repeated nightmares about the event), hypervigilance (i.e.
being easily startled and on-alert) and avoidance (of reminders of the event). These
symptoms frequently affect sleep and concentration, and as with the other CMHDs above to
meet diagnostic criteria the symptoms must be accompanied by considerable distress and
functional impairment.
Specific phobias
The key feature of a specific phobia is a persistent fear of a specific situation or object, for
example certain animals, flying, darkness, sight of blood or needles. The presence of the
situation/object provokes an anxiety response that is out of proportion to the actual risk or
danger of harm posed by the object. The sufferer will recognise that their response to the
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stimuli is out of proportion with the actual threat, but extreme emotional responses are
triggered, leading to the avoidance of the situation/object.
Impact and costs
The point prevalence of all CMHDs in the UK is approximately 16% (McManus et al., 2009;
Spiers et al., 2016), which would imply that a very large number of individuals may be in
need of treatment from mental health services at any given time. Depression was reported
by 6.7% of individuals surveyed in the USA in a 12 month period (Kessler, Chiu, Demler, &
Walters, 2005) and findings from the UK based Adult Psychiatric Morbidity Survey
(Stansfield et al., 2016) suggest approximately 3.3% of adults reported symptoms
commensurate with being in a major depressive episode when surveyed. Depression is
estimated to account for between 12% and 14% of UK General Practice attendances (King,
Nazareth, et al., 2008; Rait et al., 2009). Once treated, the recurrence of depression is
common. For example, large cohort studies in the USA and Europe have found that between
60% and 85% of patients treated in specialist mental health settings were found to relapse
after treatment (Hardeveld, Spijker, De Graaf, Nolen, & Beekman, 2010; Mueller et al.,
1999).
The most common anxiety disorder is GAD, which was reported in 5.9% of the UK
population in 2014 (Stansfield et al., 2016), and is estimated to be present in 8% of primary
care patients (Wittchen, 2002). PTSD is estimated to affect between 3% and 4% of
individuals in the UK (Fear et al., 2016; McManus et al., 2009). Panic disorder and OCD are
the least common CMHDs, and estimated to affect 0.6% and 1.3% of the general population
respectively (Stansfield et al., 2016).
Considering the prevalence of CMHDs, and the distress and dysfunction associated with
them, they impact not only the sufferer but family and carers too. At the population level they
result in significant societal costs with impact on occupational functioning and healthcare
burden on services. CMHDs can have a major effect on performance in employment and
evidence suggests that suffering from a CMHD may adversely affect one’s ability to work
(Mauskopf et al., 2009). Depression was found to be the fourth most common reason for
loss of disability-adjusted life years (DALYS) worldwide and it is predicted that it will be the
second most common reason in 2020 (Murray & Lopez, 1997). A report by the King’s Fund
(McCrone, Dhanasiri, Patel, Knapp, & Lawton-Smith, 2008) highlighted the loss of earning in
2007 due to depression as £5.82 billion and £7.7 billion from anxiety, with these figures
predicted to rise to £9.19 and £12.15 billion respectively by 2026. The identification of best
available interventions for individual patients could result in a significantly reduced societal
burden, increased productivity and reduced psychological distress.
21
CMHDs also have a significant effect on interpersonal relationships. Depression can
negatively affect marital and family relationships, and parental depression can lead to
neglect of children, which may contribute to childhood difficulties and disturbances
(Ramchandani & Stein, 2003). Suicide attempts, which can have a dramatic effect on social
and family relationships, are between 4 and 20 times more likely in individuals with
depression compared to the general population (Bostwick & Pankratz, 2000), and the
lifetime risk of suicide in depression is estimated at around 15% (Guze & Robins, 1970).
CMHDs are also associated with an increased frequency of poor physical health outcomes
and reduced life expectancy (Chesney, Goodwin, & Fazel, 2014).
Given the social, occupational and clinical impacts of CMHDs, timely optimised treatments
are required to improve the health of sufferers (Habert et al., 2016), but also to best use the
available healthcare resources. The cost of depression and anxiety to mental health services
in England during 2007 was estimated to be £2.92 billion, and projected to rise to £5.0 billion
by 2026 (McCrone et al., 2008).
The negative impact of CMHDs on occupational and personal functioning as well as the
costs associated with the treatment of these conditions suggest that more effective and
efficient means of delivering treatments are required. The development of personalised
medicine approaches to CMHD treatments could help identify groups of patients who are
more or less likely to benefit from specific interventions than other patients, and could
therefore result in improvements in CMHD treatment outcomes. This patient-centred
approach could be used to tailor the delivery of mental health treatment, and potentially
support a more efficient health service.
Treatment of CMHDs
Pharmacological interventions
Pharmacological interventions are the most frequently used treatment option for CMHDs,
with estimates suggesting 46 million prescriptions for antidepressants were issued in the UK
in 2011 (Spence, 2013). The most commonly prescribed antidepressants are selective
serotonin reuptake inhibitors (SSRIs), which are prescribed both for depression and for
many anxiety disorders, and there is good evidence that SSRIs act on the stress-adaption
system of the brain which is involved in the maintenance of both depression and anxiety
(Shelton & Brown, 2001).
Clinical trials of antidepressant treatments have frequently found that around 50% of patients
show a clinical response to treatment (Papakostas & Fava, 2010; Trivedi et al., 2006).
However analysis typically finds that the benefits of antidepressant treatment over those of
placebo treatment are usually only seen in patients with more severe levels of symptoms
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pre-treatment (Fournier et al., 2010). Although pharmacotherapy is considered a valuable
treatment for CMHDs and is usually low cost as most drugs are now out of patent, many
patients report unwanted side effects which are associated with poor treatment adherence
and early termination of treatment.
Some side effects are common: around 15% of patients report dry mouth, dizziness or
nausea while taking SSRIs (Ferguson, 2001). However, surveys have suggested that up to
75% of patients prescribed other classes of antidepressants (e.g. tricyclics) report dry mouth
as a side effect of treatment (Uher, Farmer, et al., 2009), and drowsiness is reported by 17%
of patients (Hu et al., 2004). If the distress caused by the side effects outweighs the
perceived benefits of the treatment, patients may not adhere to their pharmacotherapy
regime or may electively terminate the treatment. For this reason psychological interventions
may be more desirable for patients as an alternative to pharmacological treatments, and are
recommended for CMHDs in national guidelines (NICE, 2011c).
Psychological interventions
Psychological interventions are recommended as a first-line treatment option for many
patients with depression and anxiety disorders, and show comparable effectiveness to
pharmacological treatments in reducing symptoms and maintaining the positive effects of
treatment (NICE, 2011c). For mild-moderate depression, a number of psychological therapy
options are recommended including cognitive behaviour therapy (CBT) for which there is the
greatest amount of evidence of effectiveness (NICE, 2009), behavioural activation (BA),
counselling for depression, behavioural couples therapy, interpersonal psychotherapy (IPT)
and short-term psychodynamic therapy (STPT), all of which are supported by the literature,
though with less evidence than for CBT (van Hees, Rotter, Ellermann, & Evers, 2013).
Mindfulness-based cognitive therapy (MBCT), CBT and IPT have all been found to be
effective relapse-prevention interventions for patients at risk of relapse from depression
(Clarke, Mayo-Wilson, Kenny, & Pilling, 2015). A combination of both psychological and
pharmacological treatment is recommended for moderate to severe depression, or when
psychological treatments have shown limited effectiveness (NICE, 2009).
Psychological interventions, particularly CBT are also the recommended first-line treatment
option in UK clinical guidance for most anxiety disorders, and pharmacological interventions
are only recommended when a patient has declared a preference for drug treatment instead
of psychological treatment, or when recommended psychological interventions have already
shown limited response (NICE, 2011c, 2013). For mild to moderate presentations of GAD
and panic disorder (with or without agoraphobia), both facilitated (guided) and non-facilitated
(pure) self-help interventions are recommended, in addition to psychoeducational groups
(GAD only) due to the significant evidence-base for these interventions in the treatment of
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these disorders. CBT is recommended for moderate to severe presentations of panic
disorder or GAD with severe functional impairment.
Patients with mild to moderate presentations of OCD are recommended either individual
CBT including exposure-focused therapy which can involve self-help materials or group CBT
(NICE, 2011c). CBT or antidepressant medication is recommended for patients with
moderate functional impairment associated with OCD, whereas a combination of CBT and
antidepressants are recommended when there is severe impairment or significant
comorbidity with other CMHDs. For patients with PTSD, trauma-focused CBT or eye
movement desensitisation and reprocessing (EMDR) are recommended, whereas individual
CBT is recommended as initial treatment for social anxiety disorder (NICE, 2013), with
pharmacological treatment for either disorder only recommended when psychological
treatment is declined.
A systematic review of patients attending primary care services suggested that
psychological over pharmacological treatment are frequently preferred for depression,
mainly due to concerns over side effects (Van Schaik et al., 2004), but matching patients to
the treatment they prefer did not improve patient outcomes in this study. Although ‘side
effects’ in the biological sense do not exist with psychological interventions, there is a risk of
clinical harm and it is reported that approximately 5-10% of patients may display a
worsening of clinical symptoms from baseline to the end of treatment, referred to as clinical
deterioration (Boisvert & Faust, 2003; Crawford et al., 2016; Rozental, et al., 2017). The
monitoring of symptoms during the course of treatment is therefore recommended, as it is
with pharmacological interventions, to identify deterioration early and modify the treatment
approach if required (NICE, 2011c).
Treatment outcomes
Given the substantial costs in treating CMHDs and long-term projected resource needed to
provide care, selecting the most appropriate treatment can not only improve patients’
wellbeing, but increase the efficiency of healthcare provision. The consequences of selecting
an ‘incorrect’ treatment can have significant costs for both the individual and wider society
due to the continued illness and the associated loss of productivity (McGrath et al., 2013).
The use of a personalised treatment approach could inform which type of intervention is
likely to result in the best patient outcomes.
Evaluations of psychological interventions delivered in routine care for CMHDs suggest that
just over 45% of patients report a level of symptoms below the established clinical cut-off
after treatment (HSCIC, 2015). A recent national evaluation of treatment outcomes found
that recovery for anxiety disorders was slightly higher than for depression (when diagnosis
was recorded in the data) (NHS Digital, 2016). These recovery rates are similar to those
reported in controlled trials of psychological and pharmacological treatment for depression
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(Luty et al., 2007; Papakostas & Fava, 2010) and anxiety disorders, for example PTSD
(Morina et al., 2014), and appear higher than controlled trials for GAD (Fisher & Durham,
1999; Leichsenring et al., 2013). However, this suggests that for over half of patients the
treatment has not reduced symptoms below levels that would indicate an absence of a
CMHD. The variation in effectiveness of interventions between individual patients indicates
that interventions can be effective for some groups of patients but not others, and therefore
the potential benefit of personalised medicine is to identify which characteristics might help
identify patients likely to experience this differential response.
Head-to-head comparisons of pharmacological and psychological treatments for CMHDs
have suggested limited differences in effectiveness in trial populations. A recent individual
patient-data meta-analysis reported no differences between CBT and antidepressants in
treatment for depression either in terms of remission (scoring below a clinical threshold) or
response (symptoms reducing per a pre-established absolute value or percentage) (Weitz et
al., 2015). However, attrition is reported to be higher in pharmacological interventions than
CBT (Vittengl et al., 2016), and the benefits of treatment have been found to last
considerably longer after terminating CBT compared to pharmacotherapy (Cuijpers et al.,
2013). In social anxiety disorder CBT has been found to be more efficacious than
pharmacotherapy (Mayo-Wilson et al., 2014), and the comparative benefit of CBT over
pharmacological treatment has also been found in the treatment of panic disorder
(Roshanaei-Moghaddam et al., 2011) and for OCD (Lack, 2012).
Despite the few conditions for which there is evidence of a significant difference in the
efficacy or effectiveness of psychological and pharmacological treatments for CMHDs, for
most disorders the comparison of different types of psychological treatment (e.g. CBT vs
IPT) tend to show equivalence in head-to-head trials. Therefore clinical guidance is often
driven by cost-effectiveness analyses (e.g. National Institute for Health and Clinical
Excellence, 2011). This has led to the recommendation of less resource intensive self-help
and group interventions which have shown approximately equivalent clinical outcomes with
high intensity treatments such as CBT for mild to moderate depression and several anxiety
disorders (NICE, 2009, 2011c).
There has been increasing research into the use of combination treatments for CMHDs,
where both psychological and pharmacological interventions are delivered concurrently. For
example, Hollon et al (2014) compared the effectiveness of combined cognitive therapy and
antidepressant treatment to antidepressant monotherapy for depression, finding improved
effectiveness of the combination treatment. Systematic reviews have supported the use of
combination therapy in depression, OCD and panic disorder (Cuijpers, Sijbrandij, et al.,
2014). However, the benefits of combined treatments are most often limited to severe
presentations of CMHDs (Cuijpers et al., 2014; Pampallona, et al., 2004).
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Despite the potential benefits of providing combination treatments for CMHDs, there is
limited evidence for the cost-effectiveness of doing so routinely for all adult CMHD patients
(NICE, 2011c), due in part to the side effects and harms with both pharmacological and
psychological interventions discussed above. Different mechanisms of action between
psychological and pharmacological interventions have been suggested (DeRubeis, Siegle, &
Hollon, 2008) which may indicate the potential for an interaction between treatments. This
interaction may be to the benefit of some patients with particular disorders or presentations,
but it may be a hindrance for other patients with differing presentations. Therefore a
personalised medicine approach that has the ability to identify which monotherapy or
combination therapy patients are most likely to benefit from, or indeed if they are likely to
experience harm from a particular course of treatment, would have clear value to individuals
and potentially at the service-level by helping improve clinical outcome and the efficiency of
mental health treatment services.
Treatment dropout
Patients dropping out of treatment early are likely to have worse outcomes as the amount or
dose of treatment they receive will likely be inadequate. Although these individuals may be
less likely to take up further treatment in the short term, in the longer-term they may require
further treatment and this may be more costly in terms of healthcare resources (Wade &
Häring, 2010). A comprehensive review of dropout in controlled psychological intervention
studies suggested that just under 20% of patients dropped out of treatment, and that dropout
was more likely when the intervention was delivered by a less experienced clinician (Swift &
Greenberg, 2012). A more recent systematic review of dropout from CBT found that around
26% of participants from included studies dropped-out during treatment (Fernandez, Salem,
Swift, & Ramtahal, 2015). Studies of pharmacotherapy for CMHDs have reported similar
rates of dropout: 23.5% of participants receiving Duloxetine compared with 23% of those on
SSRIs dropped out from treatment (Gueorguieva, Mallinckrodt, & Krystal, 2011); a
systematic review of dropout across antidepressant studies indicated that there has been a
decreasing trend in dropout by decade with an average dropout rate of 40% indicated from
studies in the 1980’s, decreasing to 24% in studies conducted in the most recent decade
(Schalkwijk, Undurraga, Tondo, & Baldessarini, 2014).
Dropout rates from routine treatment services are higher than in controlled trials, with over
30% of patients estimated to dropout of out-patient mental health treatment (Wells et al.,
2013). A recent analysis of dropout in UK psychological treatment services found that 34%
of patients dropped out of treatment, 53% of which occurred by the third treatment session
(Saxon, Barkham, Foster, & Parry, 2017). Non-attendance at treatment sessions can not
only negatively affect an individual’s clinical outcome, but also impacts on the efficiency of
healthcare services (Oldham, Kellett, Miles, & Sheeran, 2012). Understanding and predicting
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when dropout is more likely and using these predictions to try and reduce dropout rates,
therefore has the potential to improve outcomes for patients and contribute to a more
effective use of healthcare resource. Although meta-analyses have suggested little
moderating effect of patient characteristics on dropout rates (Swift & Greenberg, 2012),
analyses from individual studies has suggested that some patient characteristics, for
example being male and younger, are associated with an increased risk of dropout in the
treatment of CMHD (Henzen, Moeglin, Giannakopoulos, & Sentissi, 2016; Reneses, Muñoz,
& López-Ibor, 2009). Investigations of the patient characteristics associated with dropout,
especially to different treatments, have been limited to-date, however such investigations
could have a considerable impact on treatment decisions. Better knowledge about the
probability of dropout with particular treatments would have added value as part of a wider
personalised medicine approach to the treatment of CMHDs, and by potentially helping
reduce the risk of non-compliance and dropout could further help improve outcomes for
patients and services alike (Warden et al., 2009).
Limitations of diagnoses
Diagnostic guidelines for mental health disorders, such as ICD-10 (WHO, 1992) or DSM-5
(American Psychiatric Association, 2013), typically use the presence of particular symptoms
over a specified period of time in order to make a formal diagnosis. A clinician can use the
checklist of symptoms to inform a decision about a specific diagnosis, yet this alone may not
yield a reliable and valid diagnosis (Lieblich et al., 2015). The inter-rater agreement between
diagnoses of CMHD has improved between versions of the DSM, although kappa
agreement values for diagnoses of GAD and depression were 0.67 (Brown et al., 2001).
While this would indicate ‘good’ agreement, the potential level of disagreement indicated
would suggest that basing treatment selection decisions on diagnosis alone risks ignoring
other potentially important characteristics which could inform the selection of appropriate
treatment. The identification of CMHDs in primary care services, where there may not be
time for clinicians to use full diagnostic interviews, is found to be particularly poor (Carey et
al., 2014). For example, Mitchel and colleagues (2009) found that general practitioners
(GPs) interviewing patients were only able to correctly identify depression in 50% of patients
who met criteria according to diagnostic tests.
One issue is that the point at which low mood reaches clinical significance and meets
diagnostic criteria (for example in major depression) is not always clear. Instead,
researchers and clinicians have both argued that these conditions may be better considered
dimensionally, with symptoms occurring on a continuum (Ayuso-Mateos, et al, 2010). A
further issue with the diagnosis of CMHDs is the considerable overlap between defining
symptoms and experiences, such as excessive worry or panic attacks which are both
common across many CMHDs, as well as substantial comorbidity in the presentation of
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these disorders (Kessler et al., 2005). For example, depression and anxiety are frequently
comorbid with up to 50% of patients attending primary care for one condition meeting
diagnostic criteria for the other (Hirschfeld, 2001).
The comorbidity between CMHDs may also have important implications for the treatment of
these conditions and clinicians may need to consider co-occurring symptoms when planning
interventions. Individuals with co-occurring symptoms of depression and anxiety are
frequently found to have worse outcomes following treatment than individuals with
depression alone (Fava et al., 2008). However, more recent findings have suggested that
the pre-treatment levels of anxiety may not affect overall outcome, but may instead influence
the speed of response to treatment (Forand & DeRubeis, 2013). It is possible that treatment
for depression and for anxiety may treat a common underlying problem to both conditions
(Kircanski, LeMoult, Ordaz, & Gotlib, 2017), and trans-diagnostic psychological interventions
have been developed (Díaz-García et al., 2017; Mansell, Harvey, Watkins, & Shafran,
2009).
Critics of the current diagnostic framework commonly cite the lack of evidence from
biological, genetic or neuroimaging data to underpin distinct diagnostic groups, and argue
that mental illnesses should instead be viewed as overlapping across multiple symptom
dimensions (Adam, 2013; Cuthbert & Insel, 2013). The considerable variation in outcomes
between individuals with the same diagnosis to the same interventions indicates that current
diagnostic categories may not easily facilitate the prediction of response to treatment,
suggesting that this approach to categorising signs and symptoms may not be capturing
underlying ‘mechanisms of dysfunction’ (Insel et al., 2010). Instead more multi-dimensional
nosological systems that classify mental illnesses based on behavioural responses, such as
the Research Domain Criteria (RDoC) (Cuthbert & Kozak, 2013) offer a different way of
considering CMHDs in the absence of biomarkers that can clearly demarcate one disorder
from another. By viewing mental disorders on continua, advocates of these systems suggest
a more dynamic and flexible method of assessing mental illness can be created (Cuthbert &
Insel, 2013). An alternative multi-factorial approach, that considers personal and social
factors may also be more reliable than current nosological systems, and could provide a
clinically valuable way of understanding human behaviour and distress, which in turn could
lead to more tailored interventions (Yee, Javitt, & Miller, 2015).
Despite the limits with current diagnostic systems for CMHD, alternative systems such as
the RDoC have not received sufficient backing to replace the existing ICD and DSM
manuals in mental health treatment services. At present, evidence-based practice in the
treatment of mental health disorders is diagnosis specific, and one could argue that there is
a need to categorise disorders to identify the most relevant clinical guidance to aid clinical
decision making. A further benefit is that adapting diagnostic systems reduces the risk of
over-medicalisation, such as referring to any teenager who avoids social situations as
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suffering from social anxiety, and therefore identifying individuals below clinical cut-offs is
equally valuable (Callard, Bracken, David, & Sartorius, 2013).
Whereas diagnosis has been fundamental in the development of evidence-based practice in
the treatment of CMHDs, the variation in outcomes between individuals with the same
diagnosis could suggest that diagnoses may have a more limited role in a personalised
medicine approach (Perna & Nemeroff, 2017). Instead, incorporating a range of patient
characteristics, which may include symptoms and demographic factors may have greater
potential to identify stratified groups of patients that respond differently to treatments.
Current service configuration
In order to develop a personalised medicine approach to the psychological treatment of
CMHDs, understanding the services which would benefit from and utilise such an approach
is essential. National Health Service (NHS) mental health treatment services in the UK have
adopted a stepped care approach to the treatment of CMHDs (NICE, 2011; see Figure 1.1
for details), with 90% of patients seen in primary care (England, Nash, & Hawthorne, 2017).
The first point of contact with health services is usually a GP, who plays a vital role in the
detection and treatment of CMHDs. If there is a suspicion that a CMHD may be present then
a brief symptom screening could be used, and if such a screening suggests the presence of
a CMHD then more detailed questionnaires or clinical interviews may be used (Department
of Health, 2011). In some scenarios the identification of a CMHD may be straight forward
due to clear presenting symptoms, and therefore screening may be sufficient to confirm a
likely CMHD. Part of this overall consideration of whether a patient is suffering with a CMHD
is the assessment of the level and intensity of symptoms. In general practice it is common
place to ask one or two questions from the Patient Health Questionnaire 9-tems (PHQ-9)
(Kroenke, Spitzer, & Williams, 2001) as a brief screen of depression and if the patient
endorses symptoms in these questions then the full PHQ-9 is often given. The GP or other
primary care worker may then refer the patient to a relevant mental health services or offer a
recommended pharmacological intervention (such as an antidepressant) if appropriate. In
England, this referral for psychological treatment is increasingly to an Improving Access to
Psychological Therapies service (IAPT).
The IAPT program was initiated in 2007 by the Department of Health to tackle the increasing
financial and social burden of CMHDs by increasing the availability of evidence-based
psychological interventions. The British government agreed to invest over £300 million over
three years in IAPT services to deliver such treatments (Mental Health Policy Group, 2006;
Richards & Suckling, 2009). This included the delivery of programs to train 3600 therapists
by 2010/2011 (Department of Health, 2008). These therapists would then deliver National
Institute of Health and Care Excellence (NICE, 2011a) recommended psychological
treatments. An additional £400 million was pledged by the UK government to further support
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the implementation and development of IAPT services between 2011 and 2015 (Department
of Health, 2014). IAPT services now receive over 1.25 million referrals nationally per year
(NHS Digital, 2016) yet this is estimated to be meeting the needs of just 15% of the
population. A recent Mental Health Taskforce report (Farmer & Dyer, 2016) suggests that
services should be expanded to meet at least 25% of the need, allowing 1.5 million patients
access to such care each year.
IAPT services are built on the stepped care model of treatment (Figure 1.1). In this model,
IAPT services provide Step 2 and Step 3 interventions, with Step 1 delivered by GPs and
Step 4 typically provided by specialist units, crisis teams or inpatient care. As most CMHD
patients referred to IAPT services will enter treatment in Step 2 or Step 3 of the stepped care
model, the focus of this thesis will be on these two levels of interventions. The stepped care
model provides a tiered care pathway, such that patients initially receiving Step 2 treatments
may be stepped up to Step 3 within services should they require more intensive treatment.
Conversely, they may be stepped down to less intensive treatment as appropriate.
Figure 1.1. The stepped care model (Taken from NICE, 2009)
Step 2 or Low Intensity interventions (referred to as LI interventions from here on) are
typically provided by Psychological Wellbeing Practitioners (PWPs) and are primarily offered
to clients with mild to moderate difficulties. Some CMHDs have very limited evidence of
effectiveness at LI (e.g. PTSD or Social Anxiety Disorder) and so patients with such
conditions are typically started at Step 3. LI interventions are mainly cognitive-behavioural in
approach, and include guided self-help (facilitated by the PWP), computerised or internet
delivered CBT (cCBT), or psychoeducational groups. For depression, other LI interventions
based on Behavioural Activation and Structured Exercise are also available in most IAPT
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services. Despite the limited direct contact provided as part of LI interventions, meta-
analyses have shown them to be effective in the treatment of CMHDs (Bower et al., 2013).
High-Intensity (HI) interventions delivered at Step 3 are designed to treat moderate to severe
depression and anxiety disorders within IAPT services, as well as for the full range of
severity for disorders with no, or limited evidence for the effectiveness of LI interventions.
The types of interventions that may be available include individual or group based CBT,
Counselling for Depression, Behavioural Couples Therapy, IPT, Dynamic Interpersonal
Psychotherapy (DIT), EMDR, Collaborative Care, and, for relapse-prevention, MBCT (CSIP,
2007).
The healthcare utilisation cost associated with LI interventions is lower than costs of HI
interventions, chiefly due to the lower number of sessions delivered as standard with LI
interventions (up to 6 sessions on average, compared to 12 for HI interventions; CSIP,
2007), but also due to the lower salaries for LI therapists compared to HI. LI therapists
typically have a post-graduate diploma in the delivery of LI interventions compared to HI
therapists, who usually have professional qualifications such as doctorates in clinical or
counselling psychology, or a professional qualification in the delivery of HI CBT
interventions. These costs may be important to treatment selection considerations as all
services have limited financial resources available to them. A recent evaluation of the cost of
IAPT treatments calculated the cost per session of LI treatment at £99 compared to £177 for
HI sessions when all staff and service costs were included (Radhakrishnan et al., 2013). The
authors calculated the average cost of complete HI treatment at £1416 per patient compared
to £493 for LI. These costs will have important implications at the service-level particularly as
services attempt to meet the increased access to care targets, seeing more patients each
year than at present. If a patient is likely to benefit from an LI intervention then it would be an
overuse of resource to deliver a much costlier treatment when there is no need for it, so
personalisation of care in IAPT services will necessarily require the consideration of costs
associated with LI compared to HI treatment for any treatment decision aids to be
implementable.
Potential for personalised medicine in IAPT
A personalised medicine approach has the potential to optimise the delivery of care in IAPT
services, bringing about more rapid improvement in psychological wellbeing during
treatment and improved outcomes post-treatment. This could result in more efficient use of
healthcare resource, if patient characteristics can be identified that allow for the accurate
prediction of treatment outcomes.
All IAPT services in England are mandated to collect the same standardised ‘minimum
dataset’ (MDS) of patient characteristics, which are to be collected at referral for all patients.
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In addition, services are required to implement routine outcome measure (ROM), the
collection of sessional patient-reported outcome measures that provide information about
the impact of treatment at each contact with the service (IAPT, 2011). The collection of
standardised patient characteristics for all patients provides an opportunity to explore the
role of potential factors with treatment outcomes, and understand which characteristics at
referral are associated with response to different intensities of IAPT treatment. The use of
ROM has the capacity to provide feedback on treatment progress to both the clinician and
patient, informing decisions about the progress of treatment. If a lack of symptom
improvement has been shown over the first few sessions of treatment then this information
could provide an opportunity to consider a change in treatment approach, such as stepping
up from LI to HI interventions.
When new referrals are received by IAPT services, a telephone triage assessment is usually
performed to gather information about the patient’s clinical needs. In many services this
triage assessment is typically conducted by a PWP and following this assessment the
patient may be discussed with their clinical supervisor before a clinician is allocated and a
treatment plan formulated. It should be noted that this process can vary between IAPT
services, for example senior clinicians may conduct screenings before deciding on
appropriate treatment. There has been an increasing rise in the number of self-referrals to
services, and these will normally be followed up with a telephone call before starting
treatment. A small number of patients may be referred directly to HI treatments by their GP
and will have their initial assessment with a HI therapist rather than a PWP.
There is the potential for a personalised medicine approach to inform treatment choices for
new patients and their assessing/treating clinicians at the point of assessment within IAPT
services. This could be achieved with the use of a decision support tool, developed to
support treatment selection decisions based on patient characteristics recorded during a
patient’s screening or assessment in the IAPT services. Identifying patient’s characteristics
that indicate an increased benefit of HI treatment instead of LI, or situations where IAPT
delivered treatments would be unlikely to benefit a patient could improve healthcare
efficiency and result in more efficient provision of treatment.
Such a decision support tool could reduce the number of patients who are stepped up during
treatment, and instead could identify individuals for whom HI would be a more appropriate
treatment. A national evaluation of IAPT services suggested that on average over 28% of
patients were stepped up (Gyani, Shafran, Layard, & Clark, 2013), and therefore it could be
argued that LI treatments were delivered inappropriately for over a quarter of patients.
However, as LI treatments are effective for treating CMHDs in a large number of patients
(Bower et al., 2013) and are significantly cheaper to deliver (Radhakrishnan et al., 2013),
identifying patient characteristics that indicate an increased benefit of HI over LI, and those
which suggest equivalent response to the different intensities of intervention could optimise
the use of healthcare resource.
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The target of IAPT services is to achieve recovery in 50% of patients receiving treatment,
levels similar to those achieved in controlled trials (NHS Digital, 2016). Evaluations of
service performance nationally have found that many services have achieved or exceeded
this target and the nationwide average is now close to reaching this target as 46% of
patients recover nationwide (NHS Digital, 2016). However, around 50% of patients referred
to IAPT services decline treatment or dropout nationwide, with considerable variation
between services (HSCIC, 2015). There will be a number of reasons why patients decline
treatment, including the lack of perceived need for treatment as well as preference for
alternative treatments other than psychological interventions, and it would therefore be of
clinical value to understand the patient characteristics that are associated with treatment
dropout. These figures suggest that the nationwide IAPT program has been successful in
reducing psychological distress for a large number of patients, although the lack of positive
outcomes for over half of patients and the relatively high number of patients not completing
treatment may indicate that inappropriate interventions were selected in some
circumstances. More consideration of patient characteristics that may be associated with
treatment response to psychological interventions and treatment dropout could improve
outcomes for patients and services alike.
Due to the vast numbers of patients seen in IAPT services, as well as prevalence of these
conditions in the UK, methods of optimising treatment that can increase recovery rates by
even a few percentage points will have a dramatic impact on the efficiency of these services
(NHS Digital, 2016; Spiers et al., 2016). Telephone triage assessments as well as the
increasing number of self-referrals to IAPT provide a large amount of standardised patient
characteristics in advance of treatment selection for the majority of patients, which provides
an ideal opportunity to incorporate a decision support tool into clinical practice. A
personalised medicine approach in IAPT services could therefore be used to identify which
intensity of treatment is most appropriate, as well as potential situations where IAPT
treatment may not be appropriate due to a lack of predicted benefit.
The next chapter explores the types of clinical decisions that are required in treatment
services as well as methods to aid decision making in clinical settings that may inform
personalised medicine approaches. This includes a description of some decision support
tools that are available in physical as well as mental healthcare, and more recent methods to
identify patient characteristics associated with treatment outcomes.
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Chapter 2. Clinical decision making &
decision support tools
Abstract
This chapter introduces clinical decision making, choosing between different options in
patient care, with a focus on decisions that could be supported by personalised treatment
approaches for CMHDs. These clinical decisions can include those made during
assessment about the nature of the presenting problem (for example possible diagnosis),
deciding which treatments will be most appropriate (treatment selection), and decisions
made during care (treatment monitoring). Theoretical models of decision making including
Prospect Theory (Kahneman & Tversky, 1979), Expected Utility Theory (Schoemaker, 1982)
and Bayesian Reasoning (Richardson, 2007) are considered in relation to clinical decisions,
as well as factors that can impact on decision making. The final section of this chapter
discusses the potential for decision support tools (DSTs), such as clinical prediction
algorithms (e.g. the QRISK, Hippesely-Cox, et al., 2007), to support clinical judgement
across healthcare. Researchers have used patient characteristics to develop predictive
models of treatment response that could inform personalised treatment selection (e.g.
DeRubeis et al, 2014), although these have not been translated into available DSTs at
present. Systems to aid treatment monitoring decisions have been developed (e.g. Lambert
et al, 2001), and these use sessional outcome measurement data to suggest whether the
change in symptoms is indicative of a poor treatment prognosis or not. These systems could
be further adapted to provide more patient-centred information on treatment progress, for
example by identifying groups of patients who respond differently to particular treatments.
Currently, there are no routinely available DSTs that can inform both treatment selection and
treatment monitoring decisions in CMHDs, but there is potential for such a system to be
developed using data collected routinely by IAPT services.
Introduction
Clinical decision making in healthcare can be defined as choosing between alternative
options in the care of a patient (Dowding & Thompson, 2003). This can include decisions
about which of the available treatments would be most appropriate, whether to stop or
continue with the current treatment, as well as decisions about adjusting treatment as it
progresses. These judgements are likely to have an effect on a patient’s wellbeing and
therefore a clinician will usually aim to choose the optimal treatment, both to improve the
patient’s wellbeing and efficiently use healthcare resources.
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How decisions are made can depend both on the complexity of the decisions and the
characteristics of the decision maker. For more simple and routine decisions the use of
intuition (understanding without the need for conscious reasoning) and heuristics (simple
automatic rules used in judgement) may be appropriate, however as decisions become more
complex, a more analytical or evidence-based approach may be necessary (Bhugra, 2008).
Clinical judgement is developed through training and practice (Kienle & Kiene, 2011),
therefore the amount of previous experience with specific clinical situations will contribute to
variations in the way that decisions are made. This would suggest that clinicians with less
experience will be at higher risk of making incorrect or sub-optimal decisions, which may be
evident in audits reporting that less experienced clinicians are associated with higher
treatment costs than more experienced colleagues (Mehrotra et al., 2012).
In the UK NHS it is recommended that clinicians adhere to published guidance on evidence-
based care, such as the National Institute for Health and Care Excellence (NICE) guidelines,
when making clinical decisions across healthcare. The development of treatment guidance
is built around the best available evidence to inform and support good clinical decision
making and the appropriate choice of treatment (Ioannidis & Lau, 2000). One of the main
benefits of evidence-based medicine has been the introduction of more objective and
quantifiable estimates of clinical variables into healthcare (Sackett & Rosenberg, 1995), as
well as the reduction of uncertainty around clinical decisions, for example due to a lack of
previous experience with a particular clinical presentation.
Most healthcare guidelines for UK mental health treatment are diagnosis specific (e.g.
depression, social anxiety disorder) and evidence on the effectiveness of treatments is
typically gathered from randomised controlled trials (RCTs). RCTs are viewed as the gold
standard study design to investigate the efficacy of a given treatment and are therefore
critical to the development of the evidence-base about particular treatments. However a
common criticism of RCTs is that the participant inclusion criteria of many trials can be
restrictive, and so those taking part in such studies may not be fully representative of the
population of patients attending routine treatment services (Zimmerman, Mattia, &
Posternak, 2002). As a result, clinicians regularly supplement knowledge gained from clinical
guidance by using their own specialist knowledge and previous experience to support
clinical decision making (Schwartz & Elstein, 2009). This leaves a clear gap for clinicians
hoping to not only deliver evidence-based treatments but to offer their patients the ‘best
available’ treatment for them as individuals.
Adopting a personalised medicine approach offers the opportunity for clinicians to provide
treatments tailored to the individual presentations of their patients and to offer these
treatment options based on sound evidence for the likelihood of achieving a desired clinical
outcome. This approach will require clinicians to take into account multiple patient
characteristics that may impact on clinical outcomes, and might include demographics,
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biomarkers (including genetic information), social and family factors, in addition to diagnostic
information (Konrad et al., 2015; Pirmohamed, 2014).
Shared decision making
Although decision making has often been considered a clinician based function, increasing
value has been placed on the involvement of the patient in clinical decisions (Spatz,
Krumholz, & Moulton, 2016). Shared decision making (SDM) can be defined as a
collaborative process where the patient and clinician participate in care decisions jointly,
discussing the options, potential harms and benefits as well as patients goals (Hoffmann,
Montori, & Del Mar, 2014). SDM is a more inclusive approach to treatment, and can increase
a patient’s understanding of the likely treatment outcomes, which may be an important factor
in patient consent to treatment. This collaborative approach can empower patients, and can
lead to the selection of treatment that increases the likelihood of outcomes prioritised by the
patient (Hargraves & Montori, 2014).
However, all patients are different and despite the potential benefits of SDM, research has
found that some patients may not want to engage with the process, and instead may prefer
to trust clinician judgement (Eliacin, Salyers, Kukla, & Matthias, 2015). Involvement in SDM
can also fluctuate over time and the course of treatment. Patients are usually keen to have
all the information initially, but are often happy to allow the decisions to be made by the
clinician as treatment progresses (Deber, Kraetschmer, & Irvine, 2014). Research into the
association between patient preferences and treatment outcomes has reported significant
variation regarding the potential benefits. Williams and colleagues (2016) suggested that
patients who expressed preferences were less likely to report that treatment had helped
them when their preferences had not been met. Other researchers have found that meeting
treatment preferences reduced the risk of treatment dropout, but did not significantly affect
treatment outcomes (Dunlop et al., 2017). The variation in findings may be linked to the
methods used to report treatment outcome, as Eiring et al (2015) found that often outcomes
from studies exploring the impact of preference on response to pharmacological treatment
used clinician reported rather than patient elicited symptom measures.
Types of clinical decisions
The types of clinical decisions made during the course of assessment and treatment can
broadly be grouped as: i) decisions made about possible diagnoses or clinical problems; ii)
decisions regarding the most appropriate treatment to prescribe/allocate, and iii) decisions
made in response to treatment progress through monitoring. These are briefly described
below:
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Assessment and diagnosis
Information gathered as part of the initial assessment is fundamental to understanding the
presentation and underlying issues causing the patient discomfort or distress. This will likely
include clinical symptoms such as low mood or worry, and in mental health settings will
regularly involve assessment of the social and occupational impact of these symptoms. This
information may be used to diagnose the presenting problem, or to formulate the problem
and consider what is maintaining/preventing it from improving without any treatment. If there
is insufficient evidence available in the initial assessment then further assessment may be
required, such as the use of specialist diagnostic equipment in physical healthcare (e.g. CT
scans) or further psychological assessment (e.g. cognitive assessment) in mental health
settings.
Treatment selection
Following the assessment of the presenting problem(s) and maintaining factors, the next
clinical decision will concern the selection of appropriate treatment. The personalised
medicine approach aims to incorporate patient characteristics such as demographics and
clinical symptoms into this decision, alongside relevant clinical guidance.
For some clinical scenarios the decision will be straight forward due to either the nature of
the condition, or lack of alternative treatment options. However, some clinical decisions,
especially those with more complex presentations or scenarios where a number of
alternative options are available, will be more challenging for the decision maker. Identifying
patient characteristics that are associated with treatment outcomes could therefore help to
determine the most appropriate choice. For example, in the treatment of most breast
cancers there are a number of options to be considered, but research has shown that
patients with higher expression of human epidermal growth factor (HER-2) respond
particularly well to Herceptin (Verma & Mukesh, 2012), which can therefore inform the
treatment selection decision. In IAPT services, a personalised treatment approach would
aim to help make decisions about which type, or intensity of psychological intervention is the
most appropriate given the patient’s characteristics at presentation to the service.
Monitoring treatment
Once the selected treatment has been initiated, there will likely be further decisions made in
response to information collected during routine monitoring of the patient, and their progress
during treatment. This monitoring will provide information about the impact of the treatment
on the patient’s wellbeing, for example whether treatment is having the desired effect in
reducing symptoms, or if there are significant side effects which may indicate that a change
in treatment should be considered. The use of routine outcome measurement (ROM), the
collection of patient information at multiple points during the course of treatment, is usually
vital for treatment monitoring decisions. Should the patient’s ROM data suggest that there
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has been limited response to treatment, then this can inform decisions about whether the
treatment should be continued or if an alternative approach should be considered.
Theoretical models of clinical decision making
Given the fundamental role that decision making plays in healthcare there have been
various attempts to theorise about how these decisions are made, although relatively little
research has been conducted in the context of mental health treatment (Wills & Holmes-
Rovner, 2006). Research has suggested that experienced clinicians will often use initial
referral information to form an early hypothesis about diagnoses and or appropriate
treatment, before or during their first contact with a patient (Elstein & Schwartz, 2002).
Clinicians will most often consider clinical guidance and evidence-based knowledge when
making their decisions, but those with less experience may not be as able to supplement this
with clinical judgement. Instead, clinical judgement is thought to improve over time with
experience and training, until in some situations judgement may become automatic. These
automatic decisions have been referred to as ‘affective heuristics’ (Slovic, Finucane, Peters,
& MacGregor, 2002), and will develop with experience. Although clinician experience has
been associated with increased healthcare costs (Mehrotra et al., 2012), research in
psychotherapy outcomes suggests that patient outcomes for more experienced clinicians
can be worse than outcomes for less experienced clinicians (Goldberg et al., 2016). It may
be that more experienced clinicians are more likely to be allocated more complex and
difficult to treat patients, but researchers have also suggested a phenomenon known as
‘therapist drift’, where clinicians do not keep up with the evidence-based compared to more
recently trained clinicians (Waller & Turner, 2016), which may reduce the effectiveness of
interventions they deliver.
Some prominent theoretical models of clinical decision making are described below:
Bayesian reasoning
As the evidence-based approach to clinical guidance in CMHDs has broadly focused on
identifying the best treatments for specific conditions, usually one of the first decisions for a
clinician will be a formulation of the patient’s problem in the context of their current
circumstances. This may include the identification of a potential diagnoses, which could then
be used to inform further clinical decisions, for example drawing on knowledge of relevant
clinical guidance to support a treatment plan. The decision as to whether or not a specific
diagnosis is present can be represented as a probabilistic choice between an event
(diagnosis) existing or not, as a model of Bayesian reasoning (Richardson, 2007).
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Bayesian reasoning is derived from Bayes theorem (Bayes, 1763), and posits that clinicians
use information from both the patient assessment and existing knowledge about the
likelihood of the event occurring (pre-test probability) to determine whether a diagnosis is
present or not. The pre-test probability is based on the likelihood of that disorder naturally
occurring in that clinical environment (i.e. prevalence of the disorder in the service), and
therefore relies on either the clinician’s previous experience of that diagnosis in the service.
Patient information collected at assessment is then used to increase or decrease the
clinician’s estimated likelihood of the diagnosis (Fahey & Van Der Lei, 2009). As new
information is acquired during assessment, the clinician’s estimate of the likelihood of
diagnosis is updated (Schwartz & Elstein, 2009). The post-test probability of the disorder
being the ‘correct’ decision is therefore a function of the pre-test probability and the strength
of the available evidence.
Bayesian diagnostic reasoning has generally been applied to physical healthcare, where
there is more availability of objective measurement values (e.g. blood pressure), whereas
the measurement of symptoms in mental health relies more on the subjective measurement
of psychological distress from symptom scales (Bhugra, 2008). However, Bayesian
reasoning could be evident in mental health treatment services where a clinician may
combine assessment information with the local prevalence of CMHDs (pre-test probability)
then estimate the probability of a specific diagnosis (e.g. panic disorder) being present. If the
clinical presentation suggests a number of symptoms common to panic disorder, and there
is a sufficient pre-test probability of individuals with panic disorder being referred to the
service then the clinician may decide that panic disorder is the likely diagnosis and an
appropriate treatment plan can be formulated.
Prototypes
An alternative theory about how clinicians make decisions about both the presentation of the
patient and appropriate treatment choices is the use of in-built “prototypes”, representations
of particular illness/disorders constructed by the clinician (Garb, 2005). These prototypes are
internally derived representations of how a typical ‘type’ of patient, for example with social
anxiety disorder, would present to services and the clinician would compare a new patient
against their existing prototypes to identify an appropriate match (the prototype which
appears most similar).
The use of prototypes to identify stratified groups of patients with similar characteristics
complements the aims of personalised medicine approaches to treatment, as certain
prototypes may be associated with differential outcomes to treatments in IAPT services.
However, as these representations are generated by individual clinicians, they will be highly
subjective and heavily biased by previous experience of different patient groups. The use of
prototypes may explain some of the variance in the inter-rater reliability often found in
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diagnostic studies, as different clinicians are likely to have slightly different prototypes for the
same diagnosis (Pies, 2007). There could be some overlap between the patient
characteristics common to prototypes developed by two independent clinicians, but a system
of grouping patients that is to have utility across services will need a more objective method
of stratifying patients that would be common to all clinicians.
Expected Utility Theory
Treatment selection decisions will consider which of the available treatments are most likely
to result in the best outcome for the patient, and therefore require some estimate of the
potential value of the treatment outcomes to the patient. The most commonly cited
normative theory of clinical decision making is Expected Utility Theory (EUT) (Schoemaker,
1982), which is used across healthcare to model decisions (Chapman & Sonnenberg, 2000).
In EUT, each possible outcome from each available treatment is given both a likelihood of
occurrence (probability) and a value of that outcome to the patient (utility). Utilities are
usually given as a range from 1 to 0, with 1 being a perfect state (perfect health) and 0 the
worst state (e.g. death), and therefore the best decision is one that results in the highest
utility.
These utilities are normally taken from patient and clinician recorded measures of quality of
life, and in the context of CMHD treatment could be linked to the level of decreased distress
and functional impairment caused by the clinical symptoms. The most appropriate treatment
is therefore the one with the highest probability of the best outcome for that patient. The
probability of outcomes is derived from either the clinician’s prior knowledge (experience) or
from published research if it exists for the specific situation. Therefore, the clinician’s
decision is based on their subjectively judged probability of whether the event will happen or
not. EUT also attempts to explain how clinicians consider trade-offs in clinical decisions by
weighing up the benefits and costs of certain decisions on eventual outcome (Wills &
Holmers-Rovner, 2006).
Prospect Theory
An alternative theory of decision making in the presence of clinical uncertainty is Prospect
Theory (Kahneman & Tversky, 1979; Tversky & Kahneman, 1992) and differs from EUT as it
is concerned with describing observed decisions assuming the decision maker has inbuilt
descriptive rules, rather than assuming the decision maker is rational and able to estimate
perfect accuracy (normative). Prospect theory suggests two phases in decision making; an
initial editing phase before a subsequent evaluation stage. In the editing phase, all potential
outcomes from the decision are ranked based on certain heuristics of the decision maker,
specifically around an outcome they consider a reference point and compared to which all
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other outcomes are either losses or gains. Using this method, the probability of events
occurring can be compared. In the evaluation phase, values are allocated to each outcome
(comparable to utilities in EUT) and the decision is made in light of the outcome with the
highest value. The major difference between prospect theory and EUT is that the decision
maker in EUT does not compute a reference point and therefore focuses only on improving
gains, rather than reducing losses in specific situations. In IAPT services this may be a
comparison of the probability of treatment success (utility) for either low intensity or high
intensity treatment, or whether there is an increased value of allocating to more resource
intensive HI treatment over LI interventions.
The similarities between Bayesian reasoning, Prospect Theory and EUT models of decision
making are that they all suggest the decision making will use the expected probability of an
event (diagnosis or outcome) to inform the decision. This requires either prior experience of
the situation or some reference with which to predict the likelihood of the event. As this
information is not always available, decision making in these circumstances is vulnerable to
bias resulting in either incorrect or over risk adverse decisions that may not be favourable to
the patient.
Challenges in making effective decisions
The models of decision making discussed above (for example EUT) propose that the
clinician making the decision requires a reliable estimate of both the presence of a specific
disorder and the expected value or benefits of appropriate treatment. However, research has
frequently shown that clinician’s estimates are prone to biases and errors, in both test and
clinical environments. Research from the US has indicated that of closed malpractice cases
across all healthcare settings, 64% involved diagnostic error suggesting that incorrect
treatments may have been selected due to incorrect estimates from the clinician (Gandhi et
al., 2006). It is possible that there is an increased risk of this ‘diagnostic error’ in mental
health services where there is often a lack of objective ‘gold standard’ measurement tools
and systems, compared to physical health settings where many conditions have objective
tests (e.g. blood pressure or liver function tests).
Although heuristics can be useful strategies for clinical decision making (Slovic et al., 2002),
they also increase the likelihood of systematic biases in judgement (Fahey & Van Der Lei,
2009). As discussed above in relation to Bayesian reasoning, the estimates of pre-test
probability (the likelihood of a disorder naturally occurring) and the expected utilities of
treatment will be both informed and biased by the level of experience of the clinician as well
as the environment in which they work. Clinicians from secondary or tertiary care services
will typically see more complex or severe presentations, which are rare in less specialist
services and therefore may overestimate the likelihood of more severe illnesses in other
settings (e.g. primary care). This may result in a very different set of heuristics for these
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clinicians, for example how they judge the risk of suicide in complex patients. One study by
McGinn and colleagues (2002) asked a group of junior doctors to estimate the likelihood of a
pulmonary embolism after reading a clinical vignette of a patient’s symptoms, and found that
estimates ranged from 5% to 80%. These estimates may be heavily biased by either
experience, perception of risk or clinical specialism.
One challenge with clinical decision making is that individuals can struggle to estimate the
probabilities of events from basic available information. Yamagishi (1997) used a simple
experiment where undergraduate participants were asked to decide which particular causes
of death (e.g. cancer) were the most likely, based on a provided incidence of mortality.
Information on the number of deaths were provided in relation to increasing denominators
(e.g. 24.14 out of 100, 1,286 out of 10,000) and results showed that participants would
frequently rate 1,286 out of 10,000 as higher risk of mortality than 24.14 out of 100 despite
24.14% being higher than 12.86%. It would appear that the absolute number of events,
rather than the percentage of events influenced the perceived risk in the sample.
Although this experiment was conducted on non-clinician participants, the findings may be
very relevant to shared decision making, as patients may be equally vulnerable to perceived
risk and therefore considering the way in which information is presented could reduce
potential biases (Jefferies-Sewell et al., 2015). Further research suggests that individuals
often underestimate probabilities of difficult to recall or vague events whereas there is an
overestimate for more vivid events (Elstein, 1999). Incidents that are widely reported in the
media are found to be considered more probable than their prevalence suggests (Elstein &
Schwartz, 2002).
A further issue with the estimation of probabilities is the phenomena of ‘compression error’
where small probabilities are over-weighted and large probabilities under-weighted
(Fischhoff, Bostrom, & Quadrel, 1993). The notion is that humans are not comfortable being
absolutely certain of an event occurring and therefore the difference between 99% and
100% will be assumed as further in distance than the difference between 40% and 41% for
example. This distortion is further exacerbated when the exact probability is not known, and
individuals will tend to be more conservative in estimation (Schwartz & Elstein, 2009). This
has important implications for treatment selection where a slightly riskier intervention may
not be selected as the clinician may not be “100% sure“ of its success, despite all
information indicating that it is the most appropriate treatment option. This may be true of a
psychological intervention that has a higher than average incidence of clinical deterioration
but is strongly associated with positive outcomes in a specific sub-group of patients.
Research has suggested that psychologists can struggle to accurately predict patient
outcomes, and are likely to be over-optimistic of their own patient’s progress (Walfish,
McAlister, O’Donnell, & Lambert, 2012). For example, Hannon et al, (2005) asked 48
therapists to use their clinical judgement and predict which patients in their care would
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deteriorate during treatment. The clinicians predicted only 3 out of a total of 550 patients
would deteriorate, whereas 40 (7.3%) patients reported a worsening of symptoms post-
treatment. Although deterioration is less likely than positive outcomes from treatment for
most patients, these results suggest that clinicians may struggle to predict treatment
response in CMHD psychological treatment from initial assessment, which may make their
estimates of expected outcomes and utilities prone to error.
Due to the potential challenges with clinical decision making, there has been increasing
research to develop methods of supporting decisions in healthcare. These aids to clinical
judgement aim to inform decisions on appropriate care and have the potential to incorporate
patient characteristics in decision making, creating a more patient-centred approach to
healthcare. The next section of this chapter explores the role of decision support tools in
healthcare, and the potential for these aids to inform clinical decisions in IAPT services.
Decision support tools (DSTs)
One potential method for aiding decision making in clinical settings is the use of ‘decision
support tools’ (DSTs) in routine care settings. Clinical DSTs can refer to any system that
provides patient-specific advice, for example whether clinical information suggests more
detailed screening is required (e.g. for cancer) or which treatment is recommend for a given
condition (Geissbuhler & Miller, 2000). DSTs are designed to support clinical decision
making about individual patients in real-time (Berner & Lande, 2007), and many DSTs are
now computerised for ease of use and their ability to provide information efficiently. The aim
of many DSTs has been to improve patient safety, for example by reducing medical errors,
with many DSTs originally designed to simulate human decision making processes (Jia et
al., 2016).
One of the biggest areas of improvement gained by the use of DSTs is in medication
administration, where a large number of medical errors (such as wrong dosage or drug)
have historically occurred (Kohn, Corrigan, & Donaldson, 2000). DSTs in these
environments may be set up to replicate current evidence-based treatment guidelines, and
therefore prompt clinicians with recommended treatment options including dosage.
Additionally, such tools may have the facility to alert clinicians to dangerous drug
interactions, thereby minimising errors and potential side effects. These tools can add
structure to medical knowledge and provide clinicians with standardised patient information
(Saverno et al., 2011). The utility of DSTs is greatly enhanced by incorporating them within
local clinical information and electronic patient management systems (EPMS), as this greatly
reduces the amount of information having to be shared across isolated systems
(Geissbuhler & Miller, 2000).
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DSTs are also used to aid decisions on screening options (e.g. cancer screening) and the
management of conditions such as diabetes and cardiovascular disease (Sheehan &
Sherman, 2012). DSTs can vary in format, for example some tools are presented as a
sequential treatment/procedure flow chart (e.g. NCCC, 2009) whereas others are derived
from computerised prediction algorithms that use patient information and provide real time
clinical recommendations, such as the Fracture Risk Assessment Tool (FRAX) tool for
assessing risk of osteoporosis and fracture (Cadarette et al., 2000; Hillier et al., 2011). Some
examples of these are presented below:
Flow charts / sequenced decision support tools.
Sequenced DSTs are typically presented as detailed flow diagrams whereby the clinician or
patient is asked a question (e.g. “is systolic blood pressure over 150mmHg?”) and the
answer determines whether an intervention is recommended (e.g. ‘prescribe statins’), or
whether additional questions are needed before a recommendation can be provided. This
DST could be presented as a paper diagram which could be easily followed by the user, or it
could be hosted via a computer-based system that required the user to answer a series of
sequential questions. Each question could be considered to act like a ‘decision node’, with
simple sequenced DSTs having just two or three nodes, and more complex having over 10
nodes with questions to consider.
One group of sequenced DSTs recommended for use in UK emergency care are the NICE
stroke and transient ischaemic attack (TIA) algorithms (NICE, 2008). These algorithms
provide a series of sequenced questions and recommendations that the clinician should
consider when managing a suspected stroke or TIA. For example, if a TIA is suspected and
neurological symptoms have resolved then the first decision node asks “is history compatible
with TIA?”. If yes, then 300mg aspirin is recommend alongside additional statins or lifestyle
management, with the next decision node asking the clinician to assess risk of stroke using
a validated measure. If the risk of stroke is high then one path is followed, with a series of
recommendations for treatment and assessment, whereas if the risk is low then an
alternative care path is followed on the flow diagram.
Clinical prediction rule algorithms.
Prediction rule algorithms differ from sequenced DSTs as they are more likely to provide a
recommendation or prognosis drawing on a submission of information at one time point, for
example information collected at an initial assessment. These DSTs normally have an
underlying algorithm that uses a number of patient characteristics (e.g. demographic, family
history, clinical symptoms) to generate a treatment recommendation or the risk/likelihood of
illness. These algorithms differ from sequenced DSTs as they usually combine a number of
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patient characteristics in one calculation to estimate risk or provide a treatment
recommendation, rather than needing a number of stages to be completed by the user.
The QRISK (Hippisley-Cox et al., 2007) is a widely used risk prediction algorithm in primary
care to provide a 10-year estimate of the risk of cardiovascular events for patients. DSTs
such as these can be used to provide a personalised approach to prevention for
cardiovascular events, and clinicians can tailor recommendations, such as lifestyle changes,
following the information provided by the QRISK. The use of these DSTs has evolved to use
genetic information to personalise healthcare, for example pharmacogenetic profiling to
inform medication management in older people, and a recently developed DST has been
shown to reduce hospitalisation and emergency department visits in this population (Brixner
et al., 2016)
Many of these sophisticated prediction algorithms have been developed using large routine
patient datasets, rather than those from controlled trials, as these cohorts increase the
available statistical power for predictive analyses (Abbasi, 2017). For example, the QRISK
algorithm was developed using a dataset of over 1.25 million patients registered at GP
practices across the UK (Hippsley-Cox et al., 2007). The growing use of EPMS and outcome
measurement in healthcare can provide data on a huge number of patients over a large
range of patient characteristics, which has the potential for development of a range of clinical
DSTs.
Impact of decision support tools
Reviews evaluating the use of DSTs across medicine have suggested they can deliver
improvements in clinician performance as measured by increased incidence of tests or
examinations performed (i.e. increased outcome measurement and monitoring), although
improvements in patient outcomes have been more varied (Bright et al., 2012; Garg et al.,
2005; Hunt, Haynes, Hanna, & Smith, 1998). A systematic review conducted by Kawamoto
and colleagues (2005) evaluated which components of DSTs were associated with improved
clinical practice. From the 77 included studies of DSTs across healthcare, 68% suggested a
significant improvement in clinical practice. Four features of systems were linked to clinical
benefit: i) the automatic provision of decision support as part of clinician workflow; ii)
provision of support at the time and location of decision making; iii) provision of a
recommendation rather than used for assessment only, and iv) computer-based generation
of decision support. Of the 32 DSTs with all four of these aspects, 94% were shown to
significantly improve clinical practice.
One potential barrier to the uptake of DSTs can arise when clinicians do not agree with the
guidance from the new system, which can result in clinicians ignoring recommendations or
refusing to use the DST (Keeffe et al., 2005). This would suggest that providing training to
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clinicians, as well as seeking their views during the development of the DST that they will be
expected to use may be of value and could increase clinician uptake.
DSTs could also provide a more prominent role for patients within their care, by informing
them about potential risks and benefits of available treatment options (Moynihan, 2013). This
is especially true of DSTs that have user-friendly formats that can engage the patient into
the decision-making process. Critics however, suggest that patients tend to make more
cautious decisions, which in turn may increase costs to healthcare (McCarthy, 2013; Walsh
et al., 2014).
Decision support tools in mental health settings
Whereas physical health has seen a range of developments with DSTs, the development
and evaluation of DSTs has been slower in mental healthcare (Sheehan & Sherman, 2012).
However, a small number of potential methods have been developed for treatment selection
decisions for both pharmacological and psychological interventions, although few have been
made available to services or evaluated in clinical practice. These decision support methods
can broadly be considered as either treatment selection tools which aim to aid clinicians in
deciding which of a number of available interventions will result in ‘the best’ outcome, or
treatment monitoring tools which are designed to provide an indication of whether to
continue or change the current course of treatment, e.g. if there is limited or no clinical
response. The main work in the mental health field has been for the treatment of depression
(e.g. Chekroud et al., 2016; DeRubeis et al., 2014)
Treatment selection decision support tools.
The development of predictive models and methods of using patient characteristics to inform
treatment selection decisions has grown in the past years, with a number of recent
publications.
Researchers have used datasets collected during RCTs which have compared the
effectiveness of psychological and pharmacological interventions, to develop methods of
identifying patients who are more likely to benefit from one type of intervention over the
other. Wallace, Frank and Kraemer (2013) have created a single combined moderator value
(referred to as M*) (using methods described by Kraemer, 2013) from weightings of key
patient characteristics and used this composite moderator value to predict which treatment
for depression will be most effective. A significant difference was found between treatment
outcomes for patients scoring at the higher and the lower values of the combined moderator,
suggesting treatment outcome could be predicted in individuals at the extremes of this M*
value. DeRubeis and colleagues (2014) developed the ‘Personalized Advantage Index’ (PAI)
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to predict the final symptom score for a given patient under both psychological and
pharmacological treatments for depression. This algorithm used a range of characteristics
including IQ, employment, life stressors, previous treatment and comorbid personality
disorder, and was able to show a significant advantage of one treatment type over the other
for 60% of patients in the development sample.
A couple of recent studies (Chekroud et al., 2016; Iniesta et al., 2016) have developed
statistical models to predict outcomes from different antidepressant medications. Chekroud
et al (2016) used data from nearly 2000 participants from the Sequenced Treatment
Alternatives to Relieve Depression (STAR*D) trial (Trivedi et al., 2006) and used a machine
learning driven clustering method (hierarchical clustering) to identify a method of predicting
response to citalopram, before validating model performance in data from the COMED trial
(Rush et al., 2011). From 164 available patient characteristics, the model was reduced to the
25 best characteristics and the final model included individual symptoms across two
depression measures as well as demographic variables (e.g. ethnicity, years of education),
and the model showed good performance across three of the four drug treatments. Iniesta et
al (2016) used data from the Genome-based Therapeutic Drugs for Depression (GENDEP)
(Uher, Huezo-Diaz, et al., 2009), to develop a machine learning driven regression model to
predict response to escitalopram or nortriptyline from n=793 participants. The dataset
included a wide range of patient characteristics, including demographic characteristics such
as BMI, marital status, number of children, clinical symptom data across four depression
measures, medication history and details about stressful life events. The best model
structure varied between treatment type and models could explain 5-10% of the variance in
a clinical significant reduction in symptoms, and around 15% of the variance in remission,
which was considerably above the authors’ benchmark 6.3% of variance explained in order
to be clinically important (Uher, Tansey, Malki, & Perlis, 2012).
Although these studies have identified patient characteristics associated with treatment
outcomes and used statistical modelling to develop methods of predicting differential
response, each of the samples were derived from relatively small clinical trial populations.
These methods have not yet been translated into formal DSTs that have been evaluated for
effectiveness in routine clinical practice. Clinical trial samples can be highly selected for the
specific purposes of the trial and therefore are at risk of not reflecting the typical range of
patients attending mental health services (Zimmerman, Walsh, Chelminski, & Dalrymple,
2017), and therefore further evaluation of these models in routine care samples would be
recommended.
The Wallace et al (2013) and DeRubeis et al (2014) methods used the available patient
characteristics in datasets to group patients into those would were expected to respond
better to medication and those for whom psychological therapies were likely to be most
beneficial. However, little research has investigated treatment selection between different
types of psychological therapies (Fonagy, 2010). As increasing evidence suggests patients
47
tend to prefer psychological treatment over pharmacotherapy for psychiatric disorders
(McHugh, et al., 2013), it would appear that methods to improve treatment selection in
psychological therapies would be of benefit, especially for use in IAPT services. Currently
two DSTs have been developed and trialled in mental health settings.
One study, from the child mental health literature, used an algorithm to determine whether
trauma-focused cognitive-behavioural therapy (TF-CBT) is likely to lead to a positive
outcome, based on the current research evidence (Lang, Ford, & Fitzgerald, 2010). Although
informative on deciding whether to use the treatment or not, it is limited by an inability to
suggest an alternative intervention if TF-CBT is not recommended. An algorithm that could
recommend one intervention over another could be of more value to clinical staff and
patients.
A second decision support tool has attempted to allocate patients to one of two
psychological interventions, either CBT or psychodynamic therapy (Watzke et al., 2010).
The decision on treatment selection was made by integrating assessments and clinical
interviews, with 86% of decisions made at least partly on the patient’s goals of treatment
(goals around modifying behaviour and coping with situations recommended to CBT, and
goals around understanding unconscious emotions recommended to psychodynamic
treatments), and 74% incorporating diagnosis into the decision. However, the evaluation of
this DST in clinical practice showed no significant differences in patient outcomes when
compared to random treatment allocation.
One potential reason for the lack of a positive effect of using the Watzke et al (2010) DST
may be that the decision was made predominantly on just two factors: the patient’s goal for
treatment and the diagnosis at assessment, with limited use of other information. The multi-
dimensional nature of mental illnesses suggests that there are many patient specific
characteristics that could be important to account for in treatment selection decisions, and
methods such as those employed by DeRubeis et al (2014) or Iniesta et al (2016) suggest a
number of patient characteristics can inform differential response.
A very recent study has used a sample from IAPT services in the North of England to
explore regression models for predicting a reduction in symptoms, rather than IAPT recovery
(Delgadillo, Moreea, & Lutz, 2016). The IAPT MDS for this analysis was supplemented with
additional patient characteristics not routinely available in the IAPT dataset, such as patient
expectancy of treatment outcome, family history of illness and disability. The final regression
model using available characteristics was able to explain approximately 13-15% of variance
in patient outcomes, and was developed using a dataset of 1347 patients. A risk weighting
called the “Leeds Risk Index” (LRI) was developed from the regression coefficients and has
been used to create a ‘traffic light’ system indicating the risk of poor treatment outcomes,
classifying patients as ‘low risk’ (green), ‘moderate risk’ (amber) and ‘high risk’ (red) (J.
Delgadillo, personal communication, 27th April, 2016). These groups were associated with
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differing likelihoods of achieving significant change in depression and anxiety symptoms,
with the low risk group more likely to achieve positive outcomes and the high-risk group the
least likely. Outcomes were better for the high-risk group following HI treatments compared
to LI for both depression and anxiety symptom reduction, and the LRI could be used to
develop a DST to identify high risk patients and recommend high intensity treatment for
these patients to increase the likelihood of positive outcomes.
To date the majority of these treatment selection methods have not been trialled in mental
health settings despite the potential benefit to patient care. One DST which has been trialled
in treatment services (by Watzke et al, 2010) found no benefit of using the treatment
selection tool over existing treatment selection methods (usual treatment allocation), but this
DST was limited regarding patient characteristics used to inform the treatment selection
decision (goal of treatment or diagnosis were the predominant characteristics used). One
possible reason for the lack of uptake of these current methods of personalising mental
health treatment in routine services is that the majority were developed in controlled trial
populations and therefore may not reflect populations receiving routine treatment for
CMHDs. It might be argued that using data from local services to develop a DST may
increase the likelihood of uptake by treatment services.
Most of the methods considered above have used regression-based analyses to identify
patient characteristics predicting treatment outcome. As a result, these models provide
evidence for the association of included patient characteristics with the outcome of interest
but do not inform on the role of these characteristics with other potentially important
outcomes. For example, methods developed by DeRubeis et al (2014) and Iniesta et al
(2016) were focused on identifying patient characteristics associated with a reduction in
psychological symptoms, but the association between these characteristics and other
clinically important outcomes such as treatment dropout cannot be explored in the same
model. For treatment services such as IAPT, a number of treatment outcomes can be
important, especially if the evaluation of treatment outcome in these services is determined
from more than one measure of psychological wellbeing (NHS Digital, 2016). Therefore,
alternative approaches to modelling data that can enable multiple outcomes to be
considered may have additional benefit for IAPT services.
Treatment monitoring decision support tools
DSTs that focus on treatment monitoring decisions usually require the use of ROM to
feedback information about the patient’s progress in treatment, which can then be used to
inform decision making. Typically the algorithms and DSTs appear to differ between those
for pharmacological treatments and psychological interventions. DSTs developed for drug
treatments are linked to the sequencing of treatments based on response (or not) to
previous drugs (Rush, Crismon, et al., 2003; Stein et al., 2012), and can be viewed as flow
charts of decision rules. Monitoring systems for psychological interventions instead focus on
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the change in symptoms, and indicate to clinicians when progress during treatment is not
following the expected course for the patient (Lambert, 2013).
One major study on the sequencing of pharmacological treatments in CMHDs is the
Psychopharmacology Algorithm Project Harvard South Shore Program, which has produced
algorithms for anxiety and depressive disorders (Stein, et al. 2012). The algorithm’s
approach is to recommend pharmacological interventions in a set order (as a flow chart),
and suggests a change in treatment following non-response to the previous stage. The
algorithm behind the recommendation sequence is drawn from clinical trial evidence of the
individual drugs, however past research into the use of sequential methods for treatment
delivery has found little evidence for their benefit over standard clinical decision making
(Hatcher, 2008). Although some patient characteristics are taken into account within certain
algorithms (such as sleep issues in PTSD; (Bajor, Ticlea, & Osser, 2011)), the algorithms
function mainly as an ordered list of interventions that the prescriber is recommended to
follow.
A second algorithm project, also focused on pharmacological interventions, is the Texas
Medication Algorithm Project (TMAP), which has produced decision aids for depression, as
well as schizophrenia and bipolar disorder (Crismon et al., 1999; Rush, Crismon, et al.,
2003). In a similar fashion to the Harvard South Shore Program described above (Stein, et
al. 2012), these algorithms also use sequenced approach to decision making. One key
difference between these algorithms, is that the TMAP recommends routine outcome
monitoring by the prescribing clinician, with the Quick Inventory of Depressive
Symptomatology scale (QIDS-16) (Rush, Trivedi, et al., 2003) completed at regular clinician-
patient meetings, whereas the Harvard algorithm does not. The score on this outcome
measure then informs the clinician on the level of response or non-response to the
intervention, and therefore the need to move onto the next treatment sequence, with the
outcome measurement system being vital to the decision to maintain or change treatment.
Algorithms such as those described above are based on a sequence of different
interventions, with failure or limited response for one treatment leading to recommendations
for the next designated treatment, which is common to recommended treatment algorithms
for physical health conditions such as breast cancer (NCCC, 2009). However, these
algorithms are designed so that every patient will go through each stage until they respond
to an intervention. To be allocated to the eventual ‘successful’ treatment, patients must first
complete an adequate dose of treatment at all previous, non-successful stages, and these
ineffective interventions will be costly to both services and patients regarding time and
finance, as well as potential side effects.
DSTs for treatment continuation during psychological interventions have not considered the
provision of different types of therapeutic model but instead monitoring whether the patient is
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responding or not, flagging non-response and providing information to the clinician that more
input, or change of approach is needed (Lambert, 2013).
The OQ-45 psychotherapy outcome management system developed by Lambert and
colleagues (Lambert, 2001; Lambert et al., 2001) has a large amount of research evidence
supporting its clinical utility in improving patient outcomes (Hannan et al., 2005; Shimokawa,
Lambert, & Smart, 2010; Slade, et al., 2008). The Outcome Questionnaire-45 (OQ-45)
(Lambert, 1983) is a measurement tool designed to capture the range of clinical symptoms
for CMHDs, as well as symptoms of additional psychiatric disorders, and the OQ-45 system
relies on sessional collection of this outcome measure.
The measure and system were initially developed in university counselling centres, and for
each new patient an expected response curve is generated, which is the predicted trajectory
of change in OQ-45 score over time if a positive outcome is to be achieved. Research into
the trajectory of change in psychotherapy typically finds that change is largest (a greater
effect) in the first few sessions of therapy and this levels out as the number of sessions
increases (Kopta et al., 1994). The OQ-45 score is completed by the patient at each session
and entered into the system, after which advice is returned to the clinician about the patient’s
current trajectory and whether they are “On track” (expected good outcome) or “Not on
track” (predicted poor prognosis). This prompt signals that the clinician may need to consider
alternative treatment options in order to get the patient back “on track”. Alternative feedback
systems have been developed, which provide similar recommendations to those of the OQ-
45 systems and a meta-analysis indicated a small effect in favour of using these DST to
improve patient outcomes (Knaup, Koesters, Schoefer, Becker, & Puschner, 2009).
Although there are patient benefits associated with the use of the OQ-45 system, with
research indicating that flagging patients as ‘not on track’ can improve outcomes (e.g.
Shimokawa et al., 2010), there are some potential limitations to its use in improving
decisions in routine treatment services, such as IAPT. Firstly, the OQ-45 measure is
relatively long for a ROM, and although the author suggests these 45 items can be
completed in five minutes (Lambert, 1983), this may be optimistic as there are suggestions
that 10 items can take up to 15 minutes to complete (Marks, 1998), and this lack of brevity
may make the assessment tool too time consuming for routine use in highly time pressured
services (Clifford, 1998). IAPT services currently use the Patient Health Questionnaire 9
item version (PHQ-9) (Kroenke et al., 2001) and the Generalised Anxiety Disorder scale 7
item version (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 2006) as sessional outcomes
measures. The PHQ-9 and GAD-7 are both estimated to take 2 minutes each to complete
(Duffy et al., 2008; Sousa et al., 2015), and therefore it is likely that asking patients to
complete an additional 29 items will increase the time burden significantly, and may result in
reduced data completion.
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An extension of this method of identifying expected treatment response and providing
feedback to patients was developed by Lutz and colleagues (Lutz et al., 2006; Lutz, Stulz,
Martinovich, Leon, & Saunders, 2009). These researchers used a ‘nearest neighbours’
modelling approach to identify patients with similar presentations of symptoms to generate
expected response curves to psychological treatment. These curves can be used to provide
information about whether a current patient receiving treatment is ‘on track’ or not based on
their change in psychological symptoms, like that provided by the OQ-45 system (Lambert,
2001). This nearest neighbour approach is based on an analysis of patients who had
previously received treatment and their response to that treatment. The system can identify
for new patients entering treatment, which historic patient they most resemble based on
presentation to the service (i.e. identify their ‘nearest neighbour’). The expected response for
the current patient is therefore expected to be similar to that of the nearest neighbour, and
the system can flag up situations when the current patient’s response to suggests that there
are not on track compared to their nearest neighbour’s response. The nearest neighbour
matching is based on subscale scores on measures of psychological symptoms (e.g.
depression, anxiety) collected at assessment. This approach therefore extends to the
Lambert (2001) OQ-45 model by considering subscale of symptoms rather than just total
psychological symptoms scores. However, it is possible that this approach could be further
personalised by including addition patient-specific characteristics, including demographics,
which may further inform the expected response to psychological treatments.
Very recently Lutz and colleagues (Lutz, Zimmermann, Müller, Deisenhofer, & Rubel, 2017)
have published a protocol paper for a randomised controlled trial of a personalised
prediction and feedback tool for psychological treatment. The trial will include a group of
patients randomised to receive a treatment selection recommendation based on the
identification of their nearest neighbours in an historic database and the treatment that
resulted in the best outcomes for these similar patients. Feedback on treatment progress
(‘on track’ or not) will also be provided to clinicians in this intervention group. This group will
be compared against a control group were nearest neighbours are not considered and
therefore a treatment recommendation is not provided to the clinician. This will likely be the
first published study of a method of using both treatment selection and treatment monitoring
decision support in the treatment of CMHDs.
DSTs that can aid treatment monitoring decisions in CMHDs have been developed and are
able to identify patients who are at risk of poor outcomes, notifying clinicians that a change
in treatment approach may be required. The trajectory of change in symptoms that the
patient is expected to follow is generated from the OQ-45 total score but does not use
additional patient characteristics to personalise this expected response. There have also
been recent developments in predicting which treatment is likely to be most beneficial for
individual patients, with some models suggesting that differential response can be identified
in over 60% of patients (e.g. DeRubeis et al, 2014; Huibers et al, 2015), and recent models
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have also been generated using IAPT samples (Delgadillo et al, 2016) to identify groups of
patients who are at higher risk of poor outcomes. However, these models have not been
translated into DSTs that are routinely available in clinical practice, or evaluated in treatment
services. In addition, no DST has been developed that is able to support both treatment
selection and treatment monitoring decisions in CMHDs. A DST that is able to use patient
characteristics to recommend which treatment is likely to result in the best outcome for a
patient, as well as the expected trajectory of change during this treatment, could support a
personalised medicine approach for treatment services such as IAPT.
Using data to inform clinical decision making
As described in Chapter 1, one contributing factor to the increase in personalised medicine
approaches in healthcare is the availability of large patient datasets which offer the
opportunity to explore the association of a number of patient characteristics across cohorts.
Using large datasets in this way provides more power for statistical modelling approaches,
which have contributed to a large amount of the success of personalised medicine in health
care (Abbassi, 2017).
However, mental health generally lacks large standardised patient datasets that allow the
exploration of patient characteristics and outcomes (Ozomaro et al., 2013). Most of the
current large mental health datasets available have been used to develop predictive models
of diagnoses, typically of depression, from either routine patient data (King, Walker, et al.,
2008; Wang et al., 2013) or genetic information (Hyde et al., 2016). However, there has
been limited use of large mental health datasets in the prediction of treatment response, with
a few exceptions using datasets approaching 1500 (Delgadillo et al., 2016) and 2000
patients (Chekroud et al., 2016).
The standardised approach to ROM used by IAPT services and the use of a minimum
dataset has resulted in a large national dataset of patients attending IAPT services. Each
IAPT service collects the same standardised patient characteristics for every individual
referred to, and receiving treatment from the service. As over 1.25 million referrals are
received nationally by IAPT services each year (HCSIS, 2015; NHS Digital, 2016), and
patient data from all IAPT services is centrally aggregated for NHS Digital’s annual reporting
of service outcomes, there is a huge potential dataset if this information were made available
to researchers. The average number of referrals to each IAPT service was just over 5000
patients by each clinical commissioning group (CCG) between 2012 and 2013 (HSCIC,
2014), therefore a dataset derived from individual services rather than the whole of the
national programme would itself provide a large dataset, and would be considerably larger
than most RCTs conducted in CMHDs.
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Developing a DST for IAPT services
Research on the use of DSTs in healthcare has shown improvements in clinician
performance by incorporating these systems into care, as well as potential benefits in patient
outcomes (Bright et al., 2012). There is currently limited research on the use of DSTs to aid
treatment selection decisions in CMHDs, despite several potential methods developed in
datasets (e.g. Wallace et al., 2013). Given the high prevalence and health burden of CMHDs
(Spiers et al., 2016), DSTs could provide significant improvements for both patients and
services. Considering the high volume of patients referred to IAPT as well as the potential
availability of large patient datasets from these service, there is great potential for the
development of a DST to support personalised treatment in IAPT. The growing social and
economic costs of treating CMHDs in the UK (McCrone et al., 2008) indicate an increasing
need for healthcare resource, and methods to optimise care could help reduce this burden.
The development of a predictive DST that is able to support both treatment selection and
treatment monitoring decisions in IAPT could be used to allocate patients, based on relevant
characteristics, to treatments more effectively and efficiently (Goldburger et al., 2013).
A number of the predictive modelling approaches that have been developed to inform
treatment selection in CMHD have focused on specific diagnoses, such as depression, in
the included samples (e.g. DeRubeis et al., 2014; Iniesta et al., 2016; Chekroud et al.,
2016). However, a DST developed for use in routine treatment services would more
beneficial if it were developed for patients across a number of potential diagnoses rather
than just one, not only due to the potential limitations of diagnoses (Cuthbert & Insel, 2013)
but also due to the high level of comorbidity between CMHDs (Mueller et al, 1999). A further
issue with the use of a diagnosis-driven DST in IAPT is the relatively low availability of
diagnostic information for patients attending some of these services. National reports
indicate that a ‘primary problem’ (either formal diagnosis, or disorder most representing the
presenting symptoms) is only available for half of IAPT patients nationwide, though there is
significant variation between services with high rates of diagnosis recorded in some and very
low rates in others (HSCIC, 2015). The low availability of diagnosis is likely due to the
increasing number of self-referrals to IAPT services, who would be unlikely to provide
diagnostic information at assessment as this would usually be provided by a healthcare
professional. Instead a DST for use in IAPT services would benefit from the use of routine
patient characteristics that can be collected through patient self-reporting. This would likely
increase data completion, but a DST using patient-report information only would reduce the
need for clinician input, potentially freeing up more resource within the services.
IAPT services have adopted ROM, and so there is the potential is to incorporate this
sessional symptom measure information in to a DST to inform more personalised treatment
monitoring decisions. Treatment monitoring systems in psychological interventions such as
the OQ-45 (Lambert, 2001) have not been adopted in IAPT at present. The expected
response curves used as part of this system are not tailored to the patient other than being
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based on their pre-treatment OQ-45 score, but the identification of patient characteristics
associated with the likelihood of being ‘not on track’ could be used to tailor treatment. The
identification of groups of patients with different responses to treatments could be
supplemented with the identification of different expected response curves, to enable the
development of a DST capable of being used for both treatment selection and treatment
monitoring decisions. The elements of a successful DST were found to be provision of
decision support as part of workflow, at the time the decision is made, providing a
recommendation not assessment and being computer based (Kawamoto, Houlihan, Balas, &
Lobach, 2005). Incorporating these elements where possible should therefore be considered
in the development of a DST for CMHDs.
The stepped care model adopted by IAPT services provides a clear treatment selection
decision (LI or HI) at initial treatment for which a DST could be developed, as well as the
need for treatment monitoring decision support to as whether a patient is displaying
symptomatic improvement or whether a change in treatment, for example stepping up from
low to high intensity, is needed. In addition, IAPT services include a number of clinicians
who have more limited experience of working in mental health settings, and could be
considered paraprofessionals, and therefore these individuals might benefit most from
decision support to improve both patient and service outcomes. The development of such a
DST would also provide an opportunity to adopt a more personalised approach to treatment
in IAPT services, by accounting for patient-specific characteristics that may be associated
with treatment response.
The current allocation of patients to either LI or HI treatment in IAPT services cannot be
considered random, as there are a number of clinical reasons why HI treatment may be
considered more appropriate for certain patients. For example, for certain diagnoses such as
PTSD and social anxiety disorder there is not an established evidence base for the use of LI
interventions, and therefore HI treatments are recommended. Therefore, if these diagnoses
are identified then it may be expected that clinicians allocate these patients to HI. In addition,
it is generally accepted that HI treatments are more appropriate for individuals with more
severe presentations of CMHD symptoms (NCCMH, 2011) which may inform some
decisions to allocate to more intensive treatment. Therefore, it is possible that confounding
by indication, which occurs when clinical information informs the selection a particular
treatment also affects the outcome (Kyriacou & Lewis, 2016), may occur in relation to the
choice to treatment for some IAPT patients, with an expectation that individuals who receive
HI treatments will be more severe in nature than those routinely receiving LI. The
measurement of symptom severity is available in IAPT datasets and can be used to explore
whether there are differences in the patients receiving the different intensities of treatment,
but it is also possible that there are unobservable factors that determine the allocation of
treatments in IAPT. These may include patient specific characteristics such as childhood
abuse which is not collected in IAPT minimum datasets but is linked to poorer response to
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treatment (Williams, Debattista, Duchemin, Schatzberg, & Nemeroff, 2016) but also factors
linked to service delivery such as the limited availability of HI therapists and wait-times.
These will not be considered in this thesis.
The points raised above also inform the design of the studies presented in this thesis, and
the question about whether patient characteristics can be deemed prescriptive or prognostic
in nature. A characteristic would be considered prognostic if it were to indicate which
patients are at an increased likelihood of an outcome relative to other patients, whereas
prescriptive characteristics would indicate differential outcomes from one treatment
compared to another (Fournier et al., 2009). These between-treatment comparisons can
inform upon which treatment is the best for similar patients, but this prescriptive assumption
assumes that all patients allocated to the compared treatments are the same. This
assumption more likely holds true to randomised controlled trial (RCT) designs, where the
random allocation of patients to treatments is expected to remove potential confounders of
treatment choice. The use of data from routine treatment services, where randomisation is
not used, instead lends itself to prognostic designs, where within treatments comparisons
between patients would be explored. In order to develop a DST that can support decision
making in the delivery of psychological interventions, an understanding of which patient
characteristics are associated with outcomes is required. The next chapter presents a
systematic review of patient characteristics associated with CMHD treatment outcomes,
which could be used as part of a DST to support decision making in IAPT services.
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Chapter 3. Patient characteristics
associated with outcomes.
Abstract
The development of a DST to support a personalised treatment approach in CMHDs
requires the identification of patient characteristics which have been associated with
outcomes from treatment. A number of routinely available patient-specific characteristics
(characteristics of the patient, not of the intervention, clinician or service) have been
associated with treatment outcomes, for example, symptom severity and demographic
information such as age or ethnicity (Arnow et al., 2007; Warden et al., 2009), and a
systematic search of all potential predictors could provide more clinical utility to a DST for
use in mental health services. The aim of this chapter was to conduct a meta-review; a
systematic review of previously conducted reviews which had explored the associated
between patient characteristics and treatment outcomes in people with CMHDs. A total of
K=46 systematic reviews were identified in the literature, with K=22 focusing on predictors of
outcome following pharmacological interventions, K=15 on predictors of psychological
treatment outcome and K=9 considering both types of intervention. A range of patient
characteristics were identified across reviews; severity, age, gender and comorbid mental
health problems (including personality disorder) were the most frequently identified in
reviews focusing on treatment response. Characteristics such as age and gender were
inconsistently associated with treatment response across reviews, whereas other
characteristics, for example higher pre-treatment symptom severity and the presence of
comorbid conditions were more consistently associated with poor response to treatment.
Some characteristics including duration of illness, personality characteristics and
employment status, were associated with response to treatment but were only identified in a
limited number of reviews yet may have potential value for a personalised treatment
approaches. There was less available evidence on characteristics associated with treatment
dropout, with only one review focusing on psychological interventions and K=9 providing
information about associations with dropout from pharmacological interventions. Findings
suggested that younger age and fear of stigma were frequently associated with increased
dropout, and other patient characteristics were found to have inconsistent association with
the likelihood of treatment dropout. The results of this meta-review provide information on
the potential value of patient characteristics in predicting treatment outcomes, however the
inconsistent associations for a number of characteristics suggests more research is
required, and that associations could be specific to the interventions or environments in
which treatment was delivered.
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Introduction
The variation in outcomes for individuals with CMHDs receiving psychological interventions
suggests that a more personalised approach to treatment selection may be of benefit
(Cuijpers & Christensen, 2017). An understanding of which patient characteristics are
associated with treatment outcomes is required to develop such an approach, as this
information would likely inform which characteristics are of value to include in a DST to
support treatment decisions. This includes the consideration of patient characteristics
associated with dropout treatment, due to the cost associated with non-completion (Oldham
et al., 2012). Allocating a patient to a treatment they will likely to not attend or complete
would be considered a poor use of resource, and therefore incorporating this information into
a potential DST could optimise healthcare delivery, as well as improving patient outcomes.
The patient’s attitude towards treatment and their experience of any harms (e.g. side effects)
can influence whether treatment will be completed, and this is especially true of drug
treatments where studies have found that nearly 50% of patients leave treatment within the
first 12 months (Sansone & Sansone, 2012; Warden et al., 2009). Although concerns about
side effects are a common reason for dropout of drug treatments, the fear of discussing
uncomfortable issues in psychological interventions may also lead to the avoidance of
treatment (Paige & Mansell, 2013).
A wide range of patient characteristics have been associated with positive outcomes from
treatment (defined as ‘treatment response’ in this chapter), such as a clinically meaningful
reduction in symptoms, as well as dropout from treatment. The level of pre-treatment
symptom severity of the mental health disorder has regularly been proposed as a predictor
of treatment response, but the direction of the association appears inconsistent, with some
findings suggesting that higher symptom severity is more predictive of poorer outcomes,
whereas others suggest higher severity increases the likelihood of response of treatment
(Grammer et al., 2015; Mululo, de Menezes, Vigne, & Fontenelle, 2012; Solomon et al.,
2008; Van, Schoevers, & Dekker, 2008). Other characteristics such as age, previous
treatment, level of functioning and ethnic groups have also been associated with treatment
dropout, as well as response to treatment (Arnow et al., 2007; Papakostas et al., 2003;
Warden et al., 2009). Social characteristics, including martial distress or relationship quality
have also been linked to outcomes following psychological treatment of depression (Snyder,
Castellani, & Whisman, 2006).
Clinical characteristics including the presence of comorbid mental health conditions have
also be proposed as predictive of treatment outcome, and researchers have suggested that
both comorbid substance use disorders (Parker, Wilhelm, Mitchell, & Gladstone, 2000) and
Axis-II disorders (personality disorders) (Newton-Howes, Tyrer, & Johnson, 2006) predict
poorer outcomes, which has important implications for clinical practice. Population surveys
have found that 20% of individuals meeting clinical criteria for depression, and 15% of those
with an anxiety disorder also meet criteria for a substance use disorder (Grant et al., 2004),
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and comorbid personality disorder, identified using structured clinical interviews, was found
in 50% of outpatients with major depression (Sanderson, Wetzler, Beck, & Betz, 1992;
Zimmerman, Rothschild, & Chelminski, 2005).
In addition to demographic and clinical characteristics of the patient, there has been growing
interest in the role of biomarkers in predicting response to treatments in CMHD. One area is
neuroimaging and the identification of areas of brain activation associated with treatment
response. For example, research investigating cognitive biases in CMHDs suggests that
abnormal cognitive processing may be involved in the development of symptoms, and
therefore the potential focus of targeted treatments (Roiser, Elliott, & Sahakian, 2012).
Functional magnetic resonance imaging (fMRI) has allowed researchers to assess levels of
brain activation whilst undertaking cognitive processing tasks, such as facial recognition
tests, and have found biases in emotional processing in individuals with mental health
disorders (Surguladze et al., 2005). Others have suggested that levels of activation in
specific brain regions to emotional stimuli can predict the response to both psychological
interventions (Doehrmann et al., 2013; Siegle, Carter, & Thase, 2006) and pharmacological
treatment (Fu et al., 2004) in depression and anxiety disorders. Further findings suggest that
treatment may modify these processing biases in patients (Beard, 2011).
However, the costs and practical complications with administration involved with
neuroimaging scanning may be too high to justify their use for all patients entering treatment,
therefore limiting their current use in clinical practice (Evans et al., 2006). Further work is
required, and there is potential for the development of more simple tests that can extrapolate
information on specific brain areas, for example through measuring pupil dilation, which
would allow a proxy measurement of brain activation in this area (Graur & Siegle, 2013).
As discussed in Chapter 1, genotyping has underpinned much of the recent advances in
personalised medicine, but currently it has led to limited developments in the prediction of
outcome in CMHDs (Oestergaard & Møldrup, 2009). A number of genetic markers have
been investigated; the majority of these have focused on genes coding for proteins, such as
the serotonin transporter (5-HTT) and the serotonin 5-HT-2 receptors (Papakostas & Fava,
2008). However, there has been little success with any translation of these findings into
clinical practice, and the limited evidence at present does not support the use of routine
genetic screening in routine treatment services for the purpose of treatment prediction in
CMHDs (Licinio & Wong, 2011; Munafò et al., 2014).
There has also been research into the potential association between non-patient
characteristics and treatment outcomes, for example characteristics of the therapists or
treatment delivery that may predict treatment response. The analysis of therapist
characteristics has become more increasingly popular, for example therapist adherence to
intervention framework (Webb, DeRubeis, & Barber, 2010) and therapist alliance (Strunk,
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Cooper, Ryan, DeRubeis, & Hollon, 2012), which would likely be influenced by patient
characteristics such as personality disorder (Bender, 2005). Findings suggest that therapist
effects may explain around 9% of the variance in outcomes between patients in IAPT
services (Green, Barkham, Kellett, & Saxon, 2014), which is above the threshold for clinical
importance proposed by researchers (Uher et al., 2012). However, the amount of variance
explained seems low when compared to the variance that is explained by within treatment
factors, for example the change in symptoms over the first three sessions, which is reported
to explain up to 40% of the variance in eventual outcome (Lambert, 2013). Intervention
delivery factors, such as more frequent sessions have also been found to improve outcomes
in psychological treatment (Erekson, Lambert, & Eggett, 2015).
At present there is a lack of consistent evidence supporting the utility of costly and
technically demanding patient data from genetic or neuroimaging procedures for predicting
treatment outcomes in CMHDs. Instead, the use of routinely available patient characteristics
to inform a personalised treatment approach in mental health services may have more
clinical utility and applicability. IAPT services nationally collect the same standardised
minimum dataset, and a DST which includes these characteristics would be applicable to all
IAPT services in England.
However, it was expected that the review might also identify additional patient characteristics
associated with treatment outcomes that were not collected by IAPT. If there was sufficient
evidence for the ability of such characteristics to predict treatment outcomes, then this might
support the inclusion of these characteristics in the IAPT MDS and a DST to support
treatment decisions. The aim of this meta-review was to identify patient-specific
characteristics which can be routinely collected in mental health services and have been
associated with treatment outcomes in CMHDs. Findings from this review could then be
used as the first stage in development of a DST that is able to predict the likelihood of
treatment outcomes for patients entering IAPT services.
Method
From scoping searches conducted to identify primary randomised control trials (RCTs) and
cohort studies of patient characteristics associated with outcome, it was found that there was
a huge number of potential studies, typically post-hoc moderator analyses that were highly
variable with regard to quality. It would not have been feasible to consider all this evidence
within this thesis, so instead a more focused meta-review (a systematic review of previously
conducted systematic reviews) was performed.
Meta-reviews are considered as an appropriate and efficient method of using existing
literature where significant evidence exists (Harder, Remschmidt, Haller, Eckmanns, &
Wichmann, 2016), and was seen as a method of identifying the best available evidence
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within the resource limitations of this thesis. Previously conducted, high-quality systematic
reviews arguably include the best available evidence, with a reduced risk of bias with regard
to included studies and patient characteristics (Egger, Smith, & Altman, 2001). The review
protocol is presented in Table 3.1 and described below. The search was first completed in
July 2012, and then the same search string was repeated from July 2012 to February 2015
to identify additional reviews that had been published in the intervening period.
Table 3.1. Review protocol
Electronic databases EMBASE, MEDLINE, PsycINFO
Date searched Search 1 - Database inception to July 2012
Search 2 - July 2012 to February 2015
Study design Systematic reviews
Population Participants receiving pharmacological, psychological or a
combination of the two treatments for common mental health
disorders, which was the primary diagnosis.
Excluded populations Diagnosis of severe mental illness (e.g. schizophrenia).
Primary diagnosis of eating disorders or substance use disorders.
Patients in remission before intervention (e.g. Relapse
prevention).
Interventions Any psychological or pharmacological intervention for common
mental health disorders.
Included
characteristics
Any patient specific characteristics, identifiable at pre-treatment
assessment and/or interview (e.g. age, severity of illness).
Excluded
characteristics
Non-patient characteristics (e.g. specific intervention type,
therapist characteristics).
Characteristics unidentifiable in routine assessment / interview
(e.g. requiring neuroimaging data, genotyping).
Although the primary focus of this project is patient characteristics associated with treatment
response to psychological interventions, scoping searches of the literature showed that
many reviews combined predictors of both pharmacological and psychological interventions
together. The presentation of these reviews made separating out psychological and
pharmacological treatment predictors impractical as results were often combined, and
therefore it was decided to include reviews of pharmacological treatment in addition to
psychological. Including pharmacological interventions would also provide more information
about potential patient characteristics associated with outcomes in CMHDs. This meta-
review across types of intervention was conducted first, before a more detailed synthesis
including only the reviews of patient characteristics associated with outcomes in
psychological treatment was performed.
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Study selection
The included clinical population was adults diagnosed with CMHDs, who were undergoing
treatment for these disorders. The CMHD diagnoses considered were depressive disorders,
panic disorder, generalised anxiety disorder (GAD), social anxiety disorder, obsessive-
compulsive disorder, specific phobias and post-traumatic stress disorder.
Systematic reviews including populations with comorbid psychological illnesses (e.g.
substance use disorders or personality disorders) were included, provided the CMHD was
the primary diagnosis. Excluded populations were participants diagnosed with severe mental
illness (such as psychosis or bipolar disorder) and reviews where interventions were
conducted on participants already in remission from mental illness (such as relapse
prevention interventions). Some reviews were conducted across all mental health conditions,
and these were included as long as information on predictors of outcome in CMHDs could
be extracted separately from the reporting.
The meta-review included only patient-specific characteristics that may be associated with
treatment outcomes, including dropout. ‘Patient characteristics’ was defined as information
related to the patient (not to the treatment or clinician) that could be routinely collected in
mental health services, and made available to a clinician performing the pre-treatment
assessment, for example level of symptom severity, comorbid conditions and employment
status. Characteristics that need additional resource to collect, such as neuroimaging data or
genotyping were therefore excluded. Characteristics related to the therapist, intervention or
service (e.g. therapist alliance, type of intervention) were also excluded. Focusing on only
patient-specific characteristics was important for the development of a personalised
approach to treatment decisions in IAPT, as a DST developed for this thesis could only
include characteristics that could be easily collected by both the patient and clinician.
Search strategy
The search strategy for this meta-review is presented in Appendix A, and was based on
search strings originally developed for the NICE clinical guideline on CMHDs (NICE, 2011b),
which included a review of recent systematic reviews (from 1993-2010) on treatment
predictors. For the present review, the search strings were amended to include additional
keywords and MeSH terms around decision making, algorithms and patient satisfaction, in
addition to removing the lower limit on the date of publication (therefore including all titles
since database inception).
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Data extraction
Data was extracted from all included reviews by the author. The data extracted included:
Information about the clinical diagnosis of the CMHD population that was under
investigation, the type of intervention (psychological, pharmacological or both), whether
response or dropout was the primary outcome explored by the review, the type of primary
studies included by the review (controlled or uncontrolled studies) and the patient
characteristics included in the review. Data was then extracted about the association
between each included patient characteristic and treatment outcomes.
Review Quality
An assessment of quality and risk of bias was completed for each review using the
methodology checklist: systematic reviews and meta-analyses adopted by NICE (NICE,
2009) (see Appendix B). The checklist includes five areas that are important to consider in a
well-conducted review and asks the assessor to determine whether the included review
satisfies each statement with “Yes”, “No” or “Unclear”. The five areas are: clarity of the
research question, relevance of included studies, the coverage of the literature searches,
whether study quality is reported and that the methods used are adequately reported.
Each review was given a quality score made up of the responses to the five checklist items,
where a ‘Yes’ resulted in 1 point, ‘no’ resulted in 0 points and ‘unclear’ resulted in 0.5 points.
Reviews were therefore scored out of a max of five points over the five checklist items.
Scores of 4.5 and above were designated “very high” quality, scores of 4 were classed as
“high quality”, scores of 3 and above were rated “moderate” quality and below 3 considered
“low” quality. Any review that was considered as low quality following assessment was
excluded from the meta-review.
Results.
Search 1.
Literature Search 1 identified 5206 citations. From initial screening of the titles and abstracts
of these papers, 4892 citations were considered not relevant to the current meta-review. The
remaining 314 papers were assessed for eligibility. From reviewing these studies, it was
found that 39 were either books, conference reports or book chapters, 28 were focused on
excluded populations, 113 were considered not relevant to the review as they included no
relevant outcomes/predictive characteristics (for example genetics or biomarkers), and a
further 92 papers were excluded as they were not systematic reviews.
The remaining 42 articles were judged relevant to the review question, and were assessed
for quality and risk of bias using the methodology checklist. After assessing the systematic
review quality, five of the systematic reviews were rated as poor quality, with a very high risk
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of bias, and therefore excluded. This left 37 systematic reviews from search 1 to be included
in the synthesis. A PRISMA (Moher, Liberati, Tetzlaff, Altman, et al., 2009) flow diagram for
Search 1 is presented in figure 3.1.
Figure 3.1. Flow diagram for search 1
Search 2.
Search 2 identified 2184 citations which were published between July 2012 and February
2015, of which 2062 were excluded following initial screening. Of the remaining 122 studies,
108 papers were excluded: 17 were not systematic reviews, 21 focused on excluded
populations, 7 were from books or conference abstracts and 63 did not include any relevant
patient characteristics.
The remaining 14 reviews were quality assessed using the NICE methodology checklist, and
4 studies were found to be of poor quality, with a very high risk of bias, and were excluded.
The remaining 10 reviews were included in the synthesis. A PRISMA flow diagram for
search 2 is presented in figure 3.2.
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Figure 3.2. Flow diagram for search 2.
Characteristics of included studies
The systematic reviews identified from Search 1 and Search 2 were combined to produce
the full list of included studies for this meta-review. It was found that one review in Search 1
(Pompili et al., 2009) had been updated in Search 2 (Pompili et al., 2013), and to avoid
double counting information on patient characteristics, only the updated review was
included. Thirty six (36) reviews were included from Search 1 and 10 reviews from Search 2,
resulting in 46 included systematic reviews. Data was extracted from the reviews on any
patient-specific characteristic where the association to either treatment response or dropout
was reported. Additionally, information on the type of interventions, type of included primary
studies and diagnoses of the populations included in the reviews was also extracted.
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Review Quality
The NICE methodology checklist was completed for each included review. Of the K=46
systematic reviews that were included, only K=3 were rated as ‘very high’ quality using the
methodology checklist. K=25 were rated as ‘high’ quality, and the remaining K=18 were
viewed as ‘moderate’ quality. Reviews were typically downgraded to moderate or high
quality, instead of very high quality, due to unclear literature searches or a lack of
information about how primary studies were assessed for risk of bias.
The characteristics of included studies are presented in Table 3.2 below. Information is
presented on:
 Type of intervention: Either psychological or pharmacological
 Quality of the systematic review with regard to risk of bias after completion of NICE
checklist (Appendix B).
 The treatment outcome assessed: either treatment response or dropout
 The primary diagnosis of the population.
 Type of included primary studies: either controlled or uncontrolled.
 The patient related characteristics identified/included in the review.
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Table 3.2. Key study characteristics of included reviews
Study ID Intervention
(Psychological or
Pharmacological)
Review
quality
Treatment
Response
or
Dropout
Primary diagnosis
of population
Types of
Included primary
studies
Patient characteristics identified
(1) Ackerman2002 Pharmacological High Response Anxiety (OCD) Controlled Age of participant
Age of onset/duration of illness
Severity
(2) Al-Qasem2011 Pharmacological Moderate Dropout Medical conditions
(including CMHDs)
Controlled &
uncontrolled
Gender
Age of participant
Patient perception of treatment
Previous treatment
Education
Relationship status
(3) Christensen2009 Psychological
(internet based
interventions only)
Moderate Dropout Depression and
Anxiety disorders
Controlled Age of participant
Severity
Previous treatment
Education
(4) Cuijpers2008 Psychological High Response Depression Controlled Gender
Age of participant
Severity
(5) Cuijpers2009 Psychological High Response Depression Controlled Age of participant
(6) Cuijpers2014 Psychological and
Pharmacological
High Response Depression Controlled Gender
(7) Davis2006 Pharmacological Moderate Response Anxiety (PTSD) Controlled &
uncontrolled
Comorbidity
Severity
Subtype (trauma type)
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(8) Davis2014 Pharmacological High Response Anxiety (social
anxiety)
Controlled Gender
Age of participant
(9) Dodd2004 Pharmacological High Response Depression and
Anxiety disorders
Controlled &
uncontrolled
Comorbidity – other MH
Severity
Personality factors (large range)
Functioning
(10) Duncan2010 Psychological Very high Response All mental health
(including CMHDs)
Controlled &
uncontrolled
Shared decision making
(11) Fekadu2009 Psychological and
Pharmacological
Very high Response Depression
(treatment resistant)
Controlled &
uncontrolled
Gender
Age of participant
Previous treatment
(12) Fournier2010 Pharmacological High Response Depression Controlled Severity
(13) Gava2007 Psychological Very high Response Anxiety (OCD) Controlled Severity
(14) Haby2006 Psychological Moderate Response Depression and
Anxiety disorders
Controlled Severity
(15) Haug2012 Psychological High Response Anxiety disorders
(any)
Controlled Gender
Age of participant
(16) Ipser2012 Pharmacological High Response Anxiety (PTSD) Controlled Gender
(17) Johnston2013 Pharmacological High Dropout Depression Controlled &
uncontrolled
Age of participant
Previous treatment
Shared decision making
Patient perception/stigma
(18) Joosten2008 Pharmacological High Response
and
Dropout
Medical conditions
(including CMHDs)
Controlled Shared decision making
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(19) Knopp2013 Psychological High Response Anxiety (OCD) Controlled Age of participant
Comorbidity – other MH
Severity
Education
Employment
Relationship status
Medication use
(20) Kool2005 Pharmacological High Response Depression Controlled Comorbidity – Personality disorder
(21) Levy2011 Psychological Moderate Response All mental health
(including CMHDs)
Controlled &
uncontrolled
Attachment style
(22) Lingam2002 Pharmacological Moderate Dropout Depression Controlled &
uncontrolled
Gender
Age of participant
Previous Treatment
Patient perception/stigma
(23) Luszcyznska2009 Psychological Moderate Response Anxiety (PTSD) Controlled &
uncontrolled
Personality – self efficacy
(24) Malpass2009 Pharmacological High Dropout Depression Controlled &
uncontrolled
Patient perception/stigma
(25) Mancini2010 Pharmacological High Response Anxiety disorders
(any)
Controlled &
uncontrolled
Comorbidity – Other MH
(26) McPherson2005 Psychological Moderate Response Depression
(treatment resistant)
Controlled &
uncontrolled
Previous treatment
(27) Mulder2002 Psychological and
Pharmacological
High Response Depression Controlled &
uncontrolled
Comorbidity – personality disorder
Personality factors
(28) Mululo2012 Psychological and
Pharmacological
High Response Anxiety (Social
Anxiety Disorder)
Controlled &
uncontrolled
Gender
Age of participant
Age of onset/duration of illness
Comorbidity – personality disorder
Comorbidity – Other MH
Severity
Duration of illness
Previous treatment
Subtype
Education
Relationship status
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(29) Najt2011 Psychological and
Pharmacological
Moderate Response All mental health
(including CMHDs)
Controlled &
uncontrolled
Gender
Comorbidity- Other MH
(30) Nanni2012 Psychological and
Pharmacological
Moderate Response Depression Controlled &
uncontrolled
Age of participant
Childhood maltreatment
(31) Naudet2011 Pharmacological Moderate Response Depression Controlled &
uncontrolled
Age of participant
Severity
(32) Nelson2013 Pharmacological Moderate Response Depression Controlled Gender
Age of participant
Severity
Duration of illness
(33) Nunes2004 Psychological and
Pharmacological
High Response Depression Controlled Age of participant
Severity
(34) Ormerod2008 Pharmacological Moderate Dropout All mental health
(including CMHDs)
Controlled &
uncontrolled
Ethnicity
(35) Pompili2013 Pharmacological Moderate Dropout Depression Controlled &
uncontrolled
Age of participant
Severity
Comorbidity - personality disorder
Patient perception/stigma
(36) Powers2010 Psychological High Response Anxiety (PTSD) Controlled Age of onset/duration of illness
Subtype (trauma type)
(37) Rivero-
Santana2013
Pharmacological Moderate Dropout Depression Controlled &
uncontrolled
Gender
Age of participant
Severity
Ethnicity
(38) Sanchez-
meca2010
Psychological High Response Anxiety (Panic
disorder)
Controlled Gender
Age of participant
Age of onset/duration of illness
Comorbidity – Other MH
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(39) Serretti2009 Pharmacological Moderate Response Depression and
Anxiety
Controlled &
uncontrolled
Gender
Age of participant
Age of onset/duration of illness
Comorbidity – Other MH
Comorbidity – Personality disorders
Physical illness
Severity
Personality factors (range)
Previous treatment
Education
Ethnicity
Employment
Relationship status
Functioning
Social Support
(40) Serretti2011 Pharmacological High Response Depression Controlled Gender
Age of participant
Age of onset/duration of illness
Ethnicity
(41) Silveira2013 Psychological High Response Depression Controlled &
uncontrolled
Age of participant
Severity
(42) Sullivan2005 Psychological and
Pharmacological
High Response Depression Controlled &
uncontrolled
Comorbidity – Other MH
(43) Tedeschini2011 Pharmacological High Response Depression Controlled Age of participant
(44) Thiel2013 Psychological and
Pharmacological
Moderate Response Anxiety (OCD) Controlled &
uncontrolled
Comorbidity – Personality disorders
(45) Trivedi2011 Psychological High Response Depression
(treatment resistant)
Controlled Previous treatment
(46) Yonkers2002 Pharmacological Moderate Response
and
Dropout
Depression Controlled &
uncontrolled
Gender
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A total of K=15 reviews focused on only predictors of treatment outcome in psychological
interventions, of which K=14 were concerned with treatment response and one review on
predictors of dropout during psychological interventions. Pharmacological interventions were
the sole focus of K=22 reviews (K=13 response only, K=7 dropout only and K=2 both
response and dropout included), and the remaining K=9 included both psychological and
pharmacological interventions, all of which reported on treatment response only.
The included diagnoses also varied considerably between the reviews. K=11 reviews
included specific anxiety disorders only (OCD K=4, PTSD K=4, social anxiety disorder K=2,
Panic disorder K=1), K=2 focused on any anxiety disorder, K=23 considered only patients
with depression and K=4 reviewed both depression and anxiety disorder. The final K=6
reviews reported on characteristics associated with outcomes for any physical and/or mental
health condition, although depression and anxiety disorders were separated out in the
reviews for data extraction. Of the included reviews, K=21 included only controlled trials,
whereas the remaining K=25 included both controlled and uncontrolled studies in their
included primary studies. Uncontrolled studies included cohort and case series studies of
populations with CMHDs.
The number of patient characteristics reported within each review ranged significantly, with a
number of reviews focusing their research question to just one particular characteristic (e.g.
Yonker2002), whereas other reviews ranged from two to 15 characteristics (e.g.
Serretti2009).
Data synthesis (psychological and pharmacological
interventions)
Only a third of included reviews were focused exclusively on psychological treatments, and
therefore the first synthesis of the data included reviews on both pharmacological and
psychological interventions. This initial stage allowed the synthesis of all available
information on patient characteristics associated with outcomes, and is supplemented by a
more focused synthesis of data from reviews of psychological interventions, which is
presented further below.
Information about included patient characteristics (e.g. severity, previous treatment) varied
considerably between reviews with regard to methods of study selection, reporting,
aggregating and synthesising. Reviews that included only controlled intervention studies
were more likely to have used quantitative methods (e.g. meta-regression) to statistically
evaluate the association between patient characteristics and treatment outcomes (e.g.
Ackerman2002; Cuijpers2009). However, as less than 50% of included reviews restricted
their inclusion criteria to only controlled trials, quantitative analysis was not conducted in the
majority of reviews. In most reviews the information on predictors of treatment outcome was
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presented narratively (e.g. Davis2006; Mancini2010). Data on predictors could not be
extracted from statistical reporting in these reviews, and instead the association of specific
characteristics with outcome was determined by exploring the narrative review provided
within the study.
Due to the lack of poolable quantitative data across the included systematic reviews, a
narrative approach was adopted for this meta-review, to make best use of available
information from the identified systematic reviews on patient characteristics associated with
treatment outcomes (Popay et al., 2006). For each patient characteristic identified across the
reviews, information was extracted first on the frequency of it’s reporting in the literature,
regardless of association with outcome.
Next, data was extracted for all patient characteristics explored within the included reviews
about the reported association with treatment outcome. Evidence considered within the
reviews could suggest that each patient characteristic: was associated with outcomes (as
well as the direction of the association), had an inconsistent association (varied amongst
included primary studies) or that there was limited evidence of any association (unlikely to
predict outcome). For studies using meta-regression or other more quantitative methods, the
results of statistical analyses were used to inform the decision as to whether there was an
association or not, whereas qualitative analysis was used to inform associations in reviews
which were more narrative.
Characteristics associated with treatment response
Table 3.3 presents the patient characteristics which were explored in relation to treatment
response. Age of participant and gender were amongst the most frequently reported patient
characteristics in the literature, but both were found to have little association overall with
treatment response. The severity of illness at baseline and the presence of comorbid mental
health issues (including both personality disorders and other mental health conditions) were
also frequently explored and were often associated with treatment response. It was
generally suggested in the reviews that the presence of a co-morbidity and higher initial
severity of illness were both linked to poorer outcomes, although a few reviews indicated
that higher severity had a positive effect on treatment outcome. Both these characteristics
have been promoted as potential predictors by researchers (Shea et al., 1990; Van et al.,
2008), and findings of this review suggest that these characteristics could inform likely
treatment response.
Patients reporting previous treatment for a mental health illness were associated with poorer
response to current treatment in four of the five reviews which considered this characteristic,
and could be a useful predictor for clinical purposes considering this level of agreement
across reviews. Duration of illness, however, had a much more inconsistent association with
treatment response, with two of six reviews finding no association, one review suggesting a
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positive effect of longer duration on outcome and three reviews suggesting that a longer
duration has a negative association with response.
The remaining patient characteristics were mentioned less frequently in the literature, with
three or less systematic reviews providing information about them. Despite the lack of
previous research, these characteristics may have clinical utility in predicting treatment
response. Both older age of onset and being in a relationship where associated with better
response to treatment in two of three reviews. Higher self-efficacy/directedness was also
found to be consistently associated with positive response to treatment in all three reviews
reporting this factor. All three of these characteristics can be assessed using simple direct
questions or self-reported measures (such as the Self-efficacy scale (Sherer & Maddux,
1982)) which may be of value to consider in clinical practice, especially as the reviews noted
these associations across different diagnostic groups.
Other characteristics associated with positive treatment response reported in the literature
were higher level of interpersonal functioning, lower neuroticism, higher co-operation and
secure attachment in childhood. Patient characteristics such as ethnicity, physical illness,
medication use, social support level and employment were mentioned rarely in the literature,
and reviews including these characteristics suggested that the association with response
was limited or inconsistent.
Shared decision making was associated with better response in one systematic review, and
no association in a second review. Although this characteristic could be viewed as a
description of the assessment process rather than a true patient-specific characteristic, the
emphasis of shared decision making in IAPT would suggest that role of this characteristic
would be important to consider when developing a DST to promote personalised medicine
approaches in these services.
Characteristics associated with treatment dropout
Table 3.4 displays the patient related characteristics identified in reviews of treatment
dropout. The role of patient characteristics associated with treatment dropout have been
considerably less studied than those involved in treatment response, and only nine of the
K=46 included reviews reported any information on patient specific predictors of treatment
dropout. It should be noted that all but one of these reviews included only pharmacological
interventions, and the one review of psychological interventions was focused on internet-
delivered therapies only. Therefore their relevance to the broader range psychological
treatments delivered in IAPT services is more questionable.
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Table 3.3. Characteristics associated with treatment response.
Patient
characteristic
Number of
reviews
reporting
Reviews concluding
associations between factor and
treatment outcome
Inconsistent
association
No
association
found
Age of
participant
K=17 K = 4
- K=2 older age positive
- K=2 younger age positive
K=1 K = 12
Severity K=14 K=11
- K=4 higher severity positive
- K=7 lower severity positive
K = 3
Gender K=13 K = 3
- K=2 Males negative
- K=1 Female negative
K=2 K=8
Comorbidity –
Other MH
K=9 K = 9
- K=8 comorbidity negative
K=1
Duration of
illness
K=6 K=4
- K=3 longer duration negative
- K=1 longer duration positive
K=2
Comorbidity _
Personality
disorders
K=5 K = 3
Comorbidity negative
K=1 K=1
Previous
treatment
K=5 K=4
Previous treatment negative
K=1
Education K=3 K=1
Less education negative
K=2
Age of onset K=3 K=2
Older age positive
K=1
Relationship
status
K=3 K=2
Married/in relationship positive
K=1
Self-efficacy /
Self-
directedness
K=3 K=3
Higher efficacy positive
Illness /
trauma
subtype
K=3 K=2
-K=1 combat trauma positive
-K=1 social anxiety negative
K=1
Ethnicity K=2 K=1
Caucasian positive
K=1
Functioning K=2 K=2
Lower functioning negative
Shared
decision
making
K=2 K=1
Shared decision making positive
K=1
Neuroticism K=2 K=2
Higher neuroticism negative
Cooperation K=2 K=2
More cooperation positive
Employment K=2 K=1
Unemployed negative
K=1
Physical
illness
K=1 K=1 Negative
Medication
use
K=1 K=1
Social Support K=1 K=1
Childhood
maltreatment
K=1 K=1
Maltreatment negative
Attachment
style
K=1 K=1
Secure attachment positive
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Of the K=9 systematic reviews reporting characteristics associated with treatment dropout,
K=5 explored the patient’s initial perception of treatment and potential fear of stigma as a
potential characteristic associated with treatment dropout. Four of these five reviews found
that negative perceptions of treatment (e.g. concern about side effects), or fears around the
potential stigma of receiving treatment for mental health conditions were associated with
increased dropout from treatments. This finding would suggest that improving patient
understanding of CMHDs to reduce their fears of stigma and potential side effects could
increase adherence to treatment. Age of patient was considered in the majority of included
reviews, and results suggested that younger patients were more likely to drop out of
treatment. It is of interest that age was found to have an inconsistent association with
response, but a more clear association with treatment dropout. The association between
previous treatment and dropout also appears to differ from the association between this
characteristic and treatment response, as patients reporting previous treatment were
associated with more dropout (a poorer outcome) than patients who had not received
previous treatment.
Table 3.4. Characteristics associated with treatment dropout.
Patient
characteristic
Number of
reviews
reporting
Reviews concluding
associations between factor
and treatment dropout
Inconsistent
association
No
association
found
Age of
participant
K=6 K = 5
- K=4 older age positive
- K=1 younger positive
K=1
Patient
perception of
treatment /
stigma
K=5 K=4
Negative view has negative
impact on dropout
K=1
Gender K=4 K=4
Previous
treatment
K=4 K=4
-K=2 previous worse,
-K=2 Previous positive
Severity K=3 K=2
-K=1 lower severity positive
-K=1 lower severity negative
K=1
Education K=2 K=1
Lower education level negative
K=1
Shared
decision
making
K=2 K=2
Shared decision making
positive
Ethnicity K=2 K=1
Caucasian positive
K=1
Relationships K=1 K=1
No relationship negative
Comorbidity –
personality
disorders
K=1 K=1
Comorbidity negative
A number of demographic characteristics were also considered in reviews of treatment
dropout. Gender was found to have no association with dropout in the literature, which was
similar to findings in the reviews of characteristics associated with treatment response. Not
being in a relationship and having a comorbid condition were also associated with an
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increased risk treatment dropout. Whereas high pre-treatment symptom severity was more
frequently associated with poorer response to treatment, severity appeared to have a more
inconsistent association with dropout. The three reviews that explored severity in relation to
treatment dropout each reported different associations.
Although patient characteristics associated with dropout have received limited attention in
previous systematic reviews, some factors such as age and patient perception of treatment
were found to be consistently associated with dropout. Younger patients and patients with
more concerns about treatment, or stigma associated with mental health treatment were
associated with more dropout from mental health treatment. Other patient characteristics
were considered in a limited number of previous systematic reviews, and as a result further
research would be of value to understand the association between these characteristics and
the risk of treatment dropout.
Data synthesis (psychological interventions only)
In the next stage of analysis, only reviews of characteristics associated with outcomes
following psychological interventions were included. A more focused review of psychological
interventions was expected to provide more relevant information for predicting outcomes in
IAPT services, but it could also explain some of the inconsistencies in findings for patient
characteristics indicated in the previous analysis. Data on patient characteristics was
extracted for each review, and the assessment of review quality was also considered to
grade the quality of the evidence for each predictor.
Characteristics associated with treatment response
All included reviews of patient characteristics associated with treatment response in
psychological interventions are presented in Table 3.5. Each review is listed, as well as each
patient characteristic that was associated with treatment response in the review. The
notation (+) is used when the patient characteristic was is found to be positively associated
with treatment response in the review, (-) is used when the association was negative and (o)
is used to indicate that no association was found, or that the association was inconsistent.
The number of notations is used to indicate the strength of the evidence of this finding,
derived from the quality of the review: one notation (+) indicates that the evidence is
extracted for a moderate quality review, two notations (++) for high quality evidence and
three notations (+++) indicates evidence from a very high quality review.
There were K=2 systematic reviews focusing on psychological interventions that were rated
as very high quality using the NICE methodology checklist (Duncan2002, Gava2007). These
reviews were focused on only one patient characteristic. Duncan2002 found that although
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shared decision making had a positive effect on patient satisfaction with care, it had no
association with improved outcomes across depression or anxiety disorder treatment.
Gava2007 focused exclusively on the association of severity with treatment response in
OCD and found that lower severity levels at baseline were associated with better response
to psychological treatment. These reviews were conducted according to Cochrane standards
and the evidence provided by these reviews was considered very strong.
The high quality reviews (K=8) provided the most information on patient characteristics
associated with treatment response. Age was included as a factor in K=6 reviews, although
four of these reviews concluded a limited or inconsistent association between age and
outcome. The two reviews (Cuijpers2008; Silveira2013) which indicated an association
between age and response both suggested that younger patients were more likely to have
poorer outcomes. These two reviews were focused on depressed populations only, whereas
three of the reviews finding no association included only anxiety populations, and it is
possible that the differences here may be linked diagnosis/clinical presentations of patients.
Three of the included reviews considered gender as a potential predictor: two of the reviews
(Cuijper2009; Sanchez-Meca2010) found no association between gender and outcome,
whereas one suggested that females had poorer response to anxiety disorder treatment
(Haug2012).
Baseline severity of illness was explored as a predictor in three of the high quality systematic
reviews of psychological interventions. Although one review (Cuijper2008) found no
association between severity and response to depression treatment, two reviews
(Knopp2013; Silveira2013) found that lower severity was associated with better response to
treatment in OCD and depression populations. Lower pre-treatment severity was also
associated with better response to treatment in the very high quality review (Gava2007), and
this may suggest that this characteristic may be important when predicting response to
treatment.
The presence of comorbid mental health conditions was associated with less response to
treatment in two high quality studies (Knopp2013; Sanchez-meca2010) and type of trauma
subtype was not associated with response to PTSD treatment in the one high quality review
exploring this factor (Powers2010).
The duration of illness was included in two high quality reviews, with inconsistent findings.
One review found that there was no association between time since traumatic experience
and treatment response in PTSD patients (Powers2010) whereas a review of panic disorder
suggested a longer duration of illness was associated with poorer outcome (Sanchez-
meca2010). This impact of this characteristic on treatment response by differ between
diagnoses. One high quality review included previous treatment, and the findings suggested
that previous treatment was linked to poorer response (Trivedi2011).
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Table 3.5. Included reviews: response to psychological treatment.
Study ID
Primary
diagnosis of
participants
Y
ounger
age
Fem
ale
Low
er
severity
P
resence
of
C
om
orbidity
D
uration
of
illness
P
revious
Treatm
ent
Traum
a
subtype
S
hared
decision
m
aking
In
a
relationship
H
igher
education
U
sing
m
edication
E
m
ployed
H
igh
self-
efficacy
S
ecure
attachm
ent
Very high quality reviews
Duncan2010
All Mental
health ooo
Gava2007
Anxiety
(OCD) + + +
High quality reviews
Cuijpers2008 Depression - - oo oo
Cuijpers2009 Depression oo
Haug2012
Anxiety
disorders oo - -
Knopp2013
Anxiety
(OCD) oo + + - - + + oo oo + +
Powers2010
Anxiety
(PTSD) oo oo
Sanchez-
Meca2010
Anxiety
(Panic
disorder)
oo oo - - - -
Silveira2013 Depression - - + +
Trivedi2011 Depression - -
Moderate quality reviews
Haby2006
Depression
and Anxiety
+
Levy2011
All Mental
health
+
Luszcyznska
2009
Anxiety
(PTSD)
+
McPherson
2005 Depression
-
"+" = Positive association; "-" = negative association; "o" = No association
80
One high quality review considered a range of demographic characteristics associated with
treatment response to psychological interventions in addition to age, and was limited to OCD
populations (Knopp2013). The findings of this review suggested that being in a relationship
and in employment were associated with better response to treatment, whereas level of
education and receiving medication in additional to psychological interventions had no
impact on outcomes.
There were only K=4 moderate quality reviews of psychological interventions, and each
review was focused on only one patient characteristic. The number of previous treatments
was associated with poorer outcome to depression (McPherson2005), supporting the finding
from the higher quality review (Trivedi2011). Severity of baseline symptoms was reported in
the Haby2006 review, where findings supported both high and very high quality reviews that
lower severity was associated with better response to psychological treatments. The
Levy2011 and Luszcyznska2009 reviews focused on self-efficacy and attachment style
respectively, and findings from these reviews suggested that higher self-efficacy and a more
secure attachment were associated with better response to treatment.
Characteristics associated with treatment dropout
From the K=15 systematic reviews that focused on predictors of psychological treatment
outcomes, only one review looked at patient characteristics associated with treatment
dropout (Christensen2009). As this review included only internet-based psychological
interventions, no systematic reviews of patient characteristics associated with treatment
dropout in face-to-face psychological interventions were identified in the literature search.
The findings from the Christensen2009 review indicated that younger participants were more
likely to stay in depression treatment, although no evidence was found in relation to anxiety
disorders. As the interventions were all delivered by the internet, it is possible that younger
participants would feel more comfortable with this method of treatment delivery, which would
explain these findings. Lower pre-treatment severity of illness was associated with less
dropout in both depression and anxiety studies. Education was also explored in this review,
although no association with dropout was found.
Discussion
The findings from this meta-review have identified a number of patient characteristics that
may be associated with treatment response and dropout, in addition to characteristics that
appear to show little association or a more inconsistent association across studies and
populations. There was less available evidence on characteristics associated with response
to psychological interventions compared to pharmacological interventions, yet a number of
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characteristics were frequently associated with response in these treatments, which could
inform a personalised medicine approach in IAPT services. Only one review explored
characteristics associated with dropout from psychological treatments, and therefore it is
possible that there are important differences between characteristics associated with
dropout in pharmacological and psychological treatments that could not be identified in this
meta-review. Furthermore, the range of populations, included studies and methods of
analysis of primary studies included in the reviews synthesised in this chapter may explain
some of the inconsistencies in findings.
Review of findings: Treatment response
Higher pre-treatment severity of symptoms and the presence of comorbid mental illness
were associated with a poorer response to treatments in the majority of reviews which
considered these patient characteristics. Both high and very high quality reviews that
focused on psychological interventions identified these relationships, which suggests that
more intensive treatment might be recommended for more severe/complex patients. Four
reviews suggested that higher pre-treatment severity increased the likelihood of positive
outcomes (rather than reduced them), but as these reviews all included pharmacological
treatment, this may suggest a more inconsistent relationship in drug treatments for CMHDs.
Gender appeared to have little association with treatment response, and the age of patient
appears to have an inconsistent association with this outcome, which was evidenced across
a large number of reviews which included this characteristic. Most reviews of psychological
interventions found no relationship between age and outcome, although two reviews
(Cuijpers2008; Silveira2013) did find that older age was associated with better outcomes in
the treatment of depression. Two reviews of pharmacological interventions found that higher
age was associated with poorer outcomes (Tedeschini2001; Naudet2011) which may
suggest a differential relationship between age and type of intervention. However, as K=12
further reviews of pharmacological treatment suggested no association between age and
outcome, it may be that age only influences treatment outcomes under certain
circumstances, for example in the presence of other patient characteristics, although this
was not explored in the current review.
Participants reporting previous treatment for a CMHD were more likely to have a poorer
response to treatment across diagnoses. Two reviews (McPherson2005; Trivedi2011)
specifically focused on treatment resistant depression, which may explain why previous
treatment was frequently associated with worse outcome in these reviews. It would be of
more value if characteristics that were associated with treatment resistance could be
identified in routinely collected data, and there is potential that previous treatment may be
linked to other characteristics that could help estimate the likelihood of successful treatment.
Duration of illness was explored in relation to treatment response in six reviews, with
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inconsistent findings. Three reviews found that a longer duration of illness was associated
with poorer outcomes to treatment for depression (Serretti2011), panic disorder (Sanchez-
meca2010) and across CMHDs (Serretti2009). However, no association was found in
reviews of social anxiety (Mululo2012) and for PTSD (Power2010), whereas longer duration
was associated with positive response to depression treatment in one review (Nelson2013).
It is unclear whether the inconsistency is due to the different CMHDs under review, variation
in the quality of the interventions delivered in primary studies or whether other patient
characteristics (for example severity) may have further influenced findings.
Some patient characteristics appear to have potential value in predicting treatment
outcomes but were only considered in a limited number of reviews. For example, being in a
relationship was associated with positive treatment outcomes suggesting potential to inform
clinical decision making, but it was only considered in three of the included reviews. Other
characteristics such as ethnicity, self-efficacy and level of functioning also had limited
evidence, but the results presented in this Chapter suggest that they may have potential
utility in a DST to inform treatment decisions in CMHDs.
Although it could be argued that shared decision making is not a patient-specific
characteristic, it is an important part of IAPT delivered care and therefore should be
considered as part of a personalised medicine approach developed in this thesis and was
expected to improve outcomes following treatment. However, results were mixed with one
review of pharmacological interventions for depression suggesting better outcomes following
shared decision making, whereas a review of response in psychological interventions
suggested there was no association between sharing decisions and outcomes
(Duncan2010). It is possible that shared decision making is more important when
considering pharmacological interventions rather than psychological, and this may be linked
to concerns about side effects and perceptions that are associated with drug treatments.
Review of findings: Treatment dropout
The number of reviews exploring patient characteristics associated with treatment dropout
was significantly lower than those which focused on treatment response. The main
characteristics associated with treatment dropout in the literature were the patient’s
perception of treatment and the possible stigma attached to receiving the intervention, as
well as the age of the participant. Concerns around stigma and potential side effects of
mental health treatment were all identified in systematic reviews of pharmacological
interventions for CMHDs. Although the sole study of psychological interventions and dropout
did not mention this characteristic, it is possible that the preference for psychological over
pharmacological treatment (Eiring et al., 2015; Williams et al., 2016) reduces the impact of
patient perception on dropout in psychological treatment. Negative perception and younger
age were associated with worse adherence and more drop out in reviews of
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pharmacological treatment. Conversely, the one review of psychological interventions found
that younger age was associated with better adherence to treatment, but as this review
focused on internet-based interventions only, it may be that age is linked to the method of
intervention delivery.
The use of shared decision making was found to be positively associated with treatment
dropout, as the two reviews exploring this characteristic both reported that dropout was less
likely when a shared decision-making process is used. The potential importance of shared
decision making for reducing dropout appears important to consider for services such as
IAPT, as although shared decision making wasn’t associated with treatment response in
psychological interventions, it could improve rates of treatment completion.
Reporting previous treatment for mental health conditions was also linked to reduced rates
of dropout in two of the three reviews that included this characteristic. The opposite was
identified in reviews that focused on treatment response, where previous treatment was
linked to poorer outcomes, and the findings of this meta-review could suggest that
individuals who report previous treatment are more likely to stay in treatment, but are less
likely to benefit from it. Researchers have suggested that patients may not always
successfully recall their previous response to treatment for CMHDs such as depression, and
therefore consideration on how this information is collected at assessment is required for it
have potential clinical utility (Simon, Rutter, Stewart, Pabiniak, & Wehnes, 2012).
Limitations
One limitation of this meta-review is the level of variation across the included reviews with
regard to the populations, the types of primary studies included (controlled or uncontrolled
studies) as well as different interventions delivered. Although some reviews had used
quantitative methods, such as meta-regression, to explore the predictive nature of patient
characteristics, many more used narrative review methods. It is possible that these
differences in data aggregation could explain some inconsistencies found between reviews.
The inconsistency regarding certain patient characteristics, could also be linked to the
definition of ‘response’ used by the included reviews, as well as by the primary studies which
they included. As discussed in Chapter 1, there are differences between ‘recovery’, the
reduction in symptoms below a clinical cut-off, and ‘reliable change’, a reduction in
symptoms by a certain proportion/absolute value (Boessen, Groenwold, Knol, Grobbee, &
Roes, 2012). A large number of included reviews did not explicitly record how ‘response’
was defined in their primary studies, and therefore this could explain some inconsistencies in
the current synthesis if different approaches to defining outcomes were grouped together.
Another limitation of this review is that it has not considered the potential interaction effects
between patient characteristics that may impact their ability to predict treatment outcomes.
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Although each patient characteristic may inform a decision on possible treatment,
incorporating information across multiple characteristics would allow for a more nuanced
picture of the patient, and could better inform a DST for use in treatment services. This could
not be explored within this meta-review but using a dataset of patients receiving IAPT
treatments would provide an opportunity to explore the association of multiple patient
characteristics and treatment outcomes, potentially informing personalised treatment
decisions when many patient characteristics are available to the decision maker.
Although this thesis is focused on predicting outcome in psychological interventions, this
review also included reviews of pharmacological interventions, due to the limited number of
studies exploring predictors of psychological interventions alone. Only K=15 of the K=46
included studies were focused on psychological interventions, and only one of these looked
at treatment dropout in computerised treatments (Christensen2009). This highlights the lack
of high quality reviews into the area, especially patient characteristics associated with
treatment dropout. Using a patient dataset from psychological treatment services could
provide more information on the role of patient characteristics and risks of dropout to inform
a DST for use in IAPT services.
One further limitation of this meta-review is that the identification of reviews, rating of review
quality and the data extraction was conducted by the author only, and there was no
independent validation of the reliability. This may raise questions about the reliability of the
categorisation of reviews and patient characteristics. An independent rater was not used in
the current study due to time restrictions, but future work in this area should consider the use
of an independent rater, even if just on a subsample of identified reviews (e.g. 10% of
papers identified in the literature search), in order to assess the reliability of the
categorisations used.
Summary
The meta-review presented in this chapter has identified a number of routinely collected
patient characteristics that may be associated with outcomes in the treatment of CMHDs, as
well as characteristics which appear to have a more inconsistent association with outcomes
in the literature. This information may be of value when determining which patient
characteristics should be included as part of routine patient datasets due to their potential to
inform treatment outcomes, and some characteristics identified could be used to predict
prognosis. For example, higher severity of illness pre-treatment was frequently associated
with poorer response to psychological treatment in the included reviews, and this information
could be used as part of treatment planning to determine most appropriate treatment for
more severe patients. However, the review was limited by the variation in the included
systematic reviews with regard to diagnoses, methods of reporting and types of primary
studies that were considered, which may have resulted in some inconsistencies with regard
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to the association of specific patient characteristics and outcomes. In addition, the review did
not consider the potential interactions of co-occurring patient characteristics, which may
influence the potential predictive ability of individual patient characteristics. To address these
limitations, the next chapter presents analysis performed on a patient dataset collected in
two IAPT services, which explored the association between multiple routinely collected
patient characteristics and psychological treatment outcomes.
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Chapter 4. Patient characteristics and
IAPT treatment outcome.
Abstract
The results of the meta-review presented in the previous chapter suggested a number of
patient characteristics that may be associated with treatment outcomes, although there were
inconsistencies with some findings which may be due to differing populations and methods
of reporting treatment outcomes. Supplementing these findings with analyses of patient
characteristics and treatment outcomes from IAPT datasets was expected to yield the most
clinically useful and relevant information to help personalise treatment in these services. The
aim of this chapter was to explore the use of standardised IAPT data from two services
(n=10693 patients) in North London to understand the association between routinely
available patient characteristics and outcomes from psychological treatments delivered by
IAPT. Stepwise multiple regression was used to explore the association between nine
patient-specific characteristics available in the IAPT dataset and five outcomes; including
recovery, reliable change and improvement, deterioration and dropout from treatment.
Analysis was performed on the full sample of patients receiving treatment from the services,
but also split by patients who received only low intensity (LI) interventions, high intensity (HI)
interventions and patients who were stepped up during treatment. Results indicated that
each of the patient characteristics was statistically associated with at least one outcome
across sub-analyses, but depression and anxiety severity, functional impairment and welfare
status were most predictive of response to treatment, and depression severity, age and
welfare status were most predictive of treatment dropout. The patient characteristics
considered in this analysis could be used to inform the prediction of likely response to
treatment as well as risk of deterioration and dropout. However, the variance explained by
some of the final regression models was low, especially for treatment dropout, which may
suggest that additional characteristics not available in the dataset may better predict some
treatment outcomes.
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Introduction
In order to personalise treatment decisions in IAPT services, an understanding of which
patient characteristics are associated with treatment outcomes is needed. The systematic
review presented in the previous chapter identified a number of patient-specific
characteristics that have been consistently associated with treatment outcomes in CMHD,
for example comorbid mental health issues (Serretti et al, 2009; Mululo et al, 2012).
However, for a number of characteristics the pattern was more inconsistent which suggests
that more research is needed in order to understand their association with outcomes,
especially in relevant clinical environments. There was also significantly less evidence
available for predictors of outcomes following psychological interventions when compared to
pharmacological interventions for CMHD. Therefore further analysis was needed to
understand the association between patient characteristics and psychological treatment
outcomes, and using data from IAPT services was expected to increase the practical and
clinical utility of a DST developed as part of this thesis.
One reason for the inconsistencies found with some patient characteristics across reviews
may in part be due to the different types of study design (e.g. controlled vs uncontrolled
trials) that were included across the reviews, which might have impacted how comparative
analyses on predictors. Another possible reason is the different populations, especially with
regard to diagnoses, that were included across the reviews of CMHDs. Although IAPT
services see patients across the range of CMHDs, formal diagnosis has been generally low,
and 48.7% of patients referred to IAPT between 2014 and 2015 were reported to have an
invalid or unknown diagnostic code (HCSIC, 2015). As a result, a DST for IAPT that used
diagnosis may have little clinical utility in IAPT services, as this information may not be
routinely available for half of patients. Instead, focusing on standardised patient
characteristics that are routinely collected and able to be self-completed by patients, could
result in a DST with more clinical utility in routine services. An analysis of patient
characteristics that are routinely collected at all IAPT services would supplement the results
of the meta-review and potentially provide more relevant information on predicting outcomes
in IAPT services.
As discussed in Chapter 1, IAPT services are the main provider of psychological
interventions for CMHDs in England. IAPT services have adopted a stepped care model
(see figure 1.1, Chapter 1), and provide low intensity (LI) interventions at Step 2 or high
intensity (HI) interventions at Step 3. The main key performance indicator (KPI) for IAPT
services nationally is ‘Moving to Recovery’ (NHS Digital, 2016). IAPT defines this as scoring
clinical ‘caseness’ on either the Patient Health Questionnaire 9 (PHQ-9; Kroenke, et al.,
2001) or the Generalised Anxiety Disorder scale 7 (GAD-7; Spitzer, et al., 2006) at initial
contact with the service and then being below caseness at the end of treatment on both
symptom measures. Clinical caseness is defined as scoring 10 or higher on the PHQ-9
and/or 8 or above on the GAD-7 at initial assessment, and scoring below caseness on both
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measures at the end of treatment is defined as ‘recovery’. Considering the importance of this
KPI for evaluating IAPT services, determining patient characteristics associated with
recovery will have practical benefits for services nationally in England.
An alternative method of evaluating patient response to treatment is to consider whether
patients have reported a clinically meaningful reduction in symptom scores. One of the most
commonly used methods of estimating clinically significant reductions in symptoms used in
both research and clinical practice is the Reliable Change Index (RCI) (Jacobson & Truax,
1991), a statistic which identifies whether the change in scores is more than could attributed
to measurement error. This method can also be applied to increases in patient symptoms,
where clinically significant increases in symptom severity may indicate that the patient’s
mental health has deteriorated during treatment. This is important as an increase in
symptoms during interventions could indicate a harmful treatment effect, and previous
research suggests around 5-10% of patients could be classed as deteriorating following
psychological interventions (Boisvert & Faust, 2003; Rozental et al., 2017).
The meta-review presented in the previous chapter identified only nine previously conducted
reviews that had explored the association between patient characteristics and dropout from
treatment, none of which were for face-to-face psychological interventions. Of the n=953522
patients entering IAPT treatment between April 2015 and March 2016, n=416391 did not
complete treatment (44%) (NHS Digital, 2016), which is considerably higher than the 30%
estimated in routine psychological care (Wells et al., 2013). Identifying patient characteristics
associated with increased dropout might inform a more personalised approach to treatment,
which could increase engagement and reduce early termination of treatment in IAPT
services.
The aim of this chapter was to explore the association between patient characteristics
routinely collected as part of the standardised IAPT minimum dataset (MDS) and outcomes
following treatment from IAPT services. It was theorised that certain characteristics would
have more influence on outcomes for specific intensities of IAPT treatment, and therefore
sub-analyses were also conducted for patients receiving different intensities of psychological
interventions. The results of this analysis could be used to predict the likelihood of treatment
outcomes in IAPT services based on routine assessment data, and could inform the first
stages of a personalised treatment approach in IAPT settings.
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Methods
Patient sample & Dataset
The sample used for this analysis came from two IAPT services in North London with data
on individual patients collected between September 2008 and March 2012. This dataset
included every patient referred to the service between this period; a total of n=34741
patients. Initial assessment information (referred to as time 1; ‘T1’) including data on patient
characteristics was available for n=19817 patients. Following the T1 assessment, n=3181
patients either declined treatment from IAPT, were still in treatment or referral according to
the patient management system, or were deemed not suitable for treatment from the
services. This left n=16636 patients who were assessed and taken into treatment within the
dataset.
To calculate the key IAPT outcome, ‘moving to recovery’, data is needed on both the first
and final assessment scores on the PHQ-9 and GAD-7 for patients. Therefore, only patients
who had both T1 and T2 (Time 2; endpoint) data available on either symptom measure were
included in the analysis. A number of patients accepted into treatment at IAPT services will
have only a single treatment session for advice and consultation with a clinician, and these
patients would therefore be excluded from analysis as they would provide data for only one
time point. In addition, the moving to recovery IAPT outcome requires patients to be scoring
above caseness on either symptom measure at T1, and therefore patients who scored
below the cut-offs on both measures at T1 were not included in the current analysis (as they
did not meet caseness). From the total of n=16636 patient taken into treatment, n=2691
scored below clinical caseness on both symptom measures pre-treatment, and n=3252
patients only received a single treatment session and therefore had no T2 data collected.
This resulted in n=10693 patients included in the analysis. A full flow diagram is presented in
figure 4.1.
Patient characteristics (Indicator variables)
A number of patient characteristics identified in the systematic review of the literature
(Chapter 3) were also present in the IAPT dataset. Although some patient characteristics
(e.g. gender) were not consistently associated with outcomes in the meta-review, they were
included in this exploratory analysis to confirm whether a pattern of limited association was
observed in outcomes following IAPT treatments. The IAPT MDS is a standardised
mandatory set of information that includes a range of clinical, demographic and service
based variables to be collected at each assessment by all services (HSCIC, 2015). Nine
patient characteristics collected within the IAPT MDS were selected for this analysis, and are
presented in Table 4.1. Severity scores were taken from the T1 assessment measures on
the PHQ-9 and GAD-7. Caseness for phobia, defined as scoring 4 or above on any of the
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three IAPT phobia items included in the IAPT dataset (IAPT, 2011) was included as a
dichotomous patient characteristic. The level of social and occupational functioning was
assessed using the Work and Social Adjustment scale (W&SAS) (Mundt, Marks, Shear, &
Greist, 2002) score at T1. Although a range of categories were collected for ethnicity within
the dataset, a very large percentage were from white ethnic groups (78%) and it was
therefore decided to combine all other ethnicities into a ‘non-white’ group to reduce the risk
of the regression analysis being under powered. The dataset also contains information on
whether medication had been prescribed at T1, although there is no data regarding
medication adherence. Lastly, information on whether patients were receiving welfare
benefits was used as a dichotomous variable, as information on employment status was not
available within the dataset provided by the services.
Figure 4.1. Patient flow - analysis of treatment outcomes.
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Patients
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n = 14924
Excluded no T1
data
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declined treatment,
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in treatment /
referral
n = 2691 Excluded
Non-caseness
n = 3252 Excluded
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Table 4.1. Included patient characteristics.
Variable Type of
variable
Description
Age at referral Continuous Age of patient
Gender Dichotomous ‘Male’ or ‘female’
Self-rating of
depressive symptoms
Continuous Score on Patient Health Questionnaire (PHQ-9;
Kroenke et al., 2001)
Self-rating of anxiety
symptoms
Continuous Score on Generalised Anxiety Disorder Scale (GAD-
7; Spitzer et al., 2006)
Level of personal and
social functioning
Continuous Score on Work and Social adjustment Scale
(W&SAS; Mundt et al., 2002).
Medication
prescription status
Dichotomous ‘Prescribed’ or ‘not prescribed’ psychotropic
medication at referral.
Welfare status Dichotomous ‘Receiving benefits’ or ‘not receiving benefits’ from
UK welfare support.
Ethnic group Dichotomous ‘White’ or ‘non-white’ ethnic group
Phobia self-rating Dichotomous ‘Phobia’ or ‘non-phobia’, classified by a score of 4 or
more any one of the three phobia items (IAPT, 2011).
As discussed previously, the IAPT dataset includes a provisional diagnosis variable, or
‘problem description’ but completion of this data is poor, and missing data is recorded for
nearly half of patients (HSCIC, 2015). A DST which included this factor would potentially be
unusable for half of patients entering treatment, and therefore diagnosis was not explored in
the analysis. A number of patient characteristics identified in the meta-review presented in
Chapter 3 which were associated with outcomes were not included in the IAPT dataset (e.g.
self-efficacy, and previous treatment), and therefore could not be explored in the analysis.
Despite being encouraged by the services, information about shared decision making is not
included in the IAPT MDS and therefore was not considered in the analysis presented
below.
Outcomes
There were five outcomes of interest in this analysis, all of which were dichotomous in
nature, and these are detailed in Table 4.2.
The first outcome explored, ‘Moving to Recovery’ (Recovery), is the main IAPT national KPI
measuring service level performance and was defined as moving from caseness to non-
caseness following treatment. Patients scoring above the cut-off point on either measure at
T1 needed to score below caseness on both assessment measures (PHQ-9 and GAD-7) at
T2 to achieve this outcome. The cut-offs used by IAPT services are a score of 10 on the
PHQ-9 and of 8 on the GAD-7 (HSCIS, 2015).
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Table 4.2. Treatment outcomes: definitions and criteria.
Name Definition Criteria
Recovery Percentage of
patients recovered
Scoring above clinical caseness cut-off at initial
assessment on either symptom measure and
scoring below the cut-off on both at final
assessment following treatment.
Reliable
change
Percentage of
patient showing
reliable change
Reliable decrease in symptoms between first
and final assessment on both the PHQ-9 and
GAD-7. Calculated using the reliable change
index (Jacobsen & Traux, 1991).
Recovery or
improvement
Percentage of
patients recovered
or showing
improvement
Either in recovery or showing reliable change on
either measure, as defined above, or reliable
change in one measure whilst being non-
caseness on the second measure.
Deterioration Percentage of
patients in showing
clinical deterioration
Deterioration was defined as reliable clinical
change in a negative direction (increase in
score) between initial and final assessment on
either symptom scale. Calculated using the
reliable change index (Jacobsen & Traux, 1991)
Dropout Percentage of
patients not
completing
treatment
Defined as either dropping out of treatment as
recorded in the IAPT dataset, or as declining
treatment after two or more treatment sessions
by the service.
The second outcome of interest was whether patients showed a reliable change on both
symptom severity measures following treatment. Reliable change was calculated on both
measures for each patient using the reliable change index (RCI) formula (Evans, Margison,
& Barkham, 1998; Jacobson & Truax, 1991). This method of estimating clinically important
change in symptoms is widely used and recommended in outcome research (Bauer,
Lambert, & Nielsen, 2004). To calculate this outcome, the standard error of measurement
and the error of difference were calculated on both symptom measures using the standard
deviation of the current IAPT dataset used for this analysis and the alpha coefficient of
reliability presented in the original publications of the assessment tools (Kroenke et al.,
2001; Spitzer et al., 2006). Using these values, the reliable change index (RCI) for each
patient on both measures was generated, and RCI values over 1.96 indicated reliable
change on that measure had been achieved. Calculations of the RCI showed that a change
score of 5 or above on the PHQ and a score of 4 or above on the GAD-7 indicated reliable
change. Patients were only considered to have met reliable change if they showed reliable
change on both measures, rather than just one.
A third outcome was then generated by combining the first and second outcomes to create a
‘recovery or improvement’ outcome, to incorporate these two different types of treatment
effect calculations into one positive outcome, which may be a more valuable indicator of
overall performance from the perspective of the service. To achieve this outcome, patients
had to either meet the recovery criteria, meet the reliable change criteria (change on both
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measures) or display reliable change on one measure whilst being below the clinical cut-off
for caseness on the second scale.
In addition to positive outcomes from treatment, the analysis was also interested in potential
negative outcomes, for example increases in symptoms following IAPT treatment, and
therefore clinical deterioration was also included as an outcome. To meet criteria for clinical
deterioration, a patient must show reliable change in a negative direction (5+ on the PHQ-9
and 4+ on the GAD) on either scale. Patients were classed as ‘deteriorated’ if they met
these criteria on just one scale, regardless of whether there was a reduction in symptom
scores on the second measure.
The final outcome of interest was dropout from treatment. Data on dropout was obtained
from the ‘reason for end of contact’ record in the service records system. Patients were also
coded as dropping out from treatment if they either; 1) were recorded as ‘declining care’ but
had had two or more sessions with a clinician, 2) were recorded as ‘not suitable’ but had
received three or more contacts with the service or 3) were recorded as having dropped out
of treatment regardless of number of sessions. It was decided to code patients who were
recorded as ‘declining’ or ‘not suitable’ following multiple contacts as ‘dropout’, as these
were viewed as coding errors. Patients were expected to have completed an extended
assessment by their second contact with the service, and therefore any patient considered
as “not suitable”, or declining further sessions after the second contact was viewed as a
treatment dropout in this analysis.
Analysis was conducted on both the full sample of included patients (‘all patient’ sample),
but also by sub-groups of patients receiving specific intensities of psychological intervention.
The three subgroups were patients receiving LI interventions only, patients receiving HI
interventions only and patients who were stepped up during treatment. Stepped up patients
were defined as individuals who started treatment at Step 2 (LI) but were ‘stepped up’ to
Step 3 (HI) during contact with the services, usually due to lack of response to treatment at
Step 2.
Analysis
To explore the association between the nine patient characteristics and the five dichotomous
treatment outcomes, multiple logistic regression analysis was performed. Regression
analysis is routinely used for this type of research question, and have been used to explore
the role of patient characteristics in CMHDs previously (Blom et al., 2007; Gyani, Shafran,
Layard, & Clark, 2011).
Binary logistic regression analysis was performed on the dataset to determine which
characteristics were significantly associated with each of these five dichotomous outcomes
listed Table 4.2 above. All outcomes were coded as 1 for outcome achieved and 0 for not
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achieved. As multiple independent variables were to be added to the regression models, a
stepwise approach was adopted. There are three typical approaches to consider in stepwise
regression (Wang, Wright, Buswell, & Brownlee, 2013):
*Forward selection – starts from an empty model and adds variables one at a time until no
more variables can significantly improve the regression model based on criteria defined by
the researcher (see below). Variables are added based on pre-selection criteria.
*Backward selection – Model starts with all variables included and variables are then deleted
by the least improving variable first and so on until no more deleted variables can
significantly improve the model.
*Bidirectional elimination – Uses the forward selection procedure but at each step all
variables in the model at that step are investigated to see if any need to be deleted based on
pre-selected criteria.
For this analysis, a Bidirectional elimination method was selected with variables added one
by one, and all variables in the model at that step checked to make sure they still had a
significant association with the outcome, when controlling for all other characteristics in the
model. The criteria for including a variable in the model were a significant p-value for the
odds ratio (p<0.05) and an increase in the R2 value following the introduction on the variable,
indicating an increase in variance explained by the regression model. Analysis was
performed using STATA 12 (StataCorp LP, 2011).
The analysis for each outcome is presented below, with the Odds Ratio (OR), 95%
confidence of each patient characteristic and the R2 for the model at that step displayed. The
order that the variables were added to the regression models was informed by the results of
the meta-review presented in Chapter 3. Patient characteristics with more evidence for
association from the full review were added first, and those with more inconsistent or limited
findings were added afterwards. The order of patient characteristics added to the analyses
on recovery, reliable change, recovery or improvement and deterioration outcomes are
displayed in Table 4.3 below. As the patient characteristics associated with treatment
dropout identified in the meta-review differed from those associated with treatment
response, a different order of variable addition was employed for these analyses, and this is
displayed in Table 4.4.
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Table 4.3. Order of patient variables added to 'response' analyses.
Variable name How measured
Severity PHQ-9 T1 score
Severity GAD-7 T1 score
Comorbidity Phobia caseness at T1
Functioning W&SAS T1 score
Ethnicity White or non-white ethnic group
Welfare status On benefits at T1
Age Age at referral
Gender Gender recorded
Medication use Prescribed medication at T1
Table 4.4. Order of patient variables added to ‘dropout’ analyses.
Variable name How measured
Age Age at referral
Severity PHQ-9 T1 score
Severity GAD-7 T1 score
Comorbidity Phobia caseness at T1
Gender Gender recorded
Ethnicity White or non-white ethnic group
Functioning W&SAS T1 score
Welfare status On benefits at T1
Medication use Prescribed medication at T1
97
Results
All patients entering treatment
Table 4.5 displays the percentage of patients achieving each of the five outcomes for ‘all
patients’ entering treatment at the services (n=10693). Just over 40% of the sample
achieved the recovery and reliable change outcomes following treatment, and nearly 48% of
patients achieved the recovery or improvement outcome. The recovery rate for the services
was similar to the median rate reported by the one-year IAPT report (41%; Gyani et al.,
2011) but lower than more recent national evaluations of IAPT recovery figures (46%; NHS
Digital, 2016).
Deterioration on at least one of the symptom severity measures was recorded for just under
9% of the full sample, which falls within the 5-10% suggested by previous researchers
(Crawford et al., 2016; Rozental et al., 2016. Dropout was indicated in over 33% of patients,
which is similar to levels reported to other evaluations of routine psychological treatment
(Wells et al., 2013) and lower than the most recent national IAPT report (NHS Digital, 2016).
Although patients who dropped out did not complete treatment, the patient’s last score on
the symptom scales was available and used as T2 data for the analysis.
Table 4.5. All patients: Outcomes following treatment.
Outcome No Yes %
Recovery 6,410 4,283 40.05%
Reliable change 6,352 4,341 40.60%
Recovery or improvement 5,568 5,125 47.93%
Deterioration 9,762 931 8.71%
Dropout 7,114 3,579 33.47%
Recovery – ‘All Patients’
The results of the stepwise logistic regression for recovery in the ‘all patients’ sample is
displayed in Table 4.6. The patient characteristics were added to the regression model in the
order displayed in Table 4.3 above. At the first step of the regression model, the PHQ-9
score at T1 was found to have a significant odds ratio of 0.879 (p<0.001), suggesting that for
each increase in score on the PHQ-9 score at T1 (initial assessment), the odds of moving to
recovery following treatment drop by 0.879. This indicates that higher levels of depression
severity at assessment were significantly associated with a lower likelihood of recovery
following treatment. The variance explained by PHQ-9 score at T1 alone was 8.38%, as
indicated by the R2 value.
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Table 4.6. Stepwise regression model: recovery (all patients)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals
P-
value R
2
Model Step 1
PHQ-9 T1 0.879 0.873 to 0.886 0.000 8.38%
Model Step 2
PHQ-9 T1 0.904 0.896 to 0.912 0.000
9.53%
GAD-7 T1 0.931 0.921 to 0.941 0.000
Model Step 3
PHQ-9 T1 0.907 0.899 to 0.915 0.000
9.79%GAD-7 T1 0.937 0.926 to 0.947 0.000
Phobia caseness 0.773 0.709 to 0.844 0.000
Model Step 4
PHQ-9 T1 0.924 0.915 to 0.933 0.000
10.27%
GAD-7 T1 0.938 0.927 to 0.948 0.000
Phobia caseness 0.832 0.761 to 0.91 0.000
Functioning 0.976 0.971 to 0.982 0.000
Model Step 5
PHQ-9 T1 0.93 0.92 to 0.94 0.000
11.08%
GAD-7 T1 0.936 0.925 to 0.948 0.000
Phobia caseness 0.914 0.83 to 1.007 0.07
Functioning 0.981 0.975 to 0.988 0.000
Welfare status 0.523 0.469 to 0.584 0.000
Model Step 6
PHQ-9 T1 0.929 0.919 to 0.939 0.000
11.12%
GAD-7 T1 0.935 0.924 to 0.946 0.000
Functioning 0.981 0.975 to 0.987 0.000
Welfare status 0.515 0.461 to 0.574 0.000
At the next step, the GAD-7 score at T1 was added to the model, which increased the R2 to
9.53%, and had a significant odds ratio of 0.931 (p<0.001), suggesting higher scores on the
GAD-7 at T1 reduced the odds of recovery. By adding GAD-7 score to the regression model,
the odds ratio for PHQ-9 score was adjusted slightly to 0.904, although the PHQ-9 score
remained significant (p<0.001). Phobia caseness and the level of functioning were then
added to the model in the next two steps, and both showed significant odds ratios as well as
increasing the R2 to 10.27%. Scoring caseness for phobia at T1 and having lower levels of
social and occupational functioning (indicated by a higher scores at T1 on the W&SAS)
significantly reduced the odds of recovery following treatment. Ethnicity was added to the
model, but this characteristic was not significantly associated with the recovery (p>0.05). At
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Step 5 of the regression model, welfare status was added and this factor had a significant
association with recovery, as receiving benefits was found to reduce the odds of recovery as
well as increasing the R2 to 11.08%. However, by adding welfare status to the model, the
odds ratio for phobia caseness became non-significant (p=0.07) and this factor was
therefore dropped at Step 6. Age, gender and medication prescription status were also
included in the final stages, but none of these patient characteristics were found to
significantly improve the model and therefore the final regression model included PHQ-9,
GAD-7 and W&SAS scores at T1 as well as welfare status, and this model explained
11.12% of the variation in recovery.
Reliable change – ‘All Patients’
The stepwise regression model for reliable change in ‘all patients’ is presented in Table 4.7.
In the first step, the PHQ-9 score at T1 was found to be significantly associated with
achieving reliable change, indicated by an odds ratio of 1.057 (p<0.001). An odds ratio
above 1 indicates the odds of achieving the outcome increase with higher PHQ-9 T1 scores,
suggesting that higher depression scores at assessment increased the likelihood of reliable
change following treatment. In Step 2 of the model, GAD-7 at T1 was added and again had
a similar significant association to the PHQ-9 score, as higher T1 GAD-7 score was found to
increase odds of achieving this outcome. These findings differ to those for recovery
presented in Table 4.6 where higher scores decreased the odds of achieving the recovery
outcome following treatment.
In the next steps, caseness for phobia at T1 and level of functioning were added to the
model and both had significant associations with the outcome. Lower levels of functioning
and scoring caseness for phobia reduced the odds of reliable change following treatment.
The next step involved the addition of ethnicity group to the model, and there was a
significant association with being from a non-white ethnic group and lower odds of achieving
reliable change following treatment in the services, although just 3.21% of variance was
explained by this model. The addition of welfare status increased the R2 to 4.96% and
suggested that being on benefits reduced the odds of reliable change. However, the addition
of welfare status to the model resulted in phobia caseness becoming non-significant and
therefore phobia was dropped at Step 7. In the final step, medication prescription status at
T1 was found to be significantly associated with achieving reliable change, as individuals
prescribed psychotropic medication were less likely to reliably change on both symptom
scales following treatment. The final multivariate regression model accounted for 4.93% of
the variance.
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Table 4.7. Stepwise regression model: reliable change (all patients)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals
P-
value R
2
Model Step 1
PHQ-9 T1 1.057 1.049 to 1.064 0.000 1.70%
Model Step 2
PHQ-9 T1 1.036 1.027 to 1.044 0.000
2.26%
GAD-7 T1 1.049 1.038 to 1.06 0.000
Model Step 3
PHQ-9 T1 1.041 1.032 to 1.05 0.000
2.61%GAD-7 T1 1.056 1.044 to 1.068 0.000
Phobia caseness 0.763 0.7 to 0.831 0.000
Model Step 4
PHQ-9 T1 1.06 1.05 to 1.07 0.000
3.12%
GAD-7 T1 1.059 1.046 to 1.07 0.000
Phobia caseness 0.818 0.749 to 0.892 0.000
Functioning 0.978 0.973 to 0.983 0.000
Model Step 5
PHQ-9 T1 1.061 1.05 to 1.072 0.000
3.21%
GAD-7 T1 1.058 1.046 to 1.071 0.000
Phobia caseness 0.828 0.754 to 0.91 0.000
Functioning 0.979 0.973 to 0.984 0.000
Ethnicity Group 0.843 0.759 to 0.936 0.001
Model Step 6
PHQ-9 T1 1.074 1.062 to 1.086 0
4.96%
GAD-7 T1 1.06 1.046 to 1.074 0
Phobia caseness 0.926 0.836 to 1.024 0.135
Functioning 0.984 0.978 to 0.99 0
Ethnicity Group 0.889 0.793 to 0.996 0.042
Welfare status 0.463 0.414 to 0.518 0
Model Step 7
PHQ-9 T1 1.073 1.061 to 1.085 0
4.92%
GAD-7 T1 1.059 1.045 to 1.072 0
Functioning 0.983 0.977 to 0.989 0
Ethnicity Group 0.879 0.785 to 0.984 0.026
Welfare status 0.46 0.412 to 0.514 0
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Model Step 8
PHQ-9 T1 1.076 1.064 to 1.089 0
4.93%
GAD-7 T1 1.057 1.043 to 1.071 0
Functioning 0.985 0.979 to 0.991 0
Ethnicity Group 0.878 0.779 to 0.989 0.032
Welfare status 0.473 0.421 to 0.531 0
Medication prescribed 0.871 0.786 to 0.966 0.009
Comparing the final regression model for reliable change (Table 4.7) to the model for
recovery (Table 4.6) shows an important difference in the role of severity with these two
outcomes. Higher severity was found to decrease the odds of recovery following treatment,
but conversely increased the odds of a patient achieving reliable change. This may be
explained by the way in which the outcomes are defined and achieved. For recovery,
individuals needed to move from above to below a clinical cut off, and arguably being closer
to the cut off at T1 should make it easier to move below (as less change is needed). In
practice, patients with lower severity scores have a head start on patients scoring higher at
T1 when both are trying to reach the same goal (symptom scores under the threshold).
When considering reliable change, the goal of this outcome is to reduce symptom scores by
a certain absolute amount of scale points (5 points or more on the PHQ-9, 4 or more on the
GAD-7) and therefore patients scoring higher have more available points in which they can
decrease. This phenomenon is referred to as regression to the mean, where scoring closer
to the extreme increases the likelihood of the scoring closer to the mean on a second
measurement (Stigler, 1997). Although severity had a different association with the
outcomes, the level of functioning, phobia caseness and welfare status all had the same
association with both outcomes, suggesting that being phobic, on benefits and lower levels
of functioning decrease a patient’s odds of a positive outcome (both recovery and reliable
change) following treatment at the IAPT services.
Recovery or improvement – ‘All Patients’
Following the individual outcomes of recovery and reliable change, the results of ‘recovery or
improvement’ are presented in Table 4.8. The results of this analysis were very similar to
those for recovery (Table 4.6). Higher PHQ-9 and GAD-7 scores at T1 were significantly
associated with decreased odds of achieving a positive outcome following treatment. Phobia
caseness and lower levels of social and occupational functioning were then added to the
model and both characteristics reduced the odds of a positive outcome, with 7.53% of the
variance explained at this step. Welfare status was then added as the last step, and being
on benefits was found to significantly reduce the odds of positive outcome when controlling
for the other variables in the model. No other patient characteristics improved the model and
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the final variance explained was 8.48%.The variance explained was therefore lower than for
the regression model of recovery (Table 4.6), and suggests that the combined outcome is
more difficult to predict from the included patient characteristics, which is most likely due to
the opposing influence of initial severity on the recovery and reliable change outcomes.
Table 4.8. Stepwise regression model: recovery or improvement (all patients)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals
P-
value R
2
Model Step 1
PHQ-9 T1 0.896 0.889 to 0.903 0 6.36%
Model Step 2
PHQ-9 T1 0.908 0.9 to 0.915 0
6.57%
GAD-7 T1 0.97 0.96 to 0.98 0
Model Step 3
PHQ-9 T1 0.911 0.904 to 0.92 0
6.86%GAD-7 T1 0.975 0.965 to 0.986 0
Phobia caseness 0.757 0.696 to 0.824 0
Model Step 4
PHQ-9 T1 0.927 0.918 to 0.936 0
7.35%
GAD-7 T1 0.977 0.966 to 0.988 0
Phobia caseness 0.813 0.745 to 0.887 0
Functioning 0.978 0.972 to 0.983 0
Model Step 5
PHQ-9 T1 0.935 0.925 to 0.945 0
8.48%
GAD-7 T1 0.976 0.964 to 0.987 0
Phobia caseness 0.892 0.811 to 0.98 0.018
Functioning 0.982 0.976 to 0.988 0
Welfare status 0.505 0.456 to 0.56 0
Deterioration – ‘All Patients’
The regression model for clinical deterioration, an increase in one or both symptom scale
score(s) over the reliable change threshold following treatment, is presented in Table 4.9. In
the first two steps of the model, higher PHQ-9 and GAD-7 scores were found to be
significantly associated with lower odds of deteriorating following treatment. This suggests
that lower severity at T1 increased the likelihood of deteriorating by T2. The addition of
phobia caseness and then the level of functioning increased the variance explained to
4.62%, and the model suggested that being phobic and having lower levels of functioning
pre-treatment increased the odds of clinical deterioration.
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Table 4.9. Stepwise regression model: deterioration (all patients)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals
P-
value R
2
Model Step 1
PHQ-9 T1 0.94 0.929 to 0.951 0 1.66%
Model Step 2
PHQ-9 T1 0.976 0.963 to 0.99 0.001
3.73%
GAD-7 T1 0.903 0.888 to 0.919 0
Model Step 3
PHQ-9 T1 0.972 0.958 to 0.986 0
4.21%GAD-7 T1 0.895 0.879 to 0.911 0
Phobia caseness 1.54 1.329 to 1.784 0
Model Step 4
PHQ-9 T1 0.951 0.935 to 0.967 0
4.62%
GAD-7 T1 0.894 0.878 to 0.91 0
Phobia caseness 1.39 1.194 to 1.617 0
Functioning 1.028 1.018 to 1.038 0
Model Step 5
PHQ-9 T1 0.953 0.936 to 0.97 0
5.36%
GAD-7 T1 0.883 0.867 to 0.901 0
Phobia caseness 1.42 1.207 to 1.67 0
Functioning 1.026 1.016 to 1.037 0
Ethnicity group 1.306 1.095 to 1.556 0.003
Model Step 6
PHQ-9 T1 0.941 0.923 to 0.959 0
6.47%
GAD-7 T1 0.889 0.871 to 0.908 0
Phobia caseness 1.249 1.047 to 1.491 0.013
Functioning 1.021 1.009 to 1.032 0
Ethnicity group 1.196 0.987 to 1.45 0.068
Welfare status 2.149 1.799 to 2.567 0
Model Step 7
PHQ-9 T1 0.938 0.921 to 0.955 0
5.66%
GAD-7 T1 0.902 0.885 to 0.912 0
Phobia caseness 1.227 1.04 to 1.447 0.015
Functioning 1.022 1.011 to 1.032 0
Welfare status 2.126 1.8 to 2.511 0
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In the next step of the model, being in a non-white ethnic group was found to significantly
increase the odds of deterioration. Being on benefits was then associated with increased
odds of clinical deterioration following treatment, but the addition of this patient characteristic
to the regression model adjusted the odds ratio of ethnicity group so that it was no longer
statistically significant (p=0.068) and this variable was dropped at Step 7 of the model. No
other variables improved the model fit and the final R2 was 5.66%.
Treatment dropout – ‘All Patients’
The order of patients characteristics added to the stepwise regression model for treatment
dropout is presented in Table 4.4, and differed from the order used in the analyses of
recovery, reliable change and deteriorated presented above. The results of the multivariate
logistic regression for treatment dropout in the ‘all patient’ sample is presented in Table 4.10.
The first patient characteristic added to the model was age of patient, which was found to be
significantly associated with dropout from treatment, as older age was associated with
decreased odds of treatment dropout. In the next model step, a higher PHQ-9 score at T1
was found to increase the odds of treatment dropout. Welfare status was then added to
regression model, and the results indicated that patients who were receiving benefits had a
significantly increased risk of dropout. No other items were found to significantly improve the
model. The final R2 value was 0.0192, suggesting less than 2% of the variance in dropout
was explained by the available patient characteristics.
Table 4.10. Stepwise regression model: dropout (all patients)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals
P-
value R
2
Model Step 1
Age 0.984 0.98 to 0.987 0 0.76%
Model Step 2
Age 0.982 0.979 to 0.985 0
1.75%
PHQ-9 T1 1.043 1.036 to 1.051 0
Model Step 3
Age 0.981 0.978 to 0.985 0
1.92%PHQ-9 T1 1.036 1.027 to 1.044 0
Welfare status 1.368 1.239 to 1.512 0
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Summary – ‘All Patients’
The regression analyses of ‘all patients’ entering treatment at the IAPT services identified a
number of patient characteristics that were significantly associated with treatment outcomes
in IAPT. However, the variance explained by these models was limited, with only the final
model for the recovery outcome explaining over 10% of the variance. The regression model
for treatment dropout found that only three characteristics were significantly associated with
dropping out of treatment, and the variance explained by this model was just 1.92%.
The analysis of characteristics associated with recovery supported findings from the
systematic review presented in Chapter 3 as lower severity, being in employment and higher
levels of functioning were all associated with better outcomes. Although ethnicity group and
medication status were not associated with the recovery outcome, they were both found to
be significantly associated with the reliable change outcome, as being from a non-white
ethnic group and prescribed medication reduced the likelihood of achieving reliable change
following treatment. Potentially these two characteristics may indicate greater complexity
and/or social adversity which may result in reduced odds of a positive outcome from
treatment. When the recovery or improvement outcome was explored, the associated patient
characteristics matched those for the recovery alone outcome, but with a reduced variation
explained by the final model. It is likely that the inclusion of ‘improvement’ to the model,
which would include reliable change on one measure for some individuals, is contributing
more variability in the predictive ability of the patient characteristics, hence the reduced
variation explained.
The results of the regression analysis of clinical deterioration suggested that lower severity
at T1 is associated with a higher likelihood of symptom scores increasing by the end of
contact with the services. Although this could appear concerning, it may also be explained
by regression to the mean, as individuals who are already scoring higher on the measures at
T1 have less available points on which to increase compared to individuals scoring at the
lower range of the symptoms measures at assessment. Alternatively, lower severity may
have been associated with an increased likelihood of deterioration as some patients may
have attended the services before the symptoms had reached a peak. For example, some
patients with phobia may display an increase in anxiety symptoms as they confront their
phobia during initial treatment. The other patient characteristics associated with deterioration
were the same as those identified in the model predicting recovery, but with an opposite
direction of effort (as expected): the presence of phobia, higher levels of work and social
functioning impairment and receiving welfare benefits all increased the likelihood of
increased symptoms following treatment. These characteristics could all be linked to more
complex presentations in the services, which if combined with stressful life events and
limited social support could increase the risks of a worsening of clinical symptoms (Steger &
Kashdan, 2009).
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Increased odds of treatment dropout were associated with lower age, higher depression
scores at T1 and being on welfare benefits at assessment, although this model explained
very little variance in the outcome (1.92%). Younger age was also associated with less
treatment dropout in the meta-review, suggesting the findings of this analysis support
findings identified in the previous literature. Severity of depression was linked to treatment
dropout, but anxiety scores were not, which may explain the inconsistent role of severity
across the included systematic reviews identified in Chapter 3. Employment status was not
included in any of the included systematic reviews of treatment dropout, but the findings of
this regression analysis suggest they may be important in predicting whether a patient will
complete treatment.
The findings of the regression analyses performed identified a number of patient
characteristics that were associated with treatment outcomes in patients receiving IAPT
treatment. However, the variance explained by the models was limited for predicting reliable
change, deterioration and dropout. The variance explained by the regression model for
recovery was higher (over 11%) and was above the level that would be considered of clinical
importance to researchers (Uher et al., 2012). It was possible that the inclusion of patients
attending different intensities of psychological treatment reduced the variance explain by
some of the regression models, as characteristics may have a different association with
outcomes depending on the treatments received. Therefore the analysis was replicated
using sub-samples of patients within the dataset who received LI or HI interventions, as well
as patients who were stepped up during contact with the services.
Sub-analyses by intensity of intervention
The next stage of analysis was to explore the role of patient characteristics associated with
outcome following different IAPT-delivered interventions. However, the nature of the IAPT
services meant that one patient may have received a number of different interventions within
an episode of care. This may be because they were ‘stepped up’ during their episode of care
and therefore received both a self-help low intensity intervention and a therapist-delivered
treatment high intensity intervention. In addition, some patients may have received a change
in treatment modality during treatment, for example receiving both CBT and counselling
during an episode of care. Appendix C presents the count of interventions received by the
n=10693 included patients. Self-help (other) (51.45%) and CBT (39.67%) were the
interventions most commonly received by any patient. Specific modalities of treatment such
as IPT and Couples Therapy were received relatively infrequently in the dataset and
received by just n=63 (0.59%) and n=37 (0.35%) of the n=10693 included patients. As a
result, it was decided to group patients into the intensity of intervention they received rather
than focus on individual treatment modalities, and the sample was split by intensity of
intervention received, and regression analysis was performed by these sub-groups.
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Individuals who were stepped up were considered as a separate group as they would have
received both intensities of treatment.
Table 4.11 shows the number of patients who received interventions at each step of the
stepped care model in the dataset. Of the n=10693 patients included in the full sample
analysis, only n=38 patients were recorded as receiving treatment at either Step 1 or Step 4
and these patients were not considered for analysis, as these interventions are not typically
delivered in IAPT services. Some patients were stepped down from Step 3 to Step 2 during
the course of treatment but as this group consisted of less than 2% of the included sample,
they were not explored in this analysis. N=568 patients did not have their intervention type
recorded and therefore could not be included, but there was information on n=9894 patients
who received treatment at Step 2 (LI), Step 3 (HI) or were ‘stepped up’ during contact with
the services. This made up 92.52% of the initial included sample (‘all patients’) and
regression analyses for the five outcomes were performed on these three intervention
groups separately.
Table 4.11. Number of patients by intensity of intervention.
Step of Intervention Freq. %
Step 1 or Step 4 38 0.36%
Stepped Down 193 1.80%
Low Intensity 5,271 49.29%
High Intensity 3,063 28.64%
Stepped Up 1,560 14.59%
Not known/recorded 568 5.31%
Total 10,693
A comparison of the means and proportions of the nine patient characteristics between
patients receiving either LI, HI or ‘stepped up’ patients is displayed in Table 4.12. One-way
ANOVA and chi2 statistics indicate that the means and proportions were significantly
different between intervention groups. Age was slightly higher for HI patients than LI or
stepped up patients, which may suggest more chronic or re-occurring issues requiring higher
intensity treatment. Pre-treatment PHQ and GAD scores were higher in the stepped up
group when compared to HI and LI patients, whereas functional impairment as scored on the
W&SAS was highest in patients who received only HI treatment.
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Table 4.12. Descriptive statistics by intensity of intervention.
LI HI SteppedUp
Mean (SD) Mean (SD) Mean (SD) F p-value
Age at referral 37.4 (12.8) 39.1 (13.4) 37.0 (12.8) 22.64 <0.000
Pre-treatment PHQ-9 15.0 (5.5) 16.1 (6.0) 16.5 (5.6) 60.04 <0.000
Pre-treatment GAD-7 13.6 (4.3) 14.2 (4.7) 14.7 (4.3) 41.68 <0.000
Pre-treatment W&SAS 18.1 (8.8) 21.3 (9.5) 20.7 (9.0) 127.26 <0.000
N (%) N (%) N (%) Chi2 p-value
Gender - Female 3508 (68%) 1905 (63%) 1012 (65%) 16.25 <0.000
Phobia caseness -
Yes 2524 (50%) 1894 (63%) 924 (60%) 131.76 <0.000
Receiving welfare
benefits - Yes 1104 (25%) 1024 (38%) 394 (28%) 150.96 <0.000
Ethnic group - Non-
white 1032 (23%) 629 (23%) 286 (20%) 5.23 0.073
Medication prescribed
- Yes 1717 (34%) 1337 (55%) 572 (38%) 302.83 <0.000
Although the proportion of people from non-white ethnic background was not significantly
different between intervention groups, the other four categorical variables showed significant
differences between groups. A higher proportion of patients receiving HI treatments were
male, receiving benefits, met caseness for phobia and were prescribed medication
compared to patients receiving LI only. This would be expected if the more complex nature
of the presentation contributed to the decision to select HI intervention instead of LI. Stepped
up patients had a very similar proportions of female patients, patients prescribed medication
and patients receiving benefits compared to LI, but stepped up patients had a higher
proportion of individuals scoring caseness for phobia.
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Patients receiving Low Intensity treatments
Patients receiving LI interventions were seen for shorter periods of time than those receiving
HI interventions, and with an expectation that less intensive interventions will be satisfactory
to provide a positive outcome (IAPT, 2011). Table 4.13 displays the percentage of patients
achieving each of the patient outcomes in this subgroup. Overall, the percentages are not
dissimilar from ‘all patients’ entering treatment (Table 4.5), although more patients were
moving to recovery following LI interventions (41.4% vs 40.05%) and the percentage of
patients deteriorating is slightly lower (7.74% vs 8.71%).
Table 4.13. Low intensity: Outcomes following treatment.
Outcome No Yes %
Recovery 3,089 2,182 41.40%
Reliable change 3,126 2,145 40.69%
Recovery or improvement 2,675 2,596 49.25%
Deterioration 4,863 408 7.74%
Dropout 3,510 1,761 33.41%
Stepwise logistic regression was performed using the same nine patient variables, for the
five treatment outcomes explored in the analysis in the ‘all patient’ sample. For the stepwise
analysis, the patient variables were entered in the order presented in Table 4.3 for the
recovery, reliable change, recovery or improvement and deterioration analyses, and the
order in Table 4.4 was used in the analyses of treatment dropout.
Recovery - Low Intensity
The stepwise regression model for moving to recovery is presented in Table 4.14. The
significant associations and model steps were identical to those in the stepwise regression
model for recovery in ‘all patients’. The similarities in findings between these comparisons
may be influenced by the large number of patients in the LI group, who were therefore also
present in the ‘all patients’ sample (5271 of 10693; 49%). The ORs in the final step of the
model were very similar between the models for ‘all patients’ and LI only. The variance
explained by the LI recovery model was 10.6%, which was lower than for the ‘all patient’
sample, using the same patient characteristics.
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Table 4.14. Stepwise regression model: recovery (Low intensity)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 0.88 0.87 to 0.89 0 7.69%
Model Step 2
PHQ-9 T1 0.905 0.894 to 0.917 0
8.79%
GAD-7 T1 0.931 0.916 to 0.946 0
Model Step 3
PHQ-9 T1 0.908 0.896 to 0.92 0
8.99%GAD-7 T1 0.934 0.919 to 0.95 0
Phobia caseness 0.805 0.711 to 0.91 0.001
Model Step 4
PHQ-9 T1 0.927 0.914 to 0.941 0
9.50%
GAD-7 T1 0.934 0.919 to 0.95 0
Phobia caseness 0.862 0.76 to 0.978 0.021
Functioning 0.973 0.965 to 0.981 0
Model Step 5
PHQ-9 T1 0.935 0.92 to 0.95 0
10.56%
GAD-7 T1 0.934 0.917 to 0.95 0
Phobia caseness 0.919 0.802 to 1.055 0.23
Functioning 0.976 0.968 to 0.985 0
Welfare status 0.47 0.397 to 0.556 0
Model Step 6
PHQ-9 T1 0.934 0.92 to 0.949 0
10.60%
GAD-7 T1 0.932 0.916 to 0.949 0
Functioning 0.976 0.967 to 0.984 0
Welfare status 0.463 0.392 to 0.548 0
Reliable change - Low Intensity
The stepwise regression model for reliable change in patients attending LI interventions is
presented in Table 4.15. The results of this analysis were again very similar to those for
reliable change in the ‘all patients’ patients, with the same patient characteristics significantly
associated with the outcome.
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Table 4.15. Stepwise regression model: reliable change (Low intensity)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 1.067 1.056 to 1.078 0 2.19%
Model Step 2
PHQ-9 T1 1.046 1.034 to 1.059 0
2.73%
GAD-7 T1 1.049 1.033 to 1.066 0
Model Step 3
PHQ-9 T1 1.051 1.038 to 1.065 0
2.99%GAD-7 T1 1.054 1.037 to 1.071 0
Phobia caseness 0.803 0.712 to 0.906 0
Model Step 4
PHQ-9 T1 1.073 1.058 to 1.088 0
3.62%
GAD-7 T1 1.055 1.038 to 1.072 0
Phobia caseness 0.86 0.76 to 0.973 0.017
Functioning 0.975 0.967 to 0.983 0
Model Step 5
PHQ-9 T1 1.075 1.059 to 1.092 0
3.86%
GAD-7 T1 1.055 1.037 to 1.074 0
Phobia caseness 0.866 0.758 to 0.989 0.034
Functioning 0.975 0.967 to 0.984 0
Ethnicity Group 0.797 0.633 to 0.859 0
Model Step 6
PHQ-9 T1 1.089 1.071 to 1.108 0
5.37%
GAD-7 T1 1.057 1.037 to 1.077 0
Phobia caseness 0.926 0.8 to 1.07 0.297
Functioning 0.98 0.971 to 0.989 0
Ethnicity Group 0.764 0.646 to 0.902 0.002
Welfare status 0.499 0.421 to 0.592 0
Model Step 7
PHQ-9 T1 1.089 1.071 to 1.108 0
5.39%
GAD-7 T1 1.056 1.037 to 1.076 0
Functioning 0.979 0.97 to 0.988 0
Ethnicity Group 0.755 0.639 to 0.891 0.001
Welfare status 0.495 0.418 to 0.586 0
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Model Step 8
PHQ-9 T1 1.093 1.074 to 1.112 0
5.55%
GAD-7 T1 1.055 1.035 to 1.075 0
Functioning 0.98 0.97 to 0.989 0
Ethnicity Group 0.746 0.629 to 0.884 0.001
Welfare status 0.504 0.424 to 0.6 0
Medication prescribed 0.793 0.681 to 0.923 0.003
The initial PHQ-9, then GAD-7 score were significantly associated with achieving reliable
change, as higher scores on both measures increased the odds of reliable change. Phobia
caseness and lower social functioning (as measured on the W&SAS) were significantly
associated with reduced odds of reliable change. The next steps of the model indicated that
being from a non-white ethnic group significantly reduced the odds of reliable change, and
that receiving welfare benefits was found to further reduce the likelihood of achieving reliable
change. Adding these variables to the model resulted in the phobia caseness variable
becoming non-significant, and therefore it was removed at Step 7. Finally, at Step 8, having
medication prescribed at the time of the initial assessment was significantly associated with
a reduced likelihood of achieving reliable change following treatment. The overall variance
explained by the included patient characteristics was 5.55% which is slightly higher than the
variance explained by the same model in the ‘all patients’ sample (R2 = 0.493).
Recovery or Improvement - Low Intensity
The stepwise regression analysis exploring characteristics associated with recovery or
improvement is presented in Table 4.16. PHQ-9, GAD-7, Phobia caseness and the level of
functioning were all found to be associated with the positive treatment outcome, with lower
severity, not meeting caseness for phobia and higher levels of functioning at assessment
associated with increased odds of achieving the outcome. Welfare status was then added to
the model and was significantly associated with the outcome (being on benefits reduced the
odds of achieving the outcome), but this resulted in phobia caseness becoming non-
significant and therefore this characteristic was removed at the following step (Step 6). No
other patient characteristics were significantly associated with the outcome. The final model
included PHQ-9, GAD-7, functioning, and welfare status, and accounted for 7.65% of the
variance.
The final regression model for recovery or improvement in LI cases was similar to the
regression model for the same outcome in the ‘all patients’ sample, with the exception of
phobia caseness which remained significantly associated with the outcome in the final model
for the ‘all patients’ sample. This suggests that phobia caseness may have less impact on
this outcome in LI patients, compared to patients attending other interventions.
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Table 4.16. Stepwise regression model: recovery or improvement (Low intensity)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 0.898 0.888 to 0.907 0 5.74%
Model Step 2
PHQ-9 T1 0.908 0.896 to 0.919 0
5.86%
GAD-7 T1 0.974 0.96 to 0.99 0.001
Model Step 3
PHQ-9 T1 0.911 0.899 to 0.923 0
6.11%GAD-7 T1 0.979 0.963 to 0.995 0.009
Phobia caseness 0.772 0.685 to 0.87 0
Model Step 4
PHQ-9 T1 0.929 0.915 to 0.942 0
6.61%
GAD-7 T1 0.979 0.963 to 0.995 0.01
Phobia caseness 0.823 0.728 to 0.931 0.002
Functioning 0.976 0.968 to 0.983 0
Model Step 5
PHQ-9 T1 0.938 0.924 to 0.953 0
7.73%
GAD-7 T1 0.978 0.961 to 0.995 0.012
Phobia caseness 0.883 0.772 to 1.009 0.068
Functioning 0.978 0.97 to 0.986 0
Welfare status 0.49 0.419 to 0.572 0
Model Step 6
PHQ-9 T1 0.937 0.923 to 0.952 0
7.73%
GAD-7 T1 0.976 0.959 to 0.993 0.006
Functioning 0.977 0.968 to 0.985 0
Welfare status 0.478 0.409 to 0.558 0
Deterioration - Low Intensity
The analysis of deterioration in LI patients is presented in Table 4.17. The PHQ-9 score at
T1 was significantly associated in the first step but the addition of GAD-7 adjusted the OR
for PHQ-9 so that it was no longer statistically significant (p=0.074) and was removed by
Step 3 of the regression model. Phobia caseness, then lower levels of functioning were
found to be significantly associated with increased deterioration and added to the regression
model. Finally, being from of a non-white ethnic group was found increase the odds of
deterioration following treatment. No other patient characteristics were significantly
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associated with the outcome when controlling for the characteristics already included in the
model, and the variance explained was 5.55%.
The results of this analysis were different from those presented in the ‘all patients’ analysis
(Table 4.9). Initial severity of depression scored on the PHQ-9 was not significantly
associated with deterioration in the final LI model, whereas it was significantly associated
with the outcome in the ‘all patients’ analysis. Welfare status was also significantly
associated with deterioration for all patients, but it was not associated with deterioration in
patients who received only LI treatments, as it did not increase the variance explained by the
model. Ethnicity group was found to be significantly associated with deterioration in the final
LI regression model, but it was not in the ‘all patient’ model as it was no longer significant in
the final step. These results suggest there may be a slightly different role of patient
characteristics that are associated deterioration in symptoms following treatment between
the LI interventions and all patients receiving any IAPT interventions.
Table 4.17. Stepwise regression model: deterioration (Low intensity)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 0.941 0.923 to 0.958 0 1.45%
Model Step 2
PHQ-9 T1 0.98 0.959 to 1.002 0.074
3.76%
GAD-7 T1 0.894 0.87 to 0.718 0
Model Step 3
GAD-7 T1 0.884 0.863 to 0.906 0 3.65%
Model Step 4
GAD-7 T1 0.875 0.853 to 0.898 0
4.04%
Phobia caseness 1.404 1.13 to 1.745 0.002
Model Step 5
GAD-7 T1 0.871 0.848 to 0.894 0
4.15%Phobia caseness 1.301 1.039 to 1.631 0.022
Functioning 1.017 1.003 to 1.03 0.016
Model Step 6
GAD-7 T1 0.854 0.83 to 0.878 0
5.55%
Phobia caseness 1.419 1.11 to 1.813 0.005
Functioning 1.015 1.001 to 1.03 0.038
Ethnicity Group 1.412 1.081 to 1.845 0.011
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Treatment dropout - Low Intensity
The stepwise regression model for treatment dropout during LI interventions is presented in
Table 4.18. The order of patient variables added to the regression model were the same as
those entered in the dropout analysis for ‘all patients’, and is presented in Table 4.4. Higher
age was found to be reduce the odds of dropping out of treatment in the first step of the
model, and then higher PHQ-9 scores were found to significantly increase the odds of
dropout. Next, gender was found to be significantly associated with dropping out of
treatment, as female patients less likely to dropout of treatment compared to male patients in
receipt of LI treatments. Receiving welfare benefits was significantly associated with higher
odds of dropping out of treatment at Step 4 of the regression model, and having been
prescribed medication was then significantly associated with a higher risk of dropping out of
treatment. No other patient characteristics were significantly associated with dropout, and
the variance explained by this final regression model was just 1.58%.
Table 4.18. Stepwise regression model: dropout (Low intensity)
Step and characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
Age 0.984 0.979 to 0.988 0 0.74%
Model Step 2
Age 0.983 0.978 to 0.987 0
1.32%
PHQ-9 T1 1.034 1.023 to 1.045 0
Model Step 3
Age 0.982 0.978 to 0.987 0
1.44%PHQ-9 T1 1.034 1.023 to 1.046 0
Gender 0.84 0.742 to 0.951 0.006
Model Step 4
Age 0.982 0.976 to 0.987 0
1.50%
PHQ-9 T1 1.027 1.015 to 1.04 0
Gender 0.859 0.751 to 0.983 0.027
Welfare status 1.296 1.115 to 1.506 0.001
Model Step 5
Age 0.981 0.976 to 0.987 0
1.58%
PHQ-9 T1 1.024 1.011 to 1.036 0
Gender 0.87 0.759 to 0.997 0.045
Welfare status 1.305 1.118 to 1.522 0.001
Medication prescribed 1.21 1.052 to 1.391 0.008
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The results of the regression model for dropout of treatment was quite different from the
regression model for ‘all patients’ presented in Table 4.6. Gender and medication
prescription status were found to be associated with dropout in LI only, and not for ‘all
patients’. This suggests that these patient variables may need further consideration by
clinicians working in LI, as they may affect treatment adherence.
Summary – Low Intensity
The findings presented in these analyses of patients attending LI interventions appear
similar for the three recovery/reliable change outcomes, but differ in relation to deterioration
and dropout when compared to the ‘all patients’ analyses. As nearly 50% of the full sample
was made up of individuals receiving LI interventions only, it may not be surprising that the
final regression models for positive outcomes in this subgroup were similar to those for the
full sample for some of the outcomes. For both the recovery and reliable change outcomes,
the final regression models included the same patient characteristics in both the LI and ‘all
patients’ sample, with both the direction and magnitude of effects being very similar.
A slight difference was identified between samples for the ‘recovery or improvement’
outcome, as phobia caseness was not associated with the outcome in the LI sample, but
was included in the final regression model for the ‘all patients’ analysis. One explanation for
this is that individuals with phobias may have been viewed as a more complex group of
patients and there were more likely to be seen at HI initially, therefore had less
representation at Step 2. The final model for deterioration following LI interventions was also
different to that for the ‘all patients’ sample and suggests that although welfare status does
not increase the risk of deterioration in LI treatments, patients from non-white ethnic groups
are at greater risks of negative outcomes than white patients. This may be due to the nature
of interventions provided, as LI interventions will typically use more printed or computer-
based literature, for example cCBT or self-help books, and it is possible that these materials
may not be culturally relevant for people of non-white ethnic background, increasing risk of
poorer outcomes.
Two additional patient characteristics were associated with dropout in LI that were not
significantly associated in the analysis of ‘all patients’ entering treatment. Gender was found
to be associated with dropout, as men were more likely to drop out of treatment compared to
women, and being prescribed medication was also associated with a lower likelihood of
completing LI treatment. It may be that patients who were prescribed medication were more
severe or complex in nature than individuals who were not prescribed psychotropic
medications, which may have been linked to increased dropout. An alternative theory could
be that individuals receiving medication as well as psychological treatment preferred the
pharmacological treatment, and therefore dropped out of treatment as they no longer wished
to receive IAPT treatments. As higher severity of depression was also associated with more
dropout of treatment, it is possible that LI interventions were not sufficient to treat more
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severe or complex patients, and potentially HI interventions may have been a better initial
treatment which could have reduced the risk of dropout.
Patients receiving High Intensity treatments
The outcomes for patients attending HI interventions are displayed in Table 4.19. Compared
to the results for ‘all patients’ entering treatment (Table 4.5), there was a slightly higher
percentage of patients in recovery, achieving reliable change and recovery or improvement.
There was also much less dropout of treatment (24.84% HI vs 33.47% for ‘all patients’)
although a very slightly higher percentage deteriorating following treatment (9.08% vs
8.71%).
In comparison to outcomes for patients attending LI interventions only (Table 4.13), it was
found that the percentages of recovery and for the recovery or improvement outcome were
very similar, however a higher percentage of patients achieved reliable change following HI
interventions than LI, which may be explained by the higher pre-treatment severity scores for
patients receiving HI only (Table 4.12). There was less dropout in HI interventions than LI
(24.84% vs 33.41%) but more deterioration (9.08% vs 7.74%).
Table 4.19. High intensity: Outcomes following treatment.
Outcome No Yes %
Recovery 1,789 1,274 41.59%
Reliable change 1,774 1,289 42.08%
Recovery or improvement 1,556 1,507 49.20%
Deterioration 2,785 278 9.08%
Dropout 2,302 761 24.84%
Recovery - High Intensity
The results of the stepwise regression of recovery is presented in Table 4.20. The T1 PHQ-9
score had a significant association with recovery following treatment, and as with ‘all
patients’ and LI only patients analyses, higher depression scores at T1 reduced the odds of
recovery. Higher GAD-7 at T1 and Phobia caseness were both significantly associated with
reduced odds of recovery in the next steps of the model. The level of work and social
functioning in addition to welfare status were then found to be significantly associated with
the outcome, as higher functioning impairment and being on benefits reduced the odds of
recovery. No other patient characteristics were significantly associated with the recovery and
the variance explained by the final model was 12.03%.
The results of the logistic regression analysis for HI only patients was similar to those for ‘all
patients’ and LI only patients, with the exception that phobia caseness remained significantly
associated with recovery in HI cases. This suggests that co-occurring phobia may have
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more impact on a patient’s likelihood of recovery, when controlling for other patient
characteristics, in HI interventions compared to LI treatments.
Table 4.20. Stepwise regression model: recovery (High intensity)
Step and
characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 0.88 0.868 to 0.892 0 9.09%
Model Step 2
PHQ-9 T1 0.904 0.89 to 0.919 0
10.19%
GAD-7 T1 0.935 0.917 to 0.954 0
Model Step 3
PHQ-9 T1 0.911 0.896 to 0.926 0
10.84%GAD-7 T1 0.942 0.924 to 0.961 0
Phobia caseness 0.651 0.552 to 0.769 0
Model Step 4
PHQ-9 T1 0.924 0.908 to 0.941 0
11.25%
GAD-7 T1 0.944 0.925 to 0.963 0
Phobia caseness 0.698 0.588 to 0.828 0
Functioning 0.98 0.97 to 0.99 0
Model Step 5
PHQ-9 T1 0.933 0.915 to 0.951 0
12.03%
GAD-7 T1 0.945 0.925 to 0.965 0
Phobia caseness 0.75 0.624 to 0.9 0.002
Functioning 0.986 0.975 to 0.998 0.019
Welfare status 0.524 0.435 to 0.631 0
Reliable change - High Intensity
The results of the stepwise logistic regression analysis of patient characteristics associated
with achieving reliable change when in receipt of HI interventions are presented in Table
4.21. Higher initial depression and anxiety severity were both found to be significantly
associated with achieving reliable change following treatment. In the next steps of the
analysis, being phobic and poorer levels of functioning reduced the odds of achieving
reliable change in patients receiving HI interventions. In the final step, welfare status was
added to the regression model and it was found that being on benefits significantly reduced
the odds of reliable change. No other patient characteristics were significantly associated
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with achieving reliable change and the final model explained 5.36% of the variance in
outcomes.
The final regression model for reliable change in HI interventions differed from the models
for ‘all patients’ and LI only as neither ethnicity nor medication prescription status were found
to be significantly associated with the outcome in HI only patients. These characteristics may
have less impact on reliable change in HI interventions.
Table 4.21. Stepwise regression model: reliable change (High intensity)
Step and
characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 1.05 1.037 to 1.063 0 1.49%
Model Step 2
PHQ-9 T1 1.024 1.009 to 1.039 0.002
2.37%
GAD-7 T1 1.06 1.04 to 1.081 0
Model Step 3
PHQ-9 T1 1.031 1.016 to 1.047 0
2.81%GAD-7 T1 1.067 1.046 to 1.088 0
Phobia caseness 0.707 0.601 to 0.833 0
Model Step 4
PHQ-9 T1 1.046 1.028 to 1.064 0
3.13%
GAD-7 T1 1.069 1.049 to 1.091 0
Phobia caseness 0.755 0.638 to 0.893 0.001
Functioning 0.982 0.973 to 0.992 0
Model Step 5
PHQ-9 T1 1.064 1.044 to 1.084 0
5.36%
GAD-7 T1 1.072 1.05 to 1.095 0
Phobia caseness 0.807 0.673 to 0.968 0.021
Functioning 0.987 0.976 to 0.998 0.018
Welfare status 0.446 0.372 to 0.536 0
Recovery or Improvement - High Intensity
The results of the analysis for recovery or improvement following HI treatment are presented
in Table 4.22. The ORs for PHQ-9 and GAD-7 scores suggest that lower levels of severity at
T1 were associated with increased odds of achieving the positive outcome, whereas phobia
caseness was associated with lower odds of recovery or improvement being achieved. The
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level of functioning was then added to the model and found to be positivity associated with
the outcomes, as lower functioning at T1 was associated with reduced odds of positive
outcome. However, the addition of phobia caseness to the model resulted in the GAD-7
score becoming non-significant and therefore anxiety severity was dropped from the
regression model in the following step. In the final model step, welfare status was added,
and it was found that receiving benefits was associated with a lower likelihood of achieving
the positive outcome from treatment. No other patient variables improved the model fit, and
the variance explained was 10.12%.
Table 4.22. Stepwise regression model: recovery or improvement (High intensity)
Step and
characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 0.891 0.88 to 0.903 0 7.59%
Model Step 2
PHQ-9 T1 0.901 0.887 to 0.915 0
7.75%
GAD-7 T1 0.975 0.956 to 0.994 0.009
Model Step 3
PHQ-9 T1 0.908 0.893 to 0.922 0
8.29%GAD-7 T1 0.98 0.961 to 0.999 0.044
Phobia caseness 0.673 0.571 to 0.792 0
Model Step 4
PHQ-9 T1 0.919 0.903 to 0.936 0
8.67%
GAD-7 T1 0.983 0.964 to 1.003 0.089
Phobia caseness 0.72 0.608 to 0.852 0
Functioning 0.982 0.972 to 0.992 0
Model Step 5
PHQ-9 T1 0.913 0.899 to 0.928 0
8.60%Phobia caseness 0.706 0.597 to 0.835 0
Functioning 0.981 0.971 to 0.991 0
Model Step 6
PHQ-9 T1 0.923 0.907 to 0.94 0
10.12%
Phobia caseness 0.758 0.632 to 0.908 0.003
Functioning 0.988 0.977 to 0.999 0.036
Welfare status 0.475 0.398 to 0.568 0
The findings presented for characteristic associated with recovery or improvement following
HI treatments were similar to those for ‘all patients’ receiving treatment from the services,
except that GAD-7 was not significantly associated with the positive outcome in the final
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multivariate model. These findings are surprising considering that GAD-7 at T1 was
associated with both recovery and the reliable change alone outcomes in HI treatment.
Compared to LI interventions, phobia caseness was significantly associated with the
outcome in HI interventions, but not LI, suggesting phobia may have more influence on the
outcomes at Step 3 of IAPT treatment.
Deterioration - High Intensity
Table 4.23. Stepwise regression model: deterioration (High intensity)
Step and
characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
PHQ-9 T1 0.942 0.923 to 0.962 0 1.71%
Model Step 2
PHQ-9 T1 0.984 0.96 to 1.009 0.212
4.42%
GAD-7 T1 0.896 0.87 to 0.923 0
Model Step 3
GAD-7 T1 0.887 0.864 to 0.911 0 4.34%
Model Step 4
GAD-7 T1 0.878 0.854 to 0.902 0
4.80%
Phobia caseness 1.636 1.24 to 2.157 0
Model Step 5
GAD-7 T1 0.873 0.848 to 0.899 0
5.54%Phobia caseness 1.659 1.235 to 2.229 0.001
Ethnicity Group 1.52 1.128 to 2.048 0.006
Model Step 6
GAD-7 T1 0.857 0.83 to 0.884 0
7.95%
Phobia caseness 1.431 1.031 to 1.986 0.032
Ethnicity Group 1.324 0.952 to 1.843 0.095
Welfare status 2.333 1.717 to 3.17 0
Model Step 7
GAD-7 T1 0.864 0.839 to 0.89 0
7.11%Phobia caseness 1.416 1.042 to 1.924 0.026
Welfare status 2.311 1.734 to 3.082 0
The results of the analysis on deterioration from treatment are presented in Table 4.23.
Although a higher score on the PHQ-9 at T1 was associated with lower odds of deteriorating
following treatment initially, adding GAD-7 scores at T1 to the model resulted in depression
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severity becoming non-significant. This would suggest that baseline anxiety has a stronger
association with deterioration than baseline depression in patients receiving HI interventions.
Being phobic and from a non-white ethnic group were also found to be significantly
associated with increased odds of deterioration, but by adding welfare status in the next step
of the regression model, ethnicity became non-significant. Welfare status was included in the
final model and it was found that receiving benefits was significantly associated with
increased odds of deterioration in symptoms following treatment. No other patient
characteristics improved the model, so the final model included just GAD-7, phobia
caseness and welfare status, with 7.11% of the variation explained by these characteristics.
The results of this regression model for HI interventions was similar to that for LI
interventions, except that higher levels of impairment in work and social functioning were
significantly associated with the negative outcome in LI interventions. The regression model
for ‘all patients’ (Table 4.9) found that PHQ-9 was associated with deterioration but this was
not found to be significantly associated with deterioration in patients attending HI only.
Treatment dropout – High Intensity
The results of the logistic regression analysis for treatment dropout in HI patients is
presented in Table 4.24. The final regression model included patient age, T1 PHQ-9 score
and welfare status, with higher age decreasing the odds of dropping out of treatment,
whereas higher severity of depression and receiving benefits increased the odds of
treatment dropout. No other variables were significantly associated with treatment dropout in
the stepwise regression model.
The variance explained by the final regression model was 3.43%, which was higher than the
percentage in the regression model for dropout in the ‘all patients’ sample (1.92%) even
though it included the same patient characteristics.
Table 4.24. Stepwise regression model: dropout (High intensity)
Step and
characteristics
included
Odds
Ratio
95% confidence
intervals P-value R
2
Model Step 1
Age 0.983 0.976 to 0.989 0 0.83%
Model Step 2
Age 0.98 0.973 to 0.986 0
2.95%
PHQ-9 T1 1.064 1.048 to 1.079 0
Model Step 3
Age 0.978 0.97 to 0.986 0
3.43%PHQ-9 T1 1.048 1.032 to 1.066 0
Welfare status 1.627 1.344 to 1.969 0
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Summary – High Intensity
A number of patient characteristics identified in the low intensity analysis were also
significantly associated with outcomes in the high intensity intervention sample, suggesting
these characteristics may predict outcomes across interventions. For example, severity,
level of work and social functioning, as well as welfare status were all associated with
recovery, reliable change and the recovery or improvement outcomes in the same direction
across intervention samples. It is of interest that the variance explained by the regression
models of the HI intervention sample were typically higher than the R2 for the LI regression
models, or those for the ‘all patients’ sample.
One difference between the regression models for HI interventions when compared to LI
was that phobia caseness was significantly associated with both the recovery and reliable
change outcomes in HI, but not LI. One suggestion for this difference is that individuals
meeting caseness for phobia may have been more frequently allocated to HI interventions
as an initial step, and therefore the representation of phobia at LI was not high enough to
find an association in the LI analysis. Phobia was significantly associated with all four of the
treatment response/deterioration outcomes in the HI sample, with the presence of phobia
predicting poorer outcomes, and would suggest that it may be an important characteristic to
consider when developing HI treatment plans.
Whereas medication prescription status and ethnicity group were associated with reliable
change in LI, neither factor was significantly associated with this outcome, or any other
outcome, in HI patients. It is possible that ethnicity is not associated with outcomes in HI
interventions as the more intensive and person-centred nature of the interventions
decreases the likelihood of any cultural biases that may be present in more text-focused
interventions (e.g. self-help books at LI). Medication prescription status may be linked to
more chronic, severe or complex presentation hence the higher proportion of patients
prescribed medication referred to HI compared to LI (Table 4.12), resulting in a lack of
predictive ability of this characteristic in patients receiving HI treatments.
Stepped up patients
Patients who entered treatment at Step 2/LI treatment but were later moved to Step 3/HI are
defined as ‘stepped up’ patients. Their outcomes following treatment are presented in Table
4.25. Compared to the outcomes for ‘all patients’, the recovery rates were around 3% lower,
although reliable change was slightly higher. The percentage of stepped up patients who
dropped out was much higher than the proportion of the ‘all patient’ sample who dropped out
(38.14% versus 33.47%), and percentage of patients deteriorating were higher, approaching
10%.
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Table 4.25. Stepped up: Outcomes following treatment.
Outcome No Yes %
Recovery 985 575 36.86%
Reliable change 919 641 41.09%
Recovery or improvement 853 707 45.32%
Deterioration 1,407 153 9.81%
Dropout 965 595 38.14%
Recovery – Stepped Up
The results of the stepwise multivariate logistic regression analysis for recovery in patients
who were stepped up is presented in Table 4.26. The final model includes the same
variables as the ‘all patients’ and LI analyses, and the only difference with the final HI
regression model is that phobia caseness was not significantly associated with recovery for
stepped up patients. The variance explained was 11.23%, which is similar to that found in
the ‘all patients’ analysis.
Table 4.26. Stepwise regression model: recovery (Stepped up)
Step and
characteristics
included
Odds Ratio 95% confidenceintervals P-value R
2
Model Step 1
PHQ-9 T1 0.878 0.86 to 0.896 0 8.48%
Model Step 2
PHQ-9 T1 0.902 0.881 to 0.923 0
9.62%
GAD-7 T1 0.931 0.904 to 0.958 0
Model Step 3
PHQ-9 T1 0.918 0.895 to 0.942 0
10.07%GAD-7 T1 0.936 0.909 to 0.964 0
Functioning 0.975 0.961 to 0.989 0.001
Model Step 4
PHQ-9 T1 0.915 0.891 to 0.94 0
11.23%
GAD-7 T1 0.935 0.906 to 0.964 0
Functioning 0.98 0.965 to 0.996 0.012
Welfare status 0.621 0.468 to 0.826 0.001
It is of interest that phobia caseness was not significantly associated with recovery in
stepped up patients even in the first steps of the regression model. In LI and the ‘all patients’
analysis, the ORs for phobia caseness are statistically significant in the earlier stages of the
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stepwise regression model, but the lack of association with recovery in stepped up patients
suggests the presence of phobia may not have an important role when deciding whether
stepping up would benefit the patient or not. It may be that patients with phobia were more
likely to be referred straight to HI interventions for initial treatment.
Reliable change – Stepped Up
The results of the stepwise model for reliable change is presented in Table 4.27. The final
regression model included PHQ-9, GAD-7, the level of social and occupational functioning
and welfare status.
Table 4.27. Stepwise regression model: reliable change (Stepped up)
Step and
characteristics
included
Odds Ratio 95% confidenceintervals P-value R
2
Model Step 1
PHQ-9 T1 1.04 1.021 to 1.059 0 0.86%
Model Step 2
PHQ-9 T1 1.022 1.001 to 1.044 0.044
1.31%
GAD-7 T1 1.045 1.016 to 1.076 0.002
Model Step 3
PHQ-9 T1 1.026 1.004 to 1.048 0.023
1.69%GAD-7 T1 1.055 1.024 to 1.086 0
Phobia caseness 0.798 0.642 to 0.993 0.043
Model Step 4
PHQ-9 T1 1.045 1.019 to 1.07 0
2.22%
GAD-7 T1 1.056 1.025 to 1.087 0
Phobia caseness 0.859 0.687 to 1.072 0.179
Functioning 0.977 0.964 to 0.991 0.001
Model Step 5
PHQ-9 T1 1.044 1.019 to 1.07 0.001
2.14%GAD-7 T1 1.053 1.023 to 1.084 0
Functioning 0.975 0.962 to 0.989 0
Model Step 6
PHQ-9 T1 1.05 1.024 to 1.078 0
3.72%
GAD-7 T1 1.059 1.027 to 1.092 0
Functioning 0.979 0.965 to 0.993 0.004
Welfare status 0.476 0.366 to 0.618 0
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The results of this analysis were very similar to those for HI interventions, except that phobia
caseness did not remain significantly associated with reliable change for stepped up cases.
Compared to the analysis LI only patients, the stepped up results did not find ethnicity group
or medication prescription status to be significantly associated with reliable change whereas
they did seem important for reliable change in LI. The variance explained by the final model
for stepped up cases was very low, at just 3.72%.
Recovery or Improvement – Stepped Up
The results for the stepwise regression model for recovery or improvement is presented in
Table 4.28. Higher PHQ-9 and GAD-7 scores, lower scores on the work and social
functioning scale, receiving benefits and being female were all found to reduce the odds of
achieving a positive outcome.
The final regression looks quite different from those for the other samples. One major
difference is that gender was found to be significantly associated with the outcome, as
females were less likely to achieve a positive outcome if they were stepped up, although the
p-value was very close to non-significance (p=0.047). At 8.65%, the amount of variance
explained by the final model was higher compared the R2 of the LI model, but lower than that
for HI.
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Table 4.28. Stepwise regression model: recovery or improvement (Stepped up)
Step and
characteristics
included
Odds Ratio 95% confidenceintervals P-value R
2
Model Step 1
PHQ-9 T1 0.898 0.881 to 0.915 0 6.05%
Model Step 2
PHQ-9 T1 0.913 0.893 to 0.933 0
6.45%
GAD-7 T1 0.959 0.932 to 0.986 0.004
Model Step 3
PHQ-9 T1 0.933 0.91 to 0.956 0
6.99%GAD-7 T1 0.964 0.936 to 0.992 0.011
Functioning 0.972 0.959 to 0.986 0
Model Step 4
PHQ-9 T1 0.935 0.912 to 0.96 0
7.06%
GAD-7 T1 0.965 0.936 to 0.994 0.019
Functioning 0.93 0.959 to 0.988 0
Ethnicity group 0.731 0.55 to 0.972 0.031
Model Step 5
PHQ-9 T1 0.936 0.911 to 0.962 0
8.56%
GAD-7 T1 0.962 0.931 to 0.993 0.016
Functioning 0.979 0.964 to 0.995 0.008
Ethnicity group 0.806 0.596 to 1.091 0.163
Welfare status 0.525 0.398 to 0.692 0
Model Step 6
PHQ-9 T1 0.934 0.91 to 0.959 0
8.45%
GAD-7 T1 0.961 0.932 to 0.99 0.009
Functioning 0.978 0.963 to 0.992 0.003
Welfare status 0.538 0.413 to 0.7 0
Model Step 7
PHQ-9 T1 0.933 0.909 to 0.958 0
8.65%
GAD-7 T1 0.964 0.935 to 0.993 0.017
Functioning 0.977 0.962 to 0.992 0.002
Welfare status 0.533 0.409 to 0.695 0
Gender 0.787 0.621 to 0.997 0.047
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Deterioration – Stepped Up
The results of the stepwise regression analysis for deterioration in stepped up patients is
presented in Table 4.29. The final regression included just GAD-7 at T1 and welfare status,
with higher severity of anxiety reducing the odds of deterioration, whereas being on benefits
increased the likelihood. Although PHQ-9 at T1 and phobia caseness had a significant
association with deterioration at certain steps of the model, their adjusted ORs were not
statistically significant when controlling for the other included characteristics. The variance
explained was limited to just 4.3%.
The results of this analysis are different to the other deterioration analyses, as just two
characteristics remained in the final model. Patient characteristics such as depression
severity, phobia caseness and level of functioning were all included in the final model for
deterioration in the ‘all patients’ analysis, and ethnicity was also included in the LI final
regression model, which suggests the role of patient characteristics with deterioration in
symptoms may vary between types of intervention.
Table 4.29. Stepwise regression model: deterioration (Stepped up)
Step and
characteristics
included
Odds Ratio 95% confidenceintervals P-value R
2
Model Step 1
PHQ-9 T1 0.936 0.908 to 0.964 0 1.96%
Model Step 2
PHQ-9 T1 0.969 0.937 to 1.003 0.075
3.92%
GAD-7 T1 0.907 0.869 to 0.946 0
Model Step 3
GAD-7 T1 0.891 0.858 to 0.925 0 3.61%
Model Step 4
GAD-7 T1 0.883 0.849 to 0.919 0
3.90%
Phobia caseness 1.448 1.007 to 2.082 0.046
Model Step 5
GAD-7 T1 0.886 0.85 to 0.923 0
4.16%Phobia caseness 1.216 0.827 to 1.789 0.32
Welfare status 1.597 1.08 to 2.362 0.019
Model Step 6
GAD-7 T1 0.888 0.854 to 0.924 0
4.30%
Welfare status 1.733 1.186 to 2.532 0.004
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Treatment dropout – Stepped Up
The stepwise multivariate logistic regression for treatment dropout in stepped up patients is
presented in Table 4.30. The final regression model includes age, PHQ-9 baseline severity
and welfare status, and therefore was similar in structure to the analysis of HI and ‘all
patients’ entering treatment. The variance explained by this final model was low at 1.69%.
Table 4.30. Stepwise regression model: dropout (Stepped up)
Step and
characteristics
included
Odds Ratio 95% confidenceintervals P-value R
2
Model Step 1
Age 0.989 0.981 to 0.997 0.007 0.35%
Model Step 2
Age 0.987 0.979 to 0.995 0.002
1.06%
PHQ-9 T1 1.037 1.018 to 1.056 0
Model Step 3
Age 0.986 0.978 to 0.995 0.002
1.69%PHQ-9 T1 1.037 1.016 to 1.058 0
Welfare status 1.442 1.126 to 1.847 0.004
Summary – Stepped Up
Patients who were stepped up during treatment were the smallest subgroup included in this
analysis (less than 15% of the full sample of patients). However, the results of this subgroup
of patients indicated that some of the characteristics that are significantly associated with
outcomes in the other intervention subgroups were similarly associated with outcomes in this
sub-population, especially with regard to severity, social functioning and welfare status.
As with the results of the LI intervention analysis, phobia caseness was not associated with
the recovery, reliable change or the recovery or improvement outcomes whereas this
characteristic significantly contributed to the regression models for the HI intervention
analysis. As mentioned previously, it is possible that phobia was associated with the criteria
to allocate to HI as initial treatment as it may increase the potential complexity of the
presenting symptoms, and therefore phobia was less prevalent in the sample of individuals
who were stepped up/started at Step 2. Gender was also associated with the recovery or
improvement outcome, and the results suggested that female patients had a reduced
likelihood of achieving this outcome compared to men. As the p-value for this odds ratio was
very close to 0.05, it is possible that this finding may have limited clinical significant, and
therefore replication in another dataset would be useful to compare results.
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The final regression model for deterioration in stepped up individuals only included baseline
GAD-7 score and welfare status as significant predictors of negative outcomes following
treatment. Other patient characteristics such as social functioning and phobia caseness
were associated with this outcome in the other intervention subgroups, and the finding that
these patient characteristics did not predict deterioration in stepped up patients might be due
to patients receiving both types of intervention. This cumulative treatment effect may not be
predicted by either functioning or phobia caseness, and instead other patient characteristics
not included in the current IAPT MDS may have more association with this outcome.
Discussion.
The analyses presented in this chapter have identified a number of associations between
patient characteristics collected as part of the IAPT MDS and treatment outcomes within the
services. Many of the characteristics were shown to have consistent associations with
treatment outcomes, including across patients receiving different intensities of interventions.
Additionally, there were a number of patient characteristics that had different associations
between intensity of intervention and with different outcomes, and therefore could provide
useful information on treatment selection decisions on the choice between LI and HI
treatment. However, the amount of variance explained by any of the regression models was
quite low, with 12% the highest explained by any model.
The results from the systematic review in Chapter 3 suggested that severity is among the
most frequently reported patient characteristics associated with response to treatment,
although the direction of this association was inconsistent with some studies finding higher
severity predicted better response, others the opposite. The results of the analyses
presented in this chapter suggest that the association between severity and outcome
depends on whether absolute change in symptom scores or a decrease below a threshold is
the criteria for achieving a positive outcome. For the outcome ‘moving to recovery’, higher
severity was consistently associated with lower odds of recovery, across different
interventions. When ‘reliable change’ was the outcome of interest, higher severity was
associated with increased odds of achieving the outcome. This may be related to the criteria
for achieving the outcomes themselves, as moving to recovery requires the patient to move
from above a cut-off/threshold to below following treatment, and therefore the closer to the
threshold a patient scores at T1 (lower severity) the less symptoms needed to decrease in
order to be under the cut-off. For the reliable change outcome, a higher pre-treatment score
provides more opportunity for a decrease in symptoms to reach a clinically significant
amount, but regression to the mean (the increased likelihood of more extreme scores
moving towards to mean over multiple time points), may also contribute some of the findings
when severity is considered. As residual symptoms are found to be a factor in predicting
later relapse to depression following successful treatment (Lin et al, 1998), reducing the
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severity of symptoms may reduce the likelihood of recurrence and the need for further
episodes of treatment.
One patient characteristic that was also frequently associated with response to treatment in
the analyses was welfare status, as patients receiving benefits were regularly associated
with worse outcomes (less recovery/change, more deterioration and dropout) across the
different intervention intensities. It is possible that welfare status predicts poorer outcomes
from treatment due to the social adversity that is potentially associated with not having a job,
for example financial pressures or chronic physical illness, and previous studies have found
these to be related to poorer outcomes in CMHD regardless of treatment type (Brown et al.,
2010). Collecting more information on social adversity and employment status may help
further refine the predictive ability of this patient characteristic. For now, it would appear that
receiving welfare benefits is associated with poorer outcomes, and therefore it may be of
value for clinicians to consider this when aiming to personalise treatment.
Although severity and welfare status showed a consistent association across treatment
intensity, other patient characteristics were found to have different associations across the
different treatment intensities. Ethnicity group for example had a significant association with
treatment response outcomes in LI interventions, as non-white groups were associated with
poorer outcomes. However, ethnicity was not significantly associated with outcomes in the
HI or stepped up samples. This may be explained by the mode of delivery of LI interventions
compared to HI interventions, as LI involves more self-help manual and texts, and these
may not be seen as culturally relevant for non-white groups. Gender was also found to be
significantly associated with the recovery or improvement outcome in stepped up cases only,
with males more likely to achieve a positive outcome. However, the confidence intervals
were very close to non-significance and therefore more research on this finding would be
recommended.
The level of social functioning was frequently associated with poorer outcome following
treatment in this analysis, regardless of whether it was recovery or reliable change that was
being explored. However, it was only included in the final model for deterioration for LI cases
when controlling for the other included variables and this suggests it may have less of a role
in predicting deterioration in HI or stepped up cases. Poorer social functioning may be
associated with more severe symptoms and greater complexity, as well as additional
comorbid conditions other than depression or anxiety, which may have resulted in LI being
less appropriate treatment than HI for these cases. Clinicians may benefit from considering
the level of work and social functioning when considering LI interventions, and this may
involve focusing on social or employment support to achieve a better outcome.
It is also of interest that PHQ-9 severity was significantly associated with deterioration in the
‘all patient’ sample but was not associated with this outcome in either of the three sub-
analyses by intervention. Instead, it was found that the level of anxiety was consistently
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associated with deterioration across samples, as higher pre-treatment anxiety reduced the
odds of deterioration. One possible explanation for this finding may be that some patients
who suffer from anxiety related issues and are avoidant may present with limited symptoms
as measured on the GAD-7 but aspects of the interventions, for example behavioural
experiments, may increase anxiety as they begin to through distressing symptoms.
The amount of variance explained by the regression models for reliable change and
deterioration presented in this chapter appear low, especially for predicting treatment
dropout. However, the R2 values reported in the models for recovery ranged between 10.5%
and 12%, which was above cut-off proposed for clinical importance suggested by
researchers (Uher et al, 2012). Other analyses using IAPT data have reported higher R2
values, but only when including a number of additional patient characteristics not included in
the MDS. For example, Gyani and colleagues (2011) analysed national IAPT data using a
range of characteristics including patient specific (e.g. demographics and clinical factors) as
well as characteristics associated with treatment (e.g. type of therapy, number of sessions).
The variance explained by their final logistic regression model for recovery was around 17%,
suggesting only 6-7% more variance was explained when analysis included a large number
of additional characteristics associated with interventions and therapists. The R2 values for
the analyses of treatment dropout were comparatively low, the highest being 3.43% which
was found for HI interventions.
It is possible that patient characteristics identified in the meta-review, but not included or
available in the IAPT dataset (e.g. previous treatment, comorbid personality disorders, and
self-efficacy) could further predict IAPT treatment outcomes. One limitation of the present
IAPT dataset is that it includes only a select number of patient characteristics, and some of
these characteristics were limited as to the information they contained. For example, welfare
status was used instead of employment because information about employment status was
not available in the dataset. In addition, the only mental health comorbidity available in the
dataset was the presence of phobia caseness or not, which was scored using the three IAPT
phobia items in the dataset (IAPT, 2011). However, the psychometric properties of these
items has not be investigated thoroughly, and future research might benefit from using
additional measures of specific anxiety disorders, as well as personality disorders. This may
provide more information about comorbidities, with a view to refining the regression models
presented in this chapter. For the current project, additional characteristics could not be
collected, and therefore alternative methods of using the nine available patient
characteristics was explored in the next stages of this thesis.
Although multiple regression analysis allows the inclusion of a number of patient
characteristics within a regression model, there may be more direct interactions between
characteristics that may be associated with differential outcomes (Kraemer, 2013). For
example, it may be that the baseline level of severity moderates the effect of gender on
outcome. However, the inclusion of interaction terms in regression should always be
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facilitated by some theory of the potential association, as a lack of prior theory could be
viewed as merely ‘fishing’ (Johansson & Høglend, 2007). Therefore, further work on
theoretical models of patient characteristics associated with treatment response may provide
the ground work for further analysis of interaction terms using the patient characteristics
included in this analysis.
As there were nine included patient variables in the current analysis, exploring the
interactions between all variables within a standard regression model framework would
become too complex, but also challenging to translate into a DST which may have clinical
utility. It would also be likely that different interaction models would be built for the different
outcomes considered in these analysis, resulting in reduced practical utility. As research into
decision making has suggested that clinicians will often compare new patients to prototypes
of patients with similar characteristics (Garb, 2005), a statistical method of identifying
subgroups of patients from the available patient characteristics may prove clinically useful if
these groupings were associated with different treatment outcomes. New patients could be
compare to these subgroups, and the expected utility of treatments for each subgroup could
be calculated to aid clinicians with decision making. Exploring methods of identifying sub-
groups of patients entering treatment at the services, and comparing the likelihood of
treatment outcomes between these sub-groups was the focus of the next two chapters.
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Chapter 5. Identifying latent profiles of
patients using routine IAPT data.
Abstract
The patient characteristics included in the IAPT minimum dataset could be used to predict
the likelihood of treatment outcomes following psychological interventions. However, the
results of the regression analysis were limited by the low amount of variance explained by
the models, and therefore alternative statistical methods may provide a more clinically useful
way of using the available patient characteristics. Statistical methods of grouping patients
based on shared characteristics has been used to identify homogeneous groups of patients
in clinical populations, and could be used to identify profiles of patients with differential
response to IAPT treatment. Latent class methods, such as latent profile analysis (LPA)
(Lazarsfield & Henry, 1968) have previously been used in mental health populations to
provide information on types or profiles of patients presenting in clinical populations, but not
to inform response to treatments (Rosellini & Brown, 2014; Unick, Snowden, & Hastings,
2009). This chapter presents the results from latent profile analysis (LPA) performed on the
dataset of patients entering treatment at the IAPT services described in Chapter 4. The LPA
identified eight distinct groups of patients with statistically different constellations of patent
characteristics. For example, one profile displayed very severe symptoms, as well as a high
likelihood of receiving welfare benefits and being prescribed psychotropic medication,
whereas another profile was characterised by low symptom severity, younger aged, a low
likelihood of phobic symptoms and less functional impairment. Further details on each of the
eight profiles is described, and analysis of treatment outcomes for each of these profiles is
presented in Chapter 6.
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Introduction
The results of the multiple regression analysis presented in Chapter 4 suggest that a number
of patient-specific characteristics are associated with recovery, reliable change, clinical
deterioration and the early termination of treatment in the IAPT services. Most of these
characteristics were also identified in the meta-review presented in Chapter 3, suggesting
these characteristics may have value in predicting treatment outcomes for CMHD patients.
However, the variance explained by the regression models was generally low, with a range
of 1.58 to 12.03% across all outcomes and intensities of intervention, and therefore
alternative methods of exploring the predictive ability of these patient characteristics was
considered.
One possible reason for this relatively small amount of variance explained is that multiple
regression analysis explores the impact of each characteristic on the outcome, whilst
controlling for the other included characteristics, but it does not explore potential interactions
between variables (Cox, 1984). Whilst interactions between multiple variables can be
explored in regression analyses, prior theory is required to justify the use of interaction terms
within the analysis (Johansson & Høglend, 2007). As there were no prior theories of
interactions between all nine patient characteristics in the current analysis, and because a
regression model containing the interactions between all nine characteristics would be
difficult to interpret, an alternative method of exploring the patient characteristics together
was considered.
Previous research into clinical decision making theorises that clinicians compare new
patients to ‘prototypes’, subgroups of patients created in the clinician’s mind that they may
have treated previously and/or who may typify a specific diagnosis or illness (Garb, 2005).
The clinician may make a judgement as to which ‘prototype’ a new patient most resembles,
and therefore will likely recommend treatments they feel are most appropriate for this group
of patients, incorporating previous experience with these prototypes. Less experienced
clinicians may be at a disadvantage having seen fewer previous patients (and therefore
prototypes). Whereas prototypes are subjective in nature, an objective method of using
patient characteristics to identify common ‘prototypes’ or profiles of patients with similar
characteristics could create subgroups of patients attending the services that could be used
by all clinicians, and may be especially valuable to less experienced clinicians. There may
be further clinical utility if differential response to treatments was found between these
profiles of patients. The ‘expected utility’ of treatment outcomes for differing profiles may
have the potential to inform clinical decision making concerning treatment selection in
mental health services.
A grouping of patients in this way may also provide a better understanding of the nature of
mental illness beyond diagnosis (Insel, 2006), especially if patient demographics in addition
to clinical symptoms were included in the method of profiling patients. Clinical diagnoses
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typically concern the symptoms of the illness, however the results of the regression analysis
in Chapter 4 suggested that other characteristics such as level of social functioning and
receiving welfare benefits are also associated with treatment outcomes, across intensities of
interventions. Therefore, a multi-factorial approach using all available characteristics to
generate profiles of patients entering treatment may provide a more valuable method of
informing clinical decision making than focusing exclusively on diagnosis or individual
characteristics alone.
Identifying clusters of patients may also have the benefit of allowing multiple treatment
outcomes to be explored across stratified groupings of patients with similar characteristics,
which may increase their potential clinical utility. The regression modelling presented in
Chapter 4 resulted in a series of models, identifying different patient characteristics identified
with different treatment outcomes. The results of this modelling suggested that
characteristics may be associated with some outcomes but not others, for example, gender
was not associated with recovery or reliable change in patients receiving HI treatments,
whereas it was associated with dropout for the group. A DST that is able to consider multiple
treatment outcomes could be of more value to treatment services such as IAPT, as
identifying patients at risk of negative outcomes such as deterioration and treatment dropout
may help inform treatment selection, as well as treatment monitoring decisions. Using the
regression models presented in Chapter 4 to develop a DST therefore runs the risk that
certain patient characteristics will be associated with a higher positive likelihood for some
outcomes and lower likelihood of other outcomes, which would be difficult for clinicians to
interpret in relation to supporting a clinical decision. The benefit of a clustering approach is
that the identified groupings could be explored over a number of outcomes and potentially a
DST using a clustering method could provide the probability of each outcome to the clinician.
The probability of different treatment outcomes could then be used to estimate the likely
expected utility of treatment and could then be used to inform decisions about the most
appropriate treatment.
The two main statistical methods of identifying subgroups of patients are clustering methods,
such as K-means clustering (Cox, 1957), and latent class methods (Goodman, 1974), for
example latent class and latent profile analysis. Both methods are concerned with the
recognition of patterns within the dataset of responses or patient characteristics that can be
grouped into specific clusters or classes of responders, containing individuals with similar
patterns of responses or characteristics.
K-means clustering (Cox, 1957; MacQueen, 1967) is a partitional clustering method popular
across disciplines including the social sciences, although more frequently used as a
marketing segmentation methods in consumer research (Schreiber & Pekarik, 2014). This
method attempts to reduce all included variables into smaller groupings. The original method
of K-means clustering uses interval or ratio data only, as equal distances are needed
between values, although more recent extensions for categorical data exist (San, Huynh, &
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Nakamori, 2004). It is a simpler method of clustering to implement which has increased its
popularity amongst researchers (Jain, Murty, & Flynn, 1999). However, a major criticism of
k-means clustering is that there are no objective criteria for judging the suitability of the
clustering solution and therefore there is an inherent danger that a solution can be shaped to
fit with the researcher’s expectations. There are also concerns that K-means methods lack
rigour and consistency, as adding new data may result in a quite different cluster solution
(Krantz, Korn, & Menninger, 2009).
An alternative method of identifying distinct groups in a dataset is the use of Latent Class
(LC) methods, which are used to identify homogenous sub-groups, referred to as “classes”
or “profiles” depending on the specific analysis used, of individuals based on responses to
variables (Goodman, 1974). On one level it is similar to k-means clustering, however model
‘fit’ is established using statistics available within data output, which results in a more
objective method of determining the number of distinct profiles that exist within the dataset.
Latent class analysis (LCA) was originally developed to include categorical variables only,
and latent profile analysis (LPA) provides an extension that can incorporate categorical,
continuous and ordinal variables (Hagenaars & McCutcheon, 2002; Lazarsfield & Henry,
1968). The type of data to be included within the analysis determines whether ‘classes’ or
‘profiles’ is used to name the subgroups identified, although both LCA and LPA fall within
‘Latent Class methods’.
In LC methods, the probability of the specific pattern of responses y, P(Y = y), is a weighted
average of the C class-specific probabilities P(Y = y|X = x); expressed as:
ܲ(ܻ = ݕ) = ෍ ܲ(ܺ = ݔ)ܲ(ܻ = ݕ|ܺ = ݔ)஼
௫ୀଵ
Where P(X = x) is the proportion of individuals in Latent Class x. Groups of individuals with a
similar pattern of responses or characteristics are identified to determine statistically differing
groups within the dataset. Each individual case can be classified into a subgroup (referred to
as the individual’s latent class or latent profile) from their observed pattern of responses (e.g.
to questionnaire items, presence of particular symptoms, dichotomous variables such as
‘Male’ or ‘Female’). In LC methods, the inter-item relationship is explained by the presence
of an unknown subgroup (the latent class/profile). Individual differences in the observed item
response patterns are explained by differences in latent class/profile membership which are
probabilistic.
Simulation and comparison studies suggest results of K-means and LC method analyses
can vary, with a different number or clusters/classes identified using the same dataset
(Eshghi, et al., 2011). When directly comparing methods, the majority of researchers
suggest a better performance of latent class methods over K-means clustering (Schreiber &
Pekarik, 2014). The preference for LC methods is also linked to the availability of statistical
tests to confirm the number of classes/profiles, or model fit that do not exist in K-means
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clustering methods (Magidson & Vermunt, 2002). A further benefit is that LC methods use a
probabilistic approach, which reduces the vulnerability of these analyses to extreme scores
or outliers when compared to k-means clustering (Schreiber & Pekarik, 2014).
LC methods have been used within mental health populations previously to identify sub-
groups of patients within diagnostic groups based on a combinations of assessment scores
and demographic information such as eating disorders (Duncan et al., 2005; Wade, Crosby,
& Martin, 2006) and personality disorders (Bucholz, Hesselbrock, Heath, Kramer, &
Schuckit, 2000; Fossati et al., 2001). These analyses have typically included the presence of
certain symptoms or personality scores as indicator variables to identify clinical subgroups,
such as ‘binge-eating disorder’ or specific personality disorders. Researchers suggest that
these profiles may be useful in tailoring treatment, although these analyses did not go on to
compare treatment outcomes between the profiles identified.
Within CMHDs, researchers have used LC methods to identify subgroups based on clinical
symptoms. Rosellini and Brown (2014) performed LPA on a dataset of more than 1200
patients using six symptom severity subscale scores from questionnaires such as the Beck
Depression Inventory (Beck, Steer, & Brown, 1996), the Anxiety Sensitivity Index (Peterson
& Reiss, 1992) and the Social Interaction Anxiety Scale (Mattick, Peters, & Clarke, 1989) as
the patient characteristics, and identified 6 latent profiles of patients (for example,
“Obsessed-worried” and “Mildly neurotic”). Unick, Snowden and Hastings (2009) performed
LCA on the presence or absence of DSM depression and anxiety symptoms using the
University of Michigan Composite International Diagnostic Interview (UM-CIDI) (Kessler et
al., 1994) to create 23 dichotomous items as the included patient characteristics. An analysis
of n=1009 patients identified seven classes, for example “Mild Somatic Anxiety” and “Mild
Psychological Depression”. Both sets of authors focused only on symptom scores as patient
characteristics and did not include demographic information. Patient demographic
information may provide important information for the development of classes or profiles that
may be predictive of treatment outcome. Although Unick et al looked at differences in
service utilisation between the classes, neither sets of authors looked at differences in
outcomes following treatment between the classes/profiles they identified.
One additional benefit of LC methods as an approach to identifying groups of individuals
entering treatment for CMHDs is that any individual can be assigned to previously identified
latent classes/profiles by calculating the probability of class/profile membership, referred to
as posterior membership probability. This is calculated using Bayes rule (Bayes, 1763). For
categorical variables, this is expressed as:
ܲ(ܺ = ݔ|ܻ = ݕ) = ܲ(ܺ = ݔ)ܲ(ܻ = ݕ|ܺ = ݔ)
ܲ(ܻ = ݕ)
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For continuous variables, the probability density distribution is used, and expressed as:
(݂ݔ) = 1
ට2ߨߪ௜௝ଶ ݁ݔ݌ቆ−(ݔ௜−ߤ௜௝)ଶߪ௜௝ଶ ቇ
Where ߪ௜௝ଶ is the variance of item i within j class, ݔ௜ is the value of item i and ߤ௜௝is the mean of
item i for class j. The potential clinical value of these posterior membership probabilities for
this thesis was that they could be included within a DST to calculate class/profile
membership for any new patient entering the service. An algorithm including the posterior
probabilities from a latent class/profiles analysis would be straight-forward to develop and
could be hosted by the local treatment services’ EPMS to provide class/profile information to
clinicians, potentially in real time.
The aim of this chapter was to identify statistically distinct profiles of patients entering
treatment at the IAPT services by performing LPA on patient characteristics included in data
MDS. Once the profile structure in the dataset has been identified, an algorithm using the
posterior probabilities could be produced to generate the likelihood of profile membership for
any new patient referred to the services from their patient characteristics. The differential
treatment outcomes across the different intensities of psychological treatment was then
explored in the next chapter.
Method
Sample
The dataset used for this analysis was the same data as described in Chapter 4. Whereas
the multiple regression analyses excluded patients who received only a single treatment
session and individuals who scored below clinical caseness, it was decided to include these
individuals in the LPA. Therefore, the LPA included all patients who entered treatment at the
services and had T1 assessment information, regardless of their symptom severity or
number of treatment sessions. This decision was made so that the LPA could provide
information and probability of profile membership for any new patient entering the service
and completing an assessment, rather than just a subset who were clinical caseness or
attended more than one session. This was deemed especially important if the LPA would
have potential utility as a DST, as it would likely be more acceptable to clinicians if all
patients could be entered into it, rather than a sub-group of patients referred to services.
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The intensity of intervention was also not considered as inclusion criteria for the LPA
analysis. It was expected that individuals belonging to the same profile could receive
different intensities of intervention, and it was considered of interest to explore the
distribution of profiles to interventions in the following chapter. The potential role of a DST
would be to provide information about the most appropriate intensity of intervention for an
individual in a given profile, and therefore outcomes between interventions within an
identified profile would be explored in subsequent analyses.
From the sample of n=34741 patients who were referred to the two IAPT services in North
London between September 2008 and March 2012, n=19817 included T1 assessment data.
Of these individuals, n=3181 patients either declined treatment from IAPT, were still in
treatment or referral, or were deemed not suitable for treatment from the service. A total of
n=16636 patients were therefore included in the analysis, and a full flow diagram is
presented in figure 5.1.
Measures
The patient characteristics included in the LPA were the same variables explored in the
regression analysis presented in Chapter 4 (Table 4.1). Although some of these patient
characteristics did not appear to be significantly associated with treatment outcomes across
both intensities of psychological treatment, it was decided that they may still be of value to
the LPA, especially as they may inform specific patterns of patient characteristics and/or
contribute to specific patient profiles.
Figure 5.1. Patient flow - latent profile analysis
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Data analysis
Data analysis was conducted in Mplus version 7 (Muthén & Muthén, 2012), on the initial
Sept 2008 to March 2012 dataset. This primary dataset of n=16636 patients was split into
two independent samples and LPA was performed separately on these samples to allow
comparison and confirmation of the profile structure in two samples. This was viewed
important to confirm whether the profile structure would be replicated in independent
samples.
To identify the best fitting model for the datasets, the Vuong-Lo-Medell-Rubin Likelihood
Ratio test (VLMR-LRT) (Lo, Mendell, & Rubin, 2001) and the Bootstrap Likelihood Ratio
Difference test (B-LRT) were compared alongside the Akaike Information Criterion (AIC),
Bayesian Information Criterion (BIC) and entropy values. Both the B-LRT and the VLMR-
LRT compare the K model (current model with K number of profiles) to K-1 model (model
with one less profile), with a significant p-value indicating the K model fits the data better
than the model with one less profile. A non-significant finding (p-value >=0.05) suggests that
the model with one less profile provides a better fit for the data, and the more parsimonious
model would be preferred. Lower AIC and BIC value indicate better model fit, whereas
higher entropy values indicate higher accuracy in classification for the model.
As there was no prior hypothesis on the exact number of patient profile groups from the
data, the analysis was conducted starting with a two profile model and increasing the
number of profiles until the VLMR-LRT became non-significant. The B-LRT was then used to
confirm the K-1 model using a parametric bootstrap procedure (Asparouhov & Muthén,
2012; Geiser, 2013). Information from the AIC, BIC and entropy values were also used to
inform model fit. This method was applied to both split samples of the primary dataset to
confirm whether the same profile structures were identified across samples.
Results
A random split of the primary dataset resulted in two samples of n=8321 (Sample 1a) and
n=8315 patients (Sample 1b). LPA was conducted on both samples independently using the
same procedure, and model comparison statistics are presented in Table 5.1 for both split-
samples. The LPA for Sample 1a yielded significant p-values on the VLMR-LRT comparing
successive models, from a two-profile solution to an eight-profile solution (p=0.0057 at the
eight-profile model), as well as decreasing AIC and BIC values. Although the BIC and AIC
values were slightly lower for the nine-profile solution, the VLMR-LRT produced a non-
significant p-value (p=0.3551) suggesting that increasing the number of profiles was not a
better fit for the data (Asparouhov & Muthén, 2012; Geiser, 2013). The entropy value was
also higher for the eight-profile solution suggesting higher classification accuracy, and
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therefore the eight-profile solution was preferred. B-LRT was performed on the eight-profile
solution, with a significant finding between the eight and seven profile models (p<0.0001).
Table 5.1. Model comparison statistics for both split samples.
Sample 1a
k
model AIC BIC Adj-BIC
VLMR-
LRT (p=) Entropy
k = 2 265442 265604 265531 <0.05 0.798
k = 3 262848 263080 262975 <0.05 0.765
k = 4 262079 262382 262245 <0.05 0.725
k = 5 261548 261920 261752 <0.05 0.743
k = 6 260872 261315 261114 <0.05 0.751
k = 7 260533 261046 260814 <0.05 0.73
k = 8 260282 260865 260602 <0.05 0.722
k = 9 260044 260697 260402 0.3512 0.71
Sample 1b
k
model AIC BIC Adj-BIC
VLMR-
LRT (p=) Entropy
k = 2 265744 265906 265833 <0.05 0.788
k = 3 263059 263290 263186 <0.05 0.771
k = 4 262377 262680 262543 <0.05 0.718
k = 5 261769 262141 261973 <0.05 0.734
k = 6 261079 261522 261321 <0.05 0.745
k = 7 260689 261202 260970 <0.05 0.728
k = 8 260341 260925 260661 <0.05 0.739
k = 9 260147 260800 260505 0.094 0.714
The LPA for Sample 1b also yielded significant increases in model fit according to the
VLMR-LRT up to the eight-profile model (p<0.0001 for the eight-profile model compared to
the seven-profile model) with decreasing and AIC and BIC values, and again the nine-profile
model produced a non-significant VLMR-LRT p-value (p=0.940). The B-LRT confirmed a
significant p-value for the eight-profile model compared to the seven-profile model
(p<0.0001).
Following confirmation of an eight-profile model structure from the two independent split
samples, the dataset was re-combined, and the same method of LPA was applied to the full
sample of n=16636 to generate probabilities of profile membership for each patient included
in the analysis. As before, VLMR-LRT showed a significant p-value up to the nine-profile
model (p=0.699) with the eight-profile model selected and probability of profile membership
assigned to each patient in the sample. Each patient was allocated to a latent profile (LP) by
using the highest probability of profile membership as the patient’s LP, with probabilities
provided by Mplus.
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Table 5.2. Latent profiles and associated patient characteristics
Full
sample
LP1
(n=3002)
LP2
(n=3771)
LP3
(n=513)
LP4
(n=674)
LP5
(n=1414)
LP6
(n=1514)
LP7
(n=2070)
LP8
(n=3678)
Age -
Mean(SD)
37.9
(13.36)
33.47
(8.46)
30.74
(7.48)
66.83
(9.71)
65.16
(8.88)
54.25
(7.85)
40.72
(9.10)
42.74
(9.44)
29.68
(6.90)
PHQ-9 -
Mean(SD)
13.85
(6.67)
5.37
(3.03)
11.28
(3.16)
4.59
(3.09)
10.76
(3.59)
17.88
(3.43)
13.36
(3.38)
22.86
(2.78)
18.85
(3.14)
GAD-7 -
Mean(SD)
12.35
(5.51)
5.26
(2.71)
12.56
(2.98)
3.74
(2.58)
10.85
(3.26)
15.94
(2.88)
7.99
(2.78)
18.38
(2.50)
16.43
(2.79)
W&SAS -
Mean(SD)
17.85
(9.69)
8.69
(5.79)
14.53
(6.23)
6.99
(6.32)
11.79
(7.14)
18.15
(7.38)
20.87
(6.69)
31.72
(5.74)
22.28
(7.11)
Gender -
n(%)
female
10793
(66.15%)
1906
(65.21%)
2570
(69.46%)
335
(67.81%)
451
(68.23%)
905
(65.01%)
850
(57.32%)
1166
(57.13%)
2610
(72.06%)
Ethnic
Group – n
(%) Non-
White
3151
(22.24%)
452
(17.66%)
547
(17.33%)
46
(10.90%)
70
(12.22%)
219
(18.28%)
346
(26.59%)
498
(27.51%)
973
(30.89%)
Medication
prescribed
– n (%)
Prescribed
5802
(38.71%)
721
(26.50%)
691
(20.02%)
114
(27.60%)
195
(33.22%)
659
(52.97%)
789
(59.01%)
1357
(72.61%)
1276
(37.90%)
Welfare
status - n
(%) on
benefits
3834
(28.10%)
297
(12.00%)
262
(8.33%)
32
(8.67%)
48
(9.36%)
472
(40.45%)
679
(53.93%)
1258
(73.70%)
786
(26.12%)
Phobia
Self-rating
- n(%)
phobia
7592
(50.66%)
585
(21.30%)
1261
(36.76%)
99
(22.86%)
205
(35.28%)
755
(60.35%)
750
(54.78%)
1738
(93.09%)
2199
(66.48%)
The distribution of patient characteristics for each LP alongside the full sample descriptives
are displayed in Table 5.2 and a graphical representation of each profile is presented in
Appendix D.
Comparing the means and proportions of each of the nine patient characteristics by LP with
both the full sample and other LPs in Table 5.2 provides an understanding of the make-up of
each profile of patients. For example, members of latent profile 1 (LP1) are younger,
reporting lower symptom severity (on both PHQ-9 and GAD-7), and tend to score low the
phobia scale as well as being less likely to be in receipt of welfare benefits and psychotropic
medication when compared to the overall sample. The LP2 has a similar age, gender and
ethnic group distribution to LP1, but with higher symptom severity and lower social
functioning, as well as having a higher probability of phobic caseness. Comparing LP2 to the
full sample means and proportions suggests a similar level of anxiety symptoms, slightly
lower depression severity and nearly 15% less phobia caseness than the full population
entering treatment at the services.
The highest symptom severity scores are for patients in LP7 (means of 23 and 19 on the
PHQ and GAD), and this group also have a much higher proportion of patients receiving
welfare benefits and prescribed psychotropic medication compared to the full sample and
the other profiles. These characteristics may be inter-dependent, so higher severity of
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depression or anxiety is associated with a patient receiving welfare benefits and prescribed
psychotropic medication. However, LP8 have a considerably lower likelihood of receiving
welfare benefits compared to LP7 (26% vs 73%) yet the severity scores are similar to those
of LP7. This would suggest that the profiles are identifying clusters of patients with distinct
constellations of patient characteristics, which may result in differential treatment outcomes.
There was a large variation in the size of the patient profiles, which suggests that certain
patient groups are more typical of the service population that others. LP3 and LP4 have the
lowest share of the population with 3.1% and 4.1% respectively. LP3 are a group of patients
presenting with mild levels of severity, who are very likely to be white and very unlikely to be
receiving welfare benefits, whereas members of LP4 report higher severity than LP3 (but
less than the average for the full population). However, both LP3 and LP4 have much higher
mean age than the other groups, and it may be that these profiles occur much less
frequently in the IAPT services as these types of patients may be more likely to attend older
adult services. The profiles most frequently taken into treatment by the IAPT services were
LP2 and LP8, with 22.7% and 22.1% of the population respectively.
Description of the latent profiles
A more detailed description of each LP is provided below:
LP1.
In comparison to the full sample of patients attending the services, members of LP1 are
younger and have lower mean scores on both the PHQ-9 and GAD-7, suggesting a less
severe population of patients. The mean W&SAS score is also much lower for members of
LP1 when compared to the full sample mean, suggesting social and occupational functioning
is less impaired in this profile. Patients in LP1 were less likely to meet caseness for phobia,
be in receipt of welfare benefits or prescribed medication. The percentage of the population
in LP1 who are female is very similar to the full sample percentage, as is the proportion of
individuals from non-white ethnic groups. In sum LP1 are a younger and less severe
population, with limited functional impairment issues, low scores on the phobia scales, and
are less likely to be prescribed psychotropic medication or to be on welfare benefits. LP1
make up 18% of the population taken into treatment.
LP2.
Members of LP2 have a lower mean age than the full sample of patients attending the
services and are slightly younger than members of LP1. The mean level of anxiety severity
(GAD-7) for patients in LP2 is similar to the full sample mean, whereas mean depression
severity (PHQ-9) is slightly lower. The mean social and occupational impairment score for
this profile is lower than for the full sample suggesting less impairment from symptoms.
Individuals in LP2 have a lower probability of phobia, are very unlikely to be receiving
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welfare or prescribed medication when compared to the average patient entering treatment
at the services. The percentage of females in this profile is slightly higher than for the full
population (69% vs 66%), and the percentage of individuals from non-white ethnic groups is
slightly lower than the full sample (17% vs 22%). The description of this population suggests
a group of patients whose symptoms are less chronic or potentially the first presentation to
the services with consideration to the younger age, low probability of psychotropic
medication and welfare benefit receipt. LP2 are most frequent LP taken into treatment
(22.7% of the full sample).
LP3.
This profile of patients has the lowest mean symptom severity scores and the lowest
functional impairment issues compared to all the LPs, suggesting a less disabled group of
patients. The likelihood of receiving welfare benefits, prescribed medication and caseness
for phobia is also low for this profile. The proportion of individuals from non-white ethnic
groups is very low at 11% compared to the full sample (22%) and is the lowest of all the
profiles. LP3 is also has the highest mean age (67 years old). This sub group make up only
3.1% of the full sample taken into treatment. This is a profile of older patients, who may be
attending services for less severe common mental health disorders.
LP4.
Patients in LP4 have a mean age of 65 years old, making them the second oldest group of
patients after LP3. Other similarities to LP3 are the proportion of female patients, medication
prescription, non-white ethnic group proportion and the likelihood of receiving benefits.
However, patients in LP4 typically have higher mean symptom scores (mild to moderate
symptom severity), and more functioning issues as scored on the W&SAS compared to LP3.
The levels of severity reported by members of this profile are slightly lower than the mean for
the full sample. The percentage of the population in LP4 is just 4.1% suggesting this group
of patients are not frequent attenders of the services.
LP5.
In comparison to the full sample of patients, LP5 have a higher mean age, as well as higher
mean PHQ-9 and GAD-7 scores at presentation to the services. The level of functioning
appears to be similar to the average impairment displayed by the full sample of patients
entering treatment. The incidence of phobia, proportion prescribed medication and the
likelihood of receiving welfare benefits is higher than for the full population, which suggests
that there may be more disability as a result of symptoms in this profile of patients. LP5 have
a slightly lower percentage of individuals from ethnic groups compared to the full sample.
The incidence of LP5 in the full population is 8.5%. Compared to the previous four profiles,
LP5 appear to have more severe levels of disability, indicated by higher symptoms,
functional impairment, higher likelihood of psychotropic medication prescription and higher
incidence of phobia.
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LP6.
Whereas the other LPs and the full sample show similar levels of symptom severity on both
the PHQ-9 and GAD-7 (i.e. within a point or two on each measure), LP6 are the only profile
where there is a reasonable difference in mean depression and anxiety severity. The mean
anxiety severity is 8 compared to a mean depression score of 13 for this profile, suggesting
they may be attending the services for more depression focused symptoms and treatment.
The mean age is similar to the full sample mean, and percentage of female patients is also
close. The probability of being prescribed medication (59%) and receiving welfare benefits
(54%) is higher in this profile of patients compared to the full sample, which may suggest a
more chronic group of patients. The proportion of patients taken into treatment who are from
LP6 was 9.1%.
LP7.
Patients in LP7 present to services with the highest baseline symptom severity compared to
all other profiles, with means scores 9 and 6 points higher than the full sample means on the
PHQ-9 and GAD-7 respectively. Mean age is slightly higher than the full sample mean and
that of LP6. The level of functional impairment is also high, which may be consistent with the
higher symptom severity scores. Over 90% of the group are self-rated as phobic, over 70%
have been prescribed psychotropic medication and nearly 75% report receiving welfare
benefits suggesting a much more disabled group. The percentage of non-white ethnic
groups is higher compared to the full sample (28% vs 22%). LP7 make up over 9% of the
sample of patients entering treatment.
LP8.
LP8 are the profile of patients with the highest proportion of non-white ethnic group patients
attending the services (31%). They are also the youngest group of patients attending the
services with a mean age of almost 30 years. Individuals in this profile are more likely to be
female compared to the other profiles (72%). The mean PHQ-9 and GAD-7 scores are
higher than the full sample mean scores, and patients in this profile have the second highest
symptom scores of all profiles after LP7. The probability of receiving welfare benefits or
being prescribed medication is very similar to the overall percentage of the population and
therefore this group of patients may represent a younger and more acute profile of patients
attending the services, potentially in their first episode of care.
It is interesting to note the outcome of a meeting where the results of the LPA and profile
descriptions set out above were presented to a group of senior IAPT clinicians and PWPs as
part of a dissemination of service outcomes. The clinicians reported that they could see
value in the LPs and their descriptions, and importantly that they could recognise the
different ‘types’ of patients amongst their own current caseloads. This provides some
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encouragement for the role of LPAs in the development of a DST, as the ‘face’ validity that
this represents may make it possible to engage clinicians in the further development and use
of DSTs based on these LPs.
Discussion.
The LPA identified eight statistically reliable groups of patients in receipt of psychological
treatment from the services, and this profile structure was replicated in two independent
samples of over 8000 patients. Exploring the characteristics of the identified profiles shows a
number of key differences, as well as similarities, between the sub-groups. The profiles
alone may have potential utility in clinical audits, as they may provide a useful grouping of
patients to compare between services and treatments, before differential response to
treatments is considered.
If the patient characteristics of the LPs are compared to the results of the regression
analyses in the previous chapter, then one may start to hypothesise likely outcomes of
treatment for the LPs. Higher severity on both the PHQ and GAD were consistently
associated with a lower likelihood of recovery following treatment, as was higher functional
impairment and receiving welfare benefits. As members of LP7 have the highest average
PHQ, GAD and W&SAS scores at T1 as well as a high proportion of individuals receiving
benefits, then it appears likely that the probability of recovery will be low in this profile of
patients. Conversely, LP1 have low severity, little functional impairment and a very low
likelihood of receiving benefits, and therefore the likelihood of recovery would be predicted
as high.
The regression analyses on patient characteristics associated with reliable change following
treatment suggested that lower scores on the PHQ and GAD, higher functional impairment,
receiving welfare benefits, psychotropic medication and being in a non-white ethnic group
were associated with a lower likelihood of achieving this outcome. If we look at the
distribution of these patient characteristics across the LPs it becomes more difficult to predict
this outcome between the profiles. The profiles with the highest mean severity scores (LP7,
LP8 and LP5) may be the most likely to show reliable change due to these higher scores,
but it is unknown whether the higher proportion of individuals receiving welfare benefits and
psychotropic medication, as well as individuals from non-white ethnic groups (especially in
LP8) will contribute to a lower likelihood of this outcome being achieved for these profiles, as
suggested by the regression analysis. It would therefore be of interest to explore whether
differences in the likelihood of achieving this outcome, as well as clinical deterioration and
drop out from treatment, differs between the latent profiles identified.
149
The previous latent class method analyses in CMHD populations found a six (Rosellini &
Brown, 2014), and a seven class/profile solution (Unick, Snowden & Hastings, 2009) with
their included populations and patient characteristics. The current analysis has found that
there were eight profiles identified following the LPA, and the difference may be due to a
combination of the variables used and the number of patients in the samples. This analysis
has used a range of both clinical and demographic patient characteristics, whereas the
previous research has concentrated more exclusively on clinical measures and the presence
of diagnostic symptoms. One disadvantage of using diagnoses or clinician rated symptom
measures only is that the patients themselves cannot complete them, which may limit the
possibility of using shared decision making in the process of treatment selection. It is
possible that using a wider range of patient characteristics has resulted in the current
analysis identifying a larger number of profiles than previous studies. As this analysis
identified an eight-profile solution in two independent samples, and then reproduced this
structure in the full sample, one can be confident that the eight-profile solution is the best fit
for the included dataset from the IAPT services.
Although one can be confident in the eight-profile solution in this study, it may also be of
interest longer term to explore whether this same profile structure exists in datasets from
similar services across the country. It is quite possible that different profile structures may
exist within different datasets from IAPT services, which may reflect local demographics and
communities. Rather than being a limitation of the method, it may instead allow the
opportunity to develop locally tailored DSTs that best reflect the population entering
treatment. This is beyond the scope of this project, but it may be of value to future research
to explore the potential variation in profile structures.
As mentioned previously, LPA (as with all latent class methods) also provides output to
calculate the posterior probabilities of profile membership which can be used to allocate
patients to the identified profiles. This has huge potential value for the development of a
DST, as the results of the LPA presented could be translated into algorithmic formula and
provide the probability of profile membership to any patient assessed by the services (or at
other services). An algorithm of these posterior probabilities could be built into the services’
EPMS resulting in profile information provided to clinicians (as well as to patients), which
could be used to inform treatment and care.
The analysis was limited by the patient characteristics available in the IAPT dataset, and
characteristics identified in the systematic review (Chapter 3) but not included in the IAPT
MDS could change the profile structure if included in future LPA. If these characteristics
were considered of value to the services and collected in the future then they could be used
to refine the profile structures identified in this analysis. The same could be said for some
characteristics such as employment status that was not available in the current analysis but
could be of interest to explore in future analysis.
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Although the LPA has identified eight distinct profiles of patients attending the services, the
potential value of these profiles to a DST to inform treatment selection decisions rests on
whether they are able predict differential response to IAPT treatments. The next chapter
presents a series of analyses that explore the variation in outcomes following psychological
treatments, including recovery, reliable change, deterioration and dropout, between the
identified latent profiles.
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Chapter 6. Variation in treatment
outcomes by latent profile.
Abstract
The identification of eight statistically distinct profiles of patients entering treatment at the
IAPT services presented in Chapter 5 can inform both researchers and clinicians about the
different types of patients, or casemix attending services. The identification of these profiles
also has the potential to aid clinical decisions about treatment selection, and the aim of this
chapter was to explore the variation in treatment outcomes between profiles and also
whether the probability of outcomes varied between LI and HI interventions within these
profiles. The chapter is split into three analyses; the first explored the variation in treatment
outcomes between the profiles of patients across IAPT treatments. The second analysis
supplemented these findings by exploring the probability of treatment outcomes within an
additional dataset of n=4683 patients attending the same services at a later date to validate
the findings of Analysis 1. The third analysis explored the differences in outcome between
patients receiving LI only or HI only within in each profile, to identify profiles where different
intensities of intervention may be associated with an increased probability of a positive
outcome. The results revealed a large variation in outcomes between profiles in, for
example, recovery (74% to 15%), deterioration rates (5% to 20%), and probability of dropout
(17% to 40%), which was maintained in an independent validation sample of patients.
Further analysis of differences between the two intensities of psychological intervention
found that for some profiles one intensity was significantly more likely to result in better
outcomes than the other. The findings from these analyses suggest that the latent profiles
could be used to predict the likelihood of a range of outcomes following different intensities
of psychological treatment. An algorithm which provides details on profile membership for
new patients could then be used to optimise treatment selection decisions in services, and
thereby personalise treatment for patients.
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Introduction
The previous chapter identified eight statistically distinct profiles of patients who entered
treatment in IAPT services, which can provide useful information about the characteristics of
patients seeking treatment for CMHDs. This information on the casemix attending the
services may be of value to clinicians, managers and commissioners in understanding who
attends the services, but it could be of further value to clinical decision making if the profiles
indicated which groups of patients are more likely to respond positively to treatment. Due to
the different make-up of patient characteristics in the latent profiles, it is likely that there may
be differences in the probability of recovery, change in symptoms including deterioration and
dropout from treatment between the profiles. Providing information about the probability of
treatment outcomes to clinicians might inform decisions about appropriate care.
Understanding the probability of treatment outcomes, for example the likelihood of recovery,
for each LP would enable clinicians to have a quantifiable ‘expected utility’ of each treatment
for different groups of patients referred to the services. As expected utility theory proposes
that clinicians estimate probabilities about the expected outcome of treatment (Schoemaker,
1982), having this information readily available and built into a healthcare information system
could be valuable, especially for less experienced clinicians who may be less able to predict
the expected utility of treatments. As previous research suggests both clinicians and the
general population have limited abilities when estimating probabilities (Elstein, 1999;
Yamagishi, 1997), providing previously estimated probabilities of treatment outcome may be
especially helpful.
In addition to providing information that may aid decisions on the selection of specific
treatments, differences in outcomes between profiles could also show whether treatments
may need to be tailored for particular profiles. For example, if certain profiles have a high
incidence of patients dropping out of treatment then it may be of value to incorporate
enhanced treatment-engagement strategies into the care plan to increase the likelihood of
treatment completion and associated positive outcome. If a profile is at high risk of
deterioration during treatment this may suggest that more frequent monitoring of symptoms
is required throughout treatment. Having the probability of clinical deterioration available in
advance may also be important considering the limited validity of clinicians’ predictions of
which patients may respond negatively to treatment (Hannan et al., 2005) and may therefore
suggest alternative and potentially more effective treatments.
All IAPT services provide either Low Intensity (LI) interventions at Step 2 or High Intensity
(HI) interventions at Step 3, therefore it was considered of interest to explore whether there
are differences in outcomes within latent profiles between the different intensities of
psychological intervention. The analysis of the overall population in Chapter 4 suggested a
similar likelihood of recovery for patients receiving either LI (41.40%) or HI interventions
(41.59%). However, there may be significant differences in the likelihood of recovery
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between different intensities of psychological treatment for certain profiles of patients. Of
course, it is also possible that the probability of outcomes were similar between the different
intensities of intervention for profiles, for example it may be expected that for some patient
profiles the likelihood of recovery is high and therefore little differences between intensity of
intervention would be seen. Relaying this information to the clinician would allow them to
suggest that LI interventions be considered initially, as these interventions are more cost-
and time-effective. If results suggest that a profile has a higher likelihood of positive
outcomes in one intervention over the other then the clinician could present this intervention
as the better option to the patient. For example, if HI interventions suggest a significantly
higher likelihood of recovery than LI interventions for a specific profile then it might be
suggested that HI should be the first choice treatment, rather than initiate at LI and
potentially have to step up to HI during the episode of care. Although stepping up is an
appropriate part of the Stepped Care model, it seems a poor use of resource and time to
start an intervention knowing that it is significantly less likely to be beneficial than an
alternative.
The aims of this chapter were to explore the differences in the likelihood of outcomes
following psychological treatment between the latent profiles, as well as differences within
the profiles when different intensities of intervention were received. The chapter is split into
three separate analyses. Analysis 1 explored the variation in outcomes between the latent
profiles using the initial development sample that informed the original LPA in Chapter 5
(patients referred between September 2008 and March 2012). This analysis is then
supplemented with Analysis 2 which compared the same outcomes using an additional
dataset of patients attending the same IAPT services between April 2012 and August 2013.
The goal of this analysis was to explore whether the probabilities of treatment outcome were
maintained in an independent sample of similar patients, who received treatment at the
same services. In the final part of the chapter, Analysis 3 focuses on the differences in
outcome within each LP when different intensities of intervention were delivered to profile
members, to investigate whether there is differential response to the interventions for
patients within the same profile.
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Analysis 1 – Variation in outcomes between Latent Profiles.
The aim of this analysis was to explore the variation in the likelihood of different treatment
outcomes between the eight latent profiles (LPs) identified in Chapter 5.
Method.
Patients
Analysis 1 focused on the same dataset that was previously used for the LPA in Chapter 5,
and the regression analysis presented in Chapter 4. This dataset is referred to as the
‘development’ dataset throughout this chapter. The inclusion criteria for this analysis were
identical to those used for the regression analysis in Chapter 4, where included patients
were required to have T2 data available and be classed as caseness on either the PHQ-9 or
GAD-7 at T1. This resulted in the same n=10693 patients included from the dataset of the
n=16636 patients who entered treatment and where used in LPA presented in Chapter 5 (a
patient flow diagram is presented in figure 4.1, Chapter 4).
As the aim of this thesis was to create a DST that could be incorporated into clinical practice,
an algorithm that could assign any patient to their latent profile was developed using the
results of the LPA. An algorithm was built in Microsoft Excel 2013 that was able to take the
nine patient characteristics used in the LPA and then provide the probably of membership to
each of the eight profiles for each individual patient. The probability of profile membership
was calculated using the posterior probabilities and priors from the output of the LPA (see
equations presented in chapter 5). Each included patient was assigned to the profile to
which they had the highest probability of membership as calculated by the algorithm, and
this was their profile for the analyses of outcomes included in this chapter. The number of
patients from both the full sample of n=16636 (taken into treatment) and the included sample
(Caseness and T2 data) from each LP is presented in Table 6.1.
Table 6.1. Number of patients per LP between datasets.
Taken into treatment Caseness and T2data Patients
excludedProfile n % n %
LP1 3,002 18% 663 6% 2,339
LP2 3,771 23% 2,950 28% 821
LP3 513 3% 66 1% 447
LP4 674 4% 508 5% 166
LP5 1,414 8% 1,106 10% 308
LP6 1,514 9% 1,079 10% 435
LP7 2,070 12% 1,572 15% 498
LP8 3,678 22% 2,749 26% 929
Total 16,636 10,693 5,943
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LP1 show the largest loss of patients from the analysis (n=2339, 77.91%), mainly as these
individuals were unlikely to meet caseness at T1 (due to the low mean PHQ and GAD
scores for this profile). LP3 also have low mean severity scores, which also explains the
large number of patients from this profile who were excluded from this analysis. As only 1%
of the included sample (n=66 patients) were from LP3, the results of analysis from this
profile should be interpreted with caution.
Outcomes
The five outcomes of interest in this analysis were the same five outcomes investigated as
the dependent variables in Chapter 4 (recovery, reliable change, recovery or improvement,
deterioration and dropout), that are defined and presented in Table 4.2 (Chapter 4). The
percentage of patients who achieved each outcome was compared between the LPs. To
explore the statistical difference in outcomes between LPs, logistic regression analysis was
performed for the five outcomes to calculate the odds ratio of achieving each outcome. The
logistic regression analyses were performed by entering only two profiles on each occasion
as the independent variable (for example profile 1 vs profile 2) with the outcome (e.g.
recovery) the dependent variable, to allow a direct comparison of the odds ratio of each
outcome between profiles. Analysis was conducted using STATA 12 (StataCorp LP, 2011).
Results.
Recovery.
Table 6.2. The number and percentage of patients achieving recovery.
Profile No Yes Total %
LP1 170 493 663 74%
LP2 1,357 1,593 2,950 54%
LP3 18 48 66 73%
LP4 221 287 508 56%
LP5 776 330 1,106 30%
LP6 581 498 1,079 46%
LP7 1,340 232 1,572 15%
LP8 1,947 802 2,749 29%
Total 6,410 4,283 10,693 40%
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The percentage of patients in recovery following treatment is presented in Table 6.2. The
LPs with the highest percentage of patients in recovery were LP1 and LP3, as nearly 75% of
patients in these profiles achieved recovery after receiving psychological treatment from the
services. The latent profile with the lowest percentage of patients achieving recovery was
LP7, where only 15% of patients achieved this outcomes following treatment.
To determine whether the percentage of patients who achieved these outcomes was
significantly different between these LPs, logistic regression analysis was performed
between each of the eight profiles and odds ratios (OR) are presented as a matrix in Table
6.3. Looking at the first row of the table, the comparison between LP1 and the other profiles
is displayed. Compared to LP2, the odds of recovery for LP1 were 2.47 higher (OR=2.47,
p<0.001). Compared to LP7 (with just 15% of patients in recovery), the odds of recovery for
patients in LP1 were 16.75 higher (OR=16.75, p<0.001).
Table 6.3. Odds ratios for recovery between LPs.
LP1 LP2 LP3 LP4 LP5 LP6 LP7 LP8
LP1 x 2.47** 1.09 2.23** 6.82** 3.38** 16.75** 7.04**
LP2 0.4** x 0.44* 0.9 2.76** 1.34** 6.78** 2.85**
LP3 0.92 2.27* x 2.05^ 6.27** 3.11** 15.4** 6.47**
LP4 0.48** 1.11 0.49^ x 3.05** 1.52** 7.5** 3.15**
LP5 0.15** 0.36** 0.16** 0.33** x .5** 2.46** 1.03
LP6 0.29** 0.73** 0.32** 0.66** 2.02** x 4.95** 2.08**
LP7 0.06** 0.15** 0.06** 0.13** 0.41** 0.2** x 0.42**
LP8 0.14** 0.35** 0.15** 0.32** 0.97 0.48** 2.38** x
^ p<0.05, * p<0.01, ** p<0.001
The table shows that the odds ratios between most of the profiles are significantly different
at p<0.05, with the majority of odds ratios significant at p<0.001. The odds ratios between
LP1 with LP3, LP2 with LP4, and LP5 with LP8 were not significantly different (p<0.05),
which can be explained by the similar percentage of patients who achieved recovery in
these groups (as displayed in Table 6.2). This suggests that although the patient
characteristics of these profiles are statistically different, the constellation of characteristics
for these profiles did not result in significantly different probabilities of recovery in these
pairwise comparisons, although there may have be difference between these profile pairs for
different treatment outcomes.
Reliable change
The percentage of patients who achieved reliable change, defined as a change of 5 or more
points on the PHQ-9 and 4 or more points on the GAD-7, following interventions is
presented in Table 6.4. The results for this positive outcome following treatment were very
different to those for recovery presented above. The LP with the highest percentage of
reliable change was LP8, where over 50% of the sample achieved reliable change following
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treatment. The second highest was LP5, which was only slightly lower at 49% reliable
change. The LP with the lowest percentage of patients achieving this outcome are LP3 with
just 9% achieving reliable change. Patients in LP1, of whom 74% where in recovery at T1,
were limited to a 17% probability of profile members showing reliable change on both
measures following treatment. The low probability of reliable change in these two profiles
compared with the high probability of recovery may be explained by the lower mean scores
on both the GAD and PHQ for this profile of patients, when compared to the other profiles.
Included cases in these analyses were patients who scored above caseness on either
symptom measures, but it is possible that included LP1 and LP3 cases would have scored
above caseness on one scale and not for the other. As a result, it would be more difficult for
these patients to reduce for 5 PHQ points and 4 GAD points respectively, as scores on one
scale would likely be just above caseness (but relatively low compared to other profiles),
suggesting a floor effect.
As reported in Chapter 4, individuals with higher symptom severity scores at T1 were more
likely to achieve reliable change at T2, which may in part be due to regression to the mean
and patients scoring lower will likely have a floor effect where their symptoms cannot
decrease by as much. However, the highest mean symptom scores were for LP7, yet this
profile did not have the highest amount of reliable change and therefore the presence of
certain characteristics of this profile may have reduced the likelihood of reliable change, for
example the high likelihood of receiving welfare benefits. It may be that LP7 patients were
not suited to psychological treatment, especially those delivered by IAPT services and
therefore alternative services may be a better option to optimise outcomes for this group of
patients.
Table 6.4. The number and percentage of patients achieving reliable change.
Profile No Yes Total %
LP1 551 112 663 17%
LP2 1,742 1,208 2,950 41%
LP3 60 6 66 9%
LP4 318 190 508 37%
LP5 567 539 1,106 49%
LP6 792 287 1,079 27%
LP7 973 599 1,572 38%
LP8 1,349 1400 2,749 51%
Total 6,352 4,341 10,693 41%
The number of patients who reliably changed was very similar for LP2, LP4 and LP7 at 37-
41%. Patients in LP6 had a lower likelihood of reliable change, with only 27% achieving the
outcome, suggesting this group may have important clinical differences compared to the
other profiles. As the reliable change outcome requires a decrease on both measures, it is
possible that individuals in LP6 were more likely to change on one symptom measure only.
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As the mean GAD-7 score was considerably lower for LP6 patients than the pre-treatment
PHQ-9 values, it is possible that there was a floor effect with the GAD-7 score reducing
likelihood of reliable change on this measure. The odds ratios presented in Table 6.5 show
that the odds of reliable change on both symptoms scales was significantly different between
the majority of profiles. As with Table 6.2.2, there was no significant differences between
odds of reliable change between LP1 and LP3, LP2 and LP4 as well as LP5 and LP8, most
likely due similar probabilities of achieving this outcomes between profiles.
Table 6.5. Odds ratios for reliable change between LPs.
LP1 LP2 LP3 LP4 LP5 LP6 LP7 LP8
LP1 x 0.29** 2.03 0.34** 0.21** 0.56** 0.33** 0.2**
LP2 3.41** x 6.93** 1.16 0.73** 1.91** 1.13 0.67**
LP3 0.49 0.14** x 0.17** 0.11** 0.28* 0.16** 0.1**
LP4 2.94** 0.86 5.97** x 0.63** 1.65** 0.97 0.58**
LP5 4.68** 1.37** 9.51** 1.59** x 2.62** 1.54** 0.92
LP6 1.78** 0.52** 3.62* 0.61** 0.38** x 0.59** 0.35**
LP7 3.03** 0.89 6.16** 1.03 0.65** 1.7** x 0.59**
LP8 5.11** 1.5** 10.38** 1.74** 1.09 2.86** 1.69** x
^ p<0.05, * p<0.01, ** p<0.001
Recovery or improvement
The percentage of patients who either achieved the recovery or improvement outcome
following treatment is presented in Table 6.6. The results appear very similar to those for the
recovery outcome (Table 6.2). Both LP1 and LP3 contain the highest percentage of patients
who achieved this positive outcome. LP7 are again the group with the lowest percentage of
patients showing either reliable change or in recovery, although 7% more patients have
achieved this positive outcome when compared to the recovery alone outcome (22% vs
15%).
Table 6.6. The number and percentage of patients achieving recovery or
improvement.
Profile No Yes Total %
LP1 168 495 663 75%
LP2 1,143 1,807 2,950 61%
LP3 18 48 66 73%
LP4 199 309 508 61%
LP5 636 470 1,106 42%
LP6 537 542 1,079 50%
LP7 1,232 340 1,572 22%
LP8 1,649 1100 2,749 40%
Total 5,582 5,111 10,693 48%
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The odds ratios presented in Table 6.7 suggest that the odds of recovery or improvement
were significantly different between most of the groups. The non-significant odds ratios
(p>=0.05) were for the comparisons between LP1 and LP3, LP2 and LP3, LP2 and LP4, LP3
and LP4, as well as the comparison between LP5 and LP8. There were slightly less
statistically significant differences between profiles achieving this outcome, which may be
due to the use of multiple, different criteria in the calculation of this outcome.
Table 6.7. Odds ratios for recovery or improvement between LPs.
LP1 LP2 LP3 LP4 LP5 LP6 LP7 LP8
LP1 x 1.86** 1.1 1.9** 3.99** 2.92** 10.68** 4.42**
LP2 0.54** x 0.59 1.02 2.14** 1.57** 5.73** 2.37**
LP3 0.91 1.69 x 1.72 3.61** 2.64* 9.66** 4**
LP4 0.53** 0.98 0.58 x 2.1** 1.54** 5.63** 2.33**
LP5 0.25** 0.47** 0.28** 0.48** x 0.73** 2.68** 1.11
LP6 0.34** 0.64** 0.38* 0.65** 1.37** x 3.66** 1.51**
LP7 0.09** 0.17** 0.1** 0.18** 0.37** 0.27** x 0.41**
LP8 0.23** 0.42** 0.25** 0.43** 0.9 0.66** 2.42** x
^ p<0.05, * p<0.01, ** p<0.001
Deterioration
Table 6.8. The number and percentage of patients showing deterioration.
Profile No Yes Total %
LP1 590 73 663 11%
LP2 2,694 256 2,950 9%
LP3 55 11 66 17%
LP4 455 53 508 10%
LP5 1032 74 1,106 7%
LP6 868 211 1,079 20%
LP7 1,493 79 1,572 5%
LP8 2,575 174 2,749 6%
Total 9,762 931 10,693 9%
The percentage of patients who reported clinical deterioration on the either symptom scale
following treatment is presented in Table 6.8. The LP with the highest number of patients
who showed clinical deterioration was LP6, indicating that for one fifth of patients in this
profile there was a negative impact on either depression or anxiety symptoms following
treatment. This percentage is high compared to studies of deterioration in psychotherapy
suggest around 5-10% deterioration in patients (Chapter 1), and might suggest that there
may be important characteristics of this profile that increased the risk of negative outcomes.
LP3 had the second highest incidence with 17% of patients showing clinical deterioration.
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LP7 were the least likely to show deterioration with just 5% of patients displaying a negative
outcome, followed by LP8 with 6%.
Logistic regression analyses showed that the differences in odds of deterioration were
significant between a number of the LPs, and is presented in Table 6.9. LP6 showed
significantly increased odds of deterioration when compared to all LPs except LP3. For
example, the odds of deterioration were over 2.56 higher for patients in LP6 compared to
those from LP2 (OR=2.56, p<0.001) and 4.59 higher when compared with LP7 (OR=4.59,
p<0.001). LP1, LP2, LP3 and LP4 showed no significant differences in rates of deterioration
when directly compared, except the comparison of LP3 with LP2 (OR=2.1, p<0.05). No
significant differences were found for the odds of deterioration between members of LP5
when compared to either LP7 or LP8, and the odds did not significantly differ between
members of LP7 and LP8
Table 6.9. Odds ratios for deterioration between LPs.
LP1 LP2 LP3 LP4 LP5 LP6 LP7 LP8
LP1 x 1.3 0.62 1.06 1.73* 0.51** 2.34** 1.83**
LP2 0.77 x 0.48^ 0.82 1.33^ 0.39** 1.8** 1.41*
LP3 1.62 2.1^ x 1.72 2.79* 0.82 3.78** 2.96*
LP4 0.94 1.23 0.58 x 1.62^ 0.48** 2.2** 1.72*
LP5 0.58* 0.75^ 0.36* 0.62^ x 0.29** 1.36 1.06
LP6 1.96** 2.56** 1.22 2.09** 3.39** x 4.59** 3.6**
LP7 0.43** 0.56** 0.26** 0.45** 0.74 0.22** x 0.78
LP8 0.55** 0.71* 0.34* 0.58* 0.94 0.28** 1.28 x
^ p<0.05, * p<0.01, ** p<0.001
Dropout
The percentage of patients dropping out of treatment is presented in Table 6.10. Both LP7
and LP8 reported the highest number of patients leaving treatment early, with 40% of
patients dropping out of treatment in these profiles. LP3 had the lowest percentage of
dropout (17%), followed by LP4 (20%) and LP1 (26%).
Table 6.10. The number and percentage of patients dropping out of treatment.
Profile No Yes Total %
LP1 488 175 663 26%
LP2 2,046 904 2,950 31%
LP3 55 11 66 17%
LP4 405 103 508 20%
LP5 789 317 1,106 29%
LP6 728 351 1,079 33%
LP7 948 624 1,572 40%
LP8 1,655 1094 2,749 40%
Total 7,114 3,579 10,693 33%
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The differences in the odds of dropout are presented in Table 6.11. The odds of dropout
were significantly higher in LP7 and LP8 when compared to other profiles, as shown by
significant odds ratios between these two profiles and the other groups of patients, except
when compared these profiles were directly compared. LP3 and LP4 indicated the lowest
probability of dropout which may be linked to the mean age of these two profiles which is
notably higher than the other profiles. This may provide further evidence for the finding in
Chapter 3 that older age was linked to a reduction in dropout highlighted in previously
conducted systematic reviews of outcome in CMHDs. However, there may also be other
important characteristics of LP3 and LP4 which contribute to the significantly lower odds of
dropout compared to most other profiles.
Table 6.11. Odds ratios for dropout between LPs.
LP1 LP2 LP3 LP4 LP5 LP6 LP7 LP8
LP1 x 0.81^ 1.79 1.41^ 0.89 0.74* 0.54** 0.54**
LP2 1.23^ x 2.21^ 1.74** 1.1 0.92 0.67** 0.67**
LP3 0.56 0.45^ x 0.79 0.5^ 0.41* 0.3** 0.3**
LP4 0.71^ 0.58** 1.27 x 0.63** 0.53** 0.39** 0.38**
LP5 1.12 0.91 2.01^ 1.58** x 0.83 0.61** 0.61**
LP6 1.34* 1.09 2.41* 1.9** 1.2 x 0.73** 0.73**
LP7 1.84** 1.49** 3.29** 2.59** 1.64** 1.37** x 1
LP8 1.84** 1.5** 3.31** 2.6** 1.65** 1.37** 1 x
^ p<0.05, * p<0.01, ** p<0.001
Discussion
The results of Analysis 1 suggest that there is significant variation in the probability of
treatment outcomes between the LPs identified in the LPA. Table 6.12 displays the
percentage of patients achieving each outcome across the LPs. Both visual inspection of the
probability of specific treatment outcomes as well as results of the logistic regression
analyses suggest there are important differences in outcomes between the majority of latent
profiles. These differences have the potential to inform clinicians on the expected utility of
psychological treatments per profile and may be of value to consider when deciding on
appropriate treatments from the services.
The two profiles with the highest probability of recovery following treatment were LP1 and
LP3, and with almost a 75% chance of recovery, it would appear that the services offered a
very high likelihood of a positive outcome for this profile of patients. In contrast, the results
for LP7 indicate that the probability of recovery is limited to just 15% of patients, indicating
that patients were very unlikely to achieve this outcome. Providing a clinician with this
information may help them shape treatment in order to maximise the likelihood of recovery.
LP7 may be seen as a group for whom IAPT services do not offer the most appropriate
treatment and potentially other treatment options should be considered.
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The results of the regression analysis in Chapter 4 found that higher baseline severity
increased the odds of reliable change. However, the LP with the highest baseline severity
scores (LP7) was not the profile with the highest likelihood of reliable change, and instead
three other profiles had a higher probability of achieving this outcome. If we consider the
patient characteristics of LP7, which include a high probability of receiving welfare benefits,
medication and caseness for phobia, and reference these against the results of the
regression analyses in Chapter 4, then the results suggest the interaction between these
variables may be more powerful at predicting reliable change than severity scores alone.
Although much research has focused on the role of severity in predicting treatment response
(Blom et al., 2007; Fournier et al., 2010), results presented in this chapter suggest that other
patient characteristics such as demographic information may have an important role in
predicting outcomes, despite previous evidence for these characteristics identified in the
meta-review presented in Chapter 3.
The probability of clinical deterioration also showed significant differences between profiles.
Although the differences were not as large as those presented for recovery, considering the
negative impact of clinical deterioration on a patient, the differences between profiles
presented here are no less important. The results indicated that members of LP6 had the
highest probability of clinical deterioration following treatment. The probability was much
higher than all other profiles, with the exception of LP3 and it would be of interest to explore
whether there were differences between the intensities of IAPT intervention and probability
of deterioration for this profile. It could be speculated that the high incidence of deterioration
in LP3 may be linked to the older age of this profile, chronicity of the disorder, adverse social
circumstances or that physical comorbidities that could have contributed to poorer outcomes
for some members of this profile. No information on physical comorbidities was included in
the dataset, but future research might consider collecting this information.
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Table 6.12. Comparison of treatment outcomes across the latent profiles.
% of
sample
Recovery Reliable change Recovery orimprovement Deterioration Treatment dropout
Yes Total % Yes Total % Yes Total % Yes Total % Yes Total %
LP1 6% 493 663 74% 112 663 17% 495 663 75% 73 663 11% 175 663 26%
LP2 28% 1593 2950 54% 1208 2950 41% 1807 2950 61% 256 2950 9% 904 2950 31%
LP3 1% 48 66 73% 6 66 9% 48 66 73% 11 66 17% 11 66 17%
LP4 5% 287 508 56% 190 508 37% 309 508 61% 53 508 10% 103 508 20%
LP5 10% 330 1106 30% 539 1106 49% 470 1106 42% 74 1106 7% 317 1106 29%
LP6 10% 498 1079 46% 287 1079 27% 542 1079 50% 211 1079 20% 351 1079 33%
LP7 15% 232 1572 15% 599 1572 38% 340 1572 22% 79 1572 5% 624 1572 40%
LP8 26% 802 2749 29% 1400 2749 51% 1100 2749 40% 174 2749 6% 1094 2749 40%
Total 100% 4283 10693 40% 4341 10693 41% 5111 10693 48% 931 10693 9% 3579 10693 33%
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Although the probability of treatment outcomes was statistically different between the
majority of profiles, for a few direct comparisons there was no significant difference. For
example, comparisons between LP1 and LP3, LP2 and LP4 as well as LP5 and LP8 for
recovery, reliable change and deterioration indicated no significant differences. This finding
suggests that although the constellation of patient characteristics that comprise these
profiles may be statistically different, the likelihood of these outcomes for these stratified
groups of patients is very similar. However, it is possible that outcomes vary between these
profiles when different intensities of psychological intervention are received, but also the
probably of other outcomes (e.g. dropout) was significantly different between these
comparisons.
The findings presented in this analysis suggest that there were a number of important
differences in the likelihood of treatment outcomes between the profiles when receiving
treatment at the IAPT services. However, it was also important to explore whether the
likelihood of treatment outcomes was consistent over time, which was the aim of the next set
of analyses.
Analysis 2 – Treatment outcomes in the validation sample.
Analysis 2 compared the results of Analysis 1 to the probability of treatment outcomes in an
additional sample of patients attending the same IAPT services at a later date. The aim of
this analysis was to validate whether the probabilities of treatment outcome were consistent
over time and within an independent sample of patients.
Method
The sample used for this analysis was a dataset of patients referred to the same IAPT
services between April 2012 and August 2013, and is referred to as the ‘validation sample’
throughout this chapter.
The same inclusion criteria as used in Analysis 1 was employed for this analysis and
resulted in n=4683 patients included. Patients were assigned to the latent profile to which
they had the highest probability of profile membership using the algorithm created and
described for Analysis 1.
The same five outcomes of interest in Analysis 1 were also used in this analysis, and the
percentage of patients achieving each outcome was calculated in the same method as the
previous analysis. The results for the validation sample were presented alongside the results
of the development sample to allow comparison.
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Results
After the probability of group membership had been calculated for each of the validation
sample patients, the distribution of the profiles was compared between the two samples.
Table 6.13 displays the frequency and percentage of patients in each LP for the
development sample and the validation sample. The table suggests that the distribution of
patients in each LP was very consistent over time, with limited differences in percentage
between the development and validation sample.
Table 6.13. LP distribution: development and validation samples.
Development
sample Validation Sample
Profile n % n %
LP1 663 6% 288 6%
LP2 2,950 28% 1,248 27%
LP3 66 1% 35 1%
LP4 508 5% 261 6%
LP5 1,106 10% 495 11%
LP6 1,079 10% 488 10%
LP7 1,572 15% 709 15%
LP8 2,749 26% 1,159 25%
Total 10,693 4,683
Recovery
The number and percentage of patients in recovery in both the validation and development
sample is presented in Table 6.14. The percentage of patients in recovery following
treatment for each profile was consistent for the majority of LPs, with a variation of just one
or two percentage points. The profile with the largest difference between datasets was LP2,
where 54% of patients were in recovery in the development sample but this dropped to 49%
in the validation sample. A 3% drop in the likelihood of recovery was indicated in LP8
between the development and validation samples. Overall the differences between the
likelihood of recovery was similar between the development and validations samples for
each profile.
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Table 6.14. Development vs validation sample: recovery
Validation sample Development sample
Profile Inrecovery Total %
In
recovery Total %
LP1 218 288 76% 493 663 74%
LP2 613 1,248 49% 1,593 2,950 54%
LP3 26 35 74% 48 66 73%
LP4 152 261 58% 287 508 56%
LP5 140 495 28% 330 1,106 30%
LP6 221 488 45% 498 1,079 46%
LP7 95 709 13% 232 1,572 15%
LP8 303 1,159 26% 802 2,749 29%
Total 1,768 4,683 38% 4,283 10,693 40%
Reliable change
The percentage of patients who achieved reliable change between the two samples is
slightly more variable for some profiles between the datasets and presented in Table 6.15.
Overall, the number of patients who achieved reliable change following treatment was lower
in the validation sample than the development sample by 4% (37% vs 41%). This pattern
appears reasonably consistent across the LPs, and the largest difference was for LP5 where
41% of the validation showed reliable change compared to 49% in the development sample.
LP3 also showed a 6% difference in probability of reliable change between datasets, as only
3% of LP3 members from the validation sample achieved reliable changed, compared to 9%
of the development sample. Again, it should be noted that the number of LP3 patients in the
validation sample was very low, with only 35 LP3 patients included, and therefore these
results should be viewed with caution and potentially replicated in a large sample with higher
representation of LP3.
Table 6.15. Development vs validation sample: reliable change
Validation sample Development sample
Profile Reliablechange Total %
Reliable
change Total %
LP1 41 288 14% 112 663 17%
LP2 457 1,248 37% 1,208 2,950 41%
LP3 1 35 3% 6 66 9%
LP4 94 261 36% 190 508 37%
LP5 202 495 41% 539 1,106 49%
LP6 138 488 28% 287 1,079 27%
LP7 269 709 38% 599 1,572 38%
LP8 546 1,159 47% 1400 2,749 51%
Total 1,748 4,683 37% 4,341 10,693 41%
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Recovery or improvement
The number and percentage of patients who were in recovery or improvement in both
samples is presented in Table 6.16. The results were very similar to those for recovery
presented in Table 6.14 and indicate that the percentage of patients who achieved this
outcome was largely consistent between the independent samples. The two profiles showing
more than 2% variation are LP2 (4%) and LP5 (7%) with both profiles showing less recovery
or improvement in the validation sample than development.
Table 6.16. Development vs validation sample: recovery or improvement
Validation sample Development sample
Profile Recovery orimprovement Total %
Recovery or
improvement Total %
LP1 220 288 76% 495 663 75%
LP2 715 1,248 57% 1,807 2,950 61%
LP3 26 35 74% 48 66 73%
LP4 160 261 61% 309 508 61%
LP5 174 495 35% 470 1,106 42%
LP6 240 488 49% 542 1,079 50%
LP7 150 709 21% 340 1,572 22%
LP8 438 1,159 38% 1100 2,749 40%
Total 2,123 4,683 45% 5,111 10,693 48%
Deterioration
The percentage of patients who reported clinical deterioration following treatment for both
samples is presented in Table 6.17. The overall percentage of deterioration was the same
for both datasets (9%), and generally the variation between the samples for individual
profiles was very low. LP6 had the highest probability of deterioration across both samples,
as 20% of patients in this profile deteriorated in both independent samples. The main
difference between samples is for LP3 where 17% reported deterioration in the development
sample, but this was reduced to 9% in the validation sample. This may suggest
improvements by the service in treating this profile of patients, but the very low number of
included patients from this sample suggests caution with any interpretation of findings for
this group.
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Table 6.17. Development vs validation sample: deterioration
Validation sample Development sample
Profile Deterioration Total % Deterioration Total %
LP1 27 288 9% 73 663 11%
LP2 105 1,248 8% 256 2,950 9%
LP3 3 35 9% 11 66 17%
LP4 23 261 9% 53 508 10%
LP5 35 495 7% 74 1,106 7%
LP6 96 488 20% 211 1,079 20%
LP7 52 709 7% 79 1,572 5%
LP8 87 1,159 8% 174 2,749 6%
Total 428 4,683 9% 931 10,693 9%
Treatment dropout
The largest variation in outcome between the development and the validation sample is for
dropout of treatment (presented in Table 6.18). Overall there was more dropout in the
validation sample than for the development sample (38% vs 31%). Exploration of the
individual LPs shows that the increase in percentage dropout was low for LP1, LP4, LP6 and
LP7 (less than 3% increase for these profiles) but much higher for the other four groups of
patients. It is unclear whether this increase in dropout is due to a change in practice at the
service, or potentially the recording of dropout on the system, but it appears that over time
the number of treatment dropout has increased. The findings presented here suggest that
this increase in dropout is focused more on certain profiles, and potentially these groups of
patients could be considered for treatment engagement interventions. It may also be
possible that some individuals were allocated to more inappropriate treatments, hence why
patients left treatment early, and an exploration of difference in dropout between intensities
of intervention may be of value.
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Table 6.18. Development vs validation sample: dropout
Validation sample Development sample
Profile DroppedOut Total %
Dropped
Out Total %
LP1 77 288 27% 175 663 26%
LP2 441 1,248 35% 904 2,950 31%
LP3 9 35 26% 11 66 17%
LP4 54 261 21% 103 508 20%
LP5 185 495 37% 317 1,106 29%
LP6 172 488 35% 351 1,079 33%
LP7 302 709 43% 624 1,572 40%
LP8 534 1,159 46% 1094 2,749 40%
Total 1,774 4,683 38% 3,579 10,693 33%
Discussion
The findings of analysis 2 indicate that the variation in outcomes between groups was
largely replicated in an independent sample of patients attending the services. For most
profiles, the percentage of patients who achieved each outcome was very similar in the two
independent samples and suggests that the latent profiles can predict the likelihood of
treatment outcomes across profiles and time.
The probability of recovery following treatment was consistent across profiles over time and
suggests that LPs may be useful in predicting the likelihood of a positive outcome. As
recovery is the main key performance indicator (KPI) for IAPT services nationally and a likely
goal of many patients, a robust method of predicting the likelihood of recovery based on
patient characteristics may be of real value to patients, services and clinicians. For
commissioners, the differences in overall recovery rates for a service could be further
explored by analysing recovery in relation to the distribution of profiles entering treatment
locally. Services with higher number of patients from profiles with a low probability of
recovery (e.g. LP7) will likely have lower overall recovery rates. This information may be
equally valuable comparisons of reliable change, deterioration and dropout between
services.
The likelihood of dropping out of treatment showed the largest variation between the
validation and development samples, although this variation was still within a few
percentage points across the profiles. It is possible that changes to the services over time
may have contributed to an increased rate of dropout in the most recent time period. IAPT
services are required to achieve an access target of at least 15% of adults with relevant
disorders (HSCIC, 2015), and therefore there may have been increasing pressure to take
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patients into treatment, even if it was not necessarily the most appropriate treatment.
Alternatively, other service-related factors such as a decrease in staffing levels may have
had an impact on dropout.
Although the results of Analyses 1 and 2 suggest consistent variation in treatments across
the profiles, it would be of further value for clinical decisions on treatment selection if
differences between intensities of IAPT treatments were considered. This is the focus of the
next analysis.
Analysis 3 – Variation in outcomes between interventions.
The results of Analysis 1 and Analysis 2 indicate that there is significant variation in
outcomes between the latent profiles identified, which is largely consistent between
independent samples of patients attending the service. This information alone may be
important to clinicians, as it may help them predict how likely a patient is to achieve a
positive outcome from treatment, or terminate early, and therefore may inform decisions on
treatment planning. However, it does not necessarily help decide on which type of treatment
would be most appropriate. Therefore, exploring whether the outcomes vary between
intensities of intervention within latent profiles could provide further information to inform
treatment choice. The following analysis focused on the differences in treatment outcomes
between low and high intensity interventions for each latent profile.
Methods
For this analysis, it was decided to combine the development and validation samples to
create one single dataset of n=15376 patients who were caseness at T1 and included T2
data. Combining datasets was performed to maximise the number of patients included in the
within profile analysis, as some profiles (e.g. LP3 and LP4) had low representation within the
dataset. IAPT services essentially provide Low Intensity (LI) and High Intensity (HI)
psychological interventions and these were the focus of the current analysis. As the aim of
this analysis was to compare individuals receiving specific intensities of interventions, any
patient who received more than one intensity of intervention was excluded, for example
patients stepped up or stepped down during treatment.
The number of patients who received each intensity of treatment, or who were stepped
up/down is displayed in Table 6.19. Approaching half of patients received LI interventions
only (45.04%) compared to 28.06% who received only HI treatments. Over 15% of patients
were stepped up during contact with the service. The number of individuals who were
stepped down, or who attended either Step 1 or Step 4 treatments was very low, as these
interventions are most commonly delivered by GPs (Step 1) or inpatient facilities (Step 4).
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Information on intensity of treatment was missing for n=1451 (9.44%) patients. A total of
n=11240 patients receiving LI or HI interventions only were the focus of this analysis.
Table 6.19. Number of patients by intensity of intervention.
Step of intervention Number of
patients
Percentage
of sample
Stepped Down 263 1.71%
LI 6,926 45.04%
HI 4,314 28.06%
Stepped UP 2,367 15.39%
Step 1 or Step 4 55 0.36%
Not known/recorded 1,451 9.44%
Total 15,376
As the current dataset was collected as part of routine service evaluation, the allocation of
each patient to either LI or HI interventions was decided by clinicians in consultation with the
patient and potentially with the clinicians’ supervisor(s). The decision to allocate to either
intervention was made following a clinical assessment and would have considered baseline
severity of depression and anxiety as well as other factors. It was possible that there may
have been differences between baseline symptom scores between patients allocated to LI
instead of HI interventions, as it might be expected that more severe patients would be
allocated to HI treatment. In order to test this assumption, independent samples t-tests were
performed on the mean PHQ and GAD scores at T1 for patients receiving LI interventions
and those receiving HI intervention in each LP.
The results are presented in Table 6.20 and show that there were significant differences in
baseline severity in LP1 and LP2 respectively, but not for the other profiles. Individuals in
LP1 who received HI interventions had a significantly higher mean PHQ score at T1 than
those receiving LI interventions, however the mean GAD score was significantly lower for
LP1 patients receiving HI interventions compared to those receiving LI. The opposite was
found for LP2, as significantly lower PHQ and higher GAD scores at T1 were found in the HI
group, compared to individuals from LP2 who received LI interventions. No other LPs
showed significant differences in mean symptom severity scores at T1 between patients
receiving LI and those receiving HI interventions. Of course, a range of variables other than
scores of a symptom severity scale influence the presentation and course of a mental
disorder, and may have influenced the decision to allocate a patient to treatment.
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Table 6.20. Comparison of mean symptom scores by intervention
Initial PHQ9 score Initial GAD7 score
Low
Intensity
High
Intensity t-test
p-value
Low
Intensity
High
Intensity t-test
p-valueMean SD Mean SD Mean SD Mean SD
LP1 6.71 3.12 7.33 3.24 0.01 8.22 2.16 7.74 2.45 0.01
LP2 11.38 3.11 10.86 3.31 0.00 12.53 2.95 12.85 2.93 0.01
LP3 7.83 3.80 8.41 3.63 0.47 5.87 3.39 5.00 3.22 0.23
LP4 10.59 3.45 11.11 3.61 0.07 11.16 3.15 10.91 3.55 0.36
LP5 17.64 3.36 17.95 3.45 0.13 15.92 2.70 15.81 2.95 0.51
LP6 13.92 3.05 13.62 3.27 0.10 8.13 2.65 8.30 2.70 0.27
LP7 22.73 2.74 22.84 2.93 0.43 18.28 2.52 18.33 2.62 0.69
LP8 18.69 2.98 18.73 3.38 0.76 16.29 2.73 16.47 2.96 0.11
The percentage of patients achieving each of the five outcomes was compared within each
LP for patients who received LI interventions only and HI interventions only. Logistic
regression analysis was conducted to explore whether the difference in percentage of
patients was statistically significant between interventions within each profile, with intensity
of treatment included as the independent variable. Odds ratios and the associated p-value
were presented.
Results
The distribution of patients receiving LI interventions only and those receiving HI
interventions only is presented in Table 6.21. With the exception of LP7, LI was the
dominant choice of intervention for the profiles, although there was variation between LPs.
Nearly 70% of individuals in LP1 and LP2 were allocated to LI interventions. The LP with the
third highest allocation of LI interventions was LP8 which is interesting considering the high
mean severity scores for this group of patients (means of 18.85 and 16.43 on the PHQ and
GAD respectively at T1).
Table 6.21. Distribution of LI and HI patients by Latent Profile
Total Receiving LI Receiving HI
n % n %
LP1 742 511 68.87% 231 31.13%
LP2 3109 2192 70.50% 917 29.50%
LP3 86 47 54.65% 39 45.35%
LP4 608 372 61.18% 236 38.82%
LP5 1181 739 62.57% 442 37.43%
LP6 1200 675 56.25% 525 43.75%
LP7 1634 675 41.31% 959 58.69%
LP8 2680 1715 63.99% 965 36.01%
Total 11240 6926 61.62% 4314 38.38%
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Recovery
The percentage of patients who were in recovery after receiving either LI or HI interventions
only for each LP is presented in Table 6.22. This table also presents the Odds Ratio (OR),
95% confidence intervals and p-value for recovery between LI and HI. The percentage of
LP1 patients in recovery following LI interventions was 75% compared 79% after HI
interventions, suggesting a slightly increased chance of recovery if more intensive treatment
was delivered for this profile of patients. Logistic regression analysis indicated that the
increase in odds for HI interventions was not statistically significant (p=0.227) over LI. The
results for LP2 suggest that there was a 7% increase in the likelihood of recovery following
HI interventions compared to LI (59% vs 52%), and this difference was statistically
significant (OR=1.32, p=0.001). This indicated a significant benefit of HI interventions over LI
for LP2, although the probability of recovery was over 50% following either type of
intervention.
Table 6.22. LI vs HI comparison by LP: recovery
Low Intensity High Intensity
OR 95% CIs p-value
Profile
Total
cases in
LP
%
recovery
Total
cases in
LP
%
recovery
LP1 511 75% 231 79% 1.26 0.87, 1.84 0.227
LP2 2,192 52% 917 59% 1.32* 1.13, 1.54 0.001
LP3 47 72% 39 72% 0.97 0.38, 2.51 0.955
LP4 372 58% 236 56% 0.89 0.64, 1.24 0.493
LP5 739 30% 442 31% 1.05 0.81, 1.35 0.718
LP6 675 45% 525 53% 1.39* 1.11, 1.75 0.004
LP7 675 11% 959 17% 1.66* 1.24, 2.22 0.001
LP8 1,715 29% 965 32% 1.11 0.94, 1.32 0.215
Total 6,926 42% 4,314 41% 0.98 0.9, 1.06 0.551
The odds of recovery increased for patients who received HI interventions instead of LI in all
LPs except LP3 and LP4, where results suggested a slight increase in the probability of
recovery when LI interventions where received, although this difference was not statistically
significant (p>=0.05). The reason for the decrease in odds of recovery for LP3 and LP4
when receiving HI interventions compared to LI may be due to treatment preferences for
these groups of patients. However, the very low number of patients from LP3 compared to
all other profiles suggests that these results should be interpreted with caution and that
further analysis with more LP3 patients may be of value. Although HI interventions increased
the odds of recovery for most LPs, the difference was only statistically significant for LP6
(OR= 1.39, p=0.004) and LP7 (OR= 1.66, p=0.001) in addition to LP2.
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Reliable change
The percentage of patients who achieved reliable change on both symptom measures is
presented in Table 6.23. Overall the results suggest that the odds of achieving reliable
change increased when patients received HI rather than LI interventions for all LPs except
LP3 and LP4, although this difference is not significantly different for any LP except LP1.
The percentage of patients showing reliable change increased by 11% (13% vs 24%) when
HI interventions were received by members of LP1, suggesting the likelihood of achieving
reliable change more than doubled if a HI intervention was received instead of LI (OR=2.18,
p<0.001). An increase in reliable change would likely be expected when HI interventions
were received instead of LI, mainly due to the increase number of sessions delivered.
However, as this difference was not statistically significant in any LPs other than LP1, it
suggests that the number of sessions alone does not significantly predict reliable change.
Table 6.23. LI vs HI comparison by LP: reliable change
Low Intensity High Intensity
OR 95% CIs p-value
Profile
Total
cases in
LP
% reliable
change
Total
cases in
LP
%
reliable
change
LP1 511 13% 231 24% 2.18* 1.46, 3.26 <0.000
LP2 2192 41% 917 43% 1.08 0.92, 1.26 0.331
LP3 47 9% 39 5% 0.58 0.1, 3.36 0.544
LP4 372 39% 236 35% 0.85 0.61, 1.19 0.345
LP5 739 48% 442 51% 1.12 0.89, 1.42 0.333
LP6 675 28% 525 30% 1.09 0.84, 1.4 0.525
LP7 675 37% 959 40% 1.13 0.93, 1.39 0.225
LP8 1715 51% 965 53% 1.1 0.94, 1.29 0.227
Total 6926 40% 4314 42% 1.09 1.01, 1.17 0.037
Recovery or improvement
The results for recovery or improvement outcome were very similar to those for the recovery
alone outcome and are presented in Table 6.24. The odds of achieving this positive outcome
increased when patients received HI interventions in all profiles except LP3 and LP4
(although this was not statistically different). Statistically higher probabilities of recovery or
improvement were found for LP2 (OR=1.28, p=0.002), LP6 (OR=1.29, p=0.027), LP7
(OR=1.33, p=0.022) and LP8 (OR=1.19, p=0.036) when individuals from these profiles
received HI interventions instead of LI.
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Table 6.24. LI vs HI comparison by LP: recovery or improvement
Low Intensity High Intensity
OR 95% CIs p-value
Profile
Total
cases
in LP
% recovery
or
improvement
Total
cases
in LP
% recovery
or
improvement
LP1 511 75% 231 79% 1.25 0.86, 1.82 0.249
LP2 2192 60% 917 66% 1.28* 1.09, 1.51 0.002
LP3 47 72% 39 72% 0.97 0.38, 2.51 0.955
LP4 372 64% 236 59% 0.82 0.58, 1.14 0.234
LP5 739 41% 442 44% 1.11 0.87, 1.4 0.403
LP6 675 49% 525 56% 1.29* 1.03, 1.63 0.027
LP7 675 19% 959 24% 1.33* 1.04, 1.69 0.022
LP8 1715 39% 965 44% 1.19* 1.01, 1.4 0.036
Total 6926 49% 4314 49% 0.97 0.9, 1.04 0.382
Deterioration
A comparison of the percentage of patients deteriorating following treatment is presented in
Table 6.25. Typically, the odds of deteriorating from treatment increased when individuals
received HI interventions instead of LI, which may in part be explained the higher complexity
expected for patients allocated to HI treatments. However, the only statistically significant
increase in odds of deterioration was for LP7 (OR=1.73, p=0.023). LP5 was the sole profile
where less deterioration was indicated following HI treatments, although the difference was
not statistically significant (p=0.07). A large increase in the odds of deterioration was
suggested within LP3 when HI interventions were received compared to LI (21% vs 6%),
however this difference was not statistically significant, most likely due to the low number of
patients from this profile entering treatment at the services.
Table 6.25. LI vs HI comparison by LP: deterioration
Low Intensity High Intensity
OR 95% CIs p-valueProfile
Total
cases
in LP
%
Deterioration
Total
cases
in LP
%
Deterioration
LP1 511 10% 231 10% 1.09 0.65, 1.83 0.735
LP2 2,192 7% 917 8% 1.11 0.84, 1.49 0.458
LP3 47 6% 39 21% 3.78 0.93, 15.41 0.063
LP4 372 7% 236 11% 1.51 0.86, 2.68 0.154
LP5 739 7% 442 5% 0.61 0.36, 1.04 0.07
LP6 675 17% 525 21% 1.26 0.94, 1.69 0.116
LP7 675 4% 959 6% 1.73* 1.08, 2.76 0.023
LP8 1,715 6% 965 7% 1.2 0.87, 1.67 0.261
Total 6,926 8% 4,314 9% 1.19* 1.04, 1.36 0.014
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Dropout
The results of the comparison between LI and HI interventions for percentage of patients
dropping out of treatment is presented in Table 6.26. Overall, there was significantly less
dropout in HI interventions compared to LI interventions for the full sample (OR=0.73,
p<0.001). LP3 was the only profile where the opposite was indicated, although the difference
in the likelihood of dropout was not statistically significant (p=0.496). There was a significant
decreased likelihood of dropout during treatment for LP2 (OR=0.59, p<0.001), LP4
(OR=0.44, p=0.001), LP6 (OR=0.66, p=0.002), LP7 (OR=0.74, p=0.004), and LP8
(OR=0.75, p=0.001) when patients are in HI interventions rather than LI.
Table 6.26. LI vs HI comparison by LP: dropout
LI interventions HI Interventions
OR 95% CIs p-value
Profile
Total
cases in
LP
%
Dropout
Total
cases in
LP
%
Dropout
LP1 511 24% 231 21% 0.85 0.58, 1.23 0.383
LP2 2192 31% 917 21% 0.59* 0.49, 0.71 <0.000
LP3 47 15% 39 21% 1.47 0.48, 4.51 0.496
LP4 372 22% 236 11% 0.44* 0.28, 0.72 0.001
LP5 739 28% 442 24% 0.8 0.61, 1.05 0.109
LP6 675 32% 525 23% 0.66* 0.51, 0.85 0.002
LP7 675 39% 959 32% 0.74* 0.6, 0.91 0.004
LP8 1715 39% 965 32% 0.75* 0.64, 0.89 0.001
Total 6926 32% 4314 26% 0.73* 0.67, 0.8 <0.000
These findings suggest that for the majority of patients, there is likely to be a significantly
higher incidence of dropout from LI interventions. One reason for this may be that patients
receiving self-help treatments may not feel they are supportive enough, or prefer more
contact with a clinician, and therefore leave treatment. It is also possible that individuals in LI
who are completing self-help materials in their own time at home may feel they are able to
manage this this treatment themselves and so withdraw from the service. Although their
symptoms may have improved, as they did not make any further contact with the services
they were coded as dropping out of treatment, although this single code does not capture
reasons for leaving treatment.
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Table 6.27. Treatment outcomes by latent profiles and intervention
Profile
Recovery Reliable change Recovery or improvement Deterioration Dropout
LI - % HI - % Oddsratio LI - % HI - %
Odds
ratio LI - % HI - %
Odds
ratio LI - % HI - %
Odds
ratio LI - % HI - %
Odds
ratio
LP1 75% 79% 1.26 13% 24% 2.18* 75% 79% 1.25 10% 10% 1.09 24% 21% 0.85
LP2 52% 59% 1.32* 41% 43% 1.08 60% 66% 1.28* 7% 8% 1.11 31% 21% 0.59*
LP3 72% 72% 0.97 9% 5% 0.58 72% 72% 0.97 6% 21% 3.78 15% 21% 1.47
LP4 58% 56% 0.89 39% 35% 0.85 64% 59% 0.82 7% 11% 1.51 22% 11% 0.44*
LP5 30% 31% 1.05 48% 51% 1.12 41% 44% 1.11 7% 5% 0.61 28% 24% 0.8
LP6 45% 53% 1.39* 28% 30% 1.09 49% 56% 1.29* 17% 21% 1.26 32% 23% 0.66*
LP7 11% 17% 1.66* 37% 40% 1.13 19% 24% 1.33* 4% 6% 1.73* 39% 32% 0.74*
LP8 29% 32% 1.11 51% 53% 1.1 39% 44% 1.19* 6% 7% 1.2 39% 32% 0.75*
Total 42% 41% 0.98 40% 42% 1.09* 49% 49% 0.97 8% 9% 1.19* 32% 26% 0.73*
* Indicates significant odds ratios at p<0.05
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Outcomes by profile
The results from the comparison between LI and HI interventions suggest that for a number
of profiles there are significant differences in outcomes when different intensities of
treatment are received by members of the same profile. The findings are summarised in
Table 6.27 and a summary for each profile is set out below:
LP1: Patients in this profile have a high likelihood of recovery following treatment for both LI
and HI interventions, which at 75% is considerably higher than the IAPT national recovery
figure of 46% (NHS Digital, 2016). However, the probability of reliable change is significantly
higher following HI interventions than LI and this is the only profile where there is a
significant difference in favour of HI for reliable change. The odds of deterioration and
dropping out of treatment were not significantly different between the interventions. When
selecting an intensity of interventions for patients in this LP, the limited differences between
outcomes would suggest that LI interventions would be sufficient to provide a good outcome
for the majority of patients. However, there may be situations where LI would not be an
appropriate intervention, for example for patients with PTSD for whom there is no evidence
based LI treatments.
LP2: This profile also show a high percentage of patients recovering with LI treatment, with
over 50% of patients moving to recovery. However, there was significantly more recovery for
LP2 patients who received HI interventions compared to HI. There were no significant
differences between intervention intensities for achieving reliable change or deteriorating for
members this LP, although there was significantly less dropout in HI interventions. When
selecting an appropriate treatment for this LP, HI interventions will significantly increase the
likelihood of recovery and keeping patients in treatment, although a high percentage of
patients in this profile (52%) will meet criteria for recovery following LI interventions delivered
by the services. One suggestion may be to initiate LI interventions, but be prepared to step
up to HI if there is limited improvement after three sessions as recommended by some
researchers in the field (Lambert, 2013).
LP3: Analyses on this profile included only a small number of patients and therefore the
results should be interpreted with caution. The findings of the analyses suggested that
although differences are not statistically significant, LI interventions typically increased the
likelihood of recovery and decreased the likelihood of deterioration and dropout for this
profile of patients. The findings for most profiles indicated that HI treatments improved the
likelihood of recovery and reliable change, even if the difference was not statistically
significant, and therefore the results for LP3 suggest that these patients may better more for
LI treatment.
LP4: Members of LP4 also had an increased likelihood of recovery and reliable change
following LI treatments when outcome to members of this profile who received HI
treatments, although the differences were not statistically significant. This profile were
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therefore the only other profile, in addition to LP3, to show a benefit of LI treatments over HI.
However, the incidence of dropout is significantly different between the interventions, and
was in favour of HI interventions (22% LI vs 11% HI). When selecting treatments for this
profile, unless it is felt that the patient is at risk of dropping out, the lack of significant
difference in response to treatment outcomes, and the trend supporting increased benefits of
LI interventions, would suggest that lower intensity treatment be recommended as an initial
step.
LP5: The profile of patients in LP5 suggest moderately severe symptoms, and this profile
were found to have a low likelihood of recovery following both LI and HI treatment.
Interestingly, there was no significant difference in the likelihood of any of the five outcomes
between members of this profile who received LI and HI interventions. This suggests that LI
interventions may be an appropriate treatment, despite the low probability of positive
outcomes (30% recovery) and therefore consideration might be given to other services or
more intensive interventions that could provide more appropriate treatment.
LP6: Individuals in this profile show significantly increased odds of recovery and reduced
dropout following HI interventions compared to LI. The probability of recovery following LI
interventions was very similar to that of the national average (45% vs 46%), and therefore
treatment recommendations may be either to initiate HI interventions as the first step, or
potentially an LI intervention with an increased number of sessions. The major risk with this
profile of patients is the relatively high probability of deterioration following treatment (20%),
and this level of deterioration was notably higher than the estimated average of 5-10%
(Boisvert & Faust, 2003; Crawford et al., 2016; Rozental et al., 2016). This may suggest that
clinicians consider alternative non-IAPT interventions or monitor progress carefully with
patients of this profile. Further analysis of this profile using information not collected routine
by IAPT services may help predict which patients are most at risk of deterioration.
LP7: Overall, LP7 reported the lowest percentage of patients who were in recovery following
treatment, although there were significantly increased odds of recovery in HI treatments
compared to LI (17% vs 11%). When an improvement in symptoms was considered
alongside recovery (‘recovery or improvement’) the probability of a positive outcome
increased to 25% following HI treatments. There was significantly decreased risk of dropout
during HI interventions, although the risks of deterioration where higher when HI treatment
was received compared to LI. With consideration of these findings, it might be suggested
that IAPT services were not the most appropriate setting to treat this profile of patients, and
that referral to alternative services may increase the likelihood of a positive outcome. If
treatment was to be delivered in IAPT services, HI would be recommended as the initial
treatment step.
LP8: The findings for these patients suggested that although the odds of recovery were not
significantly different between LI and HI interventions, but the HI treatments were found to
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significantly increase the likelihood of the ‘recovery or improvement’ outcome being
achieved. As there was no significant difference between interventions for deteriorating or
reliable change, and as HI treatment were significantly associated with reduced odds of
dropout, it might be suggested that HI treatment would be recommend for LP8 patients as
initial IAPT treatment.
Stepped up patients.
Although the main comparison of outcomes following different intensities of treatment is
focused on individuals receiving LI or HI interventions only, a description of the probability of
treatment outcomes for individuals who were stepped up from LI to HI interventions is
included in this section. As the number of stepped up patients meeting inclusion criteria
within some of the profiles was very low, logistic regression analyses comparing the
probability of outcome between ‘Stepped up’ and patients who received LI or HI only within
profiles were not performed due to a lack of power. A total of n=2367 patients were stepped
up during their episode of care with the services, compared to n=6926 who received LI
interventions only, and n=4314 who received only HI interventions (Table 6.19). Instead the
percentage of patients achieving each outcome is compared between patients in each of
these three intervention groups.
Recovery
The percentage of patients who were in recovery after being stepped up is compared to
individuals who received LI or HI interventions only in Table 6.28. Overall, individuals who
were stepped up during the course of treatment at the services had a lower probability of
being in recovery than individuals who received only LI or HI interventions (37% compared
to 42% and 41%). LP4 were the only LP where the probability of recovery was higher for
stepped up individuals than for individuals receiving HI or LI treatments only. As stepped up
individuals were not responding to the initial LI intervention, there may have been important
patient characteristics that were contributing to this lack of response, not available in the
IAPT MDS. Stepping up to HI treatment may have no improved the situation for a number of
patients as these patients were unlikely to benefit from either intensity of IAPT treatment.
This may explain why the probability of recovery was generally lower for stepped up patients
than those for patients who received HI treatment only.
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Table 6.28. Probability of recovery across LI, HI and Step up interventions.
Profile Low intensity High Intensity Stepped Up
Total Yes % Total Yes % Total Yes %
LP1 511 384 75% 231 183 79% 99 74 75%
LP2 2,192 1,145 52% 917 541 59% 602 321 53%
LP3 47 34 72% 39 28 72% 5 3 60%
LP4 372 217 58% 236 131 56% 86 53 62%
LP5 739 225 30% 442 139 31% 267 73 27%
LP6 675 304 45% 525 280 53% 189 83 44%
LP7 675 76 11% 959 167 17% 381 59 15%
LP8 1,715 501 29% 965 304 32% 738 217 29%
Total 6,926 2,886 42% 4,314 1,773 41% 2,367 883 37%
Reliable change
Individuals who were stepped up during contact with the services did not appear to have a
greatly increased probability of achieving reliable change either, as presented in Table 6.29.
As HI interventions did not significantly increase the likelihood of reliable change compared
to LI treatments for any profile except LP1, it is not surprising that Stepped up patients
appeared to have a similar probability of this outcome to patients allocated to LI or HI
treatments only. For LP5, the probability of reliable change was considerably lower for
Stepped up patients compared to LI (42% vs 48%), but as these patients were already not
benefiting from LI treatments it may not be surprising that changing treatment did not
significantly improve the situation, and instead allocating to HI initial for this profile of
patients may have improved outcomes.
Table 6.29. Probability of reliable change across LI, HI and Step up interventions.
Profile Low intensity High Intensity Stepped Up
Total Yes % Total Yes % Total Yes %
LP1 511 64 13% 231 55 24% 99 18 18%
LP2 2,192 891 41% 917 390 43% 602 246 41%
LP3 47 4 9% 39 2 5% 5 0 0%
LP4 372 145 39% 236 83 35% 86 32 37%
LP5 739 353 48% 442 224 51% 267 112 42%
LP6 675 188 28% 525 155 30% 189 51 27%
LP7 675 253 37% 959 388 40% 381 148 39%
LP8 1,715 870 51% 965 513 53% 738 374 51%
Total 6,926 2,768 40% 4,314 1,810 42% 2,367 981 41%
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Recovery or improvement
The percentage of individuals achieving recovery or improvement across the three
intervention groups is presented in Table 6.30. Stepping up increased the likelihood of
recovery over LI only for LP1, LP6, LP7 and LP8 but all were very marginal increases in the
probability of the outcome.
Table 6.30. Probability of recovery or improvement across LI, HI and Step up
interventions.
Profile Low intensity High Intensity Stepped Up
Total Yes % Total Yes % Total Yes %
LP1 511 385 75% 231 183 79% 99 77 78%
LP2 2,192 1,317 60% 917 604 66% 602 364 60%
LP3 47 34 72% 39 28 72% 5 3 60%
LP4 372 237 64% 236 139 59% 86 54 63%
LP5 739 306 41% 442 194 44% 267 100 37%
LP6 675 332 49% 525 292 56% 189 94 50%
LP7 675 131 19% 959 232 24% 381 87 23%
LP8 1,715 677 39% 965 421 44% 738 302 41%
Total 6,926 3,419 49% 4,314 2,093 49% 2,367 1,081 46%
Deterioration
The likelihood of clinical deterioration is presented in Table 6.31 and the analysis suggested
that individuals who were stepped up had a slightly increased likelihood of deterioration
when compared to patients who only received LI treatments. Poorer outcomes may be
expected here as stepped up patients would be considered a sub-group of LI only patients
who were not showing significant benefits from treatment and may have already have
displayed a worsening of symptoms, hence the decision to step up. The probability of
deterioration between stepped up and HI only patients was very similar, except for LP3
where only n=5 Stepped up patients were included, therefore making it difficult to draw
conclusions from this analysis
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Table 6.31. Probability of deterioration across LI, HI and Step up interventions
Profile Low intensity High Intensity Stepped Up
Total Yes % Total Yes % Total Yes %
LP1 511 49 10% 231 24 10% 99 11 11%
LP2 2,192 160 7% 917 74 8% 602 65 11%
LP3 47 3 6% 39 8 21% 5 2 40%
LP4 372 27 7% 236 25 11% 86 9 10%
LP5 739 53 7% 442 20 5% 267 17 6%
LP6 675 116 17% 525 109 21% 189 40 21%
LP7 675 26 4% 959 62 6% 381 23 6%
LP8 1,715 97 6% 965 65 7% 738 54 7%
Total 6,926 531 8% 4,314 387 9% 2,367 221 9%
Dropout
The likelihood of dropping out of treatment seems higher for individuals who were stepped
up than patients who attended either LI or HI interventions only, as presented in Table 6.26.
Across all profiles except LP3, the percentage of individuals dropping out of treatment was
much higher for individuals who were stepped up than for patients who received LI or HI
treatments only. This may have been linked to non-response to the initial LI treatment, and
patients who were stepped up my have believed that IAPT treatments were unlikely to help
them, and therefore terminated treatment.
Table 6.32. Probability of dropout across LI, HI and Step up interventions.
Profile Low intensity High Intensity Stepped Up
Total Yes % Total Yes % Total Yes %
LP1 511 121 24% 231 48 21% 99 31 31%
LP2 2,192 676 31% 917 191 21% 602 194 32%
LP3 47 7 15% 39 8 21% 5 0 0%
LP4 372 81 22% 236 26 11% 86 25 29%
LP5 739 207 28% 442 105 24% 267 94 35%
LP6 675 214 32% 525 123 23% 189 77 41%
LP7 675 260 39% 959 303 32% 381 168 44%
LP8 1,715 662 39% 965 310 32% 738 313 42%
Total 6,926 2,228 32% 4,314 1,114 26% 2,367 902 38%
Outcomes for stepped up patients.
The probability of positive outcomes from treatment was typically lower for stepped up
patients than for patient who received HI treatments, and similar to patients who received LI
treatments only across profiles. However, as stepped up patients could be considered a
subgroup of LI patients who were considered to be non-responders to treatment, it might be
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expected that this group of patients would continue to show a lack of response even when
stepped up, and instead argues that allocating these patients to HI treatments as the initial
step could have improved outcomes.
The sub-analysis by treatments showed that stepped up patients were at higher risk of
dropout than patients who received only one intervention. It is possible that the lack of
response to the LI treatment, followed by a wait until the HI treatment was commenced may
have disheartened patients, resulting in them leaving treatment rather than waiting for the HI
treatment. Allocating to a more appropriate HI treatment in these situations could reduce the
risk of dropout, as it could provide a positive experience of treatment earlier, rather than
using patient and service resource on a LI treatment that is unlikely to yield benefits.
Discussion
The findings from Analysis 3, which has compared outcomes between different intensities of
treatment by LP suggests that for certain profiles there may be increased benefits
associated with different intensities of intervention. Considering the patient’s LP following
initial assessment may have clinical utility in informing decisions about appropriate IAPT
treatment, and used aid treatment selection decisions. For example, as the likelihood of
positive outcomes was significantly higher following HI interventions than LI interventions for
patients in LP8, it might therefore be recommended that HI be considered as the initial
treatment for patients with this profile.
When there was a difference in outcomes between the intensities of intervention for a profile,
typically it was found that HI either increased the odds of a positive outcome, or reduced the
risks of dropping out of treatment, over LI interventions. As HI interventions typically involve
more face-to-face contact, this finding may not be surprising. Instead it is potentially more
surprising that HI interventions did not increase the magnitude of positive outcomes for more
profiles. The likelihood of recovery was only significantly higher in LP2, LP6 and LP7 when
HI treatments were received compared to LI, and reliable change was only significantly more
likely in HI for one profile (LP1). However, there may have been important reasons for the
initial selection of HI treatment, including clinical presentations such as PTSD that are not
captured in the nine included patient characteristics.
Although the difference in outcomes between interventions was very similar for some
profiles, the difference between 2% or 3% would be significant at the service or national
level as it would indicate a significant absolute number of patients who would have
benefitted from treatments. However, at the individual level the expected utility of outcomes
would be similar and might suggest that the decision could be made incorporating patient
preferences, but also worth considering that the LI intervention might be more appropriate
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due to the reduced burden on both the patient service resource, as well as reduced waiting
time in services.
Overall dropout was higher in LI interventions than for HI, but this may in part the nature and
means of delivery of these interventions. HI interventions are typically face-to-face sessions
of one-to-one therapy and therefore dropping out of treatment may be less likely as regular
contact with a clinician may strengthen the alliance with the patient and treatment (Strunk et
al., 2012). As LI interventions have more limited face to face contact, they may leave the
patient more vulnerable to dropping out of treatment. A recent meta-analysis of treatment
dropout in CBT found the probability of dropout for individual CBT was 24.6% during
treatment, which is very similar to the percentage found for HI interventions in the current
analysis, but was 34.2% for computer/technology delivered interventions (Fernandez et al.,
2015) which is perhaps more similar to the self-help interventions offered in IAPT. It is also
possible that for some patients LI treatment was successful and as a result they no longer
felt the need to stay in contact with services, but this was still recorded as dropout due to
lack of precision in coding as well as a low likelihood of follow up by the service.
It is of interest that for both LP3 and LP4 the LI interventions increased the odds of a positive
outcome following treatment compared to HI treatment, even though these differences were
not significantly different. For all other profiles HI was generally favourable, and therefore
this finding suggests that there is something within these profiles that may contribute to the
different findings. The main similarity between LP3 and LP4 is that patients in these profiles
are typically older and more likely to be from a white ethnic group than other profiles. Due to
the low numbers of patients who attend the services from these profiles, especially the
number of LP3 patients who were caseness, it is difficult to draw conclusions and further
research with increased numbers of patients from these profiles would be of value.
When individuals who were stepped up during contact with services were compared to
patients in each LP who only received either LI or HI interventions, the results suggested
minor increases in positive outcomes over LI interventions alone for some profiles, although
poorer outcomes found for others. Findings also suggested that dropping out of treatment is
higher for individuals who were stepped up than those who received either LI or HI alone. It
is quite possible that some patients who did not benefit from LI interventions and then were
offered additional HI support declined further treatment as they disheartened with their
experience of treatment from the services. They may also have had a negative experience
of treatment which would make the patient less likely to benefit from further treatment
provided by the same service. As stepping up patients did not appear to greatly increase the
likelihood of positive outcomes than receiving LI interventions alone, identifying the most
appropriate treatment following initial assessment may provide the best opportunity to
improve patient outcomes. It may be that additional patient characteristics not included in the
current IAPT MDS could help refine the profiles and help identify patients who are likely to
benefit from being stepped up.
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This analysis has provided considerable information about the probability of treatment
outcomes for LPs that may help inform clinical decisions around the most appropriate
treatment for a new patient entering the services. For some profiles of patients, the results
suggest that an allocation to HI treatment may significantly increase the chance of positive
outcomes, and therefore allocating to LI could be considered inappropriate. A
recommendation that displays the potential value of HI over LI for certain profiles of patients
could be included as part of a clinical DST to aid treatment choices by providing the
information on LP outcomes presented in this chapter. Such information could inform the
decision based on the expected utility of treatment options. For some profiles, there was no
significant difference in outcomes between interventions, which may suggest that the use of
the least intrusive and resource intensive intervention (LI) as initial treatment for patients of
these profiles. This would support the stepped care model and for some profiles of patients
such as LP7 and LP8, allocating to HI as the initial treatment may improve outcomes
quicker, increasing service efficiency.
Summary
The analyses presented in this chapter suggest that there are significant variations in the
likelihood of treatment outcomes between latent profiles that may be important to consider
for patients entering treatment. These differences were maintained in an independent
sample of patients attending the same services at a later date and provide evidence of the
reliability of the predictions of likely treatment outcome for the profiles. Identifying the profile
for each patient at initial assessment may provide valuable information about the likely
response to treatment as well as deterioration and dropout, which may be used to inform
treatment selection decisions.
In addition to providing a description of stratified groups of patients with similar
characteristics attending the services, the latent profiles can also be used to identify
differential probability of treatment outcomes. For example, the characteristics of members
of LP1 are low levels of depressive and anxiety symptom severity, limited phobic symptoms
and relatively high levels of social and occupational functioning compared to the average for
the full sample of patients. These patients appear to have a high probability of being in
recovery following treatment at the services, whether LI or HI interventions were received,
relative to the probability of recovery for the full dataset of patients (74% in LP1 compared to
40% for the full sample). With regard to treatment planning, these patients may be viewed as
a profile for whom LI interventions are likely to be sufficient for a good outcome. As 31% of
LP1 received HI interventions, this could represent an over use of healthcare resource and
an unnecessary burden for patients in some scenarios (although there may be reasons to
allocate to HI treatments, such as when a diagnosis of PTSD has been established). LP1
and LP3 share a number of similar characteristics, such as low levels of symptom severity
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and a low likelihood of being in receipt of welfare benefits, being prescribed medication or
having phobic symptoms. However, the mean age of LP3 is twice that of LP1 (33 compared
to 67), as well as being less likely to be from a non-white ethnic group (11% compared to
17%), but these differences appear to have little impact on the likelihood of recovery, which
is very similar for both profiles.
Considering patients with poorer outcomes, LP7 show relatively high levels of both
depression and anxiety symptoms which may account for the high proportion prescribed
psychotropic medication (73%) compared the full dataset (39%). These characteristics may
also contribute to the low number in work (74% were in receipt of welfare benefits). The
outcomes for this group are relatively poor for both low and high intensity interventions,
which suggest that alternative non-IAPT treatment options might be considered. As 73% of
LP7 patients have been prescribed psychotropic medication, it may be that reviewing this
treatment to ensure patients are actually taking medication could improve outcomes.
However, the significant difference in recovery between LI and HI interventions suggests
that if they were to be treated in the services included in this study, then a HI intervention
should be considered. The outcomes for recovery or improvement also suggest that HI
interventions might also be considered as the initial treatment for patients in LP8, as the
outcomes for HI interventions were significantly lower for this profile of patients.
Identifying patients at risk of deterioration is important as it may reduce the likelihood of
ineffective or harmful treatments being offered. For example, the deterioration rates for LP6
were four times higher (20%) compared to LP7 (5%), and more than double the mean
deterioration for the whole sample (9%). The mean deterioration rate for all patients entering
treatment is within the range typically seen in psychotherapy research at 5-10% (Boisvert &
Faust, 2003; Crawford et al., 2016; Rozental et al., 2016), but it would be of interest to see
whether there were a subgroup of patients within other psychotherapy data sets similar to
LP6, who may also have a higher risk of negative outcomes. As the probability of recovery
for this profile at 46% was similar to the overall recovery rate for the whole sample (and
IAPT nationally), this suggests that if treatment were to be offered to this group of patients
then a number of additional factors may be worth considering, such as offering HI
interventions (as there was a significant difference between LI and HI interventions) and the
use of additional interventions (for example, medication). Similarly, as the probability of
dropout is very high in LP7 and LP8 patients who were in receipt of LI interventions (39%),
this information could be used by clinicians either to consider treatment engagement as part
of the treatment, or consider HI interventions as the initial treatment to reduce the incidence
of dropout.
One limitation of these analysis is that, although the LPs show differential outcomes, in
some cases between different intensities of interventions, there may be important patient
characteristics not currently available in the IAPT dataset that could inform current treatment
decisions. Although mean PHQ-9 and GAD-7 were not significantly different between
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members of each LP attending LI or HI treatments for all profiles except LP1 and LP2, there
may have still been additional reasons for allocation to one intensity that were not captured
as part of the dataset, for example specific diagnoses such as PTSD or social anxiety
disorder for which there are no evidence-based LI interventions recommended for IAPT. The
inclusion of anxiety disorder specific measures in future IAPT datasets and analysis may
further inform the predictive ability of the LPs, but also contribute to an IAPT-relevant DST,
as significant PTSD or social anxiety disorder symptoms could result in a recommendation
for HI treatment.
There is potential for the results of these analyses to inform clinical decision-making aids,
and for recommendations to be provided to clinicians. The algorithm developed for this
analysis uses the nine included patient characteristics described in Chapter 5 and calculates
the probability of membership to each of the eight profiles using the posterior probabilities
and priors from the LPA.
This algorithm could easily be hosted in the EPMS used by the services, and as the nine
patient characteristics are mandatorily collected as part of IAPT assessment, this information
could automatically be entered into the algorithm through the record system. Information
about profile membership and probability of treatment outcomes could then be provided to
clinicians in real time, as this has been shown to import the utility of clinical DSTs
(Kawamoto et al., 2005). The algorithm could also be hosted and accessed through mobile
phone or tablet apps to allow patients to enter their details and receive a description of their
profile, likely response to treatments and a recommendation that they could discuss with
their IAPT clinician. As IAPT services have a target to achieve recovery in 50% of patients
entering treatment (HSCIC, 2015), the overall percentage recovery of 40% for this sample
argues that the more effective allocation of patients to treatment could improve recovery
rates in order to achieve the national target.
The algorithm described above could therefore be developed into a treatment selection
decision aid and used during initial assessment to inform whether low or high intensity
interventions would be the most appropriate. It may also be possible to provide further
information to clinicians on the predicted change in symptoms during treatment, rather than
just likely prognosis. Even profiles with a high probability of a positive outcome, such as LP1,
did not have a 100% probability of recovery and therefore there will be patients who during
the course of treatment are show little benefit. It would be of value to identify these potential
treatment non-responders as soon as possible to provide an opportunity for the patient and
clinician to discuss and consider alternatives, therefore aiding treatment monitoring
decisions.
The next section of this thesis explores the expected trajectories of change in symptoms
during treatment for patients, using latent growth methods to calculate the mean change in
symptoms between sessions. Trajectories of change for individual profiles will also be
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estimated to provide a more tailored expected response trajectory. In addition, latent class
growth analysis (LCGA) (Muthén, 2001; Muthén et al., 2002) will be performed to identify
sub-populations of patients within the data who have differing forms of change, for example
those who display a continual reduction in symptoms and patients show little response to
psychological treatments.
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Chapter 7. Latent Growth Curve & Latent
Class Growth Analysis.
Abstract.
The eight latent profiles (LPs) of patients attending IAPT presented in the previous two
chapters could already be used to inform treatment selection decisions between different
intensities of psychological intervention. However, as profile membership is based wholly on
data collected at an initial screening or assessment session, it may be of further interest and
clinical utility to understand how patients’ symptoms change during the course of treatment,
with potential to aid clinical decisions made during the delivery of an intervention. In this
chapter, latent growth methods (McArdle, 1986) and latent class growth analysis (LCGA)
(Muthén, 2001) were used to identify the expected trajectories of change in symptom
severity for patients attending low intensity guided self-help treatment (n=3334) and high
intensity (n=4394) psychological interventions at the IAPT services. The mean change in
both depression and anxiety symptoms was similar between the two intensities of
intervention, with greater change in symptoms recorded during the initial sessions of
treatment, which then levelled out as the number of sessions increases. Growth curves were
also performed by LP, and it was found that although the form of change was similar across
most profiles, distinct trajectories of change existed between them. LCGA was used to
identify groups (classes) of patients with different trajectories of change for both depression
and anxiety symptoms. The distribution of these trajectories varied between LPs, indicating
that individual profiles were more likely to be associated with just two or three of the
trajectories. Providing information on expected trajectories of change for individual LPs could
inform a more personalised approach to both treatment selection and treatment monitoring
for patients entering treatment. The identification of different trajectories has potential to be
used in clinical practice to aid clinical decisions during treatment, by monitoring change and
providing feedback about whether the patient’s progress in treatment is or is not indicative of
positive outcomes at the end of therapy.
Introduction.
Being able to predict whether patients will respond or not to psychological interventions from
baseline assessment information has potential benefit in aiding clinical decision making in
routine care. The latent profiles (LP) previously identified provide information on the
probability of different treatment outcomes when either LI or HI interventions were received
at IAPT services. This could be used by clinicians to inform treatment selection at initial
assessment. However, as baseline information is necessarily limited, with potentially
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important variables either not measured, or not feasible to measure (e.g. bio-markers), there
may be additional clinical value in providing information about how a patient is responding to
a given treatment (Lambert, 2013). This could be used to determine whether or not they are
following an expected trajectory that would indicate a positive outcome at the end of
treatment. Within the context of IAPT services, this may involve decisions about whether
individuals would benefit from being stepped up from LI to HI interventions, whether the
focus or modality of the psychological intervention could be changed, if a discussion with a
GP about medication may be appropriate, or the need to refer the patient to secondary care.
Routine outcome measurement (ROM), the collection of information on a patient’s
symptoms and other clinically relevant information at multiple time points during the course
of an intervention, can provide valuable information to both the clinician and patient on the
progress of treatment (Harmon et al., 2007; Lambert & Shimokawa, 2011). IAPT services
promote the use of ROM, with scores on both the PHQ-9 and GAD-7 collected at each
treatment contact with the service as part of the IAPT service specification (CSIP, 2007).
Research evidence suggests that providing clinicians with information on their patient’s
progress during treatment can have a positive effect on treatment outcomes. For example,
the QA system designed by Lambert and colleagues (2001) which uses patient ROM
information to feedback to the clinician when change in symptoms is indicative of a poor
outcome from treatment (see Chapter 2). Patients whose reduction in symptoms is less than
expected are flagged as being ‘Not on track’ and the identification of these patients enables
the clinician to consider potential adaptions to treatment, for example changing treatment
modality or referring to secondary care services. A meta-analysis of treatment trials that
have compared the use of the QA system to control groups without feedback have found it
to be associated with better patient outcomes, especially for ‘Not on tack’ patients
(Shimokawa et al., 2010). The positive impact of feedback on patient outcomes in routine
treatment services has also been found in studies using alternative feedback methods to the
QA system (Knaup et al., 2009), including the use of pencil and pen charting (Anker,
Duncan, & Sparks, 2009).
The use of feedback in psychological interventions in this way has typically involved
‘expected response curves’, graphical representations indicating the likely trajectory of
change in symptoms over time for a typical patient (Bybee, Lambert, & Eggett, 2007).
Patients who do not appear to be following the expected response are therefore ‘Not on
track’. The typical pattern of change in psychological interventions generally shows a greater
impact of treatment on symptom reduction in the first few sessions, displayed by a steep
curve, which then levels out as the number of treatment sessions increases (Cuijpers et al.,
2013; Kopta et al., 1994). The rate of change in the first few sessions is also associated with
eventual treatment outcome (Lewis, Simons, & Kim, 2012) and it has been suggested that
up to 40% of the variance in final outcome can be attributed to change in symptom scores by
the third session of psychological intervention (Lambert, 2013). Meta-analyses of
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pharmacological interventions have reported similar findings, with two reviews of
antidepressant trials suggesting that relatively large decreases in symptom severity within
the first two weeks are predictive of eventual treatment response (Gorwood et al., 2013;
Szegedi et al., 2009).
Longitudinal structural equation modelling approaches such as latent growth curve (LGC)
modelling provide a valuable method of describing the process or form (trajectory) of change
for a sample of individuals with data from repeated time points, and has shown utility in
studies of psychological interventions (Clapp et al., 2013; Henderson, Rowe, Dakof, Hawes,
& Liddle, 2009; Stulz, Lutz, Kopta, Minami, & Saunders, 2013). In the context of the current
IAPT dataset, ROM data from both the PHQ-9 and GAD-7 could be used to identify the
expected response curve of symptoms scores for all patients entering treatment. The
expected curves could then be presented to clinicians and patients as part of the EPMS, and
this information could be made available for any new patient entering treatment. The
potential benefit to clinical practice is that change in symptoms scores can be compared to
the identified expected response curve for similar patients attending the same treatment,
and clinicians could use this information to decide whether the current treatment was having
the expected positive effect or not. The use of LGC modelling could be combined with
information from the previously identified LPs to tailor the expected response curve to
specific profiles of patients, and so increasing both the precision of the estimates and their
potential utility in clinical practice.
LGC analysis can be extended to identify different subgroups, or classes of
curves/trajectories of change within the sample using growth mixture modelling (GMM)
approaches, such as latent class growth analysis (LCGA) (Muthen, 2001; Muthen et al.,
2002). The aim of these methods is to identify homogeneous groups (classes) of individuals
with similar trajectories within a heterogeneous sample of individuals. For example, there
may be two statistically distinct classes in the sample – one displaying a general decrease in
symptoms over time points, whereas a second ‘curve’ (class) may display a flat line
indicating a lack of change over time (non-response to treatment). These approaches have
been used in modelling treatment outcomes and symptom change in CMHDs in routine
treatment (Rubel et al., 2015; Stulz, Lutz, Leach, Lucock, & Barkham, 2007), the probability
of mental health diagnosis over time (Paksarian et al., 2016) and trajectories of service
utilisation (Musliner et al., 2016).
A GMM analysis on a dataset of 192 patients that received six sessions of psychological
interventions in routine treatment services by Stulz et al (2007) using the CORE-OM
symptom scale identified five distinct classes of patients over first six sessions of treatment.
Four of the identified classes showed relatively flat response trajectories, suggesting little
change in symptoms over the first six sessions, and the main variation between these
trajectories was the different levels of initial symptom severity or intercept values. However,
one class, defined as ‘early improvement’ indicated a group of patients who demonstrated a
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steady and consistent decrease in symptoms over the first six sessions of treatment.
Although this analysis was conducted on only the first six sessions, rather than through to
the end of treatment, this number of sessions is around the average number received in
IAPT services, especially low intensity interventions (Chan & Adams, 2014; Radhakrishnan
et al., 2013). As HI interventions are expected to include more than six sessions of treatment
(NHS Digital, 2016), analysis using an increased number of time points would be more
valuable to a potential DST in IAPT services. Other authors have found less distinct classes
of change during analysis of CMHD datasets from clinical trial samples. For example,
Gueorguieva, Mallinckrodt and Krystal (2011), performed GMM methods on a dataset of
patients receiving antidepressant treatment for depression and the results indicated two
classes of patients, which could be classified as responders and non-responders to the
intervention.
Although clinicians could compare symptom scale scores for an individual patient to create a
graphical representation of change in symptoms during treatment (e.g. using pen and
paper), there are a number of reasons why using all available data from comparable patients
through computer-based technology could have advantages. Firstly, research has shown
that clinicians are not always able to reliably predict which patients will benefit from
treatment (Hannah et al., 2005; Walfish et al., 2012), and therefore an objective system
based on comparable patients that could present the expected trajectory and likely outcome
may be more instructive. Secondly, creating manual reports for individual patient trajectories
would be demanding for clinicians to process, therefore the use of computer-based decision
support through the graphical reports on patient progress can be a more efficient use of
resource (Gibbons et al., 2015). Thirdly, entering ROM information in the healthcare system
can contribute to a quality assurance process, which could aid service-level decision making
and commissioning of treatments (Lambert, 2013).
Using the previously identified LPs could be a useful method of stratifying patients entering
treatment and could contribute to more personalised expected response curves for patients
receiving treatment at IAPT services, as it was theorised that trajectories could differ by LP.
The LPs could therefore be used both to personalise clinical decisions about treatment
selection but also inform decisions during the course of treatment, such as whether the
intervention is having the expected effect on clinical symptoms. If the estimation of the
expected response curves could be built into the LP algorithm developed in Chapter 6, then
this could produce a DST for personalising both treatment selection and treatment
monitoring decisions for IAPT services.
The aim of this chapter was to explore the expected response curves, as measured on both
the PHQ-9 and GAD-7, of individuals receiving treatment in the IAPT services. LGCs were
estimated for the full sample of included patients, but also by LP to identify the expected
response curve of each profile. In addition, GMM methods were used to identify distinct
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classes of patients who differed with regard to their trajectories of symptom change during
psychological interventions.
Method.
Sample.
The sample used for this analysis was taken from the same n=15376 patients attending the
two IAPT services as described in Chapter 6, including all patients reporting caseness and
with any post-treatment assessment (T2 data) from the discovery and validation datasets.
As the analysis proposed to explore the form of change in clinical symptom scores within
treatment, it was decided to focus on sub-samples of patients who received similar types of
psychological intervention. Researchers advocate a minimum sample size for structural
equation modelling, including latent growth methods, and typically around 100 to 200 cases
are the suggested minimum sample size (Barrett, 2007; Curran, Obeidat, & Losardo, 2010).
Therefore, it was decided to keep intervention types at the higher order rather than breaking
them down into more specific types (such as IPT, couples therapy) with limited numbers of
available patients. The majority of HI treatments could be easily grouped together for the
analysis, and specific low intensity interventions such as guided self-help and computerised-
CBT were grouped together as ‘Guided self-help’.
IAPT services may deliver more than one intervention type during an episode of care for a
particular patient, such as providing group-based interventions in addition to individual
psychological therapy, as well as stepping up patients from low to high intensity
interventions. For the current analysis therefore, the ‘main intervention’ was identified for
each patient as the type of intervention they received most frequently during their episode of
care with the IAPT services. In situations where two or more interventions were received in
equal amounts, the more intensive intervention was selected as the main intervention. Table
7.1 displays the frequency of each main intervention in the dataset. The majority of patients
received either guided self-help (GSH; 44.7%) or high intensity (HI; 39.9%) interventions.
The next most common interventions were non-facilitated or ‘pure’ self-help (6.3%) followed
by group-based interventions (4.4%). No intervention was recorded for 2.2% of patients and
1.9% of patients received signposting to services outside of IAPT as their main intervention.
Less than 1% of the sample received either exercise-based interventions or other
interventions that were labelled as non-standard by clinicians at the services.
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Table 7.1. Frequency of main intervention.
Main Intervention Number ofPatients
Percentage of
total
Guided SH 6,870 44.68%
HI 6,136 39.91%
Pure SH 965 6.28%
Group Intervention 671 4.36%
Not recorded 338 2.20%
Signposting 296 1.93%
Non-standard HI 89 0.58%
Exercise 6 0.04%
Non-standard LI 5 0.03%
Total 15,376
Information about the non-standard interventions was limited and as such a small number of
patients received these interventions, patients receiving these as their main interventions
were excluded from the analyses, as were the n=6 patients for whom exercise was the main
intervention. Patients who had no intervention recorded were excluded (n=338), as were
patients who received ‘sign-posting’ as their main intervention (n=296), as this was not
considered a psychological intervention. There were n=671 patients for whom ‘groups’ was
the main intervention received. However, group-based interventions delivered across
services may have very different functions, in particular relapse prevention, trauma-focused
work or psychoeducation, and can therefore vary in duration, purpose and the types of
patients for whom the groups are focused. As a result, it was decided to exclude ‘group-
based’ interventions from latent growth analysis due to the potential variation in the actual
intervention received between patients.
Patient flow for inclusion in the analysis is displayed in figure 7.1. Latent growth modelling
requires observations from at least three time points to model change in symptoms, and
therefore patients who had just two contacts with the services were excluded from the
analysis. In addition, patients were only included if they received at least three sessions of
their ‘main intervention’. Otherwise there would be a risk that any additional interventions
may have had a major effect in the change in symptom scores which could not be attributed
to the main intervention.
By using this exclusion criteria, only n=182 patients who received pure self-help as their
main intervention could still be included from an original sample of n=965 patients receiving
this as their main intervention. This loss of over 80% of all patients receiving pure self-help
was mainly due to patients having just two time points typically when receiving this
intervention, which is most likely due to the nature of self-help interventions and follows both
NICE guidance and the design of IAPT services (CSIP, 2007; NICE, 2011). As less than
200 included patients received pure self-help, and because there would be limited time
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points available for this sample due to the nature of the intervention, all patients with this as
their primary intervention were excluded.
This resulted in a sample of n=3465 patients who received low intensity GSH interventions
and n=4903 patients who received HI interventions as their main intervention type. It was
observed that a small number of patients (n=640, 7.49%) across both samples received
quite a large number of different additional interventions to their main intervention type. As
the analysis was focused on two specific interventions (HI and GSH), additional
interventions may confound the trajectories of change. As a result, patients who received
three or more additional intervention sessions that were not their main intervention type were
excluded from the analyses described in this chapter1. The final dataset of included patients
consisted of n=3334 patients who received GSH and n=4394 who received HI. The
distribution of included patients by Latent profile (LP) is displayed in Table 7.2. Guided self-
help and HI patients were modelled separately throughout the analyses described in this
chapter. LP3 included only n=10 & n=14 patients for GSH and HI respectively in the dataset,
and due to this very low number, growth curves could not be specified for this LP and it was
therefore excluded from the analysis.
Table 7.2. Number of patients receiving GSH or HI, by latent profile.
Number of patients
included (GSH)
Number of patients
included (HI)
All cases 3334 All cases 4394
LP1 133 LP1 135
LP2 1112 LP2 1052
LP3 10 LP3 14
LP4 167 LP4 180
LP5 363 LP5 453
LP6 326 LP6 487
LP7 325 LP7 924
LP8 898 LP8 1149
Measures.
Sessional routine outcome measurement (ROM) data is collected and entered into the
healthcare information system at each contact with the IAPT services, and this monitoring
information can provide cumulative session by session reporting. The current dataset used
in this analysis included symptom measure total scores at each contact.
1 Analysis was conducted on the sample which included patients with three or more additional
intervention sessions, and is presented in Appendix E. Model fit statistics for this sample were very
similar to those for the included sample.
198
Figure 7.1. Patient flow diagram - growth modelling
It was decided to use up to eight time points for the analysis of GSH interventions, which
was consisted of the initial (0) baseline time point and up to seven additional symptom
measures collected during contact with the services. Previous researchers have advocated
using upper limits on the number of included time points that are close to the mean number
of sessions in growth curve modelling, as there is a risk the slope in the LGC could be
n = 15376
Cases in previous analyses
n = 1405 excluded, main intervention not included:
* n=89: "Non-standard HI"
* n=5: "Non-standard LI"
* n=6: "Exercise"
* n=296: "Sign posting"
* n=338: No intervention recorded
* n=671: Groups
n = 13971
Cases receiving included main
intervention:
* n=6136: HI
* n=6870: Guided S-H
* n=965: Pure S-H
n = 3927 excluded
Less than 3 time points recorded on GAD/PHQ
n = 10044 included
3+ time points recorded on PHQ/GAD
* n=5193: HI
* n=4464: Guided S-H
* n =387: Pure S-H
n = 1494 excluded
Less than 3 sessions of main intervention
n = 8550 included
3+ sessions of main intervention
* n=4903: HI
* n=3465: Guided S-H
* n=182: Pure S-H
n = 182 excluded
Pure SH
n = 640 excluded
3+ session of 'additional' intervention
n = 7728 included patients in analyses
* n=4394: HI
* n=3334: Guided S-H
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distorted when relatively few patients are providing data for later time points (Lutz et al.,
2005). The mean number of GSH sessions received by included patients was five (SD=1.72)
in the current dataset, and clinicians from the services suggested that up to six sessions
were typically provided as standard. NICE guidance for GSH interventions for the treatment
of depression and anxiety recommends between five and eight sessions of GSH for CMHDs
(NICE, 2009; NICE, 2011) and therefore the eight time points included in the current
analysis should cover assessment and evidence based treatment received for the majority of
patients.
As HI interventions were expected to be more intensive and therefore more sessions would
be received by patients, it was decided to use an upper limit of 13 time points in the analysis,
which was made up of a baseline assessment symptom score and 12 additional contacts
with the service. Analysis of the current IAPT dataset found a mean of 10.9 sessions (SD =
4.31) which appears very close to the average suggested in the IAPT service specification of
12 sessions (CSIP, 2007).
Analysis plan.
The analyses presented in this chapter are split into two separate studies. Analysis 1 uses
‘latent growth curve analysis’ (LGC) on the two intervention datasets (GSH and HI) to
estimate the mean change in symptom during treatment for both the full intervention sample
and the sub-samples of LP members. Analysis 2 uses ‘Latent class growth analysis’ (LCGA)
to identify classes of trajectories in the datasets. Both analyses are described in further
detail below. Data analysis was conducted in Mplus version 7 (Muthén & Muthén, 2012).
Analysis 1 - Latent growth curve analysis
The initial phase of the analysis was to specify the form of change in both depression and
anxiety symptoms using the PHQ-9 and GAD-7 outcome scores at each time point, for both
GSH and HI interventions separately. The analyses would first specify a linear slope as the
form of change, then compare model fit statistics when a quadratic slope is specified to
observe where this is a better fit for the data. Previous research has typically identified that a
quadratic slope provides the best fit for change during psychotherapy treatment (Clapp et
al., 2013; Gueorguieva et al., 2011). In the final stage of this analysis, the residuals of each
time point would be allowed to correlate to explore whether the inclusion of a potential time-
varying factor improved model fit, as is often suggested in structural equation modelling of
longitudinal data (Cole, Ciesla, & Steiger, 2007; Landis, Edwards, & Corina, 2009; Muthén &
Muthén, 2008).
To compare the LGC models, the following model fit statistics and thresholds were used.
Firstly, the Comparative Fit Index (CFI) and Tucker-Lewis Index (TFI) values were
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considered with values >0.95 suggesting good model fit, and >0.97 excellent fit (Geiser,
2013; Schermelleh-Engel, Moosbrugger, & Müller, 2003). Secondly, the root mean square of
error of approximation (RMSEA) and the standardised root mean square residual (SRMR)
were compared, with values <0.05 indicating good model fit on both statistics (Berlin, Parra,
& Williams, 2014; Hu & Bentler, 1999).
After establishing the best model fit for change in PHQ-9 and GAD-7 scores for all included
individuals receiving either GSH or HI interventions, the LGCs for each Latent Profile (LP)
were specified to allow a comparison of expected response curves between LPs.
Analysis 2 - Latent class growth analysis
In order to identify statistically distinct classes of response curves within the IAPT samples,
latent class growth analysis (LCGA) was selected. LCGA is a specific type of GMM method
that fixes both the slope and intercept to equality across individuals within a trajectory class
(Andruff, Carraro, Thompson, & Gaudreau, 2009). Fixing the within-class variance to zero in
this manner provides a clearer identification of classes, as recommended as the preliminary
step with exploratory group trajectory models (Jung & Wickrama, 2008).
LCGA modelling uses the same model fit statistics that are considered in the latent profile
analysis (described in Chapter 5), and for this analysis the Vuong-Lo-Medell-Rubin
Likelihood Ratio test (VLMR-LRT; Lo, et al., 2001), the Akaike Information Criterion (AIC),
Bayesian Information Criterion (BIC) and entropy value were compared between models.
The VLMR-LRT is a comparison between the K model (current model with K number of
classes) and the K-1 model (model with one less class), with a p-value <.05 indicating that
the K model fits the data better than the K-1 model. A p-value >=0.05 (no longer statistically
significant) suggests that the model with one less class is a better fit for the data, and this
more parsimonious K-1 model would be preferred over the K model. Lower AIC and BIC
values for one model compared to another indicate better model fit, whereas higher entropy
values indicate higher accuracy in classification for the model.
As there were no prior hypotheses on the number of classes, the LCGA was conducted with
a two-class model, assessing fit statistics and increasing the number of classes until the
VLMR-LRT became non-significant or any of the AIC or BIC values increased compared to
the previous class solution as is standard for GMM/LCGA methods (Geiser, 2013; Musliner
et al., 2016; Rubel et al., 2015). It is also common practice to apply restrictions on the
minimum size of a class in GMM methods, with the commonly applied standard being that a
class must contain at least 5% of the sample for it to be considered meaningful and
numerically stable (Gueorguieva et al., 2011; Spinhoven et al., 2016).
LCGA was performed on the included samples of patients receiving GSH or HI interventions,
and conducted separately for the PHQ and GAD total score change over time. Following the
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identification of a class solution for each symptom measure and intervention type, the
conditional probability of class membership was extracted for each patient. This allowed
every patient to be assigned to a class following the LCGA and meant an exploration of
differences in the likelihood of each class between LPs could be performed.
Results.
Analysis 1.
Latent growth curve analysis - full sample (Guided self-help)
In the first stage of the analysis of patients receiving GSH, a linear LGC model was applied
to the both the PHQ and GAD data. Model fit statistics suggested a poor fit for both these
models (PHQ: CFI=0.908, TFI=0.917, RMSEA=0.078, SRMR=0.166; GAD: CFI=0.877,
TFI=0.889, RMSEA=0.082, SRMR=0.182). The quadratic was then selected for both
symptom measures and model fit was shown to improve, with a good fit indicated for both
symptom measure models (PHQ: CFI=0.979, TFI=0.979, RMSEA=0.04, SRMR=0.032;
GAD: CFI=0.977, TFI=0.976, RMSEA=0.038, SRMR=0.046).
In the final stage of analysis, the residuals of each time point were allowed to correlate.
Adding correlated residuals to the quadratic model resulted in an excellent fit for the data
(PHQ: CFI=0.994, TFI=0.992, RMSEA=0.025, SRMR=0.023; GAD: CFI=0.991, TFI=0.987,
RMSEA=0.028, SRMR=0.039). Figure 7.2 presents the final curves for the PHQ and GAD
for patients attending GSH. The graphs suggest a similar form of change on both symptom
measures following GSH treatment.
Figure 7.2. LGCs for PHQ-9 and GAD-7 - all patients (GSH).
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Latent growth curve analysis - full sample (High Intensity)
Analysis was also performed for both the PHQ and GAD for all patients who received HI as
their main interventions. The linear LGC displayed poor model fit, as seen previously with
the GSH data (PHQ: CFI=0.915, TFI=0.923, RMSEA=0.07, SRMR=0.1; GAD: CFI=0.9,
TFI=0.909, RMSEA=0.073, SRMR=0.118). The introduction of a quadratic curve to the
model greatly improved fit (PHQ: CFI=0.963, TFI=0.965, RMSEA=0.047, SRMR=0.04; GAD:
CFI=0.96, TFI=0.962, RMSEA=0.047, SRMR=0.045) and the further inclusion of correlated
residuals provided excellent model fit (PHQ: CFI=0.988, TFI=0.987, RMSEA=0.029,
SRMR=0.028; GAD: CFI=0.987, TFI=0.985, RMSEA=0.029, SRMR=0.034). The curves for
HI patients are displayed in figure 7.3 and appear very similar between the PHQ and GAD.
Figure 7.3. LGCs for PHQ-9 and GAD-7 - all patients (HI).
Latent growth curve analysis – Latent profiles (Guided self-help)
In the next stage of the analysis, the full sample was split into LP subgroups with LGCs
modelled for each LP. As a quadratic curve with correlated residuals provided excellent fit
for the full sample, LGC for each LP was performed specifying curves of the same structure.
LP3 was not included due to the low number of patients available for inclusion in the
analysis.
The LGC for each LP, as well as for the full sample, when GSH was the main intervention
are presented in Figure 7.4, and information on the intercept, slope and quadratic value of
each LP curve, are provided in Table 7.3.
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Figure 7.4. LGCs for PHQ-9 and GAD-7 – by latent profile (GSH)
Table 7.3. Intercept, slope and quadratic of LGC by LP (GSH)
PHQ
LP n
Intercept Slope Quadratic
Mean 95% CI Mean 95% CI Mean 95% CI
All Cases 3334 15.249 (15.07,15.43) -1.941 (-2.04,-1.84) 0.126 (0.11,0.14)
LP1 133 7.501 (6.87,8.13) -0.896 (-1.3,-0.49) 0.05 (-0.01,0.11)
LP2 1112 11.373 (11.19,11.56) -1.481 (-1.63,-1.33) 0.095 (0.07,0.12)
LP4 167 10.979 (10.45,11.51) -1.583 (-1.94,-1.2) 0.113 (0.05,0.17)
LP5 363 17.558 (17.21,17.91) -2.03 (-2.35,-1.71) 0.1 (0.05,0.15)
LP6 326 14.178 (13.86,14.5) -1.82 (-2.16,-1.48) 0.142 (0.08,0.2)
LP7 325 22.659 (22.36,22.96) -2.008 (-2.34,-1.68) 0.097 (0.05,0.15)
LP8 898 18.745 (18.54,18.95) -2.678 (-2.89,-2.46) 0.193 (0.16,0.23)
GAD
LP n
Intercept Slope Quadratic
Mean 95% CI Mean 95% CI Mean 95% CI
All Cases 3333 13.902 (13.76,14.05) -1.848 (-1.94,-1.75) 0.126 (0.11,0.14)
LP1 133 8.223 (7.74,8.71) -0.771 (-1.18,-0.37) 0.001 (-0.07,0.07)
LP2 1112 12.721 (12.54,12.9) -2.117 (-2.27,-1.96) 0.164 (0.14,0.19)
LP4 167 11.611 (-11.1,12.12) -1.908 (-2.35,-1.46) 0.142 (0.07,0.22)
LP5 363 15.998 (15.71,16.28) -2.102 (-2.4,-1.8) 0.146 (0.1,0.2)
LP6 326 8.159 (7.85,8.47) -0.129 (-0.4,0.14) -0.037 (-0.08,0.01)
LP7 324 18.102 (17.81,18.4) -1.502 (-1.8,-1.21) 0.076 (0.03,0.12)
LP8 898 16.312 (16.13,16.5) -2.209 (-2.4,-2.02) 0.151 (0.12,0.18)
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Observation of the graphs indicates that the general shape of LGCs are similar between
LPs, with the main difference being the intercept and the gradient of the slopes. By
examining Table 7.3, the largest variation between LPs is with regard to the intercept value,
which would be expected as the probability of LP membership is derived from both the PHQ
and GAD score. Therefore, the intercept for each LGC would be expected to be similar to
the mean baseline symptom measure score for that profile. It should be noted that although
caseness was criteria for inclusion in the analysis, the intercept for PHQ in LP1 was below
the clinical cutoff (10), which would be explained by patients scoring caseness on the GAD-7
but not the PHQ-9 still being eligible for inclusion. The slopes, or gradients of change,
appear to be larger for LPs with higher intercepts, which could in part be explained by
regression to the mean as described in Chapter 4, as well as these groups of patients
having more available change on the symptom measures.
The quadratic functions follow a very similar pattern for all LPs across symptom measures
for patients receiving guided SH interventions, with a decline in symptoms followed by a
levelling out of the slope as time increases. However, the curve for LP6 GAD change stands
out as the only LGC where the quadratic is reversed – the curve starts flat initially before
showing a decrease (improvement) towards later time points. This is interesting when
considered alongside the deterioration findings presented in Chapter 6, as LP6 showed
around 20% deterioration, significantly higher than all other LPs. It would suggest that
change in anxiety symptoms is different for this profile of patients.
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Latent growth curve analysis – latent profiles (high intensity)
The LGC for each LP when HI is the main intervention are presented in Figure 7.5, and
information on the intercept, slope and quadratic value of each LP curve, are provided in
Table 7.4.
Figure 7.5. LGCs for PHQ-9 and GAD-7 – by latent profile (HI).
The curves presented for HI interventions in Figure 7.5 appear very similar to those of GSH
in Figure 7.4, despite the potentially more intensive intervention being received in the Step 3
treatment. It would be predicted that individuals receiving HI interventions would have more
severe or complex clinical presentations and therefore require the more intensive
intervention and more sessions to achieve a positive outcome. The variation in intercepts
between LP is similar between the GSH and HI analysis, as is the same shape of quadratic
curve of each LP, which suggests that the available symptom measures are limited as a
measure of severity or complexity. LP6 displays the same reversed quadratic change curve
with GAD measurement over time as found for LP6 patients in receipt GSH. The main
difference between the results of the GSH and HI LGCs, however, is that the change in
slope is shallower for HI interventions compared to GSH. This could be because more
available time points were included in this analysis compared to GSH, resulting in a
shallower curve of mean change. If one were to assume that more complex and severe
patients received the more intensive HI interventions then more shallow curves of change
might be expected as the patient’s response to treatment may be slower. However, it is also
possible that a number of patents, for example in LP7, would not benefit for IAPT delivered
interventions and therefore the choice of treatment may not have been optimal, with referral
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to alternative secondary care services potentially increasing the chance of positive
outcomes.
Table 7.4. Intercept, slope and quadratic of LGC by LP (HI)
PHQ
LP n
Intercept Slope Quadratic
Mean 95% CI Mean 95% CI Mean 95% CI
All Cases 4394 16.309 (16.14,16.48) -0.855 (-0.91,-0.81) 0.033 (0.03,0.04)
LP1 135 8.269 (7.65,8.89) -0.403 (-0.61,-0.19) 0.012 (-0.00,0.03)
LP2 1052 11.003 (10.8,11.21) -0.502 (-0.59,-0.41) 0.014 (0.01,0.02)
LP4 180 10.984 (10.47,11.5) -0.645 (-0.86,-0.43) 0.021 (0.00,0.04)
LP5 453 17.816 (17.48,18.15) -0.926 (-1.09,-0.76) 0.036 (0.2,0.05)
LP6 487 13.876 (13.59,14.17) -0.819 (-0.95,-0.68) 0.036 (0.03,0.05)
LP7 924 22.698 (22.5,22.9) -1.039 (-1.15,-0.93) 0.042 (0.03,0.05)
LP8 1149 18.531 (18.33,18.74) -1.182 (-1.29,-1.08) 0.052 (0.04,0.06)
GAD
LP n
Intercept Slope Quadratic
Mean 95% CI Mean 95% CI Mean 95% CI
All Cases 4394 14.46 (14.33,15.6) -0.755 (-0.8,-0.7) 0.028 (0.02,0.03)
LP1 135 7.472 (6.96,7.99) -0.38 (-0.6,-0.17) 0.01 (-0.00,0.03)
LP2 1052 12.996 (12.81,13.18) -0.93 (-1.02,-0.86) 0.039 (0.03,0.05)
LP4 180 11.224 (10.72,11.73) -0.766 (-0.99,-0.53) 0.03 (0.01,0.05)
LP5 453 15.745 (15.47,16.02) -0.874 (-1.01,-0.74) 0.036 (0.03,0.05)
LP6 487 8.293 (8.04,8.55) 0.008 (-0.11,0.12) -0.12 (-0.02,-0.00)
LP7 924 18.267 (18.09,18.44) -0.698 (-0.79,-0.61) 0.024 (0.02,0.03)
LP8 1149 16.439 (16.26,16.62) -1.022 (-1.11,-0.93) 0.042 (0.04,0.05)
The LGC analyses describe the expected response curves for both PHQ and GAD change
for the full sample of patients receiving either GSH or HI interventions, as well as by
individual LP. There is potential for these graphs to be used by clinicians to compare against
the known session by session change for current patients. Generally, the LGCs all showed a
similar structure, and a reasonable rate of change was estimated initially, which then
flattened out over time points (sessions), which replicated the form of change typically
reported in other studies of psychological interventions (e.g. Kopta, et al., 1994). However,
LP6 displayed a different trajectory for anxiety symptoms change during both GSH and HI
interventions, and the LGC of this profile indicated that initial anxiety change is limited and
that a reduction in anxiety symptoms was more likely to occur at later sessions for this
profile. The identification of LP6 at initial assessment could therefore be used to inform the
clinician that a reduction in anxiety symptoms will likely take longer for this profile of patients.
It could be that members of LP6 represent a more avoid group of patients entering IAPT
treatment, and that the mean expected response curves is influenced by a number of
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patients who may display an initial increase in anxiety symptoms, possibly in response to
behavioural experiments.
The LGCs presented in this analysis estimate that the mean change in symptom scores
during LI and HI IAPT treatments are suggestive of a reduction in symptoms over the course
of treatment. However, as shown in Chapter 6 not all members of profiles responded to
treatment, and a number of patients reported a significant increase in symptoms that would
be follow the expected response curves presented in these LGC. As a result, it could be
theorised that there may be two or more different trajectories of change, representing groups
of patients who respond differently to the same treatment, whether that be responders or
non-responders (Gueorguieva et al., 2011) or potentially a more varied collection of patient
trajectories (e.g. such as identified by Stulz et al., 2007). The next stage of the analysis was
to explore whether different classes of trajectories existed in the IAPT dataset using LCGA.
Analysis 2.
Latent class growth analysis – Guided self-help
The LGC analysis for both the intensity of intervention and symptom scores found that a
model specifying a quadratic curve and the inclusion of correlated residuals was the best
fitting model in all scenarios. As a result, this model was specified within all LCGA analyses,
as these are an extension of the previous LGC analyses.
Model fit statistics for the LGCA including GSH patients with both PHQ and GAD repeated
measures are presented in Table 7.5. The first section of the table displays fit statistics for
the PHQ analysis, and the VLMR-LRT p-value remained <.05 until the 5-class model
(p=0.276), suggesting the 4-class model was a better fit for the data. For the GAD analysis,
the 5-class model was a better fit compared to the 4-class solution (VLMRT-LRT p<0.001),
but the 6-class model was not a better fit than the 5-class model (p=0.266). The decrease in
AIC and BIC value became shallower by the 5-class solution and therefore this model was
selected for GAD change in GSH interventions.
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Table 7.5. Model fit statistics: LCGA patients receiving GSH.
PHQ-9
k model AIC BIC Adj-BIC VLMR-LRT (p=) Entropy
% individuals in
per class
k = 2 90549 90684 90614 <0.001 0.809 65/35
k = 3 89769 89928 89845 <0.001 0.748 16/47/37
k = 4 89478 89662 89566 <0.001 0.701 31/9/24/35
k = 5 89369 89577 89469 0.276 0.668 9/33/31/14/13
GAD-7
k model AIC BIC Adj-BIC VLMR-LRT (p=) Entropy
% individuals in
per class
k = 2 86899 87034 86964 <0.001 0.79 36/64
k = 3 86382 86541 86459 <0.001 0.7 43/22/35
k = 4 86216 86399 86304 0.02 0.644 15/25/25/35
k = 5 86133 86341 86233 0.007 0.62 26/16/23/22/14
k = 6 86057 86289 86169 0.258 0.602 14/20/25/15/16/10
Figure 7.6. LCGA curves for PHQ and GAD - all patients receiving GSH
0
5
10
15
20
25
0 1 2 3 4 5 6 7
PH
Q
-9
Sc
or
e
Session number
PHQ-9: Guided Self-help
PHQ 9 - Class 1 (31.1%)
PHQ 9 - Class 2 (9.4%)
PHQ 9 - Class 3 (24.2%)
PHQ 9 - Class 4 (35.3%)
0
5
10
15
20
0 1 2 3 4 5 6 7
GA
D
Sc
or
e
Session number
GAD-7: Guided Self-help
GAD 7 - Class 1 (26%)
GAD 7 - Class 2 (15.6%)
GAD 7 - Class 3 (22.9%)
GAD 7 - Class 4 (21.7%)
GAD 7 - Class 5 (13.8%)
209
The identified curves are presented in figure 7.6, with four classes identified for PHQ
change, and five classes of GAD score change.
The PHQ classes can be described as follows:
-Class 1 (PHQ) – Early initial response, levelling out during treatment.
-Class 2 (PHQ) – Limited or no response to treatment
-Class 3 (PHQ) – Gradual improvement to treatment
-Class 4 (PHQ) – Early initial response, continued improvement during treatment
With the GAD classes described as:
-Class 1 (GAD) – Early initial response, continued improvement during treatment
-Class 2 (GAD) – Gradual improvement to treatment (less severe)
-Class 3 (GAD) – Gradual improvement to treatment (more severe)
-Class 4 (GAD) – Early initial response, levelling out during treatment.
-Class 5 (GAD) – Limited or no response to treatment
The description of the classes appears similar between the two symptoms measures. The
analysis suggests that there is one additional GAD trajectory class (class 3), which could be
described as being similar to another GAD class (class 2) but with a higher intercept (higher
symptom severity at initial assessment). This would suggest there are two statistically
different classes of patients who show a similar form of change, but with different intercept
values.
Both symptom measures include a trajectory class showing little, if any improvement in
clinical symptoms during treatment (class 2 PHQ, class 5 GAD), which could be assumed to
be non-responders. Although stepped-up patients were not included in the analysis, some LI
patients may have benefited from being stepped up by the service from LI GSH to HI
interventions during treatment, and it would be of interest to know why this decision was not
made during the episode of care for patients included in this dataset. Previous researchers
have suggested that a lack of change within the first three sessions of treatment are
predictive of eventual treatment outcome (Gorwood et al., 2013; Lambert, 2013), and the
graphs presented in figure 7.6 would indicate that these two non-responding classes could
be identified within the first three sessions. A potential DST for use in IAPT could flag
patients who are following these non-responding classes, and this information could be
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provided to clinicians to inform a discussion with the patient as to whether stepping up to a
HI intervention might be preferable, as it may increase the probability of a positive outcome.
Following the identification of the classes, the association between LP membership and the
prevalence of trajectory classes was explored. Table 7.6 presents the proportion of
individuals from each LP that were members of the PHQ classes identified. The results
suggest that each LP is predominately made up of members of two PHQ classes each for
patients receiving GSH. For example, 54% of LP2 patients are members of class 1 (early
improvement, levelling out), and 36% class 4 (early improvement, continuing during
treatment). LP2 membership to either remaining classes was limited to 10% members of
class 3 (gradual improvement). The results for LP5 suggest the majority of patients in this
profile are members of either PHQ class 3 or class 4. Most individuals from LP1 and LP3
were members of PHQ class 1, which may be due to this class having the lowest intercept
value of all the PHQ classes.
Table 7.6. Proportion of members to each PHQ class by LP (GSH).
LP
PHQ - Class
1
PHQ - Class
2
PHQ - Class
3
PHQ - Class
4 Total
n % n % n % n % n
1 108 81% 0 0% 0 0% 25 19% 133
2 597 54% 4 0% 109 10% 402 36% 1,112
3 8 80% 0 0% 0 0% 2 20% 10
4 100 60% 1 1% 16 10% 50 30% 167
5 44 12% 33 9% 141 39% 145 40% 363
6 94 29% 8 2% 77 24% 147 45% 326
7 2 1% 150 46% 117 36% 56 17% 325
8 77 9% 104 12% 339 38% 378 42% 898
Total 1,030 31% 300 9% 799 24% 1,205 36% 3,334
It is of interest that PHQ class 2, a group of patients showing little if any response to
treatment, is the identified trajectory of nearly 50% of LP7, whereas all other LPs contain
less than 12% members of this class. As LP7 have such a low probability of recovery (11%
to LI interventions) the finding that so many patients from this profile are members of class 2
may not be surprising and may suggest that this profile of patients are a clinically relevant
group to identify early in the assessment process in order to inform clinical decisions. The
finding that 9% of LP5 and 12% of LP8 were also members of PHQ class 2 suggests that it
is not just members of LP7 who have poor response to treatment but that there are some
similarities with patients from other profiles. These common characteristics between
members of different LPs could include characteristics not currently included in the dataset
but identified as having a potential association with outcome such as substance misuse or
personality disorders discussed in chapter 3.
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The proportion of each LP that are members of each GAD class are displayed in Table 7.7.
Membership to GAD classes shows more variation within and between LPs, which could be
explained by the range of anxiety disorders (for example OCD, social phobia, GAD) that may
be present within the dataset. Certain LPs show more than 15% membership of at least 4
classes, for example LP2, suggesting that there are a number of different likely trajectories
for this profile, which may be of value to explore further. Class 5, the group of patients
showing little response to treatment, rarely includes members of any profile except LPs 5, 7
and 8, which happen to be the profiles with poorest outcomes. The findings suggest that for
other profiles the GAD scores are expected to change during GSH treatment, either
gradually over sessions or showing early improvement that levels out when symptom scores
fall into the non-clinical range.
Table 7.7. Proportion of members to each GAD class by LP (GSH).
LP
GAD -
Class 1
GAD -
Class 2
GAD -
Class 3
GAD -
Class 4
GAD -
Class 5 Total
n % n % n % n % n % n
1 7 5% 34 26% 4 3% 88 66% 0 0% 133
2 340 31% 199 18% 195 18% 343 31% 35 3% 1,112
3 1 10% 1 10% 0 0% 8 80% 0 0% 10
4 43 26% 39 23% 19 11% 62 37% 4 2% 167
5 123 34% 20 6% 132 36% 23 6% 65 18% 363
6 20 6% 96 29% 24 7% 176 54% 10 3% 326
7 59 18% 5 2% 98 30% 1 0% 161 50% 324
8 308 34% 45 5% 326 36% 46 5% 173 19% 898
Total 901 27% 439 13% 798 24% 747 22% 448 13% 3,333
Results for some LPs were similar to those for the PHQ curves, as these LPs show a higher
likelihood of membership to one or two specific classes of GAD curve. For example, over
80% of individuals from LP1 and LP6 are members of either class 2 (gradual improvement,
low severity) or class 4 (early improvement, levelling out). As with the PHQ classes, it may
be that these profiles are more likely to have a high frequency of membership to trajectory
classes that have lower intercept values and are therefore closer to the mean GAD score of
these profiles.
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Latent class growth analysis – High intensity
Model fit statistics comparison for the LGCA of HI patients with both PHQ and GAD repeated
measures is presented in Table 7.8. The first section of the table shows fit statistics for PHQ
and suggests that the VLMR-LRT remained significant until the 6-class model, indicating that
the 5-class model may be a better fit for the data. However, class 1 of the 5-class solution
was made up of less than 3% of the included sample, which suggests it may not represent a
sub-group which are meaningfully differentiated from the other classes in the LCGA
analysis. As a result, it was decided to retain the 4-class solution. The results for the GAD
LCGA analysis showed that the 5-class model was a significantly better fit compared to the
4-class model VLMRT-LRT (p=0.039), and as the decrease in AIC and BIC values was
becoming shallower, the 5-class solution was selected.
Table 7.8. Model fit statistics: LCGA patients receiving HI.
PHQ-9
k model AIC BIC Adj-BIC VLMR-LRT (p=) Entropy
% individuals in
per class
k = 2 198731 198942 198837 <0.001 0.556 39/61
k = 3 198254 198490 198373 0.002 0.557 33/45/22
k = 4 197868 198130 197999 <0.001 0.598 45/13/14/28
k = 5 197759 198046 197903 0.011 0.629 3/14/43/13/28
k = 6 197701 198014 197858 0.438 0.585 22/28/13/13/20/3
GAD-7
k model AIC BIC Adj-BIC VLMR-LRT (p=) Entropy
% individuals in
per class
k = 2 195067 195271 195169 <0.001 0.847 53/47
k = 3 191764 191994 191879 <0.001 0.824 41/27/32
k = 4 190762 191018 190891 <0.001 0.772 21/30/30/19
k = 5 190440 190721 190581 0.039 0.739 21/29/17/21/12
k = 6 190064 190371 190218 0.375 0.715 20/12/13/20/18/17
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Figure 7.7. LCGA curves for PHQ and GAD - all patients receiving HI.
The identified curves are presented in figure 7.7 and show four statistically differing groups
of patients based on PHQ change over time, and five classes identified for GAD scores. The
PHQ classes can be described as follows:
-Class 1 (PHQ) – Early initial response, levelling out during treatment.
-Class 2 (PHQ) – Slow initial response, large response later in treatment.
-Class 3 (PHQ) – Rapid improvement, levelling out during treatment.
-Class 4 (PHQ) – Limited or no response to treatment.
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With the GAD Classes described as:
-Class 1 (GAD) – Limited or no response to treatment (more severe).
-Class 2 (GAD) – Early initial response, levelling out. (more severe)
-Class 3 (GAD) – Early initial response, levelling out. (less severe)
-Class 4 (GAD) – Limited or no response to treatment (less severe).
-Class 5 (GAD) – Slow initial response, large response later in treatment.
Although the same number of trajectory classes were identified in both the GSH and HI
samples for each symptom measure (4 and 5), there are some differences in the trajectories
identified. For PHQ change, the four classes identified for GSH indicate four curves with
increasing intercept values, described as ‘early response that levels out’, ‘early response
that continues’, ‘gradual improvement’ and finally ‘limited improvement’. Of the four classes
identified for PHQ change in HI, three classes have a similar intercept value but statistically
distinct forms of change. Compring the five trajectory classes for GAD change between HI
and GSH interventions suggests a few differences in the forms of change identified. The HI
trajectory classes include two ‘limited response’ curves with differing intercept values,
whereas there appears to be only one non-responding class in GSH interventions.
A further difference is that the early improving group who continue to improve during
treatment during GSH do not appear in HI, and instead a group of patients who show little
change symptoms at first, then appear to show response in the later part of HI treatment
was identified. The difference between interventions in these two curves may be linked to
the number of included time points, and it is possible that if more time points were included
for GSH then a similar curve may have been identified. Alternatively, if patients receiving HI
interventions were likely to have more complex clinical presentations then they may have
taken a little longer to engage and therefore show improvement, which may be evident in HI
PHQ class 2.
Table 7.9 presents the proportion of individuals from each LP who were members of the
PHQ classes identified when receiving HI interventions. The proportion of individuals from
each LP who are members of Class 1 (early improvement, levelling out) is very high for LPs
1, 2, 3, 4 and 6, which may be partly explained by the lower intercept value of this class
compared to the other three classes 2, 3 and 4. The mean T1 PHQ scores of these LPs are
similar or lower than the intercept of class 1 (PHQ-9 score of 12.9), which may increase the
likelihood of patients from these profiles being members of this trajectory. Class 1 is also the
most prevalent class for LP5 and LP8, although these profiles also contain members of the
other three classes in similar levels. Patients in LP7 are predominately members of Class 4,
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the non-responding group, which is likely explained by the low probably of recovery for this
profile following HI treatment (18% recovery).
Table 7.9. Proportion of members to each PHQ class by LP (HI).
LP
PHQ - Class
1
PHQ - Class
2
PHQ - Class
3
PHQ - Class
4 Total
n % n % n % n % n
1 125 93% 2 1% 1 1% 7 5% 135
2 847 81% 32 3% 57 5% 116 11% 1,052
3 11 79% 1 7% 2 14% 0 0% 14
4 146 81% 7 4% 11 6% 16 9% 180
5 176 39% 52 11% 67 15% 158 35% 453
6 332 68% 28 6% 34 7% 93 19% 487
7 103 11% 142 15% 134 15% 545 59% 924
8 412 36% 151 13% 221 19% 365 32% 1149
Total 2,152 49% 415 9% 527 12% 1,300 30% 4,394
The proportion of each LP who are members of the identified GAD classes when receiving
HI interventions are presented in Table 7.10. More variation in class membership within and
between LPs seems to exist for the GAD results, compared to the PHQ trajectories. LP2,
LP5 and LP8 show fair representation of three classes (>=20% prevalence) which would
indicate that clinicians couldn’t necessarily predict the expected trajectory of change for
these individuals at the start of treatment, and monitoring symptoms during treatment would
be needed. Class 3 (early response, levelling out) occured in 17% of the full sample but LP1,
LP3 and LP6 show a disportionately high number of members of this class, suggesting an
increased incidence of treatment response for these profiles.
Table 7.10. Proportion of members to each GAD class by LP (HI).
LP
GAD -
Class 1
GAD -
Class 2
GAD -
Class 3
GAD -
Class 4
GAD -
Class 5 Total
n % n % n % n % n % n
1 0 0% 34 25% 91 67% 9 7% 1 1% 135
2 72 7% 443 42% 257 24% 211 20% 69 7% 1,052
3 0 0% 0 0% 13 93% 1 7% 0 0% 14
4 6 3% 82 46% 59 33% 25 14% 8 4% 180
5 104 23% 129 28% 34 8% 140 31% 46 10% 453
6 11 2% 166 34% 214 44% 89 18% 7 1% 487
7 504 55% 112 12% 20 2% 178 19% 110 12% 924
8 285 25% 342 30% 66 6% 288 25% 168 15% 1149
Total 982 22% 1308 30% 754 17% 941 21% 409 9% 4,394
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Class 5 (slow initial response, greater response in later treatment) occured relatively
infrequently (9% of the full sample) but is more common in LP5, LP7, LP8, which may be
due to the higher mean GAD score at T1 for these profiles. The non-responding high
severity class (class 1) also show representation in LP5, LP7 and LP8, with little or no
representation in any of the other 5 LPs, which again may be due to the intercept value.
These two trajectories result in very different outcomes for patients, and being able to predict
which patients of these three profiles are more likely to follow the poor outcome could be
used to inform both treatment selection and treatment monitoring decisions. Class 4 (limited
response, less severe) is spread relatively evenly across LPs, except for LPs 1 and 3 where
it is very infrequent. Class 2 (gradual sustained response) is also relatively spread amongst
the LPs, except LP3 and LP7.
Discussion
The findings from this chapter provide detailed information about the trajectories of symptom
score change during the course of GSH or HI treatment in IAPT services. The LGC analyses
could be adapted to provide expected response curves for patients receiving IAPT delivered
treatment. Following the work of Lambert et al (2001) the LGC analyses could be used to
identify patients that are ‘not on track’ to recovery, and this information could be feed back to
the treating clinician so they can consider adjusting the treatment plan accordingly. By
modelling the LGCs by individual LP, a more refined expected response curve can be
provided, potentially increasing the accuracy of the estimates for individual patients and the
utility of the LGCs. The LCGA identified four statistically distinct classes of patients based on
their PHQ response curves, and five classes of GAD response curves for both intensities of
intervention. The information provided could be used to further inform decisions during
treatment, as they extend the information provided by single LGCs to show the likely
outcome for different trajectories.
The LGC analyses showed that for both symptoms measures, across both treatment
intensities, the expected response indicated a greater effect of treatment (decrease in
symptoms) in the first few sessions, with the effect reducing further into treatment. The
shape of these curves is very similar to other expected response curves identified in
psychological interventions (Clapp et al, 2013; Kopta et al, 1994). The analysis of LGC by
each LP indicated that the shape of the curves was similar between profiles. Only the GAD
curve for LP6 patients suggested a different shape to the mean trajectory across all patients,
whereby the change was shallow initially and then decreased more during later treatment
sessions. As LP6 showed a very high probability of deterioration (17% LI, 21% HI) compared
to the other LPs (full sample 8% LI, 9% HI), it may be that this expected response is
influenced by a significant number of patients whose anxiety increased initially and either
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reduced in later sessions or continued to deteriorate during treatment. This could be due to
heightened anxiety in the first few sessions due to initial exposure work that is integral to
some interventions for anxiety disorders, for example phobia (Rapee & Heimberg, 1997). As
46% of LP patients recovered from treatment, a large number of patients benefitted from
treatment and therefore identifying the sub-group of LP6 patients who are at risk of
deterioration could inform clinical decisions for this profile. Although researchers have often
suggested that change in the first few sessions is associated with eventual outcome from
psychological interventions (Lambert, 2013; Lewis, et al., 2012), the findings for LP6 suggest
that initial change may not always be predictive of eventual outcome.
The main difference between the LGCs for individual LPs was the intercept of the curves,
which can be explained by the different mean PHQ-9 or GAD-7 scores at T1 associated with
each LP. The intercept value of the LGC for each LP was very similar to the mean PHQ and
GAD score for that LP, which would be expected. Any variations between the measure
symptom measure scores (Chapter 5) and intercept values (Chapter 7) is likely due to the
reduced sample of included patients in the latent growth analyses, for example in LP1 where
many patients who were not caseness at assessment were excluded from the analysis. The
potential utility of these individual curves for each LP is that the expected response curves
could be combined with information from the estimation of profile membership. In the first
stage of a decision support algorithm, the patient can be allocated to their appropriate LP
using the calculation of posterior probabilities described in Chapter 5. In the second stage,
the relevant expected response curves for PHQ and GAD change can be provided to the
clinician (potentially through the EPMS) once the LP is identified, and the DST could provide
the expected trajectory information throughout the episode of care. This could support the
development of a personalised treatment plan, whereby a DST could aid both patient and
clinician in the treatment selection and treatment monitoring decisions.
The identification of statistically distinct trajectory classes from the LCGA could be used to
inform further decisions during the monitoring of treatment progress, especially if feedback
on an active patient’s progress could be provided alongside the identified trajectories. The
difference between the identified classes of PHQ change for GSH and HI interventions is
that for GSH there are the four classes which had distinct intercept values that could be
seen to equate to their eventual trajectory, whereas a difference in intercepts is not clear
with three of the HI PHQ classes. The LCGA results suggest that at around session three of
GSH treatment, most patients will either be following one of the early improving classes
(class 1 or class 4), the trajectory with more gradual change (class 3) or show limited
response to treatment. This supports findings by researchers that eventual outcome can be
predicted by the third treatment session in psychological interventions (Lambert, 2013), and
the first two weeks exposure to pharmacological intervention (Gorwood et al., 2013; Szegedi
et al., 2009). This could be used in practice to inform decisions during treatment, for
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example if by session three of GSH treatment there has been limited change (PHQ class 2,
GAD class 5) then potentially stepping up might increase the likelihood of positive outcomes.
However, the identified classes for PHQ change when HI interventions were received
included three classes with a very similar intercept values but differentiated forms of change,
suggesting that although patients with these three trajectories start with similar levels of
severity, their response to treatment is very different. The graph in figure 7.7 shows that
members of class 3 are likely to be distinguishable within the first few sessions due an
immediate decline in depression symptom severity, but the trajectories of class 2 and class 4
appear similar until around the 4th or 5th session. The graph suggests that at this point,
members of class 2 are more likely to have a sustained decline in depression symptoms,
whereas individuals in class 4 will likely continue to report a limited change in depression
symptoms. These findings therefore do not support the ‘three session’ rule, and instead
suggest that the expected trajectory of patients receiving HI treatments may not be
distinguishable until at least the fourth sessions. It may be of interest to further explore class
2 individuals to understand what in treatment contributed to this sudden improvement in
functioning. Identifying treatment factors that are associated with these sudden gains has
the potential to inform the development and refinement of psychological interventions, and it
may be worth exploring additional IAPT datasets to determine this finding is generalizable to
other settings.
The findings of these analyses suggest that there are potential differences in the likely
trajectory of symptom change between the two types of intervention delivered. For some
patients it is likely that the chosen intervention was not appropriate, and for others,
especially from profiles with low probabilities of recovery both at LI and HI in IAPT (e.g. LP7)
it is possible that treatment at alternative treatments should be considered. Combining
information from the probability of outcomes by profile with likely trajectories of change once
treatment has commenced could be used to inform both treatment choice but also care
planning through routine monitoring.
The results of the LCGA analyses presented in this chapter have similarities to previous
GMM analyses performed in CMHD treatment sample, which might suggest that the results
of the current analysis could be of value to mental health services beyond the IAPT services
who provided data. Stulz et al (2007) identified five distinct classes from a dataset of patients
receiving a range of psychological interventions over six sessions of treatment, the same
number of classes identified for the current LCGA of GAD score change. The response
curves presented by Stulz et al are similar to the graph of GSH GAD presented in figure 7.6,
with one rapidly improving class and four other classes with more level change curves,
although limited decrease in symptoms is suggested by the graph presented by Stulz et al.
The current analyses have some advantages over the analysis conducted by Stulz et al. The
included sample for their study was limited to just n=192 patients receiving more than 7
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sessions and with three or more outcome measures completed, which is considerably
smaller than the samples used for the analysis presented in this chapter. The lack of change
observed in four of the five classes identified by the previous researchers may be due to the
inclusion of a wide range of therapeutic models compared to the mainly CBT based
approach used in the IAPT dataset. The psychological interventions delivered by the mental
health services included in the Stulz et al (2007) analysis included a wide range of
treatments (including cognitive therapy, psychodynamic therapy, gestalt therapy and
transactional therapy in addition to other integrative treatments) and it may be that these
interventions have different efficacy from GSH delivered in IAPT services. As the authors’
inclusion criteria required patients to have had at least seven sessions, and number of
patients who benefitted from treatment early and therefore completed by the sixth session
may have been excluded, which may have altered the findings of this study.
Despite the differences in the samples used in the analyses, as the same number of
trajectories were identified, this may suggest a prognostic ability across a range of
psychological treatment settings. Further research across multiple datasets of patients
receiving routine psychological services may validate these differential responses to
treatment. Nevertheless, the results of the current analysis are quite different to those from
the GMM presented by Gueorguieva and colleagues (2011) who indicated that depression
change followed two distinct classes in their dataset compared to four depression trajectory
classes identified in the current analysis, for both GSH and HI change. The similarities
between the results of the current analysis and those of Stulz et al (2007) and the
differences with Gueorguieva et al (2011) may be explained by the samples and the range of
interventions included in the analyses. The dataset used by Gueorguieva et al was taken
from controlled trials of antidepressants and therefore strict inclusion criteria was used for
patients to be eligible to receive the treatment. As a result, the initial symptom severity levels
for all patients was similar, which is indicated by the similar intercept value of the two
classes the authors identified. By comparison, the samples used by the current analysis, and
the analysis by Stulz et al, used routine data from mental health services and therefore there
was more variation between patients on symptom severity that was used to model change,
as well as diagnoses. These analyses may therefore better inform routine clinical practice,
having more ecological validity than the selected samples from randomised controlled trials,
but the variation in initial symptom scores may be important when considering the use of
GMM type analyses, as this may contribute to the number of curves identified in the dataset.
When the distribution of LCGA classes was explored by LP, it was found that there were
usually two main trajectories of PHQ change, and two or three GAD curves associated with
each LP. For certain LPs, there was one class that was endorsed by the majority of profile
members, for example LP7 where the majority of individuals were members of the limited
response to treatment classes, and LP1 where most patients were members of the early
improving classes with good outcomes. Other LPs have members of many classes, which
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suggests even the identification of LP at initial assessment could not be used inform the
likely trajectory of change, and instead the monitoring of symptoms would be required to
determine prognosis.
Although the distribution of each LGCA class varied between LPs, it also appears that a
number of the differences in class membership may be due to the mean symptom scores
(intercept values) of the trajectory classes. For example, if the graph of PHQ classes in HI
treatment patients (figure 7.7) is observed, there are three classes with a similar intercept
value (around a score of 19 on the PHQ) and one class (class 1) with a much lower intercept
value (around 13). Class 1 was the most likely class for 49% of the entire sample of patients
receiving HI treatment, and the most likely class for LP1, LP2, LP3, LP4 and LP6. This is not
surprising as the intercept value for this class is around the mean, or below, for each of
these five classes. It may be of more value to conduct LCGA by latent profile, instead of
using the full sample, as this may provide a more patient-centred information for supporting
treatment monitoring decisions.
One potential limitation of the analysis is that diagnostic specific measures, especially for
anxiety disorders such as OCD and social phobia, were not available. Although the GAD-7
measures a range of anxiety symptoms and is considered to have some sensitivity in
identifying patients with panic disorder, social phobia and PTSD, it does not address some
of a range of specific symptoms found in other disorders (e.g. those of PTSD or OCD). This
may explain why there were more classes identified for GAD change than PHQ, as there are
more potential anxiety diagnoses influencing GAD scores. The use of anxiety disorder
specific measures (ADSMs), for example the Social Phobia Inventory (SPIN) (Connor et al.,
2000) could increase the accuracy in the predictions of likely change from initial assessment
and would be of value to explore in further analyses. The current dataset did not include
ADSMs as these were not routinely collected in IAPT until more recently, these measures
could replace the use of the GAD-7 to guide treatment decisions. Newer datasets with better
completion of these additional measures could provide more information to inform expected
change for specific anxiety disorders.
The analysis presented in this chapter explored the change in symptoms during GSH or HI
interventions, and although these were the main intervention for 85% of the original sample
(n=15376), the results of this analysis cannot be extrapolated to other IAPT delivered
interventions. Some interventions such as pure self-help and signposting would unlikely
benefit from modelling trajectories of change due to the limited number of time points
received in routine treatment, as only one or two contacts would be expected. However,
there may be clinical utility in exploring the trajectories of symptom change during ‘group-
based’ treatment in IAPT. Group interventions are a recommended psychological treatment
for CMHDs such as GAD, OCD and depression (NICE, 2011), but were the main
intervention for less than 5% of the full sample. Group treatments in IAPT can have a range
of functions, for example relapse prevention or trauma-focused work, and can vary in
221
purpose as well as duration. Due to the potential variation in actual intervention received, it
could be argued that an analysis of change in symptoms by different types of IAPT delivered
group treatments would be more clinically beneficial, but this was not possible in the current
analysis due to low number of patients who attended specific types of groups. Instead, future
analysis could supplement this dataset with data from additional IAPT services, or could use
the national IAPT data available (NHS Digital, 2016) to explore trajectories of change in a
significant cohort of patients who received group-based treatments.
A further limitation of the current analysis is that a number of potential characteristics or
factors that could impact trajectories of change were not included. For example, therapist
characteristics have shown to explain around 9% of the variation in treatment outcomes (e.g.
Green et al., 2014) and clinician information could be included in growth analysis to refine
the predicted trajectories. However, this would result in information about the clinician being
required as part of the DST used by the service, and therefore any potential algorithm
generated would need to be locally adjusted for the clinicians working in the service, and
updated with staffing changes. In addition, patient characteristics at baseline could also be
included in latent growth methods to refine the predicted trajectories of change. As the
majority of the patient characteristics available in the IAPT dataset are already included in
the probably of profile membership, conducting more focused LCGA by profiles could result
in more stratified trajectory information being made available. The next chapter presents a
series of LCGA conducted by latent profile.
Summary
The findings from this chapter provide significant information that has potential utility to aid
decisions that need to be made by clinicians during the course of treatment. For example,
whether the intervention is having a positive effect, or whether it needs to be modified to
improve the likely outcome. The LGC analyses present the expected response curve for
patients attending treatment to either GSH or HI, which can be tailored to show more
relevant information for individuals of specific LPs. This information could be used by
clinicians as a reference to compare their current patients against the trajectories of change
expected from similar patients (i.e. members of the same LP). If the current patient is
showing a change in symptoms which is less than would be expected from the active
treatment, then this information could be used to inform a discussion between the patient
and clinician as to whether they feel the treatment is working as desired, or whether an
alternative treatment should be considered. The trajectory curves identified by the LCGA
presented in this chapter could be built into an EPMS such as those used by IAPT services
to provide real-time comparison between the current trajectory of a patients and the classes
identified. However, it was found that individuals from certain LPs were understandably more
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likely to be members of classes with intercept values closer to the mean symptom score at
initial assessment. As a result, LCGA performed by LP may be of more value for informing a
DST to support treatment monitoring decisions. The next chapter focuses on LCGA
conducted by individual LPs, which may provide a more refined and personalised approach
to support treatment monitoring decisions in IAPT services.
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Chapter 8. Development of a decision
support tool for IAPT services.
Abstract.
Identifying differing classes of patients with specific trajectories of change in symptoms
during the course of treatment could be fed back to clinicians to inform on treatment
progress and aid treatment monitoring decisions. However, identifying the likely trajectories
of change for each of the latent profiles could combine the major findings from this thesis to
develop a decision support tool that can aid both treatment selection and treatment
monitoring decisions in IAPT services, and create a more personalised approach to
psychological treatment in the UK. Latent class growth analysis (LCGA) was performed by
latent profile, for patients who received either guided self-help (GSH) or high intensity (HI)
interventions. The results of the LCGA found a range of one to four identified trajectories of
change in depression or anxiety symptoms per profile. The chapter then demonstrates how
patient characteristics could be used by an algorithm to provide a probability of profile
membership at assessment, a recommendation for appropriate IAPT intensity of treatment
and then provide information about the likely trajectories of change for the patient. This
algorithm could be hosted within an IAPT service’s EPMS, where patient information
collected pre-treatment could be automatically entered into the algorithm to identify the latent
profile, before providing a potential treatment recommendation based on likely response to
IAPT treatments. Once treatment has been selected, the algorithm could then support
treatment monitoring decisions by providing information about the likely change in symptoms
for patients of the same profile, and a decision support tool combining all these elements
could be used personalise treatment decisions in IAPT services to contribute to a more
efficient healthcare system.
Introduction.
The results of the LCGA presented in the previous chapter indicate that there are a number
of distinct trajectories of change in both PHQ-9 and GAD-7 scores during Guided Self-Help
(GSH) and High Intensity (HI) interventions. This information could be used to determine
whether a positive or negative outcome was more likely given the current trajectory of
change in symptom scores, aiding decisions about the effectiveness of the intervention
being delivered. The distribution of these classes between the previously identified latent
profiles (LPs, see Chapter 5) suggests that there are predominantly one or two trajectories
224
that are likely for members of each LP. This information could be useful to clinicians, as
once a patient is identified as a member of a particular LP then the LCGA results could be
cross-referenced and the likely trajectories of change known as treatment is started.
However, the results also suggest that many of the LPs have the same likely trajectory, for
example trajectory class 1 for PHQ change during HI treatment (early reduction in
symptoms, levelling out with increasing sessions) was the primary class for five or the eight
LPs (LP1, LP2, LP3, LP4, LP6). It could argued that this type of treatment response (early
reduction, levelling out) is independent of LPs, and instead is just a typical response to
interventions across the dataset of patients.
An alternate reason for this finding could be linked to the intercept (starting) value of the
identified classes. It was typically found the most frequent trajectory identified for an LP was
the trajectory class with an intercept value closest to the mean PHQ-9 and GAD-7 score for
that LP. This would seem logical, as the outcome variable in the LCGA is also included as a
characteristic used to identify the patient’s LP. As a result, it could be argued that conducting
LCGA by individual LP may provide more valuable information to inform the likely trajectory
of change for sub-groups of patients attending the IAPT services. This would provide a more
tailored approach to the predicting of change during treatment, and it would be expected that
performing LCGA by LP would result in a more accurate prediction of outcome, increasing
potential clinical utility.
It was expected that the number of classes identified in LCGAs conducted for each profile
would be lower than the number identified for the full sample of patients presented in
Chapter 7 (4 PHQ-9 classes, 5 GAD-7 classes). This hypothesis is based on results from
previous growth modelling on CMHD samples, where patient data collected from routine
psychological treatment services across a range of disorders identified five classes (Stulz et
al., 2007) and analyses of more homogeneous clinical trial samples identified just two
classes (Gueorguieva, et al., 2011). As the LP samples to be used in the current analysis
will include patients who are expected to share similar patient characteristics (hence why
they are members of the same LP), the likely change in symptoms would also likely be less
variable. For some profiles, it is possible that only one expected response curve would be
identified, and therefore the results of the latent growth curve (LGC) analyses presented in
Chapter 7 would be the only available estimate of change in symptoms during treatment.
It would also be of interest to observe whether the differentiation in trajectories is apparent
by session three as suggested by researchers in psychotherapy outcomes (Lambert, 2013).
The results of the LCGA conducted on the full sample of patients receiving HI treatment (see
Chapter 7) suggested that PHQ-9 change was not differentiated between patients in class 2
and class 4 until at least the fourth session of treatment, and therefore conducting LCGA by
profile might uncover which patients will need longer monitoring than others before change
in the treatment approach may need to be considered.
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Once the different likely trajectories of change have been identified, a decision support tool
(DST) could be developed to aid decision making in IAPT services. An algorithm could be
constructed to provide profile membership information for any new patient attending IAPT
services based on patient characteristics assessed, and probability of treatment outcomes
for both LI and HI treatments could be provided as part of the tool. This could then be used
to inform a discussion between the clinician and patient about appropriate treatment and
likely response. Once treatment has commenced the DST could also provide the possible
trajectories of change to allow the clinician to compare change for the current patient against
that which would be expected. If progress is not following a trajectory indicative of a positive
outcome then the DST could prompt the clinician to consider alternative treatments.
Providing support from DSTs during clinician workflow through computer-based systems has
been linked to a greater impact of tools in supporting clinical decisions (Kawamoto et al.,
2005) and therefore an algorithm which is incorporated into the EPMS used by IAPT
services could provide real time information that will likely be the most beneficial.
The development of such as tool would be a prototype but by combining both treatment
selection and treatment monitoring decision support it would be able to support more clinical
decisions than other available systems in mental health treatment. For example, the OQ-45
based QA system (Lambert et al, 2001) has been developed to provide support for treatment
monitoring decisions during psychotherapy by flagging patients who are ‘Not on track’ but
does not support decisions about which type of treatment is likely to result in the best patient
outcomes. The system also relies of the use of the OQ-45 which requires 45 questions to be
collected at each session, which may make this system too burdensome for routine use in
IAPT. DSTs for treatment selection decisions in CMHDs are currently in the development
phase, with systems yet to be evaluated in routine care. However, methods such as the ‘PAI’
(DeRubeis et al., 2014) and the ‘LRI’ (Delgadillo et al., 2016) have potential to support
treatment decisions in IAPT, but do not at present include any information about within
treatment change.
IAPT services provide a unique opportunity in mental health to evaluate the use of DSTs due
to the large number of patients receiving treatment per year, but also the IAPT minimum
dataset (MDS) that provides standardised pre-treatment and within-treatment patient data.
The aim of this chapter is to explore whether there are statistically distinct trajectory classes
of patient response to IAPT treatment within each LP, providing a more personalised
estimate of likely change. Once differing trajectories of change have been identified, a DST
that combines latent profile information and the trajectories of change for each profile can be
developed for potential use in IAPT services to personalise treatment.
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Method
Sample
This analysis used the same dataset described in the previous chapter, and included all
individuals receiving GSH (n=3334) or HI (n=4394) intervention who met the previously used
inclusion criteria. These two datasets were split by latent profile, and the distribution of LPs
by intervention is presented in Table 7.2 (Chapter 7). The number LP3 members very was
low, with n=10 individuals receiving GSH and n=14 receiving HI interventions. These
numbers were considered too low to include in LCGA modelling, and therefore LP3 was
excluded from subsequent analyses.
Measures
The LCGA analysed used the PHQ and GAD symptom scale scores at each contact,
collected as part of the IAPT services’ ROM practices. As described in Chapter 7, the
number of time points included in the analyses was different between the two intervention
types. Eight time points were included for GSH, and 13 time points for HI interventions, as
were used in analyses presented in the previous chapter.
Analysis
LCGA was performed using the same method as described in Chapter 7. The Vuong-Lo-
Medell-Rubin Likelihood Ratio test (VLMR-LRT; Lo, et al., 2001), the Akaike Information
Criterion (AIC), Bayesian Information Criterion (BIC) and entropy value statistics were
compared between models for each analysis by LP. A VLMR-LRT with a p-value >=0.5 was
used to identify when increasing the number of classes no longer improved model fit,
whereas lower AIC and BIC values for a model indicated better model fit. Higher entropy
values indicated better classification accuracy for the model.
There was no prior hypothesis about the number of classes, and therefore the LCGA was
performed stating with a two-class model, assessing fit statistics and then increasing the
number of classes with the LCGA until the VLMR-LRT was no longer statistically significant
or either the AIC or BIC values increased compared to the previous model (Geiser, 2013).
As with the LCGA conducted in Chapter 7, classes were required to include at least 5% of
the sample for them to be considered numerically stable and meaningful (Spinhoven et al.,
2016).
LCGA were conducted by LP, with patients assigned to the LP to which they had the highest
probability of membership. Separate LCGA were conducted on PHQ-9 and GAD-7
measures, for patients within the LP who received GSH and for patients who received HI
interventions. This resulted in four LCGA performed for each LP.
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Results
Due to the large amount of analyses performed in this chapter, model comparison tables are
presented in Appendix F, and the LCGA results are summarised by LP below.
LP1
Guided Self-Help (PHQ = 1 class, GAD = 2 classes)
Figure 8.1. Classes identified in LCGA for LP1 (GSH).
The LCGA model comparison statistics for individuals in LP1 who received GSH are
presented in Table E1.1 (Appendix F). The K=2 model was the first LCGA performed for
PHQ change during treatment. However, the VLMR-LRT reported a non-significant p-value
(p=0.134) for the K=2 model, which would indicate that a K=1 model would be a better fit for
the data. The K=1 model (one class) was the same as the latent growth model presented in
the previous chapter for LP1. The AIC and BIC values were also compared between the K=1
and K=2 models, and although values were slightly lower in the K=2 model, the difference
was small and therefore the K=1 model was selected as the best fit for the data. This
suggests that there were no statistically different curves of PHQ change identified in the
sample in addition to the initial latent growth curve, implying that change in depression
scores for this profile of patients generally follows the expected response curve. The
trajectory curve is presented in the left section of figure 8.1.
The results of the LCGA for GAD change showed that the K=2 model was a better fit than
the K=1 as the VLMR-LRT p-value was less than 0.05, but the VLMR-LRT become non-
significant at K=3 model. The K=3 model also included a class of patients that represented
just 3% of the included sample, and therefore the K=2 model was selected for GAD change
in LP1 patients receiving GSH, indicating two statistically distinct classes of patients. The
graph presented in the right panel of figure 8.1 shows these two classes; the first (class 1)
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initially shows little change before a more rapid decrease in symptoms, whereas class 2
indicate a group of patients with larger decreases in symptoms early in treatment that levels
out with increased sessions.
High Intensity (PHQ = 2 classes, GAD = 2 classes)
Figure 8.2. Classes identified in LCGA for LP1 (HI).
The results of the LCGA for patients in LP1 who received HI interventions are presented in
Table E1.2. Model comparison statistics indicated that two classes were the best fit for both
PHQ and GAD measures. For PHQ change, the VLMR-LRT remained statistically significant
for the K=2 model, but non-significant for the K=3 model (p=0.082). The K=3 model also
showed an increased BIC value and the third class included only 1% of the sample, which
meant the K=2 model was selected for PHQ change in this sample. The VLMR-LRT test
showed a similar pattern with GAD measures, as K=2 was significant whereas K=3 moved
into non-significance (p=0.13).
The two graphs presented in figure 8.2 show the classes for individuals receiving HI
interventions in LP1. Although two classes were identified in both the PHQ and GAD scales,
the shapes of the graphs were different. The graph in the right panel of figure 8.2 shows that
GAD change in HI were very similar to GSH; one class indicated more early change that
levels out and a second class with limited change at first before a more rapid decrease in
later sessions.
The graph for PHQ change in HI presented in the left panel of figure 8.2 shows two
independent trajectories. Class 1 displays a group of patients with large decreases in
symptoms that levels out (as seen in the three previous graphs) but class 2 have a very
different trajectory, where depression symptoms increase in severity over the first few
sessions. This trajectory would indicate a deterioration of symptoms, and although this class
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make up just 6.5% of LP1 patients receiving HI interventions, providing this information to
clinicians could benefit patients by indicating that the current treatment may be having a
harmful affect.
LP2
Guided Self-Help (PHQ = 3 classes, GAD = 4 classes)
Figure 8.3. Classes identified in LCGA for LP2 (GSH).
The results of the LCGA for LP2 individuals receiving GSH is presented in Table E1.3. The
VLMR-LRT remained statistically significant until the K=4 model for PHQ score change,
indicating the K=3 model was the best fit for the data, especially when compared alongside
the limited BIC change and greatly decreased entropy value for the K=4 model. The K=3
model was therefore selected, and the trajectories presented in the left of figure 8.3. Class 1
show a group of patients who show a rapid initial decrease in symptoms which levels out,
therefore is very similar to the expected response curve for this profile, and accounts for
over half of LP2 patients (54%). Class 2 accounts for just over 10% of patients and indicates
a group of patients with a slight increase in symptoms which flattens out, suggesting little
change in depression symptoms for this class. The final class (class 3) show a steady and
relatively linear decrease in symptoms from the start of treatment to the seventh contact.
The model comparison statistics for the LCGA of GAD change (Table E1.3) suggest that a
K=4 model was the best fit for the data, represented by a non-significant VLMR-LRT value
for the K=5 model (p=0.431). The K=4 model was therefore selected, and the trajectories
presented in the right of figure 8.3. Both classes 1 and 3 show very similar shaped curves,
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with a steep initial decrease in symptoms that levels out. The main difference between the
trajectories is the intercept values which show that initial severity is higher for class 1
patients compared to class 3. Together these GAD classes account for over 60% of patients
in LP2 attending GSH. Class 2 appear to be a group of patients with a steady and linear
decrease in anxiety symptoms during treatment, and seem similar to class 3 identified in the
PHQ LCGA for LP2. The final class (class 4) indicates a group of patients with little change
in symptoms during treatment, and account for just over 12% of patients.
High Intensity (PHQ = 3 classes, GAD = 4 classes)
Figure 8.4. Classes identified in LCGA for LP2 (HI).
The results of the LCGA for patients in LP2 who received HI interventions are presented in
Table E1.4. The model fit comparison statistics indicate that for PHQ change, the VLMR-
LRT remained statistically significant until the K=4 model (p=0.504), suggesting the K=3
model was a better fit for the data. K=4 model also include a class of patients making up
less than 5% of the sample, and therefore the K=3 model was selected for PHQ change.
The LCGA results for GAD change suggested that the VLMR-LRT was significant until the
K=5 model, suggesting K=4 was a better fit for the data. The entropy value was also higher
for the K=4 model, and therefore K=4 was selected for GAD change.
The graphical representations of the identified curves are presented in the two graphs in
figure 8.4. The three PHQ curves show one group (class 2) who appear to show an initial
deterioration of symptoms and is very similar to class 2 in the LP1 PHQ HI LCGA (figure
8.2). Class 1 suggests a group of patients with high initial response to treatment that levels
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out, and accounts for over half of the sample (56.5%). The trajectory of class 3 suggests a
very limited reduction in depression symptoms during the course of HI treatment, although
by session 12 the PHQ score appears to be below caseness (<10).
The four GAD curves presented in 8.4 show one group with a very rapid reduction in
symptoms during initial sessions that levels out (class 2), a group with early response to
treatment that levels out (class 4), a group with a slow gradual decrease in anxiety
symptoms (class 3) and a class of patients with an initial deterioration in symptoms that
decreases slightly over time (class 1).
LP4
Guided Self-Help (PHQ = 2 classes, GAD = 2 classes)
The model fit comparison for LP4 patients receiving GSH is presented in Table E1.5, and
shows that for both PHQ and GAD change, a K=2 solution was the best fit for the data. In
both scenarios the VLMRT-LRT was statistically significant for the K=2 model, but not K=3,
and the reduction in BIC values between K=2 and K=3 models was limited.
Figure 8.5. Classes identified in LCGA for LP4 (GSH).
The graphs for the two identified classes in both PHQ and GAD change are presented in
figure 8.5. The graphs between the two symptom measures look very similar, one class
being an early responding group who follow the expect response curve identified in the
growth model (see Chapter 7) and a second class of patients who show a slight, gradual
reduction in symptoms over time, and account for around 22% of the sample in both
symptom measures.
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High Intensity (PHQ = 1 class, GAD = 3 classes)
Figure 8.6. Classes identified in LCGA for LP4 (HI).
The results of the LCGA for LP4 patients who received HI interventions are presented in
table E1.6. The LCGA for PHQ change found a non-significant VLMR-LRT for the K=2
model, which indicated that the K=1 (the expected response curve) was a better fit for the
data. The results of the LCGA for GAD change found a statistically significant VLMR-LRT
values up to K=4 (p=0.812). The K=3 model was therefore selected for GAD change.
The left panel of figure 8.6 shows expected response curve for PHQ in LP4 patients
receiving HI, and the three LCGA classes for GAD change in the right-hand panel. GAD
classes 1 and 3 both appear to indicate patients who do not respond to treatment, and class
1 suggest patients who are at risk of deterioration during treatment. The trajectory of class 2
is very similar to the expected response curve of this LP, showing larger change in the first
sessions with levels out over time.
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LP5
Guided Self-Help (PHQ = 1 class, GAD = 2 classes)
Figure 8.7. Classes identified in LCGA for LP5 (GSH).
The LCGA results for LP5 patients who received GSH are presented in Table E1.7. The
LCGA for PHQ found a non-significant VLMR-LRT for the K=2 model (p=0.059), suggesting
that the K=1 (expected response curve) was a better fit for the model. The LCGA for GAD
change identified that the K=2 model was a better fit for the data than the K=3 model, due to
a non-significant VLMR-LRT, lower entropy value and limited decrease in the BIC value.
The identified curves are presented in figure 8.7, with the expected response curve for PHQ
in the left panel, and the two classes for GAD change presented on the right. The two
identified GAD curves indicate one class of patients with a large decrease in symptoms early
in treatment that levels off, and a second class with a more gradual and linear reduction in
symptoms during treatment.
High Intensity (PHQ = 2 classes, GAD = 4 classes)
The model comparison table for LP5 individuals who received HI interventions is presented
in Table E1.8. The VLMR-LRT was statistically significant for the PHQ K=2 model, but not
for the K=3 model, suggesting that the K=2 was a better fit for the data. As the BIC and AIC
values showed little major decrease between models, the K=2 model was selected for
depression change during HI interventions in LP5 patients. The LCGA of GAD change found
statistically significant VLMR-LRTs up to the K=4 model, with a non-significant value for K=5
(p=0.247), as well as little decrease in BIC values between K=4 and K=5. As a result, the
K=4 model was selected for anxiety symptom change,
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Figure 8.8. Classes identified in LCGA for LP5 (HI).
The form of change for the identified classes are presented in figure 8.8. The left-hand graph
displays the two classes of PHQ change, and show one class with a large decrease in
depression symptoms during initial treatment sessions that levels out, and a second class
who show limited change in symptom scores during treatment. The right-hand graph
displays the four GAD LCGA classes, and indicate a very rapid responding group (class 1),
and more gradual responding group (class 4), a limited response group (class 3) and a class
suggesting limited change in symptoms during treatment (class 2).
LP6
Guided Self-Help (PHQ = 2 classes, GAD = 3 classes)
Figure 8.9. Classes identified in LCGA for LP6 (GSH).
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The model comparison tables for LP6 patients who received GSH are displayed in Table
E1.9. The LCGA for PHQ change indicated that a K=2 model solution was the best fit for the
data, whereas the K=3 model was the best fit for GAD change. In both cases the VLMR-LRT
became non-significant when the number of classes was increased.
The trajectories of change are presented in figure 8.9. The left-hand panel shows the two
PHQ classes identified, class 1 being a group of patients who show a more rapid response
to treatment and class 2 suggesting patients who have a more gradual and slight reduction
in symptoms. The two classes appear very similar to those for LP4 patients receiving GSH
interventions. The three classes of GAD change are displayed in the right panel of figure 8.9.
In comparison to the majority of other LCGA analyses, there is no early responding class
and instead there is a gradual response class (class 1), and limited response class (class 2)
and a deteriorating class of patients (class 3). The expected response curve of GAD change
for this LP (presented in chapter 7) suggested a different form of change from all other LPs,
therefore it would appear that early rapid change is unlikely for this profile of patients.
High Intensity (PHQ = 2 classes, GAD = 4 classes)
Figure 8.10. Classes identified in LCGA for LP6 (HI).
The results of the LCGA for HI change in PHQ and GAD scores for LP6 patients are shown
in Table E1.10. For PHQ change, the K=2 model indicated better fit than K=3, whereas the
K=4 model was selected for GAD change based on fit statistics.
The identified classes are presented in the figure 8.10. The two PHQ classes appear to
suggest one limited change class (class 1) and a second class who rapidly respond to initial
treatment before symptoms level out. The GAD classes show a variety of different
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trajectories. Class 3 and class 1 both show responders to treatment whose symptoms level
out, and the difference between classes appears to be a slightly higher intercept value for
class 1, as well as steeper early decline in symptoms apparent for class 3. Class 2 show
clinical deterioration in symptoms in the initial stages of treatment and class 4 show little
change until around session 8 where symptoms start to decrease.
LP7
Guided Self-Help (PHQ = 2 classes, GAD = 2 classes)
Figure 8.11. Classes identified in LCGA for LP7 (GSH).
The LCGA results for individuals in LP7 who received GSH are presented in Table E1.11
and show that a K=2 model solution was the best for both PHQ and GAD score change
during treatment. The graphical representation of these classes, presented in figure 8.11,
shows very similar forms of change for each LCGA. Class 1 in both models indicates a
group of patients with a gradual, moderate reduction in symptoms over time, whereas class
2 indicate an early responding group whose symptoms level off during the course of
treatment.
High Intensity (PHQ = 2 classes, GAD = 3 classes)
The model comparison table for individuals in LP7 who received HI interventions is
displayed in Table E1.12. The VLMR-LRT for PHQ change was statistically significant for the
K=2 model, but not K=3 (p=0.104). As a result, the K=2 was selected for PHQ change. The
VLMR-LRT remained statistically significant for GAD change up to the K=5 model (p=0.257),
indicating that K=4 was a better fit for the data. However, the K=4 solution included a class
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of patients representing just 3% of the sample, and therefore the K=3 model was selected as
a more conservative model.
Figure 8.12. Classes identified in LCGA for LP7 (HI).
The trajectories of the identified classes are displayed in figure 8.12. The left-hand panel
shows the two PHQ classes, class 1 indicating limited change in depression symptoms over
time, and class 2 a more rapid responding group whose symptoms level off during
treatment, which is similar to the classes identified in GSH interventions. The GAD classes
presented in the right-hand panel show three trajectories of change in anxiety symptoms
during HI interventions. The trajectory of class 1 indicates a gradual decrease in anxiety
symptoms during treatment, compared to class 2 where limited change is achieved over 12
sessions. Class 3 show a rapid response to initial treatment, indicated by a large decrease in
symptoms which then levels off over time.
LP8
Guided Self-Help (PHQ = 3 classes, GAD = 4 classes)
The results of the LCGA for LP8 patients who received GSH are presented in Table E1.13.
The analysis of PHQ change found a statistically significant p-value for VLMR-LRTs for K=2
and K=3, but non-significant for K=4 (p=0.138). As there was little reduction in BIC value
between K=3 and K=4, as well as a decrease in entropy value, the K=3 model was selected
for PHQ change. The results of the GAD analysis indicated statistically significant VLMR-
LRT values up to K=5, at which point the BIC value increased, and therefore the K=4 model
was selected.
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Figure 8.13. Classes identified in LCGA for LP8 (GSH).
The trajectories of the identified classes are presented in figure 8.13. The PHQ classes are
shown in the left panel, and the three classes could be described as a limited change group
(class 1), a gradual responding group (class 2) and a rapid responding class whose
symptoms level out (class 3). The four GAD classes are presented in the right panel, with all
classes showing a decrease in anxiety symptoms. Class 1 appear to be a group of patients
with a steady gradual and linear decrease in symptoms. The form of change for class 4
appears similar to class 1, however the lack of decrease in symptoms over the first few
sessions differentiates class 1 and class 4. The trajectory of class 3 patients is a clear and
continuous decrease in anxiety symptoms during treatment, indicating a positive response to
treatment. Class 2 however standard out, as the trajectory appears to show a very rapid
response to treatment (decrease in symptoms) but after the symptom drop they then appear
to increase in later sessions of treatment.
Although some previous curves presented show a small increase in symptoms after levelling
out, LP8 GSH GAD class 2 have the most pronounced increase. It is possible that these
individuals show a very good response to treatment that is difficult to maintain, potentially
due to more co-existing problems such as personality disorders or physical health problems,
or due to external factors such as family conflict.
0
5
10
15
20
25
0 1 2 3 4 5 6 7
PH
Q
-9
Sc
or
e
Session number
PHQ-9: GSH (LP8)
PHQ 9 - Class 1 (12.9%)
PHQ 9 - Class 2 (44.4%)
PHQ 9 - Class 3 (42.7%)
0
5
10
15
20
0 1 2 3 4 5 6 7
GA
D-
7
Sc
or
e
Session number
GAD-7: GSH (LP8)
GAD7 - Class 1 (31.4%)
GAD7 - Class 2 (22.2%)
GAD7 - Class 3 (24.6%)
GAD7 - Class 4 (21.9%)
239
High Intensity (PHQ = 4 classes, GAD = 4 classes)
Figure 8.14. Classes identified in LCGA for LP8 (HI).
The model comparison table the LCGA of LP8 patients who received HI interventions is
displayed in table E1.14. The VLMR-LRT for PHQ change remained statistically significant
from the K=2 model to K=5, with a non-significant p-value at K=6 (p=0.114). Although the
K=5 model had a slightly lower BIC value & higher entropy value than K=4, it also had a
class of patients who made up just 2% of the sample. As a result, the K=4 model was
selected for PHQ change. The results of the GAD LCGA showed a statistically significant
VLMR-LRT up to the K=5 model (p=0.104), with a limited decrease in BIC and entropy
values for K=5, and therefore the K=4 model was selected.
The identified classes are presented in figure 8.14, with four curves displayed for PHQ and
GAD change each. The left panel shows the four PHQ classes, with class 1 standing out as
a class who show limited change in the first few sessions before a large reduction in
depression symptoms as treatment sessions increase. Class 3 by comparison show little
change overall, but appear to following the trajectory of class 1 until session 3 or 4. Class 2
show reasonable response over the first few weeks which levels out, whereas class 4 are a
group of patients who appear to respond very quickly to treatment and this response levels
out over later treatment sessions.
The GAD trajectories displayed in the right-hand panel of figure 8.14 show four distinct
curves of change in anxiety symptoms in LP8 patients when HI interventions are received.
Class 1 suggests a group of responding patients with a gradual and linear change in
symptoms during the course of treatment, whereas class 2 show a group of patients with a
larger decrease in symptoms during initial sessions that levels out. Both classes together
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comprise 55% of the sample. Class 3 indicate a limited reduction in anxiety symptoms
during treatment, whereas class 4 suggest a slightly increase in anxiety that levels out, and
therefore no response to HI treatment.
Summary
The findings from the series of LCGA performed in this chapter indicate that the number of
different trajectories identified, as well as the shape of the trajectory curves, varies between
LPs. These could provide a more refined prediction of likely change in treatment based on
initial patient characteristics assessed at referral to services. Patients in LP2 for example
had three identified trajectories of change in depression symptoms when HI interventions
were received, and the results suggest that by session three or four, the clinician and patient
may already have an indication of the likely trajectory of symptom scores. This finding
supports previous suggestions by researchers (e.g. Lambert, 2013; Szegedi et al., 2009)
that it is possible to predict eventual treatment outcome by around the third session of
treatment. If a member of LP2 displays a consistent increase in symptoms over the first few
sessions then they are likely members of trajectory class 2, which is indicative of a poor
outcome from treatment (suggesting deterioration over the first few sessions). Providing this
information to clinicians could provide an opportunity for a change in treatment to be
considered, and using feedback in this way have been shown to improve patient outcomes
(Lambert et al., 2001; Shimowaka et al., 2010). If by the third session there has been very
little change in symptoms from baseline assessment then class 3 would appear the most
likely trajectory of change, suggesting limited change in symptoms during treatment. Finally,
if symptoms decrease consistently in the first few sessions then the trajectory of class 1
would seem to be followed, suggesting that a positive response to psychological treatment is
predicted.
For some LCGA comparisons, model fit statistics indicated that the K=2 solution was not a
good fit for the data, and instead the K=1 or expected response curve (presented in Chapter
7) was selected. Some examples of this are PHQ change during GSH interventions for LP1
& LP5 patients and PHQ change in LP4 patients when HI was received. The LCGA
performed for these sample identified no additional trajectories to explain the patterns of
change in these datasets, other than the expected response curve estimated in Chapter 7.
These findings may suggest that the majority of patients follow the expected course of
symptom reduction, and that the patterns of change in non-responding patients is highly
variable, hence LCGA could not identify homogeneous sub-groups with similar responses to
treatment. Although these findings suggest that only one trajectory can be identified for
these patients, and therefore only one curve can be included in a potential DST for patients
of these LPs, this expected response curve can still be of value to the clinician and the
patient. In this scenario, a potential DST could flag patients who were not following the
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expected response curve, and signal to both the clinician and patient that a potential change
in approach may increase the likelihood of positive outcome, similar to the ‘not on track’
method used as part of other systems (e.g. Lambert et al., 2001).
Although the analyses presented in this chapter typically show trajectories of change
differentiating at around the 3rd (at times 1st or 2nd) treatment contact, supporting previous
suggestions (e.g. Lambert, 2013; Szegedi et al., 2009), there were some situations where
this was not the case and more sessions were needed before the trajectory could be reliably
identified. For example, LP8 patients receiving HI interventions two trajectories (class 1 and
class 3) do not appear to differentiate until at least sessions 4 or 5, and therefore a clinician
following a ‘3 session rule’ may decide to change treatment too early. Providing clinicians
with the full information on likely trajectories for patients of each LP could be used to better
inform treatment monitoring decisions, and provide treatment for effectively.
The next section of this chapter describes how the results of the LCGA by LP analyses could
inform a DST for use in IAPT services to support clinical decision making.
Demonstration of a decision support tool for clinical
decisions in IAPT services.
Combining the findings from the latent profile analysis presented in Chapter 5, the variation
in outcomes following intensities of psychological interventions in Chapter 6 and the
trajectories of change during treatment described in this chapter could be used to build a
prototype decision support tool for IAPT services. In the first stage of such a system, an
algorithm could be used to identify LP membership for any new patient referred to the
services by entering information on the nine included patient characteristics. The DST could
then provide information about the relevant LP to the clinician and this information would be
used to support a clinical decision about appropriate treatment. This clinical decision will
likely be commencing LI treatment, allocating the patient to HI or referring the patient to
alternative services, and the DST could only be an aid to clinical judgement rather than
replacement for it.
Should the clinician select an LI or HI intervention for the patients, then the next stage of the
algorithm could provide the likely trajectories for the relevant LP when receiving the
intervention chosen for that patient, which could be used to inform the clinician about the
patient’s progress in treatment. If the current trajectory of change for the current patient
appears more similar to a trajectory indicating a low likelihood of a decrease in symptoms, or
an increase (deterioration), then this information could be used to inform a decision to either
change treatment modality or to step the patient up to a more intensive treatment. This
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section of the chapter presents the stages of a prototype DST that has been developed
using the findings presented in this thesis.
Algorithm for identifying latent profiles.
The first stage of the prototype DST was to create an algorithm that identifies the relevant
latent profile (LP) for any new patient being assessed. Once the LP has been identified,
treatment selection and treatment monitoring decisions can be tailored to members of that
LP.
The results of the LPA presented in Chapter 5 were used to generate the first stage of the
prototype algorithm, which calculates the probability of profile membership for any new
patient referred to an IAPT service after initial assessment, using the nine characteristics
included in the IAPT MDS. This algorithm calculates the posterior probabilities of profile
membership for any patient once all nine patient characteristics are provided. These
posterior probabilities are informed by the results of the LPA, using the equations presented
in Chapter 5. The patient information could be entered directly into the DST by the clinician,
or the algorithm could be hosted by the service’s EPMS. Hosting the algorithm in the system
would mean that pre-treatment assessment information could be automatically submitted to
the algorithm, once the assessment has been completed and entered into the EPMS.
Once the patient’s information from the nine patient characteristics are submitted to the
algorithm, profile membership information including the probability of membership to each
profile is calculated. The profile to which the patient has the highest probability of profile
membership is then assigned to the patient. The algorithm was used in Chapter 6 to provide
profile membership for the validation sample, and the front end (input) for this algorithm is
presented in figure 8.15 below.
Figure 8.15. Example display: Algorithm input
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The prototype algorithm presented here was developed in Microsoft Excel and allows the
use of dropdown lists for the five categorical patient characteristics (gender, ethnicity,
welfare status, medication and phobia caseness), whereas the four continuous variables
(Age, PHQ-9, GAD-7, W&SAS total scores pre-treatment) can be entered as whole
numbers.
Aiding treatment selection decisions.
Once the patient characteristics have been entered and the algorithm has identified the
patient’s latent profile, information about this profile that may be relevant to treatment
selection decisions can be made available.
The prototype algorithm could display the likelihood of treatment outcomes, for example
providing the probabilities of recovery, reliable change, deterioration and dropout for
members of the profile when either LI or HI treatments were received (results presented in
Chapter 6). These probabilities could inform an estimate of the expected probabilities, as
well as potential utilities, of the different treatment approaches, and it may be that the
likelihood of a positive outcome is low and therefore referral to alternative treatment services
may more appropriate.
In addition, the DST could also provide a treatment recommendation for the patient based
on the likelihood of treatment outcomes. For example, as members of LP7 displayed a low
probability of recovery following both LI (11%) and HI (17%) treatment, it might be argued
that IAPT delivered treatment was not the most appropriate and instead a referral to another
service might increase the likelihood of a positive outcome for the patient. The DST could
provide such a recommendation, for example if LP7 was identified:
“Unlikely to benefit from IAPT service, referral to
specialist service is recommended.”
For members of LP1, who have a high probability of recovery from both LI (75%) and HI
(79%), the recommendation might be that LI be considered the initial step of treatment.
Information about the likelihood of a positive outcome could also be included in this
recommendation to inform the clinician about the likely prognosis, for example:
“Initiate at Step 2. High probability of recovery following
treatment, low risk of treatment dropout.”
This treatment recommendation would be considered as guidance and used only to
supplement clinical judgement, not replace it. There may be important reasons why LI
treatment is not appropriate due to characteristics not considered by the algorithm, such as
a diagnosis of PTSD, or that the patient has already received LI treatment previously and not
benefitted.
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These treatment recommendations could however be considered in the treatment selection
decision as an aid to clinical judgement, and the IAPT clinician could for example discuss
the recommendation during supervision if there was uncertainty. Providing a clear
recommendation as well as the supporting evidence for this guidance in the form of
probabilities of treatment outcomes could also provide a transparent method of further
including the patient in decisions about their care.
Figure 8.16 displays the completed algorithm input as well as the profile membership for an
example patient and the treatment recommendation for this profile.
Figure 8.16. Example display: Algorithm treatment recommendation output.
In the example presented, the constellation of patient characteristics has resulted in an
allocation to LP4, to which the example patient has a 97.88% probability of membership.
The right-hand side of this output shows that the probability of membership to the other
seven profiles is low. As members of LP4 have a good likelihood of recovery following LI
interventions, and that outcomes are generally better for this treatment compared to HI for
this group of patients, the recommendation is to start with step 2 (LI) treatment for members
of this profile initially. This is shown in the bottom left corner of figure 8.16.
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Aiding treatment monitoring decisions.
The next stage of the prototype algorithm, findings from the LCGA that are presented in this
chapter could be incorporated to provide information relevant to treatment monitoring
decisions during care. Once the algorithm has identified the patient’s profile, the treatment to
which the patient has been allocated to (LI or HI) can be selected by the clinician within the
DST and the algorithm could display the expected trajectories for the profile, for both PHQ-9
and GAD-7 change.
Figure 8.17 shows the PHQ-9 and GAD-7 trajectories identified for LP4 profiles who
received LI interventions. For both symptom scores, two distinct trajectory classes were
identified, and the graph also displays the symptom scores for the example patient over the
first five sessions. The patient’s progress is superimposed and shows how their progress
compares to the identified trajectories for the relevant profile. Observing the two graphs
below shows that the trajectory of the example patient is much closer to the responding
class of patients for both measures, and therefore the clinician could conclude that the
current progress is treatment is good and that a change in treatment is not required. If the
current patient’s trajectory was closer to the non-responding class then the clinician could
use this information to consider a potential change in treatment, for example by stepping up,
or that referral to alternative treatment services is more appropriate.
Figure 8.17. Example display: Trajectories of change.
This part of the DST could be built into the EPMS used by the IAPT services to provide
feedback to clinicians as to whether treatment is indicative of positive outcome or not,
informing decisions needed during treatment monitoring. Whereas other outcome feedback
systems (e.g. the outcome assurance system; Lambert, 2013) provide just one expected
response curve and suggest that any patient not following this within the first few sessions is
not on track, it would be suggested that the prototype DST presented here would instead
display all possible trajectories. The value of showing all curves is that it provides
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information to the clinician about scenarios where a reduction in symptoms may take longer.
For example, the change in PHQ-9 scores for LP8 receiving (figure 8.14) only differs at
around sessions 5 for class 1 and class 3, and therefore providing the full range of possible
change curves may reduce clinician concern by showing that a positive outcome is still
achievable for that profile. The output from the DST could also provide the proportion of the
LP that were members of each class, as this would inform the clinician about the relative
frequency of the trajectory. As some classes may occur in only 5-10% of the LP, this pre-test
probability could be used to aid the clinician estimate the likelihood that the patient will follow
specific trajectories.
Discussion
The first aim of this chapter was to identify the distinct trajectories of change in symptoms
during treatment for individual latent profiles. Conducting LCGA by these sub-samples of
patients who share common characteristics should allow for a more accurate estimate of the
rate and nature of change, and therefore provide more valuable information for clinicians to
use in making treatment monitoring decisions. The next goal of the chapter was to develop a
DST that could be used in IAPT services to support treatment selection and monitoring
decisions, using the findings presented in this thesis. A prototype DST algorithm has been
developed combining latent profile information presented in Chapters 5 and 6, with the
results of the LCGA conducted in this chapter to provide a treatment recommendation as
well as information about the likely trajectories of symptom change during treatment. There
are currently no other DSTs supporting both these decisions in mental health services, and
considering the role IAPT services play in the delivery of psychological interventions in
England, there is great potential for improved patient outcomes and service efficiency.
It is of interest that there was a range of different trajectories identified across the LPs, which
may not have initially been expected. Although every profile had at least one trajectory class
with a similar form of change to the expected response curves presented in Chapter 7, there
was significant variation as to the form of the second, third or fourth classes identified. For a
number of profiles, at least one trajectory could be described as a non-responding, or limited
response to treatment trajectory (e.g. LP5 HI GAD class 2). This split in trajectories appears
to replicate the results of Gueorguieva and colleagues (2011), where a responding and non-
responding trajectory of patients was observed in a clinical trial dataset of pharmacological
treatment for depression.
However, a few profiles included an additional trajectory which more clearly indicated an
increase in symptoms, or clinical deterioration. As LP6 showed the highest probability of
deterioration in the analysis of outcome presented in chapter 6, it may not be surprising that
there was a class of patients showing clinical deterioration for both LI (GAD class 3) and HI
(GAD class 2) interventions. It is of interest that these classes were only identified in GAD
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trajectories, not PHQ. This suggests that the high probability of overall deterioration in the
LP6 samples is likely to be in relation to anxiety symptoms, rather than depression, which
may be worth considering both before and during treatment by the therapist. It is possible
that these patients have anxiety disorders with symptoms not well captured by the GAD-7,
e.g. specific phobias, and the start of treatment may exacerbate these symptoms and cause
an increase in worry, therefore higher GAD-7 scores. Providing clinicians with the
information that their patient appears to be following a trajectory indicating deterioration
immediately, such as the ‘not on track’ method (Lambert et al., 2001), has the potential to
inform a change in treatment and hopefully reduce the likelihood of a negative outcome from
IAPT treatments. Whereas LP6 patient appear most a risk of deterioration in anxiety
symptoms, the other two deterioration trajectories identified were identified for depression
symptom change in HI treatment (LP1 PHQ class 2; LP2 PHQ class 2).
A number of these trajectories may represent typologies of psychotherapy patients that have
been described by clinical researchers in the field. For example DeRubeis, Gelfand,
German, Fournier, & Forand (2014) have suggested that a number of patients who ‘respond’
well to treatment will be “spontaneous remitters” for whom a resolution of psychological
wellbeing will occur without treatment, as well as “easy” and “pliant” patients for whom a
positive outcome is likely when in receipt of good quality therapy. Other trajectories may
correspond to ‘harder to treat patients’ who may often be labelled as “challenging” or
“intractable” patients and for whom a positive outcome is difficult to achieve if at all. It is
possible that the distribution of these types of patients differs across profiles and may
therefore inform the composition and outcomes of the classes observed in the LCGA
analyses presented in this chapter. For example, a relatively high proportion of patients in
‘early response’ type trajectories (e.g. LP1 PHQ-9 GSH class 1 [figure 8.1]; LP1 GAD-7 HI
class 1 [figure 8.2]; LP2 PHQ-9 GSH class 1 [figure 8.3]) in some profiles may be explained
by these groups of patients containing more “spontaneous remitters”, or more pliant patients.
Profiles with higher incidences of ‘non-response’ trajectories (e.g. LP7 PHQ-9 HI class 1
[figure 8.12], LP8 GAD-7 HI class 4 [figure 8.14]) may be made up of more “intractable”
patients, for whom psychological treatment is unlikely to result in a positive outcome. The
identification of these types of patients, especially within profiles, could increase the clinical
utility of a DST in IAPT services.
The different trajectories observed may also be in response to specific components of the
therapies delivered. For example, a central component of behavioural activation includes a
focus on engaging in activities that patients typically avoid (Veale, 2008), and other
treatments for anxiety disorders may include exposure to anxiety provoking situations/items.
A consequence of these components of treatment, is that the patient’s initial symptoms may
increase, or not decrease at the same rate as they would for patients whose treatment is not
so focused on avoidance. This may, in part, explain the pattern of responses observed in
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patients of the ‘early deterioration’ types classes, as well as those classes with limited early
response or a more gradual reduction in symptoms. This type of responder may be present
in LP8 PHQ-9 HI class 8 (figure 8.14) where there is no visible response to treatment in the
first four sessions of treatment, before a quite dramatic reduction in symptoms occurs after
the fourth session. If these classes were to be tested it might be worth exploring how the
classes mapped onto clinician’s perceptions of patients using a typology such as that
developed by DeRubeis and colleagues (2014).
One limitation of this work, as with the analysis presented in Chapter 7, is that anxiety
disorder specific measures (ADSMs) were not available, and there may have been change
(or lack of) in other symptoms not included in the GAD-7 that may be of value to inform
monitoring decisions. ADSMs are not as routinely used as the GAD-7, and were not
available in the dataset used for the current analysis, but it would be of benefit for services to
increase their use. It is likely that ADSMs would provide important information that could also
be included in the DST developed in this thesis and scores on these measures could be
compared to GAD-7 change, therefore future work should explore the use of these
measures in predicting response to IAPT delivered interventions.
A further limitation of this analysis is that the algorithm can only provide advice when either
GSH or HI treatments are chosen. Although these treatments are used for the majority of
patients in the dataset, it may be that other services frequently use other interventions, for
example group interventions that were not considered in the current analysis. As discussed
in Chapter 7, group-based interventions can vary considerably in purpose, which would
make comparisons difficult and therefore analyses should be conducted within group types
(e.g. only including trauma-focused groups). In addition, as so few members of LP3 were
present in the dataset, this profile was excluded but as a result the DST would not be able to
confidently suggest an expected response curve for this profile of patients, and instead
would have to assume the trajectory of the profile which seems the most similar. Although
the samples for group-based treatments and LP3 patients included insufficient numbers for
analysis, the use of data from additional services or the national IAPT data could provide a
large dataset with greater representation of these samples, which could further inform the
prototype DST.
The prototype algorithm is limited at present to using just the nine patient characteristics
included in the LPA, but it is likely that other characteristics related to the patients, as well as
external factors, may contribute to treatment outcomes. For example, therapist
characteristics may inform both the likely success of treatments and how symptoms change
during treatment. As the LP method described in this chapter is used to identify sub-groups
of patients with similar characteristics, it is possible that some therapists may have better
outcomes for one profile of patients compared to another, because they are able to better
identify with them or have more experience working with a specific group of patients. In
addition, the prototype DST does not include diagnostic information and therefore there may
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be situations were LI treatment is recommended but there is good reason to initiate at HI
instead, for example if PTSD or social anxiety disorder is identified. As a result, the DST
treatment recommendation will not replace clinical judgement, but instead provide an aid for
it.
The DST presented in this chapter is able to provide information about the likely trajectories
of change for members of a profile, which would allow a clinician to compare the progress of
their current patient against. If there were two likely trajectories then it would likely be
straight forward to decide whether the patient was following the ‘responding’ or ‘non-
responding’ class. However, when there are four trajectories it may be more difficult to tell
which trajectory is being followed. Further development of the DST would benefit from the
inclusion of potential confidence parameters which can determine how close the current
patient’s trajectory is to all possible trajectories, and the algorithm could then identify the
probability of a poor prognosis based on the expected trajectory. The use of more
sophisticated statistical methods could provide the opportunity to further develop the
algorithm in this way, and pattern-recognition based machine learning methods could
provide the opportunity to identify and signal patients who are at risk of poorer outcomes
(Mullainathan & Spiess, 2017).
The prototype DST presented in this chapter could be used to aid clinical decision making in
IAPT services, and it would be feasible to build into existing EPMS used by the services.
Research has found that DSTs were likely to have most impact when they were available as
part of the clinical workflow, providing real time support (Kawamoto et al., 2005) and
therefore it would be recommended that this tool were hosted in the background of the
management system. However, this prototype algorithm has been developed using data
provided by the services but has not considered the clinical impact of using such as tool in
routine care. It is possible that clinicians in the services may not embrace the use of an
algorithm to support their work, and it would be important to understand how clinicians view
such a development before it was incorporated into routine care. In addition, the views of
patients are also important to consider, as patients may be uncomfortable knowing that an
algorithm was supporting decisions about their treatment. Further work leading on from the
findings presented in this thesis should consider interviews with clinicians and patients on
their views about using a DST in IAPT services, as this may shape the implementation of the
prototype algorithm in routine care.
Summary
The results of these sub-analyses provide an additional component to a prototype DST for
use in IAPT services by personalising the prediction of expected change during treatment
based on the patient’s identified profile. This information can be combined with latent profile
outcome information to create a DST with an algorithm identifying latent profiles in the front
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end of the system, and the probability of outcomes and trajectories of change provided as
system-based outputs. The use of this DST has the potential to aid both treatment selection
decisions and treatment monitoring decisions in psychological interventions, and could
greatly increase healthcare efficiency. Considering the views of patients and clinicians with
regard to the use of DSTs in services, as well as incorporating characteristics not included in
the current analyses or the IAPT data may increase the clinical utility of the DST developed
in this thesis.
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Chapter 9. Review of findings and
conclusions.
Review of findings.
The primary aim of this thesis was to explore the development of a personalised treatment
approach for common mental health disorders (CMHDs), which could support clinical
decision making about the choice of psychological interventions for people presenting to
IAPT services. This was achieved through:
* A meta-review of the literature on patient characteristics associated with treatment
outcomes in CMHDs.
* The use of regression modelling to explore the role of patient characteristics in predicting
treatment outcomes within a dataset of patients attending IAPT services.
* Conducting latent profile analysis to identify statistically distinct subgroups of patients
attending the IAPT services, and exploring differential outcomes between these profiles.
* Using latent growth curve and latent class growth analysis to identify the expected form of
change in psychological symptoms during treatment, and to explore whether different
trajectories existed between latent profiles.
* Combining information from the latent profile analysis and trajectories of change to inform
the development of a decision support tool that could be used in clinical practice to
recommend an appropriate intensity of psychological intervention, as well as providing
information about the likely trajectory of change in psychological symptoms.
* Producing a prototype decision support tool that can be hosted by relevant patient
management systems to inform both treatment selection and treatment monitoring decisions
in IAPT services.
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Personalised medicine and decision support tools
The use of personalised or stratified medicine to provide a more patient-centred approach to
healthcare is increasingly being adopted, for example, in the treatment of cancer (Verma &
Mukesh, 2012) and cystic fibrosis (Ashley, 2015). This approach aims to tailor interventions
delivered to individual patients by incorporating information about patient characteristics,
which may make them more or less likely to benefit from particular interventions, into clinical
decision making (Dzau & Ginsburg, 2016). For example, advances have been made in the
treatment of cancer by identifying individuals with specific genetic mutations which increase
the likelihood of response to particular therapies (Rossi et al., 2011; Song, Lee, & Kang,
2011). Personalised medicine is now a key government priority for the English NHS (Keogh,
2015) and has the potential to not only improve patient outcomes but also contribute to a
more efficient healthcare system by optimising treatment delivery.
Developments in the personalised medicine initiative have been supported by the growth of
large healthcare datasets and the increased power and availability of digital technology,
which has revolutionised the way patient information is collected and used (Wilson &
Nicholls, 2015). Electronic patient management systems (EPMS) are widely used across
healthcare and these systems have the potential to host large volumes of information on
patient characteristics that have the potential to inform differential treatment response. A
further benefit of large healthcare datasets is that they provide significant sample sizes for
complex statistical modelling techniques, which are increasingly used in the development of
personalised medicine approaches (Abbasi, 2017).
Whereas much of the personalised medicine initiative has focused on physical health
conditions, especially cancer, mental health has currently received little attention, with few
examples of stratified approaches (Ozomaro et al., 2013). This is despite 16% of the
population estimated to be affected by common mental health disorders (CMHD) such as
depression and anxiety (Spiers et al., 2016). One explanation for this may be the lack of
convincing evidence for the role of various bio-markers and differential treatment response
in CMHDs when compared to physical health conditions. In particular genetic markers,
frequently used in areas such as cancer, have only limited evidence for their potential in
predicting treatment outcomes in CMHDs, and therefore routine screening is neither justified
or available at present (Licinio & Wong, 2011). However, a number of mental health
services, in particular IAPT services, have large datasets on basic demographic
characteristics, treatment delivery factors and outcomes variables. For this reason, the IAPT
services were chosen as the focus for this study.
In the UK healthcare system, psychological interventions are recommended as treatment for
CMHDs, and IAPT services are the common means by which psychological interventions
are provided by the NHS in England. They deliver either Low Intensity (LI) or High Intensity
(HI) evidence based psychological treatments, and over one million patients are referred to
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IAPT services nationally each year (NHS Digital, 2016). IAPT services require a treatment
selection decision (LI or HI) and also have high quality standardised data on patient
characteristics as well as treatment outcomes, and so provide a good setting in which to
develop and test a clinical decision support tool.
There are few examples of decision support tools (DSTs) available for use in mental health
treatment (Sheehan & Sherman, 2012), which may be linked to the lack of identified bio-
markers or large patient datasets (Ozomaro et al., 2013). However, a small number of DSTs
have been delivered to support treatment monitoring decisions in mental health. Staged
pharmacological treatment algorithms have been developed to inform clinicians which order
of treatments to consider, where a lack of response to the first treatment results in the
algorithm suggesting the next treatment in the sequence. Examples of these staged
treatment algorithms include the Psychopharmacology Algorithm Project Harvard South
Shore Program (Stein et al. 2012) and Texas Medication Algorithm Project (Crismon et al.,
1999; Rush, Crismon, et al., 2003).
DSTs for treatment monitoring decisions in psychological interventions have adopted
alternative approaches, such as the Quality Assurance (QA) system of Lambert and
colleagues (Lambert, 2013). This DST does not recommend specific treatments, but instead
uses sessional outcome measurement data to display the change in symptoms over time
and flags up patients that the system considers ‘not on track’ based on their current
trajectory. Identifying patients with a poor potential prognosis in this way provides the
opportunity to change approach to treatment, with significantly reduced rates of deterioration
observed in studies where information such as this is fed back to clinicians (Hannan et al.,
2005; Shimokawa et al., 2010; Slade et al., 2008).
Whereas DSTs for treatment monitoring decisions are available for use in mental health
treatment services, methods of supporting treatment selection decisions are currently have
shown limited patient benefit when evaluated in treatment services (Watzke et al, 2010).
However, a number of recent developments have seen attempts at modelling treatment
outcomes using data from clinical trials, especially in the treatment of depression, and future
evaluation of these methods in routine is expected in the coming years. For example, the
Personalised Advantage Index (PAI; DeRubeis et al, 2014) was developed using an RCT
dataset of patients receiving either psychological treatments or pharmacological treatments,
and identifies, for individual participants in the dataset, what the likely benefit of one
intervention over the other is likely to be. This method has been employed in other trial
datasets (Huibers et al., 2015) but has not been evaluated in mental health services at
present. Alternative predictive modelling approaches have been employed with other mental
health datasets, for example creating a composite score from patient characteristics to
inform the benefits of antidepressants compared to psychological treatment for depression
(Wallace et al, 2013). However, as these analyses used small samples from more selective
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trial datasets, and as these methods require recalculation for each new dataset, there are
questions about their applicability to routine datasets such as IAPT.
A very recent paper by Delgadillo and colleagues (2016) used a dataset of n=1347 patients
who received treatment at IAPT services in northern England to develop a risk calculation
model (the ‘Leeds Risk Index’, LRI). This model uses patient characteristics included in the
IAPT minimum dataset (MDS) as well as additional characteristics collected at these local
IAPT services but are not collected nationally (e.g. family history), to group patients into
either low, moderate or high risk groups. ‘High risk’ patients were less likely to achieve
positive outcomes following treatment (defined as a reduction in 5 or more points on the
PHQ-9 and 4 or more points on the GAD-7), compare to patients in the ‘moderate’ or ‘low’
risk groups. Outcomes were better for ‘High Risk’ patients when HI treatments were
received, and the LRI can be used to identify patients for whom HI interventions would be
recommended as initial IAPT treatment. Although the LRI has potential to support treatment
selection decisions in IAPT services, one drawback of this system is that it uses a number of
patient characteristics that are not included in the IAPT MDS, and therefore it could not be
used by other national IAPT services unless they were collecting this additional patient
information routinely.
The DSTs and modelling approaches discussed in Chapter 2 show potential for aiding either
initial treatment selection or treatment monitoring decisions in services such as IAPT,
however at present there is not a system that can aid both decisions. The focus of this thesis
was to develop such a system, which has potential use for aiding clinical decisions in IAPT
services. As these services provide the majority of psychological therapies for CMHDs in
England and collect a standardised set of patient characteristics, the development of a DST
to personalise treatment in these services could potentially have a significant impact in
improving healthcare delivery.
Predictors of treatment outcomes.
A meta-review (a systematic review of previously conducted reviews) was conducted to
understand which patient characteristics are associated with outcomes in CMHDs. The
review identified a number of patient specific characteristics that had frequently been
explored in relation to treatment outcomes, for example age, gender, severity of initial
symptoms and comorbid mental health problems, including personality disorders. Some
routinely collected demographic characteristics, such as age and gender, were either
inconsistently associated with treatment response, or had limited/inconsistent evidence of an
association with outcomes in CMHDs.
The level of pre-treatment symptom severity was frequently explored within the previous
literature of predictors of treatment outcomes, and findings suggested that lower severity
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was typically associated with better response to interventions for CMHDs, especially
psychological treatments. The presence of comorbid conditions including personality
disorders, having had previous treatment for CMHDs and a longer duration of illness were
linked to poorer outcomes in the literature, across both pharmacological and psychological
treatments. The review identified a number of patient characteristics which are routinely
collected by IAPT services, some of which were consistently associated with outcomes (e.g.
severity), some which showed an inconsistent association (e.g. age) and some
characteristics which may have potential predictive ability but have been under researched
(e.g. ethnicity, functional impairment).
The meta-review identified limited previous research on predictors of treatment dropout, with
only one identified review exploring patient characteristics associated with dropout during
psychological treatment. As dropout has been estimated to occur in a third of patients
attending routine treatment services (Saxon et al., 2017; Wells et al., 2013), and is
associated with poor patient outcomes and increased long term costs (Wade & Häring,
2010), considering the likelihood of dropout in treatment selection decisions could improve
healthcare efficiency. From the identified systematic reviews, it was suggested that older
age and less perceived stigma of mental health treatment were associated with lower
dropout rates in a number of reviews, and age, gender, severity and previous treatment
were more inconsistently associated with dropout across the literature.
One limitation of the systematic review conducted in Chapter 3 was that there was a large
amount of variation between the included reviews, for example between which specific
CMHD diagnoses (e.g. depression, anxiety, all CMHDs) and the types of primary studies the
reviews included (e.g. cohort studies or only randomised trials). This may explain some of
the inconsistencies found between patient characteristics and treatment outcomes. The
limited number of reviews of characteristics associated with treatment dropout, especially for
psychological treatments, suggests that this is an area in need of further research. As the
variation between the included populations and studies may have contributed to the
inconsistency in associations, the development of a DST for IAPT services was expected to
be better informed by exploring the association of patient characteristics with outcomes in a
dataset of patients attending these services. This would also provide an opportunity to
explore the potential interactions between patient characteristics, as the meta-review only
considered the association between individual patient characteristics and outcomes and
ignored the potential impact of co-existing characteristics on treatment outcomes.
Aiding treatment selection decisions
As the aim of this thesis was to develop a DST for use in IAPT services, the next phase of
the project was to supplement the findings of the meta-review with an analysis of routine
patient data collected at two IAPT services. The use of this dataset was expected to provide
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the most relevant information to inform the DST and help develop a personalised treatment
approach for these services.
The analyses considered only routinely collected patient characteristics that were collected
as part of the IAPT MDS, as using data already collected would limit the burden on clinician
and patient time as well as increasing the applicability of the DST to IAPT services
nationally. This dataset included data on basic demographics such as age, gender and
ethnicity, as well as clinical data on symptom severity and level of functional impairment.
The dataset for analysis consisted of n=16636 patients who entered treatment at the IAPT
services, of whom n=10963 had both pre and post-treatment severity measures and were
considered to be meeting ‘caseness’ (scoring over the clinical threshold for a CMHD) at
assessment.
The first analysis (Chapter 4) used multiple regression methods to explore the association
between available patient characteristics and a number of treatment outcomes, including
IAPT recovery (scoring below clinical threshold following treatment), reliable change in
symptom scores, clinical deterioration (a significant increase in symptom scores post-
treatment) and treatment dropout. Latent profile analysis was then performed on the data to
identify statistically distinct profiles of patients entering treatment at the services based on
the available patient characteristics (Chapter 5), and the variation in outcomes between
these profiles was explored in the final chapter in this section (Chapter 6).
Regression analysis
In the first stage of analysis, multiple regression analysis was performed to explore the
association between routinely collected patient characteristics pre-treatment and eventual
treatment outcomes. Nine patient characteristics were available in the IAPT dataset, which
had all shown some association with outcomes in the meta-review conducted in Chapter 3,
and included age, gender, pre-treatment severity of depression and anxiety, social
impairment, ethnic group, welfare benefit status, presence of significant phobia symptoms
and whether psychotropic medication was prescribed.
The results of the regression analysis showed that each of the nine patient characteristics
were significantly associated with at least one of the investigated outcomes (e.g. recovery,
reliable change, deterioration and dropout), across different intensities of psychological
intervention. However, depression and anxiety severity, social impairment and welfare status
were most frequently associated with treatment response across sub-analyses by intensity
of psychological intervention. Age, depression severity and welfare status were significantly
associated with treatment dropout, for all intensities of psychological treatment received.
Consideration of these patient characteristics at initial assessment could be used to inform
likely prognosis from IAPT treatment. For example, patients with high levels of anxiety and
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depression symptom severity were less likely to be in recovery following IAPT treatment and
therefore this information could be used to inform treatment planning, potentially suggesting
the need for more intensive treatment. The differences in results between predictors of LI
and HI treatment outcomes could be used to inform which intensity might be most
appropriate for a patient given their characteristics at presentation to the services. Findings
suggested that receiving welfare benefits was linked to higher odds of deterioration in HI,
whereas it was not significantly associated with an increase in symptoms during LI
treatment. However, being from a non-white ethnic group was associated with deterioration
in LI, but not in HI and therefore consideration of demographic characteristics may be
important when deciding whether LI or HI treatment is most appropriate.
However, the ability of these results to inform a DST for use in IAPT was limited. The
variance explained by the regression models was generally low, and only above the
threshold that has been suggested to indicate a clinically meaningful benefit (Uher et al,
2012) for models predicting IAPT recovery. The variance explained by the models predicting
reliable change and deterioration was low and was limited to just 1.5 to 3.5% in models
predicting treatment dropout across the different intensities of psychological treatment.
Using regression analysis to predict the likelihood of multiple outcomes which may be of
interest to a DST was also problematic as different characteristics were associated with
different outcomes. Practically this could result in a situation where a constellation of patient
characteristics suggested an increased probability of both a positive outcome (e.g.
response) and a negative outcome (e.g. dropout) which would be difficult to reconcile in a
DST. Instead, alternative statistical methods that can identify sub-groups of patients with
similar characteristics were considered.
Latent profile analysis
To address the potential limitations of the regression analyses presented in Chapter 4, a
method of identifying sub-groups or clusters of individuals with similar characteristics was
considered. The use of clustering methods would allow for the interactions between all
patient characteristics to be considered, but it could also replicate potential clinician
heuristics where patients are compared to clinician-derived ‘prototypes’ (Garb, 2005).
Identifying sub-groups of patients could inform a stratified approach to the selection of LI or
HI treatments in IAPT
Latent profile analysis (LPA) (Lazarsfeld & Henry, 1968; Hagenaars & McCutcheon, 2002),
an extension of latent class analysis for continuous data, was selected as an appropriate
method, due to its use of model fit statistics and more robust classification when compared
to alternatives such as K-means clustering (Schreiber & Pekarik, 2014). Latent profile
methods have been used to identify sub-groups of patients with CMHDs (e.g. Rosellini &
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Brown, 2014; Unick, Snowden & Hastings, 2009) but clinical outcomes between identified
profiles/classes have not previously been explored, despite its potential for aiding
personalised medicine approaches.
LPA was performed on the dataset of all patients who entered treatment at the IAPT
services (n=16638) and included the same nine patient characteristic used in the regression
analysis. Eight latent profiles (LPs) were identified in split-sample datasets, suggesting that
co-occurrences of patient characteristics in the dataset indicate eight statistically distinct
groups of patients entering treatment at the services (Chapter 5).
Examination of the eight profiles suggested that they were made up of quite different groups
of people, which could provide important information about the casemix of patients receiving
treatment at the services. Latent profile 1 (LP1) were younger than the average age for
patients entering treatment (35.5 compared 38 years of age), had lower levels of pre-
treatment depression and anxiety severity (PHQ score 5 vs 14; GAD score 5 vs 12) and
were less likely to be receiving welfare benefits, reaching caseness for phobia or prescribed
medication. In comparison, LP8 were more likely to be from a non-white ethnic group (31%
LP8, 17% LP1), more likely to be female (72% vs 66%) and have higher levels of depression
(mean = 19) and anxiety (mean = 16) severity pre-treatment. Descriptions of the eight
profiles were shown to members of the clinical team at the IAPT services, and the clinicians
indicated that they could see how the different profiles mapped onto their own caseloads,
which may indicate potential clinical validity of these patient profiles.
In the next stage of analysis (Chapter 6), the probability of recovery, reliable change,
recovery or improvement, deterioration and dropout were explored between the profiles, with
sub analyses included by intensity of psychological treatment. The proportion of patients
within each profile who were in recovery following treatment varied considerably between
profiles. Whereas LP1 and LP3 reported recovery in around 75% of cases, only 15% of
members of LP7 were in recovery following treatment. The probability of deterioration
ranged from 5% for members of LP7 to 20% in LP6, which is significantly higher than the 5-
10% deterioration reported in the literature (Boisvert & Faust, 2003; Crawford et al., 2016),
and would suggest a group of patients who are at considerably greater risk of negative
outcomes following treatment. Treatment dropout ranged from 17 to 40% across profiles.
Profile membership was calculated for an additional validation sample, and this dataset was
explored to confirm whether the probabilities of treatment outcome by LP were maintained in
a separate sample of patients who attended the same services at a later date. The results
indicated that the proportion of patients achieving outcomes in each profile was maintained
over time, suggesting the profiles were robust in their predictive ability.
Outcomes between LI and HI treatments were also explored within profile to identify whether
one intervention intensity was associated with a significantly higher chance of positive
outcomes than the other. Results showed that the probability of recovery or reliable change
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on both symptom measures was significant higher when HI interventions were received for
four of the profiles (LP2, LP6, LP7 and LP8) but not for the other four profiles. Surprisingly
for LP3 and LP4, results suggested that the odds of recovery were higher following LI
interventions, although this difference was not statistically significant.
Given the differences in outcome likelihood between the profiles, incorporating profile
identification into a DST may have potential utility in supporting personalised treatment
selection decisions in IAPT services. The identification of LPs would enable a prediction of
likely treatment outcomes from both LI and HI treatment, which could then be used to inform
clinical decisions about appropriate treatment. For example, if at assessment a patient was
identified as being a member of LP1 then, as the probability of a positive outcome (e.g.
recovery) was similar between LI and HI treatment for this profile of patients, the less
resource intensive intervention might be favoured and suggested as the most appropriate
treatment for the patient. Conversely, members of LP7 were significantly more likely to
achieve positive outcomes from HI treatment compared to LI, and therefore the more
intensive treatment might be recommended as first line treatment.
Aiding treatment monitoring decisions
In the final section of the thesis, methods to support treatment monitoring decisions were
explored. As IAPT services have adopted routine outcome measurement, the dataset used
in the thesis included depression and anxiety symptom scores measured at each treatment
contact, which allowed for the within-treatment change in symptoms to be statistically
modelled.
The dataset used for this series of analyses included all patients who received at least three
sessions of either guided self-help (LI treatment) or HI interventions. A total of n=3334
patients were included in the analysis of guided self-help symptom change, and n=4394
were included in the HI analysis.
Latent growth curve (LGC) modelling was conducted in the first stage of analysis, and this
estimated the mean change in symptoms during treatment within the sample. Growth curves
were also estimated for each LP to provide an expected response curve (mean change in
symptoms) for each profile of patients (Chapter 7). Latent class growth analysis (LCGA) was
then conducted to identify statistically different trajectories of change for all patients
receiving either guided self-help and for patients receiving HI treatments. LCGA was then
performed for each LP to identify the distinct trajectories that could occur within profiles to
provide a more stratified estimate of likely change in symptoms (Chapter 8). The results of
this analysis were combined with the findings presented in the previous section of the thesis
to develop a prototype DST for use in IAPT services.
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Latent growth methods
To inform the potential development of a DST that could aid both treatment selection and
treatment monitoring decisions, latent growth curve (LGC) analysis was performed to identify
the trajectories or expected response curves for depression and anxiety symptom change
during IAPT treatments. Previous researchers have found a greater reduction in symptoms
over the first few sessions of psychological treatment, indicated by a steeper curve, which
levels out as the number of sessions increases (Cuijpers et al., 2013; Kopta et al., 1994),
and this finding was replicated in growth curves estimated for patients receiving the included
IAPT treatments.
Latent growth analysis was also performed for each of the eight latent profiles identified in
Chapter 5, which estimated the mean change in symptom scores for groups of patients with
similar characteristics. A similar form of change (shape of the curve) was identified between
most of the profiles, with the major variation between profiles being the intercept or starting
value pre-treatment symptom score. The change in anxiety symptoms for LP6 was the only
trajectory which had a unique form of change and suggested that anxiety symptoms remain
stable for the first few sessions for this profile of patients before reducing as the number of
sessions increases. This suggests that LP6 patients may need longer in treatment before a
reduction in symptoms is seen, and it could be recommended that clinicians should not be
immediately concerned if anxiety does not decrease in the first few sessions for patients
identified as LP6.
Latent growth curve analysis models the mean change in symptom scores for a sample,
however there could be more potential value in identifying sub-groups of patients with
statistically distinct forms of change within the sample. Latent class growth analysis (LCGA)
was selected as a method of identifying sub-groups (classes) of individuals with similar
trajectories within the full sample, as it was hypothesised that a number of different
trajectories of change could exist, for example a group of treatment responders and a group
of non-responders (who would so limited reduction in symptoms). By identifying different
classes of patients with distinct trajectories, the progress of any new patient receiving
treatment at the IAPT services could be compared against the previously identified
trajectories, to predict whether a positive outcome is likely considering the patient’s current
trajectory. Patients following a trajectory that is indicative of a poor outcome, for example a
non-responding class of patients, could be identified by the clinician and this might provide
an opportunity to decide whether an alternative treatment approach should be considered.
The results of the LCGA for patients who received guided self-help (GSH) and those who
received HI treatments identified four distinct classes of change in depression symptoms
and five classes of anxiety symptom change. Although the same number of classes were
identified, the trajectories themselves were different and suggested that the likely forms of
change varied between the two intensities of intervention. Whereas depression symptom
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change during GSH identified four classes with distinct intercept values, suggesting that the
class could be identified for a patient within the first few sessions of treatment, three of the
classes of depression change during HI treatment had a similar intercept value, with the
trajectories only becoming distinct towards the fourth or fifth session. Whereas one
depression symptom class showed a consistent PHQ-9 score during the course of
treatment, indicating no change in symptom severity, a second class showed no initial
change in the first three sessions before a dramatic decrease in depression symptoms
begins. This finding cautions against the view that prognosis can be identified by the third
session/second week of treatment (Gorwood et al., 2013; Lambert, 2013) and instead
suggests that, for some sub-groups patients at least, clinicians should wait until the fourth or
fifth session before considering a change in approach.
To further clarify this issue, LCGA was then performed by individual latent profile to identify
all potential trajectories of change for stratified groups of patients. For some profiles, no
additional classes were identified, suggesting that there was only one form of change (the
expected response curve), but for other profiles up to four distinct classes were identified.
The distribution of patients to these curves varied across profiles, and typically one class
included around 40-50% of profile members with the other classes consisting of 10-35% of
the sample. Providing this information to clinicians could be used to support a more
personalised approach to treatment monitoring decisions, as a patient’s within-treatment
change could be plotted against the likely known trajectories for members of their profile.
This might inform a discussion between the patient and the clinician as to whether a change
in treatment appropriate may be beneficial, which could result in more appropriate treatment
being made available earlier.
Application in practice
As indicated above, combining the results of the LPA (Chapters 5 and 6) and the LCGA by
latent profiles (Chapter 8) was used to develop a DST to support both treatment selection
and monitoring decisions, and thereby support the delivery of a personalised medicine
approach to the treatment of CMHDs. For any new patient entering an IAPT service, the
DST would first use information from the nine routinely collected characteristics described in
Chapter 4 to calculate the probability of profile membership to each of the eight latent
profiles, using the posterior membership probability equations in Chapter 5. The patient
would then be assigned to the profile to which they had the highest probability of
membership using an algorithm incorporating the probability calculations, and this algorithm
was created for the analyses in Chapter 6 to assign each patient in the validation sample to
a latent profile. This algorithm could be hosted by the EPMS used by a service, and as the
nine characteristics are already part of the mandatory IAPT MDS, no additional data
collection by patients or clinicians would be required.
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Details of the patient’s latent profile could be provided in real time to the clinician (and
potentially to the patient with further development), as soon as the assessment is complete.
This profile information could include the probability of different treatment outcomes,
including recovery, deterioration and dropout, following both LI and HI interventions, and
would be informed by the analyses presented in Chapter 6. The DST could also be
developed to use the information about likely treatment outcomes to provide a treatment
recommendation (e.g. LI or HI treatment) to aid clinical judgement. This recommendation
might be made available to the patient and could inform a discussion between the clinician
and patient about treatment choice. However, this system could only inform a judgement,
not replace it. There are a number of reasons for this, including the absence of diagnosis
information which would inform an automatic allocation to HI treatment for PTSD or social
anxiety disorder in IAPT services, due to the limited evidence-base for LI treatments for
these conditions. Other patient characteristics such as a high risk of self-harm or having
previous unsuccessful LI treatment would likely result in the clinician considering HI as a
more appropriate intervention and therefore the algorithm would need further development
to incorporate these characteristics.
In the second stage of the algorithm, once the latent profile has been identified and
treatment has commenced, information about the current trajectory of the patient, collected
through sessional outcome measurement, could be compared to the likely trajectories for
patients of the same profile (as identified in Chapter 8). Sessional outcome data is already
entered into the EPMS as part of routine practice in IAPT services, and therefore the DST
could be built into the system to provide information about the patient’s progress in real time.
This information could flag up when the patient is following a trajectory that would indicate a
poor prognosis, and therefore provide an opportunity for the clinician to change approach if
appropriate, or step up to a higher intensity of treatment.
In summary, the proposed DST outlined above has the potential benefit of relatively simple
technical implementation as it could be hosted on EPMS with minimal effort, and as the
included patient characteristics are already part of the mandatory dataset, there would be no
additional staff resource needed. In return, the DST can provide the probability of a range of
treatment outcomes, including both positive and negative outcomes, and produce a
recommendation about whether LI or HI might be more appropriate for the patient. Once
treatment has started, the DST could use information about the likely trajectories of
symptom change for the patient’s identified profile to inform the clinician whether the patient
is displaying a change in symptoms indicative of clinical benefit, or whether a poor prognosis
is likely. This personalised approach to treatment could be delivered in real time and inform
shared decision making between the clinician and patient, and has the potential to contribute
to a more efficient use of healthcare resources.
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Limitations
A major limitation of this project is that the datasets used were drawn from two IAPT
services only and were therefore limited with regards to available patient characteristics,
information about how treatments were chosen, and the treatments available.
The lack of randomisation of patients who received LI and HI treatments meant that the
exploration of the potential prescriptive effect of patient characteristics in the IAPT dataset
could not be explored in this thesis. Instead, the focus was on identifying patient
characteristics which were prognostic within IAPT delivered treatments. There are a number
of reasons why certain patients would have been allocated to HI treatments instead of LI. As
the analyses presented in this thesis were limited to considering only data routinely collected
by the IAPT services this meant, along with the absence of randomisation, it was not
possible to explore these factors. T-tests were conducted on the differences in mean
symptom severity between members of each profile who received LI or HI treatments, with
limited differences found, but there are likely to be further indicators of patient complexity or
severity which were not captured in the IAPT data set that may have informed treatment
allocation decisions for patients within the same profile to receive different treatments. The
use of randomised allocation to LI or HI treatment would have eliminated the risk of
confounding by indication but this method was not feasible within the current project.
The IAPT MDS is limited with regard to the number of patient characteristics that are
available, and there may be a number of important factors that could have informed the
treatment selection decisions that were made, and also be able to inform the likely response
to psychological treatment. A number of characteristics were identified by the meta-review
presented in Chapter 3, such as relationship status and past treatment history, that were
associated with response to treatment, but these characteristics were not available in the
IAPT MDS. The inclusion of these characteristics may have further informed the likelihood of
treatment outcomes, as well as the structure of the latent profiles.
The absence of reliable diagnostic information in the IAPT datasets is also presents a
significant limitation. The allocation of treatment in IAPT services are be driven by diagnosis
in some scenarios, as diagnoses such as PTSD and social anxiety disorder where current
NICE guidance recommends high intensity treatments as first line interventions (e.g. NICE,
2013). The IAPT data is very limited regarding diagnostic information, with diagnosis or
‘problem description’ missing for over half of IAPT patients in national datasets (HSCIS,
2015). The improved identification of clinical diagnoses in IAPT services would help further
inform treatment selection decisions, especially given the national guidance for treatment of
specific CMHD diagnoses.
By focusing the current project on IAPT data only, the results of this analysis have limited
generalisability to other treatment settings and would require replication in alternative
settings to explore their potential to aiding treatment decision in other settings. IAPT services
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predominately deliver CBT-based interventions, as these treatments have the largest
evidence base, but other treatment modalities have been shown to be effective (NCCMH,
2011). The number of patients in the two IAPT services receiving other modalities such as
IPT (n=63, 0.59%) or Couples Therapy (n=37, 0.35%) was very limited, but it would be of
interest to explore whether there was a method of personalising which type of treatment
modality, rather than just intensity, would be of most benefit to a patient. Alternative datasets
from different treatment services, or IAPT services where other modalities are more
commonly used could further evolve the personalisation of psychological treatment beyond
the scope of this project.
Although the dataset included a relatively large number of patients, the data was derived
from only two IAPT services in England, and replication of these analyses in other IAPT
services may result in different findings. The results of the LPA, comparison of outcomes
and LCGA may not be generalizable to other IAPT services, or other non-IAPT
psychological treatment services which may provide services for patients with more complex
needs than those typically treated in IAPT services, and therefore replication of these
methods in different datasets would be of benefit. It is also to be expected that local IAPT
services will vary in relation to local demographics, such as mean age and ethnic
backgrounds, and therefore different profile make-ups or even number of identified profiles
could exist if alternative datasets were explored. The probability of different outcomes by
individual profile could also vary between services, which may relate to the nature or quality
of care provided for certain groups of patients, and again further analysis would be of
interest to explore this. Although a number of patients treated in IAPT services are
prescribed medication (nearly 40% of the included sample), adherence to medication was
not routinely collected and so the influence of medication on profile response could not be
explored. This may be worth considering in the latent growth modelling in future analysis.
Using data from additional services could also be used to provide a more substantial dataset
for some of the sub-analyses that could not be performed in this thesis. For example, the
analysis on treatment outcomes for LP3 presented in Chapter 6 included a very limited
number of patients, and there were too few LP3 patients that could be included in the latent
growth analyses in Chapters 7 and 8. As a result, the prototype DST is limited as to its
advice for patients from this profile, and datasets providing more LP3 patients could allow
findings for this profile to be interpreted and disseminated with more confidence. In addition,
group-based treatments were not evaluated in the latent growth analyses as these
interventions could vary with respect to clinical focus (e.g. relapse prevention, bereavement)
and therefore included populations. However, acquiring data from more IAPT services could
achieve data on a significant number of patients who received different formats of group
treatment. Latent growth analysis could be performed by group-based treatment formats
(e.g. trauma-focused groups, insomnia support) and results of these analyses might provide
the DST with the ability to predict the expected treatment response by different types of
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group intervention, and therefore provide highly personalised decision support based on
treatment factors. The lower numbers of available patients in specific profiles meant that no
validation sample was available for the latent growth analyses, and further analysis would be
recommended to explore whether the same classes were identified within profiles from data
in other services.
A further limitation of the analyses presented in this thesis is that outcome data was missing
for a large number of patients, which meant they were excluded from analyses of treatment
outcomes. Of n=16636 patients entering treatment, n=3252 (19.55%) had no further data
available other than their initial assessment and were therefore missing any T2 data. For
many patients only one treatment session would be required from IAPT, especially for brief
self-help interventions or when advice only was provided, as patients may be expected to
take the materials away to complete in their own time without the need for follow-up.
Although this is in line with treatment guidance, it meant that for many patients receiving
these types of intervention the outcomes of treatment were unknown, and it is possible that
there may be subgroups of patients for whom this treatment was not effective. It would be
recommended that services follow up patients receiving these types of intervention to
understand whether treatment had been effective, as this could help personalise treatment
delivered by the services,
The lack of follow up data also limits the amount of information we have about the long-term
effectiveness of the IAPT-delivered treatments. The current analysis was focused on change
within treatment episodes of patients attending IAPT services and predicting outcomes in
these episodes only. However, data was not available to understand whether the benefits of
treatment were sustained. Some the identified profiles may be associated with differential
relapse/recurrence patterns, which could have important clinical implications for the delivery
of relapse prevention materials. It is also possible that the benefits of HI treatment over LI
that was found in some profiles may not have been sustained long term, which would need
incorporating into treatment selection decisions. It would be of value to increase the
availability of routine follow up data in services such as IAPT, and especially to explore
predictors of relapse/recurrence to inform the likelihood of future service usage.
The use of the GAD-7 as a measure of anxiety symptoms also has potential limitations, as it
is limited in its ability to capture all aspects of the range of anxiety disorders treated in IAPT
services. Anxiety disorder specific measures (ADSM) are recommended by IAPT services to
assessment specific anxiety disorders, but these are not used consistently in all IAPT
services and were not available in the dataset used for this thesis. Using ADSM has the
potential to further inform the trajectories of change for individual profiles, and it may be of
value to explore this in future IAPT datasets where there will be more completion of these
additional measures.
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In addition, existing clinical decision rules developed by the service which may reflect local
priorities, for example the management of waiting times, may have influenced choice of
initial treatment, and this may limit the applicability and generalizability of the current DST
across settings. For example, IAPT services will have only a limited amount of HI therapists
available and therefore may not be able to allocate significant numbers of patients to higher
intensity treatments, which may result in some DST recommendations for more intensive
treatment being difficult to implement. It is likely that, for a DST to be successfully
incorporated into routine clinical practice in IAPT services, it will need to take into account
available resource as well as local decision rules to improve potential uptake and
applicability.
Future directions
A number of possible future directions for further research and development are set out
below, these include:
 Testing the clinical applicability of the algorithm output as a DST.
 Replicating the analysis using data from additional services, including non-IAPT
settings.
 Refining the profiles by using additional patient characteristics.
 Expanding the use of the algorithm to involve patient participation in decision
making, and increasing access to the algorithm output.
Testing the clinical applicability of the algorithm - initial discussions with clinicians from the
IAPT services which provided the data used in this thesis suggested that the profiles
presented have reasonable face validity. However this would need to be tested empirically,
and such testing would have a minimum of two components i) the refinement of the
algorithm and its integration with existing EPMS to develop outputs which provide real time
information to support clinical decisions and ii) exploring staff opinion and experience of
using the DST in IAPT settings through feasibility studies, as well as formal evaluations (for
example, controlled trials) to understand whether using the DST can lead to improved
patient and service-level outcomes. Initial discussions with both the service in which this
initial development was undertaken and with the providers of the EPMS have been positive.
If these feasibility studies were positive, a more formal evaluation of the DST could be
considered which may take into account the outcome of other further work described below.
Testing the profile in different settings – as discussed in the limitations section, there would
be benefits in replicating this work in alternative IAPT services, as both the analyses
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presented in this thesis and a potential feasibility study would have all been conducted within
the same services. Following the presentation of the latent profile analysis and related
publications, a number of IAPT services have expressed an interest in replicating this work
with their data. Initial work with other IAPT services suggests that profile structures and
distribution are similar to those identified in this thesis. More substantial development work
could focus on the use of the statistical methods used in this thesis in non-IAPT populations
with depression and anxiety disorders, including those in receipt of psychological and
possibly pharmacological interventions. These methods could also be applied to other
mental health conditions, for example schizophrenia, if sufficient patient datasets were
available for these populations.
Refining the profiles – There is potential future development work that could focus on
collecting and incorporating additional patient characteristics into analyses, such as those
patient characteristics identified in the systematic review (Chapter 3), which are not currently
included in the IAPT mandatory dataset. In addition to characteristics such as personality
disorders and previous treatment, other factors such as relationship quality and self-efficacy
(Luszczynska et al., 2009; Mululo et al., 2012) may have potential to further inform
prognosis, and future work may wish to further explore these additional characteristics in
both IAPT and non-IAPT samples. Including these characteristics within the latent profile
analysis could be used to adjust the structure of the current profiles, or identify additional
profiles, which may result in more refined and personalised information to aid clinical
decision making.
The use of item level information from the PHQ-9 and GAD-7 assessments could also have
further predictive validity than using the total scores alone, as has been presented in the
current analysis. Item-level data on these measures was not available for the current
analysis, but as this information would be provided by the patient during clinical contacts
with the services, it should be possible to acquire and record this data in further research. As
prediction models have identified specific clusters of symptoms that are associated with
treatment outcomes (e.g. Chekroud et al., 2016), it may be that identifying sub-groups of
patients with specific clusters of symptoms could be combined with the latent profile
information presented in this thesis to create a more accurate and tailored prediction of likely
treatment outcome. This has not currently been explored, but has potential to develop a
highly personalised approach to treatment in CMHDs.
In addition, there is more patient relevant information available within the profile membership
allocation that has not been explored in this thesis, but has the potential to be used to refine
the DST recommendations. The latent profile algorithm calculates the probability of
membership to each LP for each patient using their patient characteristics, and the profile
with the highest probability of membership is allocated to the patient. In many cases this
probability will not be 100% and therefore each patient will have also have a probability of
membership to additional profiles, which could be defined as their ‘secondary profile(s)’. It is
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possible that different members of the same ‘primary LP’ (the profile to which they have the
highest probability of membership, e.g. LP2) will have different ‘secondary profiles’ (e.g.
LP2/LP1 and LP2/LP3), and there may be differences in the probability of treatment
outcomes between members of the same LP who have different ‘secondary profiles’. This
analysis has not been explored previously, and there is no mention of using secondary
profiles in this way in other datasets, but it has the potential to provide a more detailed
stratification of patients attending the IAPT services.
Finally, the growth of computational statistical and modelling techniques provides an
opportunity to further explore the role of patient characteristics in the prediction of outcomes
in mental health treatment. Although this project has focused on latent variable modelling
approaches, alternative statistical approaches such as machine learning (Friedman, 2006)
could provide alternative solutions that may further improve the prediction of treatment
outcomes. Further analysis using additional and more sophisticated approaches may
provide better solutions and are planned as the next stage of analysis in this program of
work.
Expanding the use of the algorithm to involve patient participation – the focus on almost all
DSTs is on their use by clinicians, and this has been the focus of the work presented in this
thesis. However, given the relatively accessible data that the calculation of profile
membership is based on, it would be possible to develop outputs for the algorithm that could
be used to inform patients of the potential treatment options available to them and the
likelihood of their success. If developed in collaboration with patient groups, such outputs
could be tested in a similar way to that suggested for the feasibility testing of the clinician
focused algorithm, to see if use of the DST has a positive impact on service outcomes and
healthcare efficiency.
Conclusions
The aim of this project was to explore the underlying data requirements and analysis to
support the development of a decision support tool to aid clinical decision making in
psychological treatment for CMHDs, by using routine patient data. A literature search
identified a number of patient specific characteristics that have been associated with
treatment outcomes, and there was significant overlap between these variables and the
IAPT MDS. Exploration of a dataset of patients attending IAPT services found that a number
of these characteristics were predictive of response, deterioration and dropout from
treatment. Latent profile analysis was performed on the dataset to identify stratified groups
of patients with similar presenting characteristics, and analysis found that there was
significant variation in outcomes between these profiles. For some profiles there was a
significant benefit of HI interventions over LI, which would suggest that these patients should
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be allocated to higher intensity treatments as initial treatment rather than receiving an LI
treatment which has a lower likelihood of resulting in a positive outcome.
Exploring the trajectories of symptom change for the eight identified profiles using latent
class growth analysis showed that there was variation between the groups of patients on the
likely change in symptoms during both LI and HI treatments. By combining the results of the
latent profile analysis and latent class growth analysis, a prototype decision support tool that
could be developed to inform both treatment selection and treatment monitoring decisions is
presented. This DST could be incorporated into the existing electronic patient management
systems used by the services and would provide real time information to clinicians to aid
clinical judgement. A feasibility study evaluating the use of this DST is suggested, and
further analyses using datasets from other IAPT services is proposed to replicate the
methods and findings presented in this thesis. If feasible, the use of a personalised medicine
approach developed as part of this project has the potential to optimise the delivery of
psychological treatments in IAPT services.
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Appendices
Appendix A: Search strings for the systematic review of predictors to treatment outcome.
Databases: EMBASE, MEDLINE, PsycINFO
# searches
1
anxiety/ use emez or body dysmorphic disorders/ use emez or compulsive behaviour/
use emez or obsessive behaviour/ use emez or panic/ use emez or stress,
psychological/ use emez or exp anxiety disorders/ use emez or exp depression/ use
emez or exp depressive disorder/ use emez
2
anxiety/ use mesz or exp depression/ use mesz or body dysmorphic disorder/ use mesz
or critical incident stress/ use mesz or psychotrauma/ use mesz or exp anxiety disorder/
use mesz
3
anxiety/ use psyh or body dysmorphic disorder/ use psyh or compulsions/ use psyh or
emotional trauma/ use psyh or exp anxiety disorders/ use psyh or fear/ use psyh or
obsessions/ use psyh or panic/ use psyh or panic attack/ use psyh or psychological
stress/ use psyh or traumatic neurosis/ use psyh
4
(agoraphobi$ or anxiet$ or anxious$ or body dysmorphi$ or claustrophobi$ or clean
response$ or compulsi$ or depress$ or dysmorphophobi$ or obsession$ or obsessive$
or ocd or panic$ or phobi$ or posttraum$ or post trauma$ or ptsd or recur$ thought$ or
seasonal affective disorder$ or ((acute or chronic$ or extreme or incessant$ or intense$
or persistent$ or serious$ or sever$) adj2 (apprehens$ or doom or fear$ or terror$)) or
railway spine or (rape adj2 trauma$) or reexperienc$ or re experienc$ or torture
syndrome or (trauma$ adj (neuros$ or stress$)) or (trauma$ and (avoidance or grief or
horror or death$ or nightmare$ or night mare$ or emotion$)) or (combat adj (disorder$
or fatigue or neuros$ or syndrome$)) or war neuros$ or concentration camp syndrome
or ((extreme or trauma$) adj stress) or flash back$ or flashback$ or hypervigil$ or
psych$ stress or psych$ trauma$ or psychotrauma$ or acute stress or asd or desnos or
post traumatic$ or posttraumatic$ or ptsd or stress disorder$).ti,ab.
5 or/1-4
6
"prediction and forecasting"/ use emez or disease course/ use emez or prediction/ use
emez or predictor variable/ use emez or prognosis/ use emez or decision making/ use
emez or decision support system/ use emez or algorithm/ use emez
7 "predictive value of tests"/ use mesz or exp prognosis/ use mesz or decision making/use mesz or decision support systems, clincal/ use mesz or algorithms/ use mesz
8 disease course/ use psyh or prediction/ use psyh or prognosis/ use psyh or decisionmaking/ use psyh or decision support systems/ use psyh or algorithm/ use psyh
9 (predict$ or prognos$ or decision making).ti,ab.
10
(expected treatment response or identification of treatment failure or differential
prediction$ or (patient$ adj2 deteriorat$)). ti, ab, kw.
11 or/6-10
12 risk/ use emez or recurrence risk/ use emez or risk assessment/ use emez or riskfactor$.sh. use emez or risk reduction/ use emez
13 risk/ use mesz or risk assessment/ use mesz or risk factor$.sh. use mesz
14 at risk populations/ use psyh or risk/ use psyh or risk assessment/ use psyh or riskfactor$.sh. use psyh
15 risk$.ti,ab.
16 or/12-15
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17
drug response/ use emez or hospital readmission/ use emez or patient compliance/ use
emez or recurrent disease/ use emez or recurrence risk/ use emez or relapse/ use emez
or remission/ use emez or remission induction/ use emez or exp treatment failure/ use
emez or treatment outcome/ use emez or treatment refusal/ or treatment response/ use
emez or treatment withdrawal/ use emez or patient satisfaction/ use emez
18
medication adherence/ use mesz or patient compliance/ use mesz or patient dropouts/
use mesz or patient readmission/ use mesz or recurrence/ use mesz or remission/ use
mesz or treatment failure/ use mesz or treatment outcome/ use mesz or treatment
refusal/ use mesz or patient satisfaction/ use mesz
19
psychiatric hospital readmission/ use psyh or treatment dropouts/ or treatment refusal/
use psyh or psychotherapeutic resistance/ use psyh or "relapse (disorders)"/ use psyh
or treatment compliance/ use psyh or treatment outcomes/ use psyh or client
satisfaction/ use psyh
20
(adher$ or complian$ or nonadher$ or nonrespon$ or recur$ or readmi$ or re admi$ or
rehospital$ or re hospital$ or relaps$ or remission$ or respond$ or response$ or attrition
or drop out$ or select$ or allocat$ or prefer$ or declin$ or uptak$ or ((antidepres$ or
interven$ or therap$ or treatment) adj3 (refus$ or success$))).ti,ab.
21 (expected treatment response or identification of treatment failure or (patient$ adj2deteriorat$)). ti, ab, kw.
22 or/17-21
23
((risk$ adj2 (adher$ or complian$ or nonadher$ or nonrespon$ or recur$ or readmi$ or
re admi$ or rehospital$ or re hospital$ or relaps$ or remission$ or respond$ or
response$ or ((antidepres$ or interven$ or therap$ or treatment) adj3 refus$))) or (risk$
adj4 (predict$ or prognos$))).ti,ab.
24 systematic review/ use emez or meta analysis/ use emez
25 meta analysis.sh,pt. use mesz or "review literature as topic"/ use mesz
26 literature review/ use psyh or meta analysis/ use psyh
27
(exp bibliographic database/ use emez or (((electronic or computer$ or online) adj
database$) or bids or cochrane or embase or index medicus or isi citation or medline or
psyclit or psychlit or scisearch or science citation or (web adj2 science)).ti,ab.) and
(review$.ti,ab,sh,pt. or systematic$.ti,ab.)
28
(exp databases, bibliographic/ use mesz or (((electronic or computer$ or online) adj
database$) or bids or cochrane or embase or index medicus or isi citation or medline or
psyclit or psychlit or scisearch or science citation or (web adj2 science)).ti,ab.) and
(review$.ti,ab,sh,pt. or systematic$.ti,ab.)
29
(computer searching/ use psyh or (((electronic or computer$ or online) adj database$) or
bids or cochrane or embase or index medicus or isi citation or medline or psyclit or
psychlit or scisearch or science citation or (web adj2 science)).ti,ab.) and
(review$.ti,ab,pt. or systematic$.ti,ab.)
30 ((evidence or quantitative$ or systematic$) adj2 (overview or review)).ti,ab.
31 (metaanal$ or meta anal$ or metasynthes$ or meta synthes$).ti,ab.
32 ((pool$ or combined or combining) adj2 (data or trials or studies or results)).ti,ab.
33 or/24-32
34 (5 and (or/11,16) and 22 and 33) or (and/5,23,33)
35 remove duplicates from 34
36 35 not (comment$ or dissertation$ or editorial$ or letter$).pt.
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Appendix B: NICE methodology checklist for systematic reviews and meta-analyses.
Study identification
Include author, title, reference, year of
publication
Guideline topic:
Review question
no:
Checklist completed by:
SCREENING QUESTIONS
In a well-conducted, relevant systematic
review:
Circle one option for each
question
The review addresses an appropriate and
clearly
Yes No Unclear
focused question that is relevant to the
guideline review question
The review collects the type of studies you
consider
relevant to the guideline review question Yes No Unclear
The literature search is sufficiently rigorous
to identify
all the relevant studies Yes No Unclear
Study quality is assessed and reported
Yes No Unclear
An adequate description of the methodology
used is
included, and the methods used are
appropriate to the question
Yes No Unclear
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Appendix C: Number of specific treatments delivered by the services.
Intervention Number ofpatients
Percentage of
included
patients
CBT recovery self-help book 682 6.38%
CBT anxiety self-help book 470 4.40%
Books on prescription 558 5.22%
Self-help (other) 5502 51.45%
Cognitive behavioural therapy (CBT) 4242 39.67%
Interpersonal therapy 63 0.59%
Couples 37 0.35%
Counseling 453 4.24%
Computerised CBT (CCBT) 327 3.06%
Group psycho-education 576 5.39%
Behavioural activation 1490 13.93%
Medication advice 174 1.63%
Structure exercise 276 2.58%
Signposting 2565 23.99%
information only 2586 24.18%
Custom therapy 166 1.56%
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Appendix D: Graphical representation of the latent profiles
Figure C1. Graphical representation of the distribution of patient variables between
latent profiles.
The distribution of the patient variables for each LP is presented in figure A1. Due to
the different scaling of the continuous and dichotomous items included in the latent
profile analysis, it was not possible to directly compare the mean scores and
proportions of each variable between LPs. Instead, all mean scores and proportions
for each item were standardised and z-scores were used to present the distribution
between mean scores and proportions for each profile.
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Appendix E: Latent growth curve model comparison, including patients with three or more
sessions of additional interventions.
Guided Self-help (n=3465)
PHQ-9 GAD
CFI TFI RMSEA SRMR CFI TFI RMSEA SRMR
Linear 0.907 0.916 0.08 0.58 0.878 0.89 0.083 0.172
Quadratic 0.979 0.978 0.04 0.033 0.977 0.976 0.039 0.047
Quadratic,
correlated
residuals 0.994 0.991 0.026 0.024 0.99 0.986 0.03 0.04
High intensity (n=4903)
PHQ-9 GAD
CFI TFI RMSEA SRMR CFI TFI RMSEA SRMR
Linear 0.913 0.913 0.071 0.097 0.902 0.911 0.072 0.116
Quadratic 0.961 0.961 0.049 0.04 0.959 0.964 0.048 0.045
Quadratic,
correlated
residuals 0.987 0.986 0.031 0.028 0.986 0.985 0.03 0.034
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Appendix F: Latent Class Growth Analysis by Latent profiles: model comparison tables.
LP1.
Table E1.1. Model fit statistics LP1 GSH
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals per
class
k = 2 3114 3177 3108 0.134 0.893 49/51
k = 1 3122 3192 3116 n/a n/a n/a
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals per
class
k = 2 3088 3151 3082 0.002 0.714 34/66
k = 3 3068 3143 3061 0.13 0.905 37/60/3
Table E1.2. Model fit statistics LP1 HI
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 5679 5775 5671 0.042 0.951 94/6
k = 3 5672 5780 5663 0.082 0.949 6/92/1
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 5697 5790 5689 0.02 0.815 69/31
k = 3 5655 5760 5646 0.733 0.792 34/10/56
LP2.
Table E1.3. Model fit statistics LP2 GSH
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 27982 28092 28022 <0.001 0.734 72/28
k = 3 27841 27971 27888 <0.001 0.675 54/11/36
k = 4 27805 27955 27860 0.521 0.579 43/23/9/26
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 28008 28118 28048 <0.001 0.731 26/74
k = 3 27913 28044 27961 0.001 0.646 32/12/55
k = 4 27880 28030 27935 0.033 0.619 16/25/47/12
k = 5 27856 28027 27919 0.431 0.65 18/6/45/25/8
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Table E1.4. Model fit statistics LP2 HI
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 47108 47272 47167 <0.001 0.67 70/30
k = 3 47004 47188 47070 0.003 0.693 57/5/38
k = 4 46958 47161 47031 0.504 0.626 29/50/4/18
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 47293 47452 47350 <0.001 0.814 63/37
k = 3 46832 47010 46896 0.037 0.757 42/41/18
k = 4 46612 46811 46683 <0.001 0.741 11/23/47/39
k = 5 46539 46757 46617 0.077 0.717 13/15/38/11/23
LP4.
Table E1.5. Model fit statistics LP4 GSH
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 4361 4430 4360 0.007 0.811 78/22
k = 3 4333 4414 4332 0.115 0.733 11/35/54
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 4272 4340 4271 0.007 0.786 22/78
k = 3 4257 4338 4256 0.288 0.751 68/20/12
Table E1.6. Model fit statistics LP4 HI
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 7725 7830 7726 0.293 0.682 29/71
k = 1 7703 7812 7704 n/a n/a n/a
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 7785 7888 7768 <0.001 0.818 68/32
k = 3 7735 7850 7736 0.04 0.746 14/47/40
k = 4 7722 7850 7723 0.812 0.729 7/25/49/18
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LP5.
Table E1.7. Model fit statistics LP5 GSH
PHQ
k
model AIC BIC Adj-BIC
VLMR-LRT
(p=) Entropy
% individuals
per class
k = 2 10254 10339 10270 0.059 0.702 46/54
k = 1 10211 10304 10228 n/a n/a n/a
GAD
k
model AIC BIC Adj-BIC
VLMR-LRT
(p=) Entropy
% individuals
per class
k = 2 9808 9893 9824 <0.001 0.75 51/49
k = 3 9764 9866 9783 0.16 0.678 37/24/39
Table E1.8. Model fit statistics LP5 HI
PHQ
k
model AIC BIC Adj-BIC
VLMR-LRT
(p=) Entropy
% individuals
per class
k = 2 20587 20723 20618 <0.001 0.634 44/56
k = 3 20512 20665 20547 0.1 0.678 52/26/22
GAD
k
model AIC BIC Adj-BIC
VLMR-LRT
(p=) Entropy
% individuals
per class
k = 2 19854 19985 19884 <0.001 0.774 49/51
k = 3 19598 19746 19632 0.041 0.773 50/26/24
k = 4 19491 19656 19529 <0.001 0.754 11/20/39/30
k = 5 19466 19647 19508 0.247 0.724 19/36/24/12/8
LP6.
Table E1.9. Model fit statistics LP6 GSH
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 8253 8336 8267 <0.001 0.686 64/36
k = 3 8231 8330 8247 0.325 0.7 7/40/53
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 7889 7973 7903 <0.001 0.762 68/32
k = 3 7844 7942 7860 0.015 0.798 61/34/6
k = 4 7814 7928 7833 0.091 0.725 38/5/25/31
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Table E1.10. Model fit statistics LP6 HI
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 21635 21773 21668 <0.001 0.686 30/70
k = 3 21588 21743 21626 0.175 0.564 32/21/47
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 20767 20901 20800 <0.001 0.815 40/60
k = 3 20576 20727 20613 <0.001 0.767 16/40/44
k = 4 20508 20676 20549 0.004 0.729 40/14/18/29
k = 5 20485 20669 20529 0.164 0.717 24/7/38/18/14
LP7.
Table E1.11. Model fit statistics LP7 GSH
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 8299 8382 8312 <0.001 0.742 67/33
k = 3 8253 8351 8269 0.196 0.66 46/29/25
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 7940 8024 7954 <0.001 0.819 70/30
k = 3 7910 8009 7926 0.381 0.751 14/60/27
Table E1.12. Model fit statistics LP7 HI
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 39562 39722 39617 <0.001 0.771 65/35
k = 3 39302 39480 39363 0.104 0.785 8/55/36
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 37749 37903 37801 <0.001 0.846 35/65
k = 3 37148 37322 37208 <0.001 0.818 35/50/15
k = 4 37000 37193 37066 0.028 0.838 3/15/34/48
k = 5 36897 37110 36970 0.257 0.818 10/45/11/3/31
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LP8.
Table E1.13. Model fit statistics LP8 GSH
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 23629 23735 23665 <0.001 0.69 54/46
k = 3 23502 23627 23545 <0.001 0.695 13/44/43
k = 4 23478 23622 23526 0.138 0.62 37/11/32/20
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 22672 22777 22707 <0.001 0.712 49/51
k = 3 22563 22688 22605 0.005 0.669 29/32/39
k = 4 22531 22675 22580 0.012 0.637 21/22/25/22
k = 5 22521 22684 22576 0.653 0.633 12/11/32/24/21
Table E1.14. Model fit statistics LP8 HI
PHQ
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 51149 51315 51210 <0.001 0.655 50/50
k = 3 50949 51135 51018 <0.001 0.619 29/46/25
k = 4 50846 51052 50922 0.012 0.583 17/33/23/27
k = 5 50806 51033 50890 0.001 0.642 23/35/2/14/26
k = 6 50787 51034 50878 0.114 0.585 2/26/25/14/17/16
GAD
k model AIC BIC Adj-BIC VLMR-LRT(p=) Entropy
% individuals
per class
k = 2 49475 49637 49535 <0.001 0.784 46/54
k = 3 48936 49118 49003 <0.001 0.755 31/45/24
k = 4 48809 49010 48883 0.005 0.696 36/18/27/19
k = 5 48702 48924 48784 0.104 0.667 19/25/17/16/23
